-- --------------------------------------------------------
-- Host                          :212.128.142.14
-- Versión del servidor          :5.5.29-log - MySQL Community Server (GPL)
-- SO del servidor               :Linux
-- HeidiSQL Versión              :7.0.0.4307
-- Creado                        :2014-03-12 10:44:59
-- --------------------------------------------------------

/*!40101 SET @OLD_CHARACTER_SET_CLIENT=@@CHARACTER_SET_CLIENT */;
/*!40101 SET NAMES utf8 */;
/*!40014 SET @OLD_FOREIGN_KEY_CHECKS=@@FOREIGN_KEY_CHECKS, FOREIGN_KEY_CHECKS=0 */;
/*!40101 SET @OLD_SQL_MODE=@@SQL_MODE, SQL_MODE='NO_AUTO_VALUE_ON_ZERO' */;

-- Volcando estructura para tabla farmacos.alg_cmb
CREATE TABLE IF NOT EXISTS `alg_cmb` (
  `id_alg_cmb` mediumint(6) NOT NULL AUTO_INCREMENT,
  `id_alg_n11` smallint(4) NOT NULL,
  `id_alg_n12` smallint(4) NOT NULL,
  `resultado_cmb` tinyint(3) NOT NULL,
  PRIMARY KEY (`id_alg_cmb`)
) ENGINE=MyISAM AUTO_INCREMENT=5 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.alg_cmb: 4 rows
/*!40000 ALTER TABLE `alg_cmb` DISABLE KEYS */;
INSERT INTO `alg_cmb` (`id_alg_cmb`, `id_alg_n11`, `id_alg_n12`, `resultado_cmb`) VALUES
	(1, 1, 4, 3),
	(2, 2, 4, 3),
	(3, 3, 4, 0),
	(4, 3, 5, 5);
/*!40000 ALTER TABLE `alg_cmb` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.alg_n1
CREATE TABLE IF NOT EXISTS `alg_n1` (
  `id_alg_n1` smallint(5) NOT NULL AUTO_INCREMENT,
  `id_algoritmo` smallint(4) NOT NULL,
  `parametro` tinyint(3) NOT NULL,
  `caso` tinyint(3) NOT NULL,
  `valor_min` decimal(4,1) NOT NULL,
  `valor_max` decimal(4,1) NOT NULL,
  `resultado` tinyint(2) DEFAULT NULL,
  PRIMARY KEY (`id_alg_n1`)
) ENGINE=MyISAM AUTO_INCREMENT=6 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.alg_n1: 5 rows
/*!40000 ALTER TABLE `alg_n1` DISABLE KEYS */;
INSERT INTO `alg_n1` (`id_alg_n1`, `id_algoritmo`, `parametro`, `caso`, `valor_min`, `valor_max`, `resultado`) VALUES
	(1, 1, 0, 1, 0.0, 20.0, 2),
	(2, 1, 0, 2, 20.1, 40.0, 3),
	(3, 1, 0, 3, 40.1, 100.0, 4),
	(4, 1, 4, 1, 0.0, 20.0, 3),
	(5, 1, 4, 2, 20.1, 100.0, 4);
/*!40000 ALTER TABLE `alg_n1` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.alg_results
CREATE TABLE IF NOT EXISTS `alg_results` (
  `id_result` tinyint(4) NOT NULL,
  `texto_result` varchar(25) COLLATE utf8_unicode_ci NOT NULL,
  `peso_result` smallint(6) NOT NULL DEFAULT '0',
  PRIMARY KEY (`id_result`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.alg_results: 7 rows
/*!40000 ALTER TABLE `alg_results` DISABLE KEYS */;
INSERT INTO `alg_results` (`id_result`, `texto_result`, `peso_result`) VALUES
	(-1, 'ErRROR', 0),
	(0, '??', 0),
	(1, 'Very Low', 1),
	(2, 'Low', 2),
	(3, 'Moderate', 3),
	(4, 'High', 4),
	(5, 'Very High', 5);
/*!40000 ALTER TABLE `alg_results` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.categorias_dianas
CREATE TABLE IF NOT EXISTS `categorias_dianas` (
  `id_categoria_diana` smallint(4) NOT NULL AUTO_INCREMENT,
  `descripcion_categoria_diana` varchar(50) COLLATE utf8_unicode_ci DEFAULT NULL,
  `tx1desc_cd` varchar(256) COLLATE utf8_unicode_ci DEFAULT NULL,
  `tx2desc_cd` varchar(256) COLLATE utf8_unicode_ci DEFAULT NULL,
  `comentarios_cd` varchar(256) COLLATE utf8_unicode_ci DEFAULT NULL,
  PRIMARY KEY (`id_categoria_diana`)
) ENGINE=MyISAM AUTO_INCREMENT=57 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.categorias_dianas: 55 rows
/*!40000 ALTER TABLE `categorias_dianas` DISABLE KEYS */;
INSERT INTO `categorias_dianas` (`id_categoria_diana`, `descripcion_categoria_diana`, `tx1desc_cd`, `tx2desc_cd`, `comentarios_cd`) VALUES
	(1, 'PHOSPHOINOSITIDE-3 KINASE (PI3K) INHIBITORS', 'Fatigue, dysgeusia, nausea, vomiting, hyperglycemia, alopecia, diarrhea, mucositis, dysgeusia, anemia, rash, anorexia, and mood alteration, pruritus, decreased appetite, thrombocytopenia, dysuria, cystitis,  hematuria, abdominal pain, pelvic pain and skin ', 'Thrombocytopenia, increased amylase, rash , pain, pneumonitis, hyperglycemia neutropenia, lymphopenia, thrombocytopenia, , hyponatremia, nausea, vomiting and thrombosis.', ''),
	(2, 'PI3K/mTOR INHIBITORS', 'Nausea, vomiting, diarrheas, fatigue, asthenia, anemia, anorexia, decreased appetite, rash, mucositis, hyperglycemia and constipation ', 'Nausea, vomiting, anorexia ,  AST increased, diarrhea, fatigue and  hyperglycemia\r\n', ''),
	(3, 'AKT INHIBITORS', 'Hyperglycemia, asthenia, decreased appetite, diarrhea, nausea, fatigue, vomiting, dyspepsia, rash, constipation, Skin rash pruritus and abdomainal pain. ', 'Hyperglicemia, rash, anemia, increased AST/ ALT and increased GGT.', ''),
	(4, 'MTORC1 and mTORC2 inhibitors', 'Fatigue, rash, stomatitis, hyperglycemia, anorexia, nausea, vomiting, diarrhea and decreased appetite', 'Nausea, vomiting, lethargy, abdominal pain, mucositis', ''),
	(5, 'IGF-1R INHIBITORS', 'Fatigue,neutropenia , leukopenia , thrombocytopenia , vomiting, AST increased, nausea, hyperglycemia, dysgeusia, hypotension, bradycardia, anorexia, asthenia and back pain.', 'Neutropenia, leukopenia, lymphopenia, hyperglicemia asthenia, hyperbilirrubinemia and AV block \r\n', ''),
	(6, 'HEDGEOG INHIBITORS', 'Nausea, vomiting, dysgeusia, decreased appetite, myalgia, muscle spasms and fatigue', '', ''),
	(7, 'MET INHIBITORS', ' Fatigue, nausea, hypertension, diarrhea, decreased appetite, pyrexia, proteinuria , ALT/AST increased, vomiting, alkaline phosphatase increased,, leukopenia, indigestion, headache, agitation, anemia, nausea.', 'Increased AST, thrombocytopenia,acute myocardial infarction and hypertension.', ''),
	(8, 'SRC INHIBITORS', 'Nausea, diarrhea, vomiting,  fatigue, anorexia, lethargy,  headache, proteinuria, rash, pruritus anemia dyspnea, constipation, AST, ALT increased, calcium decreased, magnesium increased, neutropenia, hypokalemia,  fever, hematuria, and lymphopenia.', 'Nausea, fatigue, pruritus, anorexia, anemia, magnesium increased and infections or cytopenias', ''),
	(9, 'AURORA KINASE INHIBITORSS', 'Neutropenia,  leukopenia,  anemia, thrombocytopenia, fatigue,  febrile neutropenia, hypertension, nausea, vomiting, somnolence,  confusion,  constipation and pain ', 'Anemia, lymphocytopenia, thrombocytopenia, hypertension,  neutropenia.   sinus bradycardia, angioedema, somnolence , vomiting, nausea, diarrhea, intestinal obstruction, herpes zoster, abdominal wall abscess, fatigue, muscular weakness, and peripheral motor', ''),
	(10, 'NOTCH INHIBITORS', '', '', ''),
	(11, 'PDGFR INHIBITORS', 'Fatigue, anorexia, diarrhea, hand-foot syndrome, hypertension, nausea, vomiting, asthenia, AST increased, dizziness, rash, stomatitis, dry skin, hedeache,  myalgia, abdominal pain,  chest pain, ALT ,ALP, AST and albumin decreased.', 'Hypertension, fatigue, nausea, vomiting, anorexia, GGT increased, ALT increased, anemia, lymphocitopenia leucopenia, neutropenia, asthenia, diarrhea, skin rash, proteinuria and ataxia.', ''),
	(12, 'ErbB inhibitors', 'Diarrhea, vomiting, fatigue, nausea,rash, dry skin, palmar-planter disorders dermatitis acneiform, mucositis', '', ''),
	(13, 'MEK INHIBITORS', 'Rash , fatigue , nausea, vomiting, diarrhea, dry skin, cough, anorexia, constipation, abdominal pain, pruritus, dyspnea, astenia, peripheral edema and dermatitis.', 'Anemia,  abdominal pain, constipation, vomiting, dyspnea, rash, diarrhea, Anasarca, hypokalemia, hyponatremia, mucositis, creatine phosphokinase increase and acneiform dermatitis.', ''),
	(14, 'PARP INHIBITORS', 'nausea, fatigue, diarrhea, leucopenia, neutropenia, anemia, vomiting, dysonea, alopecia, myelosupression', 'ALT increased and anemia', 'myelosupression is anemia, neutropenia and leucopenia.'),
	(16, 'HSP INHIBITORS', 'Diarrhea , back pain , fatigue  nausea, AST increased, muscle spams,  ALT increased , constipation, dyspnea,  pain in extremity ,anemia, thrombocytopenia , vomiting,  anorexia, abdominal pain, headache,  , rash, tachycardia,', '', ''),
	(17, 'PROTEASOME INHIBITORS', 'Fatigue, nausea, diarrhea, cough, dyspnea, Hypoesthesia, pyrexia, headache,edema, constipation, paresthesia, thrombocitopenia and rash.', 'Fatigue and dyspnea', ''),
	(18, 'POLOKINASE LIKE INHIBITORS', 'Neutropenia, nausea ,leucopenia, anorexia, fatigue, alopecia, vomiting, dizziness, anemia.', 'Neutropenia, lymphopenia, thrombocytopenia, hyponatremia, nausea, vomiting, anemia, fatigue, and leucopenia.', ''),
	(19, 'FGFR INHIBITORS', NULL, NULL, NULL),
	(20, 'VGFR INHIBITORS', NULL, NULL, NULL),
	(21, '', 'mild tremor, fatigue, nausea, diarrhea, indigestion, headache, and agitation', '', ''),
	(22, 'ALK INHIBITORS', 'Nausea , vomiting, diarrhea, thrombocytopenia, lipase increase, AST increase and abdominal pain.', 'Diarrhea and dyspnea', ''),
	(23, 'BRAF INHIBITORS', 'Cutaneous (rash, dry skin, HFSR, pruritus, keratosis pilaris, alopecia), pain in extremity, arthralgia, and fatigue. ', '', ''),
	(24, 'OTROS', '', '', ''),
	(25, 'GAMMA SECRETASE INHIBITOR', '', '', ''),
	(26, ' MENU OCULTO RECLUTING', '', '', ''),
	(27, 'CDK INHIBITORS', 'Fatigue , nausea , vomiting, constipation, diarrhea, dyspnea, arthralgia, anorexia , peripheral edema, pyrexia, hypotension, back pain, dysponea,  AST increased, neutropenia, leukopenia, hyperuricemia, asthenia, anemia, lymphopenia ,hypokalemia, hypomagnes', 'Fatigue, nausea, abdominal pain, neutropenia, leucopenia, vomiting, diarrhea, constipation, pyrexia, anorexia, back pain, headache, dysponea, cough, dyspepsia, hypophosphatemia, AST/ALT, neutropenia febril, infection, lymphopenia, neumonia and ataxia.', ''),
	(28, 'ANGIOPOIETIN INHIBITOR', NULL, NULL, NULL),
	(29, 'CTLA4 INHIBITORS', NULL, NULL, NULL),
	(30, 'HGF/SF INHIBITORS', NULL, NULL, NULL),
	(31, 'ChK1 InNHIBITOR', '', '', ''),
	(32, 'Wee1- INHIBITOR', NULL, NULL, NULL),
	(33, '', NULL, NULL, NULL),
	(34, 'PD-1 INHIBITOR', NULL, NULL, NULL),
	(35, 'CS1 INHIBITOR', NULL, NULL, NULL),
	(36, 'P38 MAP KINASE INHIBITOR', NULL, NULL, NULL),
	(37, 'EGFR INHIBITORS', NULL, NULL, NULL),
	(38, 'HB-EGF INHIBITOR', '', '', ''),
	(39, 'DR5 INHIBITOR ', '', '', ''),
	(40, 'PPRy INHIBITOR ', '', '', ''),
	(41, 'HER3 INHIBITOR', '', '', ''),
	(42, 'RAF INHIBITOR ', '', '', ''),
	(43, 'CD137 INHIBITOR', '', '', ''),
	(44, 'KIR INHIBITOR', '', '', ''),
	(45, 'JAK INHIBITOR', NULL, NULL, NULL),
	(46, '', NULL, NULL, NULL),
	(47, 'CXCR4 INHIBITOR', NULL, NULL, NULL),
	(48, 'ETBR INHIBITOR', NULL, NULL, NULL),
	(49, 'NaPi2b INHIBITOR', NULL, NULL, NULL),
	(50, 'PDL1 INHIBITOR', NULL, NULL, NULL),
	(51, 'ChK1 INHIBITOR', NULL, NULL, NULL),
	(52, 'ATM/ATR INHIBITORS', NULL, NULL, NULL),
	(53, 'HDAC INHIBITORS', '', '', 'HDAC inhibitors have been shown to cause cultured, transformed cells to undergo growth arrest, terminal differentiation, apoptosis, or autophagic cell death.1 These agents act selectively in altering the transcription of relatively few of the expressed gen'),
	(54, 'DNA-PK INHIBITORS', NULL, NULL, NULL),
	(55, 'APC INHIBITORS', NULL, NULL, NULL),
	(56, 'BCL2 INHIBITORS', NULL, NULL, NULL);
/*!40000 ALTER TABLE `categorias_dianas` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.categorias_diana_toxicidad
CREATE TABLE IF NOT EXISTS `categorias_diana_toxicidad` (
  `id_categoria_diana` smallint(4) unsigned NOT NULL DEFAULT '0',
  `id_toxicidad` smallint(4) unsigned NOT NULL DEFAULT '0',
  `tx1` tinyint(1) NOT NULL DEFAULT '0',
  `tx2` tinyint(1) NOT NULL DEFAULT '0',
  PRIMARY KEY (`id_categoria_diana`,`id_toxicidad`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.categorias_diana_toxicidad: 309 rows
/*!40000 ALTER TABLE `categorias_diana_toxicidad` DISABLE KEYS */;
INSERT INTO `categorias_diana_toxicidad` (`id_categoria_diana`, `id_toxicidad`, `tx1`, `tx2`) VALUES
	(1, 1, 1, 0),
	(1, 3, 1, 0),
	(1, 6, 1, 0),
	(1, 7, 1, 0),
	(1, 8, 1, 0),
	(1, 162, 0, 1),
	(1, 163, 0, 1),
	(1, 176, 0, 1),
	(1, 168, 0, 1),
	(1, 35, 1, 0),
	(1, 38, 1, 0),
	(1, 45, 1, 0),
	(1, 206, 1, 0),
	(1, 166, 1, 0),
	(1, 57, 1, 1),
	(1, 164, 1, 0),
	(1, 80, 1, 0),
	(1, 83, 1, 1),
	(1, 84, 0, 1),
	(1, 88, 1, 1),
	(1, 96, 1, 1),
	(1, 99, 1, 0),
	(8, 200, 1, 1),
	(1, 107, 1, 1),
	(1, 113, 1, 1),
	(1, 165, 1, 0),
	(1, 94, 1, 0),
	(1, 155, 0, 1),
	(2, 6, 1, 0),
	(2, 7, 1, 1),
	(2, 8, 1, 0),
	(2, 12, 0, 1),
	(2, 13, 1, 0),
	(2, 35, 1, 1),
	(2, 45, 1, 1),
	(16, 45, 1, 0),
	(2, 57, 1, 1),
	(2, 83, 1, 1),
	(16, 83, 1, 0),
	(2, 96, 1, 0),
	(2, 99, 1, 0),
	(2, 23, 1, 0),
	(2, 113, 1, 1),
	(16, 14, 1, 0),
	(3, 1, 1, 0),
	(3, 6, 0, 1),
	(22, 83, 1, 0),
	(3, 8, 1, 0),
	(3, 12, 0, 1),
	(3, 13, 1, 0),
	(3, 23, 1, 0),
	(3, 35, 1, 0),
	(3, 39, 1, 0),
	(3, 45, 1, 0),
	(3, 94, 1, 0),
	(3, 57, 1, 1),
	(22, 12, 1, 0),
	(3, 83, 1, 0),
	(22, 113, 1, 0),
	(3, 96, 1, 1),
	(3, 99, 1, 1),
	(22, 40, 0, 1),
	(22, 35, 1, 1),
	(3, 113, 1, 0),
	(3, 49, 0, 1),
	(4, 1, 0, 1),
	(4, 7, 1, 0),
	(4, 8, 1, 0),
	(4, 35, 1, 0),
	(4, 45, 1, 1),
	(11, 204, 0, 1),
	(4, 57, 1, 0),
	(4, 80, 0, 1),
	(4, 83, 1, 1),
	(4, 96, 1, 0),
	(4, 102, 1, 0),
	(4, 113, 1, 1),
	(4, 130, 0, 1),
	(11, 93, 0, 1),
	(13, 24, 1, 0),
	(13, 126, 1, 0),
	(5, 9, 1, 1),
	(5, 14, 1, 0),
	(13, 45, 1, 0),
	(5, 7, 1, 0),
	(13, 96, 1, 1),
	(5, 38, 1, 0),
	(5, 74, 1, 1),
	(5, 45, 1, 0),
	(5, 193, 1, 0),
	(5, 56, 0, 1),
	(5, 57, 1, 1),
	(5, 60, 1, 0),
	(5, 68, 1, 0),
	(5, 83, 1, 0),
	(5, 84, 1, 1),
	(5, 194, 0, 1),
	(5, 107, 1, 0),
	(5, 113, 1, 0),
	(5, 144, 1, 0),
	(6, 8, 1, 0),
	(16, 35, 1, 0),
	(6, 45, 1, 0),
	(6, 81, 1, 0),
	(6, 83, 1, 0),
	(6, 113, 1, 0),
	(6, 138, 1, 0),
	(6, 38, 1, 0),
	(7, 6, 1, 0),
	(7, 8, 1, 0),
	(7, 35, 1, 0),
	(7, 45, 1, 0),
	(7, 55, 1, 1),
	(22, 107, 1, 0),
	(7, 12, 1, 1),
	(7, 74, 1, 0),
	(7, 83, 1, 0),
	(7, 93, 1, 0),
	(7, 95, 1, 0),
	(7, 107, 0, 1),
	(7, 113, 1, 0),
	(7, 148, 1, 0),
	(8, 6, 1, 1),
	(8, 12, 1, 0),
	(8, 23, 1, 0),
	(8, 35, 1, 0),
	(8, 40, 1, 0),
	(8, 45, 1, 1),
	(8, 46, 1, 0),
	(8, 53, 1, 0),
	(8, 59, 1, 0),
	(8, 68, 0, 1),
	(8, 83, 1, 1),
	(8, 84, 1, 1),
	(8, 7, 1, 1),
	(8, 96, 1, 0),
	(8, 94, 1, 1),
	(8, 107, 0, 1),
	(8, 113, 1, 0),
	(9, 6, 1, 1),
	(9, 23, 1, 0),
	(9, 35, 1, 1),
	(9, 45, 1, 1),
	(9, 55, 1, 1),
	(9, 74, 1, 1),
	(9, 83, 0, 1),
	(9, 84, 1, 1),
	(23, 96, 1, 0),
	(9, 88, 1, 0),
	(9, 100, 1, 1),
	(9, 192, 1, 0),
	(9, 107, 1, 1),
	(9, 113, 1, 1),
	(11, 1, 1, 0),
	(11, 2, 1, 0),
	(11, 6, 1, 1),
	(11, 7, 1, 1),
	(11, 8, 1, 1),
	(11, 35, 1, 1),
	(11, 45, 1, 1),
	(11, 55, 1, 1),
	(11, 12, 0, 1),
	(11, 81, 1, 0),
	(11, 83, 1, 1),
	(11, 84, 0, 1),
	(11, 102, 1, 0),
	(11, 74, 0, 1),
	(11, 113, 1, 1),
	(11, 115, 1, 0),
	(11, 120, 0, 1),
	(11, 52, 1, 0),
	(12, 1, 1, 1),
	(12, 3, 1, 0),
	(12, 6, 1, 1),
	(12, 7, 1, 1),
	(12, 13, 1, 0),
	(12, 23, 1, 0),
	(12, 28, 1, 1),
	(12, 35, 1, 1),
	(12, 40, 1, 0),
	(12, 45, 1, 1),
	(12, 12, 1, 1),
	(12, 74, 1, 1),
	(12, 80, 1, 0),
	(12, 83, 1, 1),
	(12, 84, 1, 1),
	(12, 96, 1, 1),
	(12, 99, 1, 0),
	(12, 113, 1, 1),
	(13, 13, 1, 0),
	(13, 23, 1, 1),
	(13, 35, 1, 1),
	(13, 83, 1, 0),
	(13, 113, 1, 1),
	(14, 3, 1, 0),
	(14, 6, 1, 0),
	(14, 35, 1, 0),
	(14, 40, 1, 0),
	(14, 45, 1, 0),
	(14, 74, 1, 0),
	(14, 83, 1, 0),
	(14, 84, 1, 0),
	(14, 113, 1, 0),
	(22, 189, 1, 0),
	(22, 1, 1, 0),
	(23, 94, 1, 0),
	(23, 45, 1, 0),
	(23, 9, 1, 0),
	(23, 137, 1, 0),
	(23, 126, 1, 0),
	(23, 3, 1, 0),
	(16, 12, 1, 0),
	(16, 138, 1, 0),
	(16, 23, 1, 0),
	(16, 40, 1, 0),
	(16, 137, 1, 0),
	(16, 6, 1, 0),
	(16, 107, 1, 0),
	(16, 113, 1, 0),
	(16, 7, 1, 0),
	(16, 1, 1, 0),
	(16, 52, 1, 0),
	(16, 96, 1, 0),
	(16, 201, 1, 0),
	(13, 7, 1, 0),
	(13, 1, 1, 1),
	(13, 94, 1, 0),
	(13, 40, 1, 1),
	(13, 33, 1, 1),
	(13, 41, 1, 0),
	(13, 6, 0, 1),
	(13, 59, 0, 1),
	(13, 155, 0, 1),
	(13, 80, 0, 1),
	(13, 196, 0, 1),
	(7, 186, 1, 0),
	(7, 52, 1, 0),
	(7, 185, 1, 0),
	(7, 202, 0, 1),
	(11, 205, 1, 0),
	(11, 13, 1, 1),
	(11, 36, 1, 0),
	(11, 96, 1, 1),
	(11, 126, 1, 0),
	(11, 19, 1, 0),
	(11, 168, 0, 1),
	(11, 49, 0, 1),
	(17, 45, 1, 1),
	(17, 40, 1, 1),
	(17, 35, 1, 0),
	(17, 83, 1, 0),
	(17, 24, 1, 0),
	(17, 58, 1, 0),
	(17, 95, 1, 0),
	(17, 52, 1, 0),
	(17, 41, 1, 0),
	(17, 23, 1, 0),
	(17, 89, 1, 0),
	(17, 107, 1, 0),
	(17, 96, 1, 0),
	(18, 84, 1, 1),
	(18, 83, 1, 1),
	(18, 74, 1, 1),
	(18, 7, 1, 0),
	(18, 45, 1, 1),
	(18, 3, 1, 0),
	(18, 113, 1, 1),
	(18, 36, 1, 0),
	(18, 6, 1, 1),
	(18, 107, 0, 1),
	(18, 168, 1, 0),
	(18, 155, 0, 1),
	(8, 130, 1, 0),
	(8, 52, 1, 0),
	(8, 93, 1, 0),
	(8, 168, 1, 0),
	(8, 207, 1, 0),
	(27, 45, 1, 1),
	(27, 83, 1, 1),
	(27, 113, 1, 1),
	(27, 23, 1, 1),
	(27, 40, 1, 0),
	(27, 9, 1, 0),
	(27, 7, 1, 1),
	(27, 95, 1, 1),
	(27, 60, 1, 0),
	(27, 14, 1, 1),
	(27, 132, 1, 1),
	(27, 12, 1, 1),
	(27, 35, 1, 1),
	(27, 41, 1, 0),
	(27, 84, 1, 1),
	(27, 74, 1, 1),
	(27, 13, 1, 1),
	(27, 168, 1, 1),
	(27, 99, 1, 0),
	(27, 24, 1, 1),
	(27, 6, 1, 0),
	(27, 52, 0, 1),
	(27, 149, 1, 0),
	(27, 59, 1, 0),
	(27, 154, 1, 0),
	(27, 1, 0, 1),
	(27, 153, 0, 1),
	(27, 85, 0, 1),
	(27, 39, 0, 1),
	(27, 68, 0, 1),
	(27, 92, 0, 1),
	(27, 204, 1, 1);
/*!40000 ALTER TABLE `categorias_diana_toxicidad` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.categorias_link
CREATE TABLE IF NOT EXISTS `categorias_link` (
  `tipo_link` tinyint(3) unsigned NOT NULL DEFAULT '0',
  `link_ffda` tinyint(1) unsigned zerofill DEFAULT '0',
  `link_finv` tinyint(1) unsigned zerofill DEFAULT '0',
  `descripcion_tipo_link` varchar(50) COLLATE utf8_unicode_ci DEFAULT NULL,
  PRIMARY KEY (`tipo_link`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.categorias_link: 7 rows
/*!40000 ALTER TABLE `categorias_link` DISABLE KEYS */;
INSERT INTO `categorias_link` (`tipo_link`, `link_ffda`, `link_finv`, `descripcion_tipo_link`) VALUES
	(0, 1, 1, 'OTHER LINKS'),
	(1, 1, 0, 'FDA full prescription information'),
	(2, 1, 1, 'Chemical structure '),
	(3, 1, 1, 'Clinical data investigational agent abstract'),
	(4, 0, 1, 'Asociated link abstract'),
	(5, 1, 1, 'Drug sensibility '),
	(6, 1, 0, 'Link to drugbank database');
/*!40000 ALTER TABLE `categorias_link` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.categorias_mutaciones
CREATE TABLE IF NOT EXISTS `categorias_mutaciones` (
  `id_tipo_mutacion` tinyint(3) unsigned NOT NULL,
  `descripcion_tipo_mutacion` varchar(25) DEFAULT NULL,
  PRIMARY KEY (`id_tipo_mutacion`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

-- Volcando datos para la tabla farmacos.categorias_mutaciones: 5 rows
/*!40000 ALTER TABLE `categorias_mutaciones` DISABLE KEYS */;
INSERT INTO `categorias_mutaciones` (`id_tipo_mutacion`, `descripcion_tipo_mutacion`) VALUES
	(0, ' '),
	(1, 'Driver'),
	(2, 'Passangers'),
	(3, 'Predisposition'),
	(4, 'Driver/Predisposicion');
/*!40000 ALTER TABLE `categorias_mutaciones` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.categorias_toxicidad
CREATE TABLE IF NOT EXISTS `categorias_toxicidad` (
  `id_categoria` tinyint(3) DEFAULT NULL,
  `descripcion_categoria` varchar(50) COLLATE utf8_unicode_ci DEFAULT NULL
) ENGINE=MyISAM DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.categorias_toxicidad: 5 rows
/*!40000 ALTER TABLE `categorias_toxicidad` DISABLE KEYS */;
INSERT INTO `categorias_toxicidad` (`id_categoria`, `descripcion_categoria`) VALUES
	(0, 'Grade All'),
	(1, 'Grade1'),
	(2, 'Grade 2'),
	(3, 'Grade 3'),
	(4, 'Grade 3-4');
/*!40000 ALTER TABLE `categorias_toxicidad` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.dianas
CREATE TABLE IF NOT EXISTS `dianas` (
  `id_diana` int(10) NOT NULL AUTO_INCREMENT,
  `descripcion_diana` varchar(50) COLLATE utf8_unicode_ci DEFAULT NULL,
  `id_diana_n0` smallint(5) NOT NULL DEFAULT '1',
  PRIMARY KEY (`id_diana`)
) ENGINE=MyISAM AUTO_INCREMENT=104 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.dianas: 103 rows
/*!40000 ALTER TABLE `dianas` DISABLE KEYS */;
INSERT INTO `dianas` (`id_diana`, `descripcion_diana`, `id_diana_n0`) VALUES
	(1, 'Abl', 2),
	(2, 'Akt', 3),
	(3, 'AKT S473', 3),
	(4, 'AKT T308 ', 3),
	(5, 'Akt1', 3),
	(6, 'Akt2', 3),
	(7, 'Akt3', 3),
	(8, 'APPL', 1),
	(9, 'Aurora A ', 4),
	(10, 'Aurora B', 4),
	(11, 'Aurora C', 4),
	(12, 'A&#946;38', 1),
	(13, 'A&#946;40', 1),
	(14, 'A&#946;42', 1),
	(15, 'Bcr-Abl', 2),
	(16, 'Btk', 1),
	(17, 'c-Alb', 2),
	(18, 'CDK1/Cyclin B', 8),
	(19, 'CDK2/Cyclin A', 8),
	(20, 'CDK3/Cyclin E', 8),
	(21, 'C-KIT', 2),
	(22, 'c-Kit (D816V)', 2),
	(23, 'c-Kit (WT)', 2),
	(24, 'C-MET', 5),
	(25, 'c-Raf', 2),
	(26, 'C-RET', 5),
	(27, 'CSF-1R', 5),
	(28, 'c-Src', 2),
	(29, 'EGFR', 5),
	(30, 'EGFR L858R/T790M', 5),
	(31, 'EGFRL858R', 5),
	(32, 'EGFRwt', 5),
	(33, 'ErbB2', 5),
	(34, 'ErbB3', 5),
	(35, 'FGFR', 5),
	(36, 'FGFR1', 5),
	(37, 'FGFR2', 5),
	(38, 'FGFR3', 5),
	(39, 'Flk-1', 1),
	(40, 'Flt-1', 5),
	(41, 'FLT3', 5),
	(42, 'Flt-3', 5),
	(43, 'Flt3D835Y', 5),
	(44, 'Flt-4', 5),
	(45, 'Hep 3B', 1),
	(46, 'Hep G2', 1),
	(47, 'HER2', 5),
	(48, 'HuH7', 1),
	(49, 'JACK 3', 2),
	(50, 'JACK2', 2),
	(51, 'KDR', 1),
	(52, 'KIT', 2),
	(53, 'm TOR', 3),
	(54, 'm TOR1', 3),
	(55, 'm TOR2', 3),
	(56, 'MEK', 2),
	(57, 'MEK1', 2),
	(58, 'MEK2', 2),
	(59, 'MEK5', 2),
	(60, 'MER', 1),
	(61, 'MET', 5),
	(62, 'Notch', 6),
	(63, 'PI3K', 3),
	(64, 'p110&#945;', 3),
	(65, 'p110&#945; (wild type)', 3),
	(66, 'p110&#945; (mutant)', 3),
	(67, 'p110&#946;', 3),
	(68, 'p110&#947;', 3),
	(69, 'p110&#963;', 3),
	(70, 'p38&#945;', 2),
	(71, 'PDGFR', 5),
	(72, 'PDGFR-&#945;', 5),
	(73, 'PDGF?V561D', 5),
	(74, 'PDGFR&#945; (D842V)', 5),
	(75, 'PDGFR&#945;(purified)', 5),
	(76, 'PDGFR-&#946;', 5),
	(77, 'PDGFR&#946; (purified)', 5),
	(78, 'PI3K', 3),
	(79, 'PLC/PRF/5', 2),
	(80, 'PLK1', 4),
	(81, 'RET', 2),
	(82, 'RON', 2),
	(83, 'SMO', 6),
	(84, 'Smo (mouse)', 6),
	(85, 'Smo (human)', 6),
	(86, 'Src', 2),
	(87, 'S-src', 2),
	(88, 'TbAUK1', 1),
	(89, 'TIE2', 5),
	(90, 'v-Abl', 2),
	(91, 'VEGFR', 7),
	(92, 'VEGFR1', 7),
	(93, 'VEGRF-2', 7),
	(94, 'VEGFR3', 7),
	(95, 'Akt', 3),
	(96, 'PARP1', 9),
	(97, 'PARP2', 9),
	(98, 'PARP', 9),
	(99, 'CDK4/Cyclin D1', 8),
	(100, 'CDK6/Cyclin D3', 8),
	(101, 'CDK5/P35', 8),
	(102, 'HER1', 5),
	(103, 'CDK7', 8);
/*!40000 ALTER TABLE `dianas` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.dianas_n0
CREATE TABLE IF NOT EXISTS `dianas_n0` (
  `id_diana_n0` smallint(5) unsigned NOT NULL AUTO_INCREMENT,
  `descripcion_diana_n0` varchar(100) COLLATE utf8_unicode_ci NOT NULL,
  PRIMARY KEY (`id_diana_n0`)
) ENGINE=MyISAM AUTO_INCREMENT=10 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.dianas_n0: 9 rows
/*!40000 ALTER TABLE `dianas_n0` DISABLE KEYS */;
INSERT INTO `dianas_n0` (`id_diana_n0`, `descripcion_diana_n0`) VALUES
	(1, 'other'),
	(2, 'Intracellular Signalling'),
	(3, 'PI3K-mTOR'),
	(4, 'Cell division'),
	(5, 'Membrane protein kinases'),
	(6, 'Differentiation'),
	(7, 'Angiogenesis'),
	(8, 'Cell cycle'),
	(9, 'DNA repair');
/*!40000 ALTER TABLE `dianas_n0` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.farmacos
CREATE TABLE IF NOT EXISTS `farmacos` (
  `id_farmaco` mediumint(9) unsigned NOT NULL AUTO_INCREMENT,
  `nombre_farmaco` varchar(100) COLLATE utf8_unicode_ci DEFAULT NULL,
  `observaciones_farmaco` varchar(256) COLLATE utf8_unicode_ci DEFAULT NULL,
  `clasificacion_toxicidad_farmaco` varchar(256) COLLATE utf8_unicode_ci DEFAULT NULL,
  `tipo_farmaco` tinyint(1) unsigned NOT NULL DEFAULT '1',
  `farmaco_principal` mediumint(9) unsigned DEFAULT '0',
  PRIMARY KEY (`id_farmaco`),
  KEY `id_farmaco` (`id_farmaco`)
) ENGINE=MyISAM AUTO_INCREMENT=62 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.farmacos: 57 rows
/*!40000 ALTER TABLE `farmacos` DISABLE KEYS */;
INSERT INTO `farmacos` (`id_farmaco`, `nombre_farmaco`, `observaciones_farmaco`, `clasificacion_toxicidad_farmaco`, `tipo_farmaco`, `farmaco_principal`) VALUES
	(1, 'XELODA 1250MG/M2(Capecitabine)+ DOCETAXEL75MG/M2 3 WEEKS', 'BREAST CANCER', 'NCI CTCAE version 2.0 ', 3, 2),
	(2, 'XELODA (Capecitabine)', 'COLON CANCER', '', 2, 0),
	(3, 'GEMCITABINE (GEMZAR)', 'PANCREATIC CANCER', '', 1, 0),
	(4, 'TOPOTECAN', 'SMALL CELL LUNG CANCER', '', 1, 0),
	(5, 'OXALIPLATINO (for injection)', 'COLON CANCER', 'NCI CTC scale, Version 2 ', 2, 0),
	(6, 'OXALIPLATINO + IRINOTECAN', 'COLON CANCER', '', 3, 5),
	(7, 'OXALIPLATINO + 5FU/LV', 'COLON CANCER', '', 3, 5),
	(8, 'IRINOTECAN (CAMPTOSAR)', 'COLON CANCER', 'NATIONAL CANCER INSTITUTE COMMON TOXICITY CRITERIA (V 1.0)', 1, 0),
	(9, 'VINORELBINE TARTRATE (for injection)', 'NON SMALL CELL LUNG CANCER (NSCLC)', '', 2, 0),
	(10, 'VINORELBINE 25MG/M2 + CISPLATIN 100 MG/M2', 'NON SMALL CELL LUNG CANCER (NSCLC)        4 PATIENTS DIED FOR GRANULOCITOPENIA SEPSIS', '', 3, 9),
	(11, 'CARBOPLATIN (PARAPLATIN)', 'OVARIAN CANCER\r\n', '', 1, 0),
	(12, 'ETOPOSIDO (TOPOSAR)', 'SMALL CELL LUNG CANCER', '', 1, 0),
	(13, 'PEMETREXED (ALIMTA)', 'NON SMALL CELL LUNG CANCER (NSCLC)', '', 1, 0),
	(14, 'TAXOTERE (DOCETAXEL) 60 MG', 'BREAST CANCER                                        ', 'NCIC-CTC Adverse Reactions in Breast Cancer Patients Previously Treated with Chemotherapy Treated at TAXOTERE 60 mg/m2', 2, 0),
	(15, 'TAXOTERE (DOCETAXEL) 100 MG', 'BREAST CANCER   \r\n\r\nSEPTIC DEATH 2 PATIENT', 'NCIC-CTC Adverse Reactions in Breast Cancer Patients Previously Treated with Chemotherapy Treated at TAXOTERE 100 mg/m2', 3, 14),
	(16, 'TAXOL (PACLITAXEL) 175 MG 3 WEEKS', 'OVARIAN CANCER', '', 1, 0),
	(17, 'DOXORRUBICIN (ADRIAMICIN) for injection', 'BREAST CANCER', '', 1, 0),
	(18, 'DOXORUBICIN (DOXIL)', 'OVARIAN CANCER', '', 1, 0),
	(19, 'CYCLOPHOSPHAMIDE', 'BREAST CANCER', '', 1, 0),
	(20, 'CISPLATIN (PLATINOL) + CHEMOTERAPEUTICS AGENTS', '', '', 1, 0),
	(21, 'ERIBULIN (HALAVEN)', 'BREAST CANCER', '', 1, 0),
	(24, 'CABEZITAXEL (JEVTANA)', 'PROSTATE CANCER', '', 1, 0),
	(25, 'AVASTIN(BEVACIZUMAB) + IFL', 'COLON CANCER', '', 3, 26),
	(26, 'AVASTIN(BEVACIZUMAB) + 5-FL/UV', 'COLON CANCER', '', 2, 0),
	(27, 'HERCEPTIN (TRASTUZUMAB)', 'BREAST CANCER', '', 1, 0),
	(28, 'Lapatinib (Tykerb) + CAPECITABINE ', 'BREAST CANCER', '', 3, 29),
	(29, 'Lapatinib (Tykerb) +LETROZOLE', 'BREAST CANCER', '', 2, 0),
	(30, 'ERLOTINIB (TARCEVA) > o igual a 3%', 'NON SMALL CELL LUNG CANCER (NSCLC)', '', 3, 31),
	(31, 'ERLOTINIB (TARCEVA) 3%-10%', 'NON SMALL CELL LUNG CANCER (NSCLC)', '', 2, 0),
	(32, 'ERLOTINIB (TARCEVA) + gemcitabine', 'TOXICIDADES CON PLACEBO + GEMCITABINE MUY IGUALES', '', 3, 31),
	(33, 'GEFITINIB (IRESSA)', 'NON SMALL CELL LUNG CANCER (NSCLC)\r\n', '', 1, 0),
	(34, 'SORAFENIB (NEXAVAR)>10%     HCC', 'HEPATOCELULAR CARCINOMA                        TOXICIDAD MAYOR EN PLACEBO', 'CTCAE V.3', 3, 35),
	(35, 'SORAFENIB (NEXAVAR)>10%  RCC', 'RENAL CELL CARCINOMA', '', 2, 0),
	(36, 'EVEROLIMUS (AFINITOR)', 'PANCREATIC CANCER\r\n', 'NATIONAL CANCER INSTITUTE COMMON TOXICITY CRITERIA (V 1.0)', 1, 0),
	(37, 'PAZOPANIB(VOTRIENT)', 'RENAL CELL CARCINOMA', '', 1, 0),
	(38, 'SUNITINIB MALATE( SUTENT)', 'GASTROINTESTINAL STROMAL CANCER', '', 1, 0),
	(39, 'TEMSIROLIMUS (TORISEL)', 'RENAL CELL CARCINOMA', '', 1, 0),
	(40, 'VEMURAFENIB (ZELBORAF)', 'METASTASIC MELANOMA\r\n', '', 1, 0),
	(41, 'CABOZANTINIB (COMETRIQ)', 'MEDULARY THYROIDES', '', 1, 0),
	(42, 'CRIZOTINIB (XALKORI)', 'NON SMALL CELL LUNG CANCER (NSCLC)', '', 1, 0),
	(43, 'YONDELIS (Trabectedin)', 'OVARIAN CANCER', '', 1, 0),
	(44, 'MEKINIST(trametinib)', '', '', 1, 0),
	(45, 'TAFINLAR (Dabrafenib)', '', '', 1, 0),
	(46, 'STIVARGA (Regorafenib)', 'COLON CANCER', '', 1, 0),
	(47, 'CAPRELSA(Vandetanib)', 'THYROID CANCER', '', 1, 0),
	(48, 'VECTIBIX (panitumumab)', 'METASTASIC COLORRECTAL CANCER', '', 1, 0),
	(49, 'BORTEZOMIB (VELCADE)', 'Multiple Myeloma', '', 3, 0),
	(51, 'ELLENCE (EPIRUBICIN)', '', '', 1, 0),
	(52, 'GILOTRIF (AFATINIB)', 'NON SMALL CELL LUNG CANCER (NSCLC)', '', 1, 0),
	(53, 'YERVOY (ipilinumab)', '', '', 1, 0),
	(54, 'ERBITUX (cetuximab)', '', '', 2, 0),
	(55, 'ERBITUX (cetuximab) + irinotecan', '', '', 3, 0),
	(56, 'ERBITUX (cetuximab) + irinotecan', '', '', 3, 54),
	(57, 'SPRYCEL (dasatinib)', '', '', 1, 0),
	(58, 'GLEEVEC (IMATINIB)', '', '', 1, 0),
	(59, 'XTANDI (enzalutamide)', '', '', 1, 0),
	(60, 'PERJETA (PERTUZUMAB) +TRASTUZUMAB+DOCETAXEL', '', '', 1, 0);
/*!40000 ALTER TABLE `farmacos` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.farmacos_indicaciones
CREATE TABLE IF NOT EXISTS `farmacos_indicaciones` (
  `id_farmaco` mediumint(9) NOT NULL DEFAULT '0',
  `id_indicacion` smallint(4) NOT NULL DEFAULT '0',
  `testado` tinyint(1) DEFAULT '0',
  `observaciones_indicacion` text COLLATE utf8_unicode_ci,
  PRIMARY KEY (`id_farmaco`,`id_indicacion`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.farmacos_indicaciones: 88 rows
/*!40000 ALTER TABLE `farmacos_indicaciones` DISABLE KEYS */;
INSERT INTO `farmacos_indicaciones` (`id_farmaco`, `id_indicacion`, `testado`, `observaciones_indicacion`) VALUES
	(1, 2, 1, ''),
	(2, 1, 1, ''),
	(2, 13, 0, ''),
	(3, 2, 0, ''),
	(3, 9, 1, ''),
	(3, 11, 0, ''),
	(34, 19, 0, NULL),
	(4, 8, 0, ''),
	(4, 10, 1, ''),
	(5, 1, 1, ''),
	(5, 13, 0, ''),
	(6, 1, 0, ''),
	(7, 1, 0, ''),
	(8, 1, 1, ''),
	(8, 13, 0, ''),
	(9, 10, 0, ''),
	(9, 11, 1, ''),
	(10, 11, 1, ''),
	(11, 10, 0, ''),
	(18, 5, 1, NULL),
	(12, 7, 0, ''),
	(12, 10, 1, ''),
	(13, 11, 1, ''),
	(14, 2, 1, ''),
	(14, 11, 0, ''),
	(14, 14, 0, ''),
	(14, 15, 0, ''),
	(14, 16, 0, ''),
	(15, 2, 1, ''),
	(15, 11, 0, ''),
	(15, 14, 0, ''),
	(15, 15, 0, ''),
	(15, 16, 0, ''),
	(24, 15, 1, NULL),
	(17, 2, 1, ''),
	(17, 5, 0, ''),
	(17, 6, 0, ''),
	(17, 14, 0, ''),
	(17, 24, 0, ''),
	(16, 5, 1, NULL),
	(18, 17, 0, ''),
	(19, 2, 0, ''),
	(19, 5, 0, ''),
	(20, 5, 0, ''),
	(20, 6, 0, ''),
	(20, 7, 0, ''),
	(21, 2, 1, ''),
	(48, 13, 1, NULL),
	(25, 1, 1, ''),
	(25, 11, 0, ''),
	(25, 13, 0, ''),
	(25, 18, 0, ''),
	(25, 19, 0, ''),
	(26, 1, 1, ''),
	(27, 2, 1, ''),
	(27, 14, 0, ''),
	(28, 2, 1, ''),
	(29, 2, 1, ''),
	(30, 11, 1, ''),
	(31, 9, 0, ''),
	(31, 11, 1, ''),
	(32, 11, 1, ''),
	(33, 11, 1, ''),
	(34, 21, 1, ''),
	(35, 19, 1, NULL),
	(35, 21, 0, ''),
	(38, 19, 0, NULL),
	(36, 2, 0, ''),
	(36, 9, 1, ''),
	(37, 19, 1, NULL),
	(36, 19, 1, NULL),
	(38, 9, 0, ''),
	(39, 19, 1, NULL),
	(38, 23, 1, ''),
	(11, 5, 1, NULL),
	(40, 4, 1, ''),
	(41, 24, 1, ''),
	(42, 11, 1, ''),
	(49, 17, 1, NULL),
	(51, 2, 1, NULL),
	(53, 28, 1, NULL),
	(54, 1, 1, NULL),
	(55, 1, 1, NULL),
	(57, 29, 1, NULL),
	(58, 29, 1, NULL),
	(59, 15, 1, NULL),
	(60, 30, 1, NULL),
	(45, 28, 1, NULL);
/*!40000 ALTER TABLE `farmacos_indicaciones` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.farmacos_inv
CREATE TABLE IF NOT EXISTS `farmacos_inv` (
  `id_farmaco` mediumint(9) unsigned NOT NULL AUTO_INCREMENT,
  `cod_farmaco` varchar(10) COLLATE utf8_unicode_ci DEFAULT NULL,
  `nombre_farmaco` varchar(256) COLLATE utf8_unicode_ci DEFAULT NULL,
  `autores` varchar(256) COLLATE utf8_unicode_ci DEFAULT NULL,
  `categoria_diana` smallint(4) NOT NULL,
  `lk1` varchar(256) COLLATE utf8_unicode_ci DEFAULT NULL,
  `lk2` varchar(256) COLLATE utf8_unicode_ci DEFAULT NULL,
  `tx1desc` varchar(256) COLLATE utf8_unicode_ci DEFAULT NULL,
  `tx2desc` varchar(256) COLLATE utf8_unicode_ci DEFAULT NULL,
  `comentarios` varchar(256) COLLATE utf8_unicode_ci DEFAULT NULL,
  `lk3` varchar(256) COLLATE utf8_unicode_ci DEFAULT NULL,
  `tipo_ensayo` varchar(50) COLLATE utf8_unicode_ci DEFAULT NULL,
  `celular_process` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  PRIMARY KEY (`id_farmaco`),
  KEY `id_farmaco` (`id_farmaco`)
) ENGINE=MyISAM AUTO_INCREMENT=428 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.farmacos_inv: 392 rows
/*!40000 ALTER TABLE `farmacos_inv` DISABLE KEYS */;
INSERT INTO `farmacos_inv` (`id_farmaco`, `cod_farmaco`, `nombre_farmaco`, `autores`, `categoria_diana`, `lk1`, `lk2`, `tx1desc`, `tx2desc`, `comentarios`, `lk3`, `tipo_ensayo`, `celular_process`) VALUES
	(1, '', 'Pictilisib (GDC-0941)   PI3K', 'Links D. D. Von Hoff ASCO 2011', 2, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=80533                                                http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=81458', NULL, 'Nausea, diarrhea, vomiting, fatigue, decreased appetite, dysgeusia, and rash ', '', '', 'http://www.ncbi.nlm.nih.gov/pubmed/21876152?dopt=Abstract   http://www.ncbi.nlm.nih.gov/pubmed/22773810?dopt=Abstract      http://www.ncbi.nlm.nih.gov/pubmed/21317224?dopt=Abstract', 'Phase I trial', 'Cell survival'),
	(2, 'A2', 'CH5132799  PI3K', 'Aurelius Gabriel Omlin, ASCO 2012', 2, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95044', NULL, 'Diarrhea, nausea, fatigue, anorexia and anemia. (IN HEPATOCELLULAR CARCINOMA)', 'Grade 3 elevated LFT (pt with HCC)', 'CH5132799 is a novel PI3K inhibitor, selectively inhibiting class I PI3Ks (&#945;, &#946;, &#948; and &#947;) with no inhibition of class II and III or mTOR, and with potent antitumor activity in preclinical studies', NULL, 'phase I trial', 'Cell survival'),
	(3, '', 'BKM120  (NVP-BKM120, Buparlisib)  PI3K ', ' Bendell JC,, J Clinic Oncol 2012', 2, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83854 ', NULL, ' Rash, hyperglycemia, diarrhea, anorexia, and mood alteration (37% each); nausea (31%); fatigue (26%); pruritus (23%); and mucositis (23%).', 'Dose-limiting toxicities were grade 2 mood alteration (80 mg), grade 3 epigastralgia, grade 3 rash, grade 2 and grade 3 mood alteration (100 mg), and two grade 4 hyperglycemia (150 mg). ', 'BKM120, a potent and highly specific oral pan-Class I PI3K inhibitor.', 'http://www.ncbi.nlm.nih.gov/pubmed/22340590?dopt=Abstract', 'phase I trial', 'Cell survival'),
	(5, 'A4', 'PX-866   PI3K', 'Hong DS, Clin Cancer Res 2012', 2, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=42490', NULL, 'Nausea, vomiting, diarrhea and fatigue', '', ' PX-866 is a potent, pan-isoform inhibitor of PI3K with IC50s of 39 ± 21, 88 ± 27, 124 ± 26 nmol/L and 183 ± 25 against PI3K&#945;, PI3K&#946;, PI3K&#948;, and PI3K&#947;, respectively.', NULL, 'PHASE I', 'Cell survival'),
	(6, 'A5', 'SF1126   PI3K ', 'E. G. Chiorean ASCO 2009', 2, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34927', NULL, 'SF1126 is well tolerated with SD as the best response in patients with advanced malignancies.', 'No other grade 3/4 drug related toxicities have been reported. No consistent effects on blood glucose levels noted', ' SF1126 is composed of the pan PI3K inhibitor LY294002 conjugated to an RGD targeting peptide. It is designed to increased solubility and binding to integrins expressed on tumor vasculature', NULL, 'PHASE I', 'Cell survival'),
	(7, '', 'XL765 (SAR245409)   PI3K', 'I. Brana, ASCO 2010', 2, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=48412', NULL, 'Nausea, diarrhea, anorexia, elevated liver enzymes, skin disorders, and vomiting', '', 'XL765 is a potent and selective inhibitor of class I PI3K isoforms, TORC1, and TORC2. XL765 has shown dose-dependent target modulation and tumor growth inhibition or shrinkage in multiple human xenografts. ', NULL, 'PHASE I', 'Cell survival'),
	(8, '', 'XL147 (SAR245408)   PI3K ', 'Shapiro ASCO 2009  Edelman ASCO 2010', 2, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=34767', NULL, 'Skin rash,  transaminase elevation hiperglycemia', 'Arterial thrombosis', ' XL147 is a selective inhibitor of class I PI3K isoforms. In preclinical cancer models, XL147 is cytostatic or cytoreductive as monotherapy and enhances the efficacy of targeted agents and chemotherapeutics', 'http://www.ncbi.nlm.nih.gov/pubmed/22576015?dopt=Abstract', 'phase I trial', 'Cell survival'),
	(10, 'A8', 'PF-05212384 (PKI-587)  PI3K', 'Millham, AACR 2011', 2, 'No link', NULL, 'Mucositis (44%), nausea (42%), fatigue (28%), rash (28%), hyperglycemia (26%)', 'DLTs included mucositis, rash, tranaminase elevation, hpyerglycemia', ' PF-05212384 is a dual-specificity inhibitor of PI3K and mTOR that is formulated for intravenous (IV) administration. PF-05213384 is the first IV PI3K/mTOR inhibitor to be tested in a clinical trial.', NULL, 'phase I trial', 'Cell survival'),
	(11, 'A10', 'BYL719  PI3K ', 'Ana M. Gonzalez-Angulo, ASCO 2013', 2, 'No link', NULL, 'Hyperglycemia (49%), nausea (45%), diarrhea (40%), decreased appetite (38%), vomiting (30%), and fatigue (27%). ', '', 'BYL719 is an oral small-molecule inhibitor of the p110&#945; catalytic subunit of phosphatidylinositol 3-kinase (PI3K), which is encoded by the PIK3CA gene, one of the most commonly mutated genes in human cancers.', NULL, 'phase I trial', 'Cell survival'),
	(90, NULL, 'BI 2536', 'Mross K,J Clinic Oncol 2008', 18, NULL, NULL, 'Neutropenia, nausea ,leucopenia, anorexia, fatigue,alopecia, vomiting and dizzines. ', 'Neutropenia and leucopenia', 'BI 2536 is a novel, potent, and highly specific inhibitor of polo-like kinase 1 (Plk1), which has an essential role in the regulation of mitotic progression', NULL, 'PHASE I', ''),
	(12, 'A13', 'BAY80-6946 PI3K ', 'Patnaik, ASCO 2011', 2, 'https://meetinglibrary.asco.org/content/82099-102', NULL, 'Fatigue (3/30), Dysgeusia (4/30), Nausea/vomiting (3/30), hyperglycemia (9/30)  Gr 1/2 fatigue, nausea, vomiting, alopecia, diarrhea, mucositis and dysgeusia and Gr 2/3 anemia. ', 'Thrombocytopenia (1), Increased amylase (1), Rash (2), pain (1), pneumonitis (2), Hyperglycemia (5)', 'BAY 80-6946 is a potent and highly selective reversible pan-Class I PI3K inhibitor with anti-tumor activity in a panel of preclinical models', NULL, 'phase I trial', 'Cell survival'),
	(13, '', 'CAL-101 (GS-1101)  PI3K ', 'Phase I in combination', 2, 'http://www.asco.org/portal/site/ascov2/gsasearch?src=abstracts&return_page=menuitem.a1c60e38cd6d5b9f01ae0094ef37a01d&return_channel=874911ff7fefd110VgnVCM100000ed730ad1RCRD&q=noQstring&search_mode=adv&the_meeting_ids=126%2C127%2C125%2C114%2C116%2C115%2C111', NULL, '', '', 'CAL-101, a selective inhibitor of PI3K&#948;, displays clinical activity in CLL, causing rapid lymph node shrinkage and a transient lymphocytosis.', ' http://www.ncbi.nlm.nih.gov/pubmed/22927247?dopt=Abstract          http://www.ncbi.nlm.nih.gov/pubmed/22079609?dopt=Abstract     http://www.selleckchem.com/search.html?searchDTO.searchParam=+%28GS-1101%29', 'PHASE I', ''),
	(14, 'A19', 'Rigosertib   PI3K ', 'Daniel W. Bowles ASCO 2012', 2, 'https://meetinglibrary.asco.org/content/98060-114', NULL, 'Anemia, thrombocytopenia, fatigue. Grade 2/3 toxicities related to rigosertib included dysuria (5/1), cystitis (4/0), urinary frequency (3/0), hematuria (2/1), abdominal pain (2/0), pelvic pain (1/1) and nausea (1/0)', 'Neutropenia, lymphopenia, thrombocytopenia, death, hyponatremia, nausea, vomiting', ' Rigosertib (ON 01910.Na) is a new multi-targeted inhibitor of several kinases, including polo-like kinase 1 and PI-3 kinase, and is in advanced trials for myelodysplastic syndrome and pancreatic cancer as an IV agent. ', 'http://www.ncbi.nlm.nih.gov/pubmed/23404835?dopt=Abstract', 'phase I trial', 'Cell survival'),
	(15, 'B1', 'NVP-BGT226           DUAL PI3K/mTOR    ', 'Markman B, Ann Oncol 2012', 2, 'http://www.ncbi.nlm.nih.gov/pubmed/22357447', NULL, 'Nausea (68%), diarrhea (61%), vomiting (49%), and fatigue (19%)', 'Nausea/vomiting, diarrhea', '', NULL, 'phase I trial', 'Cell survival'),
	(16, 'B2', 'PF-04691502', 'NO LINK', 26, 'No link', NULL, 'Dual PI3K/mTOR Inhibitors', 'NO LINK', '', NULL, '', 'Cell survival'),
	(18, 'B4', 'GSK2126458(GSK458)   mTOR', 'P. N. Munste ASCO 2011', 2, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82568', NULL, 'Rash 22%, fatigue 15%, nausea 15%, diarrheas 12%', 'Fatigue, nausea , diarrhea', 'GSK458 is an oral, potent inhibitor of PI3K (&#945;, &#946;, &#947;, &#948;), mTORC1, and mTORC2.', NULL, 'PHASE I', 'Cell survival'),
	(19, 'B6', 'BEZ235   DUAL PI3K/mTOR', 'Burris ASCO 2010 ', 2, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=53432', 'http://www.cancerrxgene.org/translation/Drug/1057', 'Nausea, vomiting, diarrheas, fatigue/asthenia, anemia and anorexia', 'no G3-5 events reported', 'BEZ235 is a potent and highly selective reversible PI3K pathway inhibitor with antiproliferative and apoptotic activity in cancer cells.', 'http://www.ncbi.nlm.nih.gov/pubmed/21821710?dopt=Abstract     http://www.ncbi.nlm.nih.gov/pubmed/21803746?dopt=Abstract    http://www.ncbi.nlm.nih.gov/pubmed/21803746?dopt=Abstract', 'Cell survival', 'Phase I trial and Ib in combination with Everolimus'),
	(20, 'B8', 'GDC-0980  (RG7422)   DUAL PI3K/mTOR', 'A. J. Wagner,, ASCO 2011', 2, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=50963', NULL, 'Fatigue, diarrhea, decreased appetite, nausea, rash, mucositis, hyperglycemia, vomiting, and constipation', 'Rash and symptomatic Gr 3 hyperglycemia', 'GDC-0980 is a potent, selective, oral inhibitor of class I PI3K and mTOR kinase.\r\nGDC-0980 demonstrates broad activity in xenograft cancer models (breast, ovarian, lung, and prostate).', NULL, 'Phase I', 'Cell survival'),
	(21, 'C1', 'MK-2206 ', 'Yap TA, J Clinical Oncol.2011', 3, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=34855', 'http://www.cancerrxgene.org/translation/Drug/1053', ' Skin rash (51.5%), nausea (36.4%), pruritus (24.2%), hyperglycemia (21.2%), and diarrhea (21.2%).', '', 'MK-2206 is a potent, oral allosteric inhibitor of all AKT isoforms with antitumor activity in preclinical models. ', 'http://www.ncbi.nlm.nih.gov/pubmed/21841310?dopt=Abstract   http://www.ncbi.nlm.nih.gov/pubmed/21803746?dopt=Abstract    http://www.ncbi.nlm.nih.gov/pubmed/22180495?dopt=Abstract', 'Phase I trial', 'Cell survival'),
	(22, 'C2', 'GSK2110183', 'NO LINK', 26, 'No link', NULL, 'AKT INHIBITOR', 'NO LINK', 'NO LINK', NULL, '', 'Cell survival'),
	(23, 'C4', 'GDC-0068', 'Tabernero, ASCO 2011', 3, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82750', NULL, 'Hyperglycemia, asthenia, nausea, decreased appetite', 'No DLTs were observed', 'GDC-0068 is a highly selective ATP-competitive small molecule that inhibits all three isoforms of Akt  \r\nMTD not reached...', NULL, 'phase I trial', 'Cell survival'),
	(24, '', 'GSK2141795 (GSK975)', 'H. A. Burris, ASCO 2011', 3, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=80659', NULL, 'Diarrhea (47%), nausea (33%), fatigue (26%), vomiting (18%), decreased appetite (15%), dyspepsia (15%), hyperglycemia (15%), and rash (15%)\r\n\r\nIn combination  were nausea (26%; G3/4 0%), AST elevation (22%; G3/4 9%), fatigue (22%; G3/4 0%), rash (22%; G3/4', 'Hyperglycemia (11%) and rash (3%)', 'GSK795 is a potent pan-isoform inhibitor of AKT. ', NULL, 'Phase I trial', 'Cell survival'),
	(25, 'C7', 'Perifosine', 'Unger C, Eur J Cancer. 2010 ', 3, 'http://www.ncbi.nlm.nih.gov/pubmed/?term=Unger+perifosine+2010', NULL, 'Nausea 69%, diarrhea 56%, vomiting 53%, abdomainal pain 14%, sweating increased 11%, fatigue 11%', '', 'Perifosine (also KRX-0401) is a drug candidate being developed for a variety of cancer indications.', NULL, 'Phase I trial', 'Cell survival'),
	(26, 'C8', 'LY2780301 ', 'Calvo E ASCO 2012', 3, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=99941', NULL, 'Constipation (7pts, 22 %), fatigue (5pts, 15 %), nausea (4pts, 12 %), diarrhea (3pts, 9 %), and vomiting (3pts, 9 %)', 'Anemia (3pts 9 %), increased ALT/AST (1pt 3%), and increased GGT (1pt 3%). ', 'LY2780301is an oral potent, highly selective ATP competitive inhibitor against p70S6 kinase and AKT.', NULL, 'Phase I Trial', 'Cell survival'),
	(27, '', 'AZD2014    mTOR', 'Banerji U ASCO 2012', 2, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=94229', NULL, 'Fatigue, stomatitis, decreased appetite, nausea and diarrhea', 'SAEs (nausea, vomiting, lethargy, abdominal pain, mucositis\r\n\r\nDLTs were seen at both 100 mg (Gr 2 and 3 lethargy/fatigue, n=4/4) and 70 mg (Gr 3 mucositis, Gr 2 lethargy, n=2/4);', 'AZD2014 is a potent, dual mTORC1/mTORC2 inhibitor with clear activity in in vivo and in vitro experimental models', NULL, 'PHASE I', 'Cell survival'),
	(28, '', 'CC-223   mTOR', 'Andrea Varga, ASCO 2013', 2, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98214', NULL, 'Fatigue, rash, stomatitis, hyperglycemia, anorexia, nausea, vomiting and diarrhea', '', 'CC-223 is an ATP-competitive inhibitor of the mTOR kinase, including both TORC1 and TORC2. CC-223 was selected to address resistance of rapamycin analogues mediated by TORC2 activation. ', NULL, 'phase I trial', 'Cell survival'),
	(29, '2', 'MK-0646 (Dalotuzumab)', 'Atzori F, Clinical Cancer Res 2011 3 abstracts and 1 article ', 5, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34730', NULL, 'Asthenia, hyperglycemia, back pain, and aspartate aminotransferase elevation', 'Hyperglicemia and asthenia.', '1-Extensive-stage small cell lung cancer (ES SCLC)WITH CISPLATINE AND ETOPOSIDE\r\n2- Gastrointestinal Cancers Symposium\r\n3- D.J.Wadkins ASCO 2009 with cetuximab and irinotecam', NULL, 'Phase II', 'Cell survival'),
	(30, '4', 'R1507', 'Kurzrock R, Clinical Cancer Res 2010', 5, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=31929', NULL, 'The only drug-related AEs reported in more than one patient were fatigue (8%) and anorexia (5%).', 'Only two grade &#8805;3 drug-related AEs were noted: hyperbilirubinemia grade 3 (in a patient with extensive hepatic metastases) and cerebral ischemia grade 4.', 'R1507  is a fully human IgG1 type monoclonal antibody directed against the human insulin-like growth factor-I receptor.', NULL, 'Phase I', 'Cell survival'),
	(31, '6', 'AMG 479( Ganitumab)', 'Murakami H, Cancer Chemother Pharmacol. 2012', 5, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=34042', NULL, 'fatigue, infusion-related reaction and neutropenia ( 42%), leukopenia (37 %), thrombocytopenia (32 %), vomiting (26 %), AST increased and nausea (21 %) ', 'Neutropenia (21 %), leukopenia (16 %) and lymphopenia (11 %)', '', NULL, 'Phase I trial', 'Cell survival'),
	(32, '8', 'XL228', ' DC Smith ASCO 2010', 5, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=53431', NULL, 'Hyperglycemia, neutropenia, nausea, dysgeusia, hypotension, and fatigue.   Serious events: hypotension, bradycardia.', 'Neutropenia and hyperglycemia.\r\n\r\nSerious events Grade 4 AV block  during or post infusion have occurred in 5 pts.', 'XL228 is a multitargeted protein kinase inhibitor targeting IGF1R, the AURORA kinases, FGFR1-3, ABL, ALK, and SRC family kinases.', NULL, 'Phase !', 'Cell survival'),
	(33, '', 'LDE225 (NVP-LDE225,Erismodegib)', ' HA Tawbi ASCO 2011', 6, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=80034', NULL, 'Nausea, vomiting, dysgeusia, decreased appetite, myalgia, muscle spasms and fatigue', '', 'LDE225 is a potent and selective inhibitor of Smo, a key regulatory protein in the Hedgehog (Hh) signaling pathway, which is linked to the pathogenesis of many human cancers', NULL, 'Phase I', 'Cell survival'),
	(34, '', 'AMG 208', 'David S. Hong, 2013 Genitourinary Cancers Symposium', 7, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=134&abstractID=106477', NULL, ' Fatigue (n=24), nausea (n=18), hypertension (n=12), and diarrhea (n=11)', 'Increased AST (200 mg), a G3 thrombocytopenia (200 mg), a G4 acute myocardial infarction (300 mg), a G3 prolonged QT (300 mg), and two G3 hypertensions (400 mg)', ' Genitourinary Cancers Symposium 2013', NULL, 'Phase I trial', 'Cell survival'),
	(35, '', 'Golvatinib (E7050)', 'Toshihiko Doi, ASCO 2012', 7, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=95142', NULL, 'proteinuria [50.0% (8/16)], ALT increased [43.8% (7/16)], AST increased, nausea, vomiting [37.5% (6/16)], and blood alkaline phosphatase increased, decreased appetite, diarrhea, leukopenia [31.3% (5/16)], which were all mild to moderate in severity with ? ', '', ' Golvatinib is a highly potent, small molecule ATP-competitive inhibitor of the c-Met receptor tyrosine kinase and multiple members of the Eph receptor family as well as c-Kit and Ron, based on isolated kinase assays', NULL, 'Phase I trial', 'Cell survival'),
	(36, '', 'Foretinib (GSK1363089)', 'Thomas Cheung Yau, ASCO 2012', 7, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=98320', NULL, ' Hypertension (36%), decreased appetite (23%), and pyrexia (21%)', '', 'Foretinib is an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR', 'http://www.ncbi.nlm.nih.gov/pubmed/21697284?dopt=Abstract      ', 'Phase Ib', 'Cell survival'),
	(37, '', 'MK 2461', 'MET INHIBITOR', 26, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=36302', NULL, 'PDGFR INHIBITORS', '', '', NULL, '', 'Cell survival'),
	(38, '', 'MGCD265', '  MA Drouin ASCO 2010', 7, 'http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=50255', NULL, ' Grade 2 adverse events considered at least possibly related to the treatment included: hypertension, anemia, nausea and diarrhea', '', ' MGCD265 is a multikinase inhibitor, with nanomolar IC50 against Met, VEGFR 1, 2, and 3, Tie-2, and Ron', NULL, 'Phase I trial', ''),
	(39, '', 'Dasatinib (BMS-354825)', 'Demetri GD, Clin Cancer Res 2009', 8, 'https://meetinglibrary.asco.org/content/99141-114', 'http://www.cancerrxgene.org/translation/Drug/51', ' Nausea, anorexia, fatigue, diarrhea, lethargy, vomiting, headache, proteinuria, rash, pruritus anemia dyspnea, constipation, AST, ALT increased, calcium decreased, magnesium increased.', 'Nausea, fatigue,pruritus, anorexia, anemia and magnesium increased.', 'Dasatinib (D) is a first in class Src kinase inhibitor, and inhibits BCR-Abl, c-Kit, PDGFR-beta, EPHA2 and Src family kinases including Src, Lck, Yes, Fyn at nanomolar concentrations. ', 'http://www.ncbi.nlm.nih.gov/pubmed/21423276?dopt=Abstract   http://www.ncbi.nlm.nih.gov/pubmed/21106726?dopt=Abstract   http://www.ncbi.nlm.nih.gov/pubmed/21177802?dopt=Abstract', 'Phase I', ''),
	(40, '', 'IBRUTINIB (PCI-32765)', 'John C. Byrd ASCO 2012', 8, 'https://meetinglibrary.asco.org/content/99350-114', '', 'Diarrhea, nausea, and fatigue.', 'Infections or cytopenias', 'PCI-32765 (P) an oral, selective, irreversible inhibitor of BTK inhibits CLL cell proliferation, migration and adhesion.', 'http://www.ncbi.nlm.nih.gov/pubmed/22927247?dopt=Abstract', 'Phase IB/II', 'Cell survival'),
	(41, '', 'Bosutinib (SKI-606)', 'Daud AI, Clin Cancer Res 2012', 8, 'https://meetinglibrary.asco.org/content/52917-74', 'http://www.cancerrxgene.org/translation/Drug/1019', 'Nausea (60% patients), diarrhea (47%), vomiting (40%), fatigue (38%), and anorexia (36%).', '', 'Bosutinib, a potent ATP-competitive, quinolinecarbonitrile Src/Abl kinase inhibitor, was tested in this first-in-human phase I trial in patients with advanced solid tumor malignancies.', 'http://www.ncbi.nlm.nih.gov/pubmed/20709760?dopt=Abstract    http://www.ncbi.nlm.nih.gov/pubmed/20068039?dopt=Abstract   http://www.ncbi.nlm.nih.gov/pubmed/21177802?dopt=Abstract', 'Phase I', 'Cell survival'),
	(42, '', 'KX2-391', 'A. A. Adjei ASCO 2009', 8, 'https://meetinglibrary.asco.org/content/35459-65', '', 'Elevated ALT/AST, neutropenia,fatigue, hypokalemia, anemia,dyspnea, fever, vomiting, constipation, hematuria, and lymphopenia.', 'No grade 3 or 4 adverse events.', '', '', 'Phase I', 'Cell survival'),
	(44, '', 'VX-680 (MK-0457, Tozasertib)', 'Traynor AM, Cancer Chemother Pharmacol. 2011', 9, 'https://meetinglibrary.asco.org/content/32568-65', 'http://www.cancerrxgene.org/translation/Search', 'Nausea, vomiting, diarrhea and fatigue', 'grade 3 vomiting and grade 4 neutropenia; grade 3 anemia, nausea, diarrhea, intestinal obstruction, herpes zoster, abdominal wall abscess, fatigue, muscular weakness, and peripheral motor neuropathy.', 'MK-0457 is a pan-aurora kinase inhibitor with activity against wild-type and mutated BCR-ABL, including the T315I form, FLT3, and JAK-2.', 'http://www.ncbi.nlm.nih.gov/pubmed/21820309?dopt=Abstract    http://www.ncbi.nlm.nih.gov/pubmed/22306067?dopt=Abstract   http://www.ncbi.nlm.nih.gov/pubmed/23301855?dopt=Abstract', '', 'Cell survival'),
	(45, '', 'MLN8237 (Alisertib)', 'Dees EC,  Clin Cancer Res. 2012', 9, 'https://meetinglibrary.asco.org/content/95196-114', '', ' Fatigue, nausea, and neutropenia', '', 'MLN8237 is an investigational oral, selective AAK inhibitor being studied in both hematologic (phase III) and nonhematologic malignancies.', ' http://www.ncbi.nlm.nih.gov/pubmed/21072059?dopt=Abstract   http://www.ncbi.nlm.nih.gov/pubmed/23345402?dopt=Abstract    http://www.ncbi.nlm.nih.gov/pubmed/20426425?dopt=Abstract', 'Phase I', 'Cell survival'),
	(46, '', 'Barasertib (AZD1152)', 'Boss DS, Ann Oncol 2011', 9, 'https://meetinglibrary.asco.org/content/97805-114', '', '', '', 'AZD1152-hQPA is a highly potent and selective inhibitor of Aurora B compared with Aurora A [9]. Consistent with inhibition of Aurora B kinase, addition of AZD1152-hQPA to tumor cells in vitro inhibits cytokinesis, but allows endoreduplication, such that la', 'http://www.ncbi.nlm.nih.gov/pubmed/21820309?dopt=Abstract   http://www.ncbi.nlm.nih.gov/pubmed/20651058?dopt=Abstract   http://www.ncbi.nlm.nih.gov/pubmed/20959462?dopt=Abstract', 'Phase I', 'Cell survival'),
	(47, '', 'Danusertib (PHA-739358)', ' P. J. Rosen ASCO 2010', 9, 'https://meetinglibrary.asco.org/content/44260-74', '', 'Anemia, leucopenia, neutropenia, neutropenic fever,anorexia, diarrhea, nausea and fatigue.', 'Anemia, lymphocytopenia and thrombocytopenia ', 'Danusertib is a small molecule that inhibits a urora kinases, proteins regulating mitosis implicated in tumorigenesis and overexpressed in BC and OC', 'http://www.ncbi.nlm.nih.gov/pubmed/22100984?dopt=Abstract', 'Phase II', 'Cell survival'),
	(48, '', 'MLN8054', ' T. Macarulla, Mol Cancer Ther. 2010', 9, 'http://www.ncbi.nlm.nih.gov/pubmed/20724522', '', 'Somnolence, asthenia, insomnio and anorexia.', 'Somnolence', 'MLN8054, an oral, selective, small-molecule inhibitor of Aurora A kinase. \r\nSomnolence and transaminitis were DLTs. ', 'http://www.ncbi.nlm.nih.gov/pubmed/22227008?dopt=Abstract', 'Phase Itrial', 'Cell survival'),
	(49, '', 'AT9283', 'R. Kristeleit ASCO 2009', 9, 'https://meetinglibrary.asco.org/content/32863-65', '', 'Treatment was well tolerated with febrile neutropenia the only dose limiting toxicity. Other adverse events considered possibly related to AT9283 were reversible and included gastrointestinal disturbance and fatigue.', '', 'AT9283 is a multitargeted kinase inhibitor, inhibits several closely related tyrosine and serine/threonine kinases including Aurora A and B, JAK and ABL. ', 'http://www.ncbi.nlm.nih.gov/pubmed/23301855?dopt=Abstract', 'Phase I trial ', 'Cell survival'),
	(50, '', 'SNS-314', 'F. Robert ASCO 2009', 9, 'https://meetinglibrary.asco.org/content/34949-65', '', 'Nausea (31%), fatigue (28%), vomiting, constipation, and pain (16% each)', 'No Grade 3+ toxicities of &#8805; 15% incidence.', 'SNS-314 is a selective pan-AK inhibitor with low nanomolar IC50s', 'http://www.ncbi.nlm.nih.gov/pubmed/22197704?dopt=Abstract', 'Phase I trial', 'Cell survival'),
	(51, '', 'ENMD-2076', 'Diamond JR, Clin Cancer Res. 2011', 9, 'https://meetinglibrary.asco.org/content/34778-65', '', ' Hypertension, nausea/vomiting, and fatigue.', 'Hypertension and neutropenia.', 'ENMD-2076 is a unique orally bioavailable Aurora kinase and VEGFR inhibitor. ', '', 'PHASE I', 'Cell survival'),
	(52, '', 'AMG 900', 'Michael Anthony Carducci ASCO 2012', 9, 'https://meetinglibrary.asco.org/content/92852-114', '', 'Neutropenia, 8(42%); leukopenia, 4 (21%); anemia, 2 (11%); thrombocytopenia, 1 (5%)and FN, 1 (5%)', '4 DLTs: G4 neutropenia > 7 days at 24 mg (n=1) and 30 mg (n=1); G4 neutropenia > 7 days + G4 thrombocytopenia at 30 mg (n=1); and febrile neutropenia (FN) at 30 mg (n=1). ', 'AMG 900 is an investigational,highly selective inhibitor of aurora A, B, and C that demonstrated activity in drug-resistant cell lines and human tumor xenografts.', '', 'Phase I trial', 'Cell survival'),
	(53, '', 'MK-5108 (VX-689) with Docetaxel', 'S. E. Minton ASCO 2010', 9, 'https://meetinglibrary.asco.org/content/43466-74', '', '', '', 'MK-5108 is a novel small molecule with potent inhibitory activity against Aurora-A kinase. Although most of the Aurora-kinase inhibitors target both Aurora-A and Aurora-B, MK-5108 specifically inhibited Aurora-A kinase in a panel of protein kinase assays. ', '', 'PHASE I', 'Cell survival'),
	(54, '', 'Semagacestat (LY450139)', 'NOT DATA FOUND', 26, 'ONLY INHIBITORS', '', 'NOTCH INHIBITORS', '', '', 'http://www.ncbi.nlm.nih.gov/pubmed/22334705?dopt=Abstract', '', 'Cell survival'),
	(55, '', 'YO-01027', 'NOT DATA FOUND', 26, 'ONLY INHIBITORS', '', 'NOTCH INHIBITORS', '', '', '', '', 'Cell survival'),
	(56, '', 'Axitinib', 'Fujiwara Y, Invest New Drugs. 2012', 11, 'https://meetinglibrary.asco.org/content/32749-65', 'http://www.cancerrxgene.org/translation/Drug/1021', 'Fatigue (83%), anorexia (72%), diarrhea (67%), hand-foot syndrome (67%) and hypertension (61%).', 'Hypertension (33%) and fatigue (28%). No grade 3/4 fatigue occurred in patients who started thyroid hormone replacement therapy when TSH was elevated. ', 'Axitinib is an oral, potent and selective inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3.', 'http://www.ncbi.nlm.nih.gov/pubmed/22576211?dopt=Abstract   http://www.ncbi.nlm.nih.gov/pubmed/21297102?dopt=Abstract', 'PHASE I', 'Cell survival'),
	(57, '', 'Nintedanib (BIBF 1120)', 'Mross K, Clinical Cancer Res 2010', 11, 'http://www.ncbi.nlm.nih.gov/pubmed/23008829', '', 'Nausea (68.9%), vomiting (45.9%), and diarrhea (44.3%), fatigue and dizziness.', 'reversible liver enzyme elevations', '', ' http://www.ncbi.nlm.nih.gov/pubmed/21993628?dopt=Abstract   http://www.ncbi.nlm.nih.gov/pubmed/20300113?dopt=Abstract  http://www.ncbi.nlm.nih.gov/pubmed/21290212?dopt=Abstract', 'PHASE I', 'Cell survival'),
	(58, NULL, 'Ponatinib (AP24534)', 'M. Talpaz ASCO 2011', 11, 'https://meetinglibrary.asco.org/content/81698-102', 'http://www.cancerrxgene.org/translation/Search', 'Ponatinib was well tolerated', '', 'Hematological malignances', 'http://www.ncbi.nlm.nih.gov/pubmed/23287417?dopt=Abstract', 'PHASE I', 'Cell survival'),
	(59, '', 'Linifanib (ABT-869)', 'Asahina H,Cancer Chemother Pharmacol. 2012', 11, 'https://meetinglibrary.asco.org/content/40737-74', '', '', '', '', 'http://www.ncbi.nlm.nih.gov/pubmed/22133064?dopt=Abstract', 'PHASE I', 'Cell survival'),
	(61, '', 'Masitinib (AB1010)', 'Soria JC, Eur J Cancer 2009', 11, NULL, '', 'Nausea, diarrhea, vomiting, eye disorders, investigations, metabolism and nutrition disorders, musculoskeletal and connective tissue disorders, nervous system disorders, renal and urinary disorders and Skin and subcutaneous tissue disorders.', 'Anemia, lymphocitopenia  leucopenia, neutropenia, asthenia, diarrhea, cytolytic hepatitis, and skin rash ', '', '', 'PHASE I', 'Cell survival'),
	(62, '', 'Tivozanib (AV-951)', 'Eskens FA. Clin Cancer Res. 2011', 11, 'https://meetinglibrary.asco.org/content/72482-104', '', 'Hypertension, fatigue, diarrhea, nausea, rash, anorexia, stomatitis, dry skin, hedeache, vomiting and myalgia', 'Proteinuria, hypertension and  ataxia', 'Tivozanib (formerly AV-951, KRN-951) is a potent and selective VEGFR tyrosine kinase inhibitor (IC50 value of 0.21, 0.16, and 0.24 nmol/L for VEGFR-1, -2, and -3, respectively) and inhibits angiogenesis and vascular permeability in tumor tissues (3). ', '', 'PHASE I', ''),
	(63, '', 'Amuvatinib (MP-470)', 'Tibes R,Cancer Chemother Pharmacol. 2013', 11, 'Amuvatinib (MP-470)', '', 'MTDS: nausea, anxiety, somnolence, dyspnea, vomiting, and anorexia.', 'MTD: Anxiety', 'Amuvatinib is a novel orally administered tyrosine kinase inhibitor with in vitro pharmacological activity against mutant KIT, platelet-derived growth factor receptor alpha (PDGFR&#945;), and Rad51.', '', 'PHASE I', 'Cell survival'),
	(64, '', 'TSU-68 (SU6668)', 'Ueda Y, Cancer Chemother Pharmacol. 2011', 11, 'https://meetinglibrary.asco.org/content/105654-133', '', 'Diarrhea, fatigue, anorexia, abdominal pain, nausea, chest pain, vomiting, ALT ,ALP, AST and albumin decreased.', '', 'TSU-68 is a novel small molecule that competitively inhibits the tyrosine kinase of the receptors for VEGF, basic FGF, and PDGF', 'http://www.ncbi.nlm.nih.gov/pubmed/22644563?dopt=Abstract', 'PHASE I', 'Cell survival'),
	(65, '', 'Crenolanib (CP-868596)', 'Lewis NL, J Clinic Oncol 2009', 11, 'http://www.ncbi.nlm.nih.gov/pubmed/19738123', '', 'Nausea, vomiting, diarrhea,asthenia and AST increased.', 'Nausea, vomiting,anorexia,GGT increased, ALT increased.(<5%)', 'CP-868,596. an oral platelet-derived growth factor receptor inhibitor, ', '', 'PHASE I', 'Cell survival'),
	(66, '', 'Telatinib (BAY 57-9352)', 'Eskens FA,J Clin Oncol. 2009', 11, 'https://meetinglibrary.asco.org/content/49065-74', '', 'Nausea (26.4%) and hypertension (20.8%', 'Hypertension 11.3%', 'Telatinib (BAY 57-9352) is an orally available tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -2, VEGFR-3, platelet-derived growth factor receptor-beta, and c-Kit.', '', 'PHASE I', 'Cell survival'),
	(67, '', 'Dovitinib (ITC-258)', 'Angevin E Clinical Cancer Res 2013', 11, 'https://meetinglibrary.asco.org/content/93667-114', '', ' Nausea (75%), diarrhea (70%), vomiting (70%), and asthenia (50%), ', ' Grade 3 events 5% or less (except asthenia, 15%) and only one grade 4 event (hypertensive crisis).', ' Dovitinib is a tyrosine kinase inhibitor with demonstrated inhibitory activity against FGFRs, VEGFRs, and PDGFRs in vivo', 'http://www.ncbi.nlm.nih.gov/pubmed/21330321?dopt=Abstract   http://www.ncbi.nlm.nih.gov/pubmed/22238366?dopt=Abstract   http://www.ncbi.nlm.nih.gov/pubmed/21119661?dopt=Abstract', 'PHASE I', 'Cell survival'),
	(68, '', 'Afatinib (BIBW2992)', 'Yap TA, J Clin Oncol. 2010', 12, 'https://meetinglibrary.asco.org/content/83807-102', 'http://www.cancerrxgene.org/translation/Drug/1032', 'Vomiting, nausea, diarrhea, rash (36 [67.9%] patients), dry skin (8 [15.1%]), palmar-planter disorders (4 [7.5%]), and dermatitis acneiform (4 [7.5%]). Of the other drug-related AEs, 10 patients (18.9%) reported grade 1 to 2 mucosal inflammation and four (', '', 'BIBW2992, an anilino-quinazoline derivative, is a novel, highly selective, potent, and irreversible inhibitor of both EGFR and HER2 kinases.', 'http://www.ncbi.nlm.nih.gov/pubmed/22317763   http://www.ncbi.nlm.nih.gov/pubmed/22091388?dopt=Abstract  http://www.ncbi.nlm.nih.gov/pubmed/23229345?dopt=Abstract', 'Phase I', ''),
	(69, '', 'Neratinib (HKI-272)', 'Wong KK,  Clin Cancer Res. 2009', 12, 'https://meetinglibrary.asco.org/content/33575-65', '', 'Diarrhea, nausea, fatigue, vomiting, anorexia, rash, abdominal pain and increased aspartate aminotransferase levels.', 'Diarrhea, anorexia, AST/ALT and neutropenia.', '', 'http://www.ncbi.nlm.nih.gov/pubmed/23229345?dopt=Abstract', 'Phase I', ''),
	(70, '', 'AZD8931', 'U. Keilholz, ASCO 2011', 12, 'https://meetinglibrary.asco.org/content/78242-102', '', 'Skin and subcutaneous tissue disorders and GI disorders were the most common system organ class AEs. ', 'Diarrhea', 'AZD8931 is an oral, equipotent inhibitor of ErbB1, ErbB2 and ErbB3 receptor signaling', NULL, 'PHASE I', ''),
	(71, '', 'AZD6244 (Selumetinib)', 'Banerji U, Clinical cancer Research 2010', 13, 'https://meetinglibrary.asco.org/content/77652-102', 'http://www.cancerrxgene.org/translation/Drug/1062', 'Acneiform rash , fatigue , nausea, vomiting,  diarrhea, dry skin, cough, anorexia,constipation, abdominal pain, pruritus, dyspnea.\r\n', 'Anemia, abdominal pain, constipation, vomiting, dyspnea and rash', '', 'http://www.ncbi.nlm.nih.gov/pubmed/21107323?dopt=Abstract  http://www.ncbi.nlm.nih.gov/pubmed/21107320?dopt=Abstract  http://www.ncbi.nlm.nih.gov/pubmed/23250956?dopt=Abstract', 'Phase I', 'Cell survival'),
	(72, '', 'GSK1120212 (JTP-74057)', ' W. A. Messersmith Cancers of the Pancreas Small Bowel and Hepatobiliary Tract', 13, 'https://meetinglibrary.asco.org/content/71253-103', '', 'Rash and diarrhea\r\n', 'Rash and diarrhea', 'GSK1120212 is a reversible, highly selective allosteric inhibitor of MEK1/MEK2. ', 'http://www.ncbi.nlm.nih.gov/pubmed/22773810?dopt=Abstract', 'PHASE I', 'Cell survival'),
	(73, '', 'MEK-AS703026', 'J. Delord ASCO 2010', 13, 'https://meetinglibrary.asco.org/content/43866-74', '', 'Asthenia (49% R1, 50% R2), diarrhea (40% R1, 28% R2), acne-like skin reactions (37% R1, 41% R2), nausea (34% R1, 25% R2), constipation (26% R1, 16% R2), vomiting (23% R1, 25% R2)', '', ' AS703026 is a highly selective and potent noncompetitive inhibitor of MEK1/2. AS703026 exhibited strong antiproliferative activity in tumor cell lines with activated mitogen-activated protein kinase (MAPK) signalling, and antitumor efficacy in numerous hu', NULL, 'PHASE I', 'Cell survival'),
	(74, '', 'TAK-733', 'Alex A. Adje, ASCO 2013', 13, 'https://meetinglibrary.asco.org/content/80411-102', '', 'Acneiform dermatitis (47%)', ' Creatine phosphokinase increase and acneiform dermatitis (each n=3, 6%)', 'TAK-733 – an oral, selective, allosteric inhibitor of MEK1/2 – in pts with advanced solid tumors.\r\n \r\n4 pts had DLTs: grade 3 acneiform dermatitis, 1 each at 11.8 and 16mg; grade 3 pustular rash and grade 2 rash/stomatitis (qualifying as a DLT) at 22mg, le', NULL, 'PHASE I', 'Cell survival'),
	(79, '', 'OLAPARIB (AZD2281)', 'Yamamoto N, Cancer Sci. 2012 ', 14, NULL, NULL, 'Nausea (50%), blood creatinine increase (33%), hematocrit decrease (33%), leukopenia (33%) and lymphopenia (33%), hematocrit decreased(33%), anemia, (25%)anorexia, red blood cell count decreased(25%), hyperglicemia(25%),dysguesia(16,7%), pruritus (16,7%), ', 'ALT increased and anemia', '', NULL, '', 'Genome maintenance'),
	(80, '', 'ABT-888 (Veliparib) + TOPOTECAN', ' PHASE I ', 14, NULL, NULL, 'Neutropenia, thrombocitopenia and febrile neutropenia', '', 'NO PHASE I DRUG ALONE ', NULL, '', 'Genome maintenance'),
	(81, '', 'Iniparib (BSI-201)', 'NO PHASE I DRUG ALONE ', 14, NULL, NULL, '', ' \r\n', 'NO PHASE I DRUG ALONE ', NULL, '', 'Genome maintenance'),
	(82, '', 'INO-1001 + TEMOZOLOMIDE', 'Bedikian AY, Cancer Invest. 2009', 14, NULL, NULL, '', 'Thrombocytopenia, neutropenia and asthenia.', '', NULL, 'PHASE Ib', 'Genome maintenance'),
	(83, '', 'MK-4827', 'W. R. Schelman, ASCO 2011', 14, NULL, NULL, 'Fatigue, anorexia, nausea and myelosuppression. ', 'DLT was observed in 4p: grade (G) 3 fatigue in 1/6p at 30mg, reversible G3 pneumonitis in 1/6p at 60mg, and reversible G4 thrombocytopenia in 2/6p treated at 400mg. ', 'MK4827 is an orally active, PARP 1/2 inhibitor with nanomolar potency. It induces selective synthetic lethality in homologous recombination (HR) repair deficient tumors with BRCA1/2 loss and in tumor cell lines with non-BRCA-related HR defects, supporting ', NULL, '', 'Genome maintenance'),
	(416, NULL, 'AZD6482', 'PI3K INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(399, NULL, 'BMN 673', 'Johann Sebastian De Bono, ASCO 2013', 14, NULL, NULL, 'Fatigue , nausea , flatulence , anemia, neutropenia, thrombocytopenia and alopecia ', 'Anemia, neutropenia and thrombocitopenia.', 'BMN 673 is the most potent and specific inhibitor of PARP1/2 in clinical development (IC50<1nM).', NULL, 'PHASE I', ''),
	(84, NULL, '17-AAG (Tanespimycin)', 'Richardson PG,  Br J Haematol. 2010', 16, NULL, NULL, 'Diarrhea (59%), back pain (35%), fatigue (38%), and nausea (35%, AST increased (31%), muscle spams (28&) ALT increased (24%), constipation, dyspnea and pain in extremity ((21%),  haematological AEs included anaemia (24%) and thrombocytopenia (21%)..', '', 'In multiple myoma', NULL, 'Phase I ', ''),
	(85, NULL, 'Ganetespib (STA-9090)', 'K. Wong  ASCO 2011 &  D. C. Cho ASCO 2011', 16, NULL, NULL, 'Diarrhea, fatigue, nausea, anorexia, constipation, dyspnea, anemia, abdominal pain, headache, vomiting', '', ' Ganetespib is a potent, next-generation Hsp90 inhibitor that is structurally unrelated to the first-generation ansamycin class of Hsp90 inhibitors and has shown superior activity to these agents in preclinical studies.', NULL, 'PHASE I & PHASE II', ''),
	(86, NULL, '17-DMAG HCl (Alvespimycin)', ' Pacey S,  Clin Cancer Res. 2011', 16, NULL, NULL, 'Nausea, vomiting, fatigue and liver enzyme disturbances were low grade and reversible ', 'Gastrointestinal, liver function changes, and ocular.', 'Toxicidades asociadas a DLT', NULL, 'Phase I', ''),
	(87, NULL, 'AT13387', ' Daruka Mahadevan ASCO 2012', 16, NULL, NULL, ' Transient and reversible GI disturbance (vomiting, nausea, dry mouth, diarrhea, abdominal pain), fatigue, local infusion site irritation and systemic infusion-related symptoms including chills, rash, itch, cardiovascular (tachycardia, bradycardia, hyperte', '', 'Local infusion site irritation and systemic infusion', NULL, 'Phase I', ''),
	(88, NULL, 'Carfilzomib (PR-171)', 'OConnor OA, Clin Cancer Res 2009', 17, NULL, NULL, 'Fatigue, nausea, diarrhea, cough, dyspnea, Hypoesthesia, pyrexia, headache,edema, constipation and paresthesia.', 'Fatigue and dyspnea.', 'Carfilzomib (formerly PR-171) is a novel proteasome inhibitor of the epoxyketone class that is selective and structurally distinct from bortezomib.', NULL, 'Phase II', ''),
	(89, NULL, 'MLN9708 (ixazomib citrate)', 'David C. Smith asco 2012', 17, NULL, NULL, 'Fatigue (40%), thrombocytopenia (39%), rash (high level term) (33%), and nausea (32%). 52% of pts experienced \r\n', '', 'MLN9708 is a potent, reversible, orally bioavailable, and specific 20S proteasome inhibitor. This study (NCT00830869) assessed the safety, MTD, PK, PD, and antitumor activity of intravenous (IV) MLN9708 in pts with solid tumors. ', NULL, 'Phase I', ''),
	(91, NULL, 'BI6727 (Volasertib)', 'Schöffski P, Euro J Cancer 2012', 18, NULL, NULL, 'Anemia (all grades 22%; grade 3: 8%), neutropenia (15%; grade 3/4: 14%), fatigue (15%; grade 3: 2%), and thrombocytopenia (14%; grade 3/4: 14%)', 'Anemia, neutropenia, thrombocytopenia , fatigue \r\n', 'Volasertib (BI 6727) is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinase (Plk). ', NULL, ' PHASE I ', ''),
	(92, NULL, 'RIGOSERTIB', '', 18, NULL, NULL, 'REGISTER IN 1.Phosphoinositide-3 kinase (PI3K) inhibitors', '', '', NULL, '', ''),
	(93, NULL, 'Ponatinib (AP24534)', '', 19, NULL, NULL, 'REGISTER IN PDGFR INHIBITORS', '', '', NULL, '', ''),
	(94, NULL, 'BIBF1120 (Vargatef)', '', 19, NULL, NULL, 'REGISTER IN PDGFR INHIBITORS', '', '', NULL, '', ''),
	(95, NULL, 'Danusertib (PHA-739358)', '', 19, NULL, NULL, 'REGISTER IN AURORA KINASE INHIBITORS', '', '', NULL, '', ''),
	(96, NULL, 'Dovitinib (TKI-258)', '', 19, NULL, NULL, 'REGISTER IN PDGFR INHIBITORS', '', '', NULL, '', ''),
	(97, NULL, 'TSU-68 (SU6668)', '', 19, NULL, NULL, 'REGISTER IN PDGFR INHIBITORS', '', '', NULL, '', ''),
	(98, NULL, 'SORAFENIB', '', 20, NULL, NULL, 'REGISTER IN FDA APPROVED DRUGS', '', '', NULL, '', ''),
	(99, NULL, 'SUNITINIB', '', 20, NULL, NULL, 'REGISTER IN FDA APPROVED DRUGS', '', '', NULL, '', ''),
	(100, NULL, 'Ponatinib (AP24534)', '', 20, NULL, NULL, 'REGISTER IN FGFR INHIBITORS', '', '', NULL, '', ''),
	(101, NULL, 'Regorafenib (BAY 73-4506)', '', 20, NULL, NULL, 'REGISTER IN FDA APPROVED DRUGS', '', '', NULL, '', ''),
	(102, NULL, 'XL-184 free base (Cabozantinib)', '', 20, NULL, NULL, 'REGISTER IN FDA APPROVED DRUGS', '', '', NULL, '', ''),
	(103, NULL, 'BIBF1120 (Vargatef)', '', 20, NULL, NULL, 'REGISTER IN PDGFR INHIBITORS', '', '', NULL, '', ''),
	(104, NULL, 'Vandetanib (Zactima)', '', 20, NULL, NULL, 'REGISTER IN FDA APPROVED DRUGS', '', '', NULL, '', ''),
	(408, NULL, 'VS-5584 (SB2343) ', 'PI3K/Mtor INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(106, NULL, 'Axitinib', '', 20, NULL, NULL, 'REGISTER IN PDGFR INHIBITORS', '', '', NULL, '', ''),
	(107, NULL, 'Foretinib (GSK1363089, XL880)', '', 20, NULL, NULL, 'REGISTERED IN MET INHIBITORS', '', '', NULL, '', ''),
	(108, NULL, 'Dovitinib (TKI-258)', '', 20, NULL, NULL, 'REGISTER IN PDGFR INHIBITORS', '', '', NULL, '', ''),
	(109, NULL, 'Tivozanib (AV-951)', '', 20, NULL, NULL, 'REGISTER IN PDGFR INHIBITORS', '', '', NULL, '', ''),
	(110, NULL, 'TSU-68 (SU6668)', '', 20, NULL, NULL, 'REGISTER IN PDGFR INHIBITORS', '', '', NULL, '', ''),
	(111, NULL, 'Brivanib (BMS-540215)', '', 20, NULL, NULL, 'REGISTERED IN FGFR INHIBITORS', '', '', NULL, '', ''),
	(112, NULL, 'Linifanib (ABT-869)', '', 20, NULL, NULL, 'REGISTERED IN PDGFR INHIBITORS', '', '', NULL, '', ''),
	(113, NULL, 'Pazopanib', '', 20, NULL, NULL, 'REGISTER IN FDA APPROVED DRUGS', '', '', NULL, '', ''),
	(114, NULL, '1 ENMD-2076', '', 20, NULL, NULL, 'REGISTER IN AURORA KINASE INHIBITORS', '', '', NULL, '', ''),
	(115, NULL, 'Golvatinib (E7050)', '', 20, NULL, NULL, 'REGISTER IN MET INHIBITORS', '', '', NULL, '', ''),
	(116, NULL, 'Telatinib (BAY 57-9352)', '', 20, NULL, NULL, 'REGISTER IN PDGFR INHIBITORS', '', '', NULL, '', ''),
	(117, NULL, 'Cabozantinib malate ', '', 20, NULL, NULL, 'REGISTER IN FDA APPROVED DRUGS', '', '', NULL, '', ''),
	(119, NULL, 'INC280 (INCB28060)', 'R. C. Donehower, ASCO 2011', 7, NULL, NULL, 'Fatigue, nausea, diarrhea, indigestion, headache, and agitation', '', 'INCB028060 is a potent and selective inhibitor of c-MET receptor tyrosine kinase (RTK).', NULL, 'Phase I', ''),
	(120, NULL, 'LDK378', 'Ranee Mehra', 22, NULL, NULL, 'Nausea (45%), vomiting (36%), and diarrhea (29%)', 'Diarrhea and dyspnea.', 'LDK378 is a novel, potent and selective small molecule anaplastic lymphoma kinase (ALK) inhibitor (IC50 0.00015 &#956;M), that does not inhibit c-MET (IC50 3.2 &#956;M).', NULL, 'Phase I', ''),
	(121, NULL, 'LGX818', 'Reinhard Dummer', 23, NULL, NULL, 'Cutaneous (rash, dry skin, HFSR, pruritus, keratosis pilaris, alopecia), pain in extremity, arthralgia, and fatigue. ', '', 'LGX818, a potent and selective BRAF inhibitor (BRAFi) being investigated in BRAF V600 mutant melanoma, has unique biochemical properties with a dissociation half-time > 10 times longer than other BRAF inhibitors. \r\nSquamous cell carcinoma was observed in 2', NULL, 'Phase I', 'In patients with BRAF V600 mutant advanced or metastatic melanoma.'),
	(122, NULL, 'MEK162 (ARRY-162, ARRY-438162) ', 'Richard S, Gastrointestinal Cancer symposium 2012', 13, NULL, NULL, 'Rash, nausea, vomiting, diarrhea, peripheral edema, fatigue and central serous-like retinopathy,\r\n', 'Anasarca, hypokalemia, hyponatremia, upper/lower gastrointestinal hemorrhage and mucositis (1 each). ', 'MEK162 (ARRY-438162) is a potent, selective, ATP&#8209;uncompetitive inhibitor of MEK1/2. ', NULL, 'PHASE I', ''),
	(124, NULL, 'CVX 060 (PF-04856884)', '', 24, NULL, NULL, '', '', 'In combination with Axitinib', NULL, 'PHASE Ib', ''),
	(125, NULL, 'PF-03084014 GAMMA', 'W. A. Messersmith,', 10, NULL, NULL, 'Nausea (25%), diarrhea (19%), and decreased appetite (19%). ', 'The only grade &#8805;3 treatment-related AE was hypophosphatemia (80 mg, 1; 100 mg, 1)', 'novel gamma secretase inhibitor\r\n', NULL, ' PHASE I ', ''),
	(126, NULL, 'PF-03446962', 'Matteo Simonelli', 22, NULL, NULL, 'Thrombocytopenia, lipase increase, AST increase and abdominal pain.', 'There were 3 treatment-related serious', 'PF-03446962 is a first in class mAb', NULL, 'PHASE I', ''),
	(127, NULL, 'LEQ506  ', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(128, NULL, 'LCL161  ', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(129, NULL, 'BGJ398', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(130, NULL, 'LFA102                       ', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(131, NULL, 'LJM716               ', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(132, NULL, 'LCI699                    ', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(133, NULL, 'LGH447', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(134, NULL, 'LGH447', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(135, NULL, 'LCL161     ', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(136, NULL, 'LEE011 ', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(137, NULL, 'LJM716  ', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(138, NULL, 'VAY736                   ', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(139, NULL, 'BHQ880                ', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(140, NULL, 'PF-05212384    ', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(141, NULL, 'PD-0325901 ', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(142, NULL, 'PF-05082566 ', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(143, NULL, 'PF-04605412             ', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(144, NULL, 'PF-04449913', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(145, NULL, '2110183', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(146, NULL, '2636771', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(147, NULL, '525762', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(148, NULL, '2110183', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(149, NULL, '2110183', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(150, NULL, '2661380†', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(151, NULL, '052230†', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(152, NULL, 'RG7155', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(153, NULL, 'RG7167', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(154, NULL, 'RG3616 vismodegib', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(155, NULL, 'RG7204 vemurafenib', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(417, NULL, 'BGT226 (NVP-BGT226)', 'Markman B,Ann Oncol. 2012 ', 2, NULL, NULL, 'Nausea, diarrhea, vomiting, decreased appetite, fatigue, anemia, abdominal pain, ', 'Diarrhea and vomiting', 'BGT226 (Novartis Pharma AG, Basel, Switzerland), an imidazoquinoline derivative, is an orally bioavailable potent pan-class I PI3K and mammalian target of rapamycin (mTOR) catalytic inhibitor. BGT226 is among the first in a novel class of agents targeting ', NULL, 'PHASE I', ''),
	(156, NULL, 'SAR125844 ', 'MET INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(157, NULL, 'DINACICLIB (SCH 727965) ', 'M. M. Mita, ASCO 2011', 27, NULL, NULL, 'Nausea (47%), diarrhea (29%), AST increased (18%),neutropenia(12%), leukopenia (12%), hyperuricemia (12%)and fatigue(12%).', 'Neutropenia (12%), leukopenia (6%),AST increased (6%), hypophosphatemia (6%) and diarrhea (6%).', 'Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM, respectively. It also blocks thymidine (dThd) DNA incorporation. ', NULL, 'PHASE I', ''),
	(158, NULL, 'RIDAFOROLIMUS   (AP23573, or MK-8669) mTOR  ', 'Seki Y, Cancer Chemother Pharmacol. 2012', 2, NULL, NULL, 'Anemia, thrombocitopenia, neutropenia, leukopenia, stomatitis,hypertriglyceridemia, hypercholesterolemia, rash, anorexia, hyperglycemia, hypoalbulinemia, constipation, fatigue, loss weight and pneumonitis.', 'Anemia, neutropenia, leucopenia, stomatitis, rash, anorexia and hyperglicemia.', 'Ridaforolimus is a non-prodrug mTOR inhibitor. ', NULL, 'PHASE I', ''),
	(159, NULL, 'LY2835219', 'Geoffrey Shapiro, ASCO 2013', 27, NULL, NULL, 'Diarrhea (52%), nausea (30%), fatigue (21%), vomiting (18%) and neutropenia (16%)', 'Diarrhea 5%, nausea 4%, fatigue 7%, vomiting 2% and neutropenia 7%.', 'LY2835219 is a selective inhibitor of CDK4/6 that shows antitumor activity in preclinical models of human cancer and also distributes efficiently to the brain. We performed a phase 1 study to evaluate safety, pharmacokinetics, pharmacodynamics, and antitum', NULL, 'PHASE I', ''),
	(160, NULL, ' PD0332991 (PALBOCICLIB)', 'Flaherty KT,Clin Cancer Res 2012', 27, NULL, NULL, 'Fatigue , nausea , vomiting, constipation,  diarrhea, dyspnea, and arthralgia.', 'Fatigue, nausea, abdominal pain, neutropenia and leucopenia', 'PD 0332991 is a novel, orally administered inhibitor of both CDK4 and CDK6 kinase activity. PD 0332991 is highly selective for CDK4 and CDK6.', NULL, 'PHASE I', ''),
	(161, NULL, 'Roscovitina (Seliciclib, CYC202)', 'Le Tourneau C,Eur J Cancer. 2010', 27, NULL, NULL, 'Nausea, vomiting, asthenia, anorexia, bilirubin increase, GGT increase, AP increase, ALT/AST, hypokalemia and creatinine increase', 'Nausea, vomiting, asthenia,GGT increased, ALT/AST and hypokalemia.', 'Seliciclib (CYC202, R-roscovitine), an inhibitor of cyclin-dependent kinases 2, 7 and 9, causing cell cycle changes and apoptosis in cancer cells.', NULL, 'PHASE I', ''),
	(162, NULL, 'Flavopiridol(Alvocidib)', 'B. Ramaswamy, ASCO 2009', 27, NULL, NULL, '', 'Diarrhea, AST/ALT, neutropenia febril, infection, fatigue and nausea.', 'Flavopiridol (Alvocidib, NSC 649890) is a serine/threonine kinase inhibitor that broadly targets cyclin-dependent kinases (CDKs), including the CDK9/cyclin T complex (pTEF-b), preventing activation of RNA polymerase II.', NULL, 'PHASE I', ''),
	(163, NULL, 'AZD5438', 'Boss DS, Ann Oncol. 2010', 27, NULL, NULL, 'Nausea, diarrhea, vomiting, constipation, fatigue, anorexia, back pain and dysponea.', 'Nausea, vomiting, diarrhea, constipation, abdominal pain, fatigue, pyrexia, anorexia, back pain, headache, dysponea,cough and dysepsia.', 'AZD5438 is an orally bioavailable inhibitor of cyclin E-cdk2, cyclin A-cdk2 and cyclin B-cdk1 complexes.', NULL, 'PHASE I', ''),
	(164, NULL, 'AT7519', 'Mahadevan D, Ann Oncol. 2011', 27, NULL, NULL, 'Nausea (50.0%), fatigue (42.9%), vomiting and anorexia (39.3% each), constipation (32.1%) and peripheral edema, pyrexia and hypotension (25.0% each). ', '', 'AT7519 is an inhibitor of multiple cyclin-dependent kinases (CDKs).AT7519 is an inhibitor of CDK1, 2, 4, 5 and 9 with potent preclinical antitumor activity, a favorable tolerability profile and robust target inhibition.', NULL, 'PHASE I', ''),
	(165, NULL, 'BMS-265246', 'CDK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(166, NULL, 'JNJ-7706621', 'CDK INHIBITORS', 26, NULL, NULL, '', '', 'CDK INHIBITORS', NULL, '', ''),
	(167, NULL, 'MK-8776 (SCH 900776)', 'CDK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(168, NULL, 'SNS-032 (BMS-387032)', 'Tong WG, J Clinic Oncol 2010', 27, NULL, NULL, 'Nausea, diarrhea, vomiting, constipation, anorexia, pyrexia, fatigue,hypokalemia, hypomagnesemia, skin disorders and cough.', 'Neutropenia, abdominal pain, AST/ALT, neumonia, asthenia and fatigue.', 'SNS-032 is a highly selective and potent inhibitor of cyclin-dependent kinases (Cdks) 2, 7, and 9, with in vitro growth inhibitory effects and ability to induce apoptosis in malignant B cells.', NULL, 'PHASE I', 'in leukemia'),
	(170, NULL, 'PHA-793887', 'Massard C,Cell cycle 2011', 27, NULL, NULL, 'Nausea, vomiting, asthenia, anemia and lymphopenia', 'Vomiting, lymphopenia and AST/ALT. ', 'PHA-793887 is an inhibitor of multiple cyclin dependent kinases (CDK) with activity against CDK2, CDK1 and CDK4.', NULL, 'PHASE I', ''),
	(171, NULL, 'PHA-767491', '', 26, NULL, NULL, '', '', 'CDK INHIBITORS', NULL, '', ''),
	(172, NULL, 'R547', 'CDK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(173, NULL, 'PHA-848125', 'Weiss GJ, Invest New Drugs. 2012 ', 27, NULL, NULL, 'Nausea, diarrhea, vomiting, fatigue, ataxia, dehydration and dizziness.', 'Diarrhea and ataxia.', 'PHA-848125AC as a potent inhibitor of the kinase activity of TRKA (IC50=53 nM) supports the rationale for testing the agent in selected cancer types where the neurotrophin/TRK receptor axis plays a relevant role in terms of cancer cell survival and dissemi', NULL, 'PHASE I', ''),
	(174, NULL, 'NU6027', 'CDK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(175, NULL, 'P276-00', 'CDK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(176, NULL, 'BAHIA 1000394', 'CDK INHIBITORS', 26, NULL, NULL, '', '', ' is an orally bioavailable pan-CDK inhibitor for CDK1/2/3/4/7/9 with IC50 of 5-25 nM. It also potently inhibits Aurora A, Clk2, ARK5, FGFR1, Flt3, and JAK2/3. Phase 1/2.', NULL, '', ''),
	(179, NULL, 'TREMELIMUMAB (CP-675,206)', 'Camacho LH,J Clin Oncol 2009', 29, NULL, NULL, 'Diarrhea, rash, pruritus, fatigue and nausea.', 'Diarrhea, rash, pruritus, fatigue and nausea.', 'Tremelimumab (CP-675,206), a fully human anti-CTLA4 monoclonal antibody, was tolerated and demonstrated antitumor activity in a single dose', NULL, 'PHASE I', 'IN MELANOMA'),
	(178, NULL, 'MEDI3617', 'Ronald B. ASCO 2012', 28, NULL, NULL, 'Fatigue (24%), diarrhea (19%), nausea (19%), dysgeusia (14%), and headache (14%), all of which were &#8804; grade 2.', '', 'MEDI3617 is an investigational monoclonal antibody that inhibits angiogenesis by preventing the interaction of angiopoietin-1 and angiopoietin-2 (Ang2) ligands with the Tie2 receptor.', NULL, 'PHASE I', ''),
	(180, NULL, 'CEP-9722', ' CEP-9722 + Temozolomide', 14, NULL, NULL, 'Was well tolerated', '', 'CEP-9722, an orally available PARP1-2 inhibitor, demonstrated single-agent antitumor activity and synergy with temozolomide (TMZ) in xenograft models', NULL, 'PHASE I IN COMBINACION', 'PHASE I'),
	(181, NULL, 'AMG 110 ', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(182, NULL, 'AMG 172', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(183, NULL, 'AMG 208', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(184, NULL, 'AMG 232', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(185, NULL, 'AMG 337', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(186, NULL, 'AMG 780', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(187, NULL, 'AMG 820', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(188, NULL, 'AMG 900', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(189, NULL, 'Blinatumumab', '', 26, NULL, NULL, '', '', 'It is an anti-CD19 x anti-CD3 (BiTE®) bispecific antibody. It is being investigated as a cancer treatment.\r\n', NULL, '', ''),
	(190, NULL, 'Trebananib (AMG386)  ', 'Toshihiko Doi, Cancer Chemotherapy and Pharmacology 2013', 28, NULL, NULL, 'Edema, constipation, fatigue,pyrexia anorexia, diarrhea, GGT increased, hypertension,abdominal pain, ascites, nausea, rash and stomatitis', 'GGT increased.', 'Trebananib (AMG 386) is an investigational first-in-class angiopoietin antagonist peptide-Fc fusion protein. It reduces tumor angiogenesis by selectively inhibiting the interaction of Ang1 and Ang2 with the Tie2 receptor ', NULL, 'PHASE I', ''),
	(191, NULL, 'AMG102', 'Gordon MS, Clin Cancer Res 2010', 7, NULL, NULL, 'Fatigue (43%), nausea (40%), vomiting (33%), anorexia/decreased appetite (33%), peripheral edema (30%), and dyspnea (28%).', '', 'A fully human hepatocyte growth factor/scatter factor (HGF/SF)–neutralizing monoclonal antibody, in patients with solid tumors.', NULL, 'PHASE I', 'HGF/SF inhibitors'),
	(193, NULL, 'GDC-0425', 'Chk1 INHIBITORS', 26, NULL, NULL, '', '', 'Solid tumors or lymphoma', NULL, '', ''),
	(194, NULL, 'GDC-0575', 'Chk1 INHIBITORS', 26, NULL, NULL, '', '', 'Solid tumors or lymphoma', NULL, '', ''),
	(195, NULL, 'GDC-0973', ' GDC-0973 + GDC-0941 Patricia LoRusso, ASCO 2012', 13, NULL, NULL, 'Diarrhea, rash, nausea, fatigue, vomiting, decreased appetite, dysgeusia, and elevated CPK.', '', 'GENERALLY WELL TOLERATED', NULL, 'Phase Ib', ''),
	(196, NULL, 'GDC-0084', 'PI3K INHIBITORS ', 26, NULL, NULL, '', '', 'GLIOMA', NULL, '', ''),
	(197, NULL, 'GDC-0032', 'PI3K INHIBITORS ', 26, NULL, NULL, '', '', 'HER2-negative metastatic breast cancer\r\nSolid tumors and HR+ breast cancer\r\n', NULL, '', ''),
	(198, NULL, 'Parsatuzumab ', '(Anti-EGFL7 MAb)', 26, NULL, NULL, '', '', 'Metastatic colorectal cancer\r\nNon-small cell lung cancer\r\n', NULL, '', ''),
	(199, NULL, 'GDC-0623', 'MEK INHIBITOR', 26, NULL, NULL, '', '', 'Solid tumors\r\n', NULL, '', ''),
	(200, NULL, 'GDC-0994', '', 26, NULL, NULL, '', '', 'Solid tumors\r\n', NULL, '', ''),
	(201, NULL, 'MK-1775 + GEMCITABINE', 'Kreahling JM,PLoS One. 2013 SARCOMA', 32, NULL, NULL, '', '', 'Inhibition of Wee1 by MK1775 has been reported to enhance the cytotoxic effect of DNA damaging agents in different types of carcinomas.', NULL, 'PHASE I', 'MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine '),
	(427, NULL, 'Saracatinib (AZD0530)', 'Fujisaka Y,Invest New Drugs. 2013', 8, NULL, NULL, '', '', '', NULL, '', ''),
	(203, NULL, 'MK-7965', 'CDK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(205, NULL, 'MK-3475', 'Amita Patnaik, ASCO 2012', 34, NULL, NULL, 'Fatigue, nausea , diarrhea, dysgeusia , breast pain and pruritus. ', '', 'MK-3475 is a humanized monoclonal IgG4 antibody against PD-1. Preclinically, MK-3475 has shown antitumor activity in multiple tumor types', NULL, 'PHASE I', ''),
	(207, NULL, 'Nivolumab', 'Suzanne Louise Topalian, ASCO 2013', 34, NULL, NULL, 'Pneumonitis', 'Pneumonitis', 'Nivolumab, an antibody against the programmed death 1 [PD-1] receptor)', NULL, 'PHASE I', ''),
	(208, NULL, 'ELOTUZUMAB', 'Zonder JA, Blood 2012', 35, NULL, NULL, 'Chills (32.4), Pyrexia (17.6), flushing	(11.8), chest discomfort(8.8), fatigue	(8.8),Headache(8.8),Sinus tachycardia (8.8), Vomiting(8.8), Anorexia(5.9), Dyspnea(5.9)', '', 'Elotuzumab is a humanized monoclonal IgG1 antibody directed against human CS1 (also known as CD2 subset-1, SLAMF7, CRACC, and CD319)', NULL, 'PHASE I', ''),
	(209, NULL, 'LY2606368', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(210, NULL, ' LY2228820', 'Matthew P. Goetz ASCO 2012', 36, NULL, NULL, 'Fatigue, nausea, rash, constipation, vomiting and pruritus.', '', ' LY2228820 is a selective small-molecule inhibitor of p38 MAPK and preclinical studies demonstrate antitumor activity as a single agent and in combination with standard agents', NULL, 'PHASE I', ''),
	(211, NULL, 'LY2784544', 'JAK INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(212, NULL, 'LY2801653 ', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(213, NULL, 'Olaratumab (IMC-3G3)', 'PDGFR INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(214, NULL, 'Narnatumab (IMC-RON8)', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(215, NULL, ' LY3007113 ', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(216, NULL, 'LY3023414', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(217, NULL, 'Necitumumab (IMC-11F8) EGFR', 'Kuenen B,Clin Cancer Res 2010', 12, NULL, NULL, 'Headache,  nausea, vomiting, acne, dermatitis, anemia, diarrhea, dry skin, fatigue, pyrexia, pruritus and hypokalemia', 'Dry skin and fatigue', 'a fully human IgG1 monoclonal antibody directed at the epidermal growth factor receptor, and to characterize the safety profile, pharmacokinetics, preliminary antitumor activity, and immunogenicity of necitumumab.', NULL, 'PHASE I', ''),
	(218, NULL, 'Icrucumab (IMC-18F1)', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(219, NULL, 'LY2780301', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(220, NULL, 'SAR125844', 'MET INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(221, NULL, '2110183', 'AKT INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(222, NULL, 'TRAMETINIB (GSK1120212)', 'Falchook GS, Lancel Oncol 2012', 13, NULL, NULL, 'Rash or dermatitis acneiform ( 82%) and diarrhoea ( 45%), edema (35%), fatigue (31%), nausea(12%), dry skin (31%) and pruritus (15%)', 'Fatigue 8% and rash 4%', 'Trametinib is a reversible, selective allosteric inhibitor of MEK1 and MEK2 (also known as MAP2K1 and MAP2K2) activation and kinase activity, with a half-maximum inhibitory concentration (IC50) of 0·7–0·9 nmol/L for these enzymes.11 ', NULL, 'PHASE I', 'MELANOMA'),
	(223, NULL, 'CHU', 'PI3K INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(224, NULL, 'U3-1565', 'Kathleen N. Moore, ASCO 2013', 38, NULL, NULL, 'Fatigue, anemia, and appetite loss', '', 'U3-1565 is a fully human anti-HB-EGF monoclonal antibody with preclinical anti-tumor and anti-angiogenesis activity.', NULL, 'PHASE I', ''),
	(225, NULL, 'DS-2248', 'HSP90 INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(226, NULL, ' DS-7423 ', 'PI3K MTOR INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(227, NULL, 'DS-3078', 'MTOR INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(228, NULL, 'RG7414', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(229, NULL, 'PA799', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(230, NULL, 'CKI27/RG7304', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(231, NULL, 'RG7167', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(232, NULL, '/RG7853', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(233, NULL, 'RG7686', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(234, NULL, 'RG7159', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(235, NULL, 'CS-1008 ', 'Marika Ciprotti,ASCO 2013', 39, NULL, NULL, 'NON TOXICITIES', '', 'NON TOXICITIES', NULL, 'PHASE I', ''),
	(236, NULL, 'EFATUTAZONE (S-7017)', 'Pishvaian MJ, Cancer 2012 ', 40, NULL, NULL, '', '', '', NULL, '', ''),
	(237, NULL, 'U3-1287  HER3', 'J. Berlin, ASCO 2011', 12, NULL, NULL, 'Fatigue, diarrhea, and nausea.', 'Anemia, rash, dyspnea and hypoglycemia. ', ' U3-1287 (AMG 888) is a fully human anti-HER3 monoclonal antibody with demonstrated anticancer activity in preclinical models. ', NULL, 'PHASE I', ''),
	(238, NULL, 'PLX3397', 'Kit/Flt3-ITD INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(239, NULL, 'TIVANTINIB', 'Rosen LS, Clin Cancer Res. 2011', 24, NULL, NULL, 'Nausea, vomiting and fatigue', '', 'Tivantinib is a selective, orally administered, non-ATP competitive inhibitor of c-MET, with an inhibitory constant of 327 nmol/L. Tivantinib has been shown, in a large kinase panel screen to be 10 to 100 times more selective for c-MET than 230 other kinas', NULL, 'PHASE I', ''),
	(240, NULL, 'ASP2215', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(241, NULL, 'ASG-15 ME', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(242, NULL, 'AMG102', 'Schöffski P, BJU Int. 2011 ', 24, NULL, NULL, 'Edema (45.9%), fatigue (37.7%) and nausea (27.9%). ', 'Edema(9.8%)', 'An investigational, fully human monoclonal antibody to hepatocyte growth factor/scatter factor (HGF/SF), in renal cell carcinoma (RCC).', NULL, 'PHASE II', ''),
	(243, NULL, 'ASG-5ME ', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(244, NULL, 'ASP3026', 'Amita Patnaik, ASCO 2013', 22, NULL, NULL, 'Constipation, vomiting, diarrhea, nausea and abdominal pain', '', 'ASP3026 (3026) is a selective, potent, ATP-competitive, small molecule oral inhibitor of ALK receptor tyrosine kinase that has not previously been tested in humans', NULL, '', ''),
	(245, NULL, 'ASP9853', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(246, NULL, 'ASG15ME', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(247, NULL, 'ASP2215', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(248, NULL, 'ASP1707', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(250, NULL, 'Refametinib', 'MEK INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(251, NULL, 'MLN1117', 'PI3K INHIBITORS ', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(252, NULL, 'MLN2480', 'Drew Warren Rasco, ASCO 2013', 42, NULL, NULL, 'Fatigue 46%, arthralgia 25%, maculopapular rash 21% and myalgia 17%.', 'Anemia, dyspnea, and fatigue. ', '', NULL, 'PHASE I', ''),
	(253, NULL, 'TAK385', 'GnRH INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(254, NULL, 'MLN0261', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(255, NULL, 'URELUMAB', 'Ignacio Melero, ASCO 2013', 26, NULL, NULL, '', '', 'Urelumab is an agonistic antibody targeting CD137 which has demonstrated antitumor activity against a variety of cancers in pre-clinical and clinical studies. ', NULL, 'PHASE I', 'CD137 INHIBITOR'),
	(364, NULL, 'BIIB021', 'Saif MW, Clin Cancer Res. 2014', 16, NULL, NULL, '', '', '', NULL, 'PHASE I', ''),
	(257, NULL, 'lirilumab (BMS-986015)', 'lirilumab (BMS-986015) + combinations', 26, NULL, NULL, 'KIR INHIBITORS NON TOXICITIES', '', 'Lirilumab, an anti-KIR antibody that potentiates innate immunity, has demonstrated modest side effects in a phase I monotherapy trial', NULL, 'PHASE I  in combination but non toxicities', ''),
	(258, NULL, 'DENENICOKIN', '', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(263, NULL, 'DEDN6526A ', 'ETBR INHIBOTOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(265, NULL, 'DNIB0600A ', 'NAPI2B INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(267, NULL, 'MPDL3280A', 'PLI INHIBOTOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(269, NULL, 'GSK690693', 'AKT INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(270, NULL, 'PF-04691502', 'AKT INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(271, NULL, 'AP26113', 'D. Ross Camidge, ASCO 2013', 22, NULL, NULL, 'Nausea (45%), fatigue (39%), diarrhea (27%)', ' Diarrhea (5%)', 'AP26113 is a novel tyrosine kinase inhibitor (TKI) that potently inhibits mutant activated forms of anaplastic lymphoma kinase (ALK+) and epidermal growth factor receptor (EGFRm), and TKI-resistant forms including L1196M (ALK) and T790M (EGFR). AP26113 doe', NULL, 'PHASE I', ''),
	(272, NULL, 'CH5424802', 'Seto T, Lancet Oncol. 2013', 22, NULL, NULL, 'Nausea, myalgia, increased ALP(13%), Stomatitis, increased CPK(15%), Neutropenia(17%), increased ALT(22%), Constipation (24%), rash, increased creatinine(265), increased bilirrubin increased AST (28%), dysgeusia (30%)', 'Increased CPK(4%), Neutropenia(4%), increased ALT(2%), rash, 2%, increased bilirrubin 2%', 'CH5424802 (RO5424802; Chugai Pharmaceutical Co, Ltd, Tokyo, Japan) is a novel, highly selective oral ALK inhibitor. In-vitro kinase assays showed that this compound selectively inhibits ALK. CH5424802 also shows high anti-tumour activity both in vitro and ', NULL, 'PHASE I', ''),
	(273, NULL, 'TAK-901', 'AURORA KINASE INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(274, NULL, 'CYC116', 'AURORA KINASE INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(275, NULL, 'GSK1070916', 'AURORA KINASE INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(276, NULL, 'PF-03814735', 'Schöffski P, Eur J Cancer. 2011', 9, NULL, NULL, 'Fatigue (53.3%), nausea ( 46.7%) and diarrhea (46.7%). ', 'Asthenia (grade 3, n = 1), neutropenia (grade 3, n = 1; grade 4, n = 2), leukopenia (grade 4, n = 1), thrombocytopenia (grade 3, n = 3) and febrile neutropenia (grade 3, n = 1).', '', NULL, 'Phase I', ''),
	(277, NULL, 'CEP-32496', 'BRAF INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(278, NULL, 'CRIZOTINIB(XALKORI) ', 'Included in FDA approved drugs', 22, NULL, NULL, '', '', '', NULL, '', ''),
	(426, NULL, 'CEP-18770 (Delanzomib)', 'Gallerani E, Eur J Cancer. 2013', 17, NULL, NULL, '', '', '', NULL, 'PHASE I', ''),
	(415, NULL, 'CUDC-907 PI3K INHIBITOR', 'REGISTERED IN HDAC INHIBITOR', 2, NULL, NULL, '', '', '', NULL, '', ''),
	(339, NULL, 'Panobinostat (LBH589)', 'Fukutomi A, Invest New Drugs. 2012', 53, NULL, NULL, 'Thrombocitopenia, hemoglobin decreased, diarrhea, nausea, vomiting, fatigue, pyrexia, weight decreased, albumin decreaed, anorexia, back pain, pain in extremity, dizziness, dysgeusia, cough and pruritus', 'Thrombocitopenia, hemoglobin decreased,  nausea, vomiting and weight decreased.', '', NULL, 'PHASE I ', ''),
	(284, NULL, ' Dabrafenib (GSK2118436) ', 'PHASE III', 23, NULL, NULL, '', '', 'Registered in FDA', NULL, '', ''),
	(285, NULL, 'KU-55933', 'ATM/ATR INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(286, NULL, 'KU-60019', 'ATM/ATR INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(287, NULL, 'CP-466722', 'ATM/ATR INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(288, NULL, 'Wortmannin', 'ATM/ATR INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(289, NULL, 'VE-821', 'ATM/ATR INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(290, NULL, 'CGK 733', 'ATM/ATR INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(291, NULL, 'ABT-737', 'BCL2 INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(292, NULL, 'Sabutoclax', 'BCL2 INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(293, NULL, 'Obatoclax Mesylate (GX15-070)', 'PHASE I OBATOCLAX + TOPOTECAN', 56, NULL, NULL, 'Ataxia(83%), somnolence(66%), mood alteration, nausea(60%,dizziness, cognitive disturbance(40%)fatigue, pain(33%), thrombocitopenia, vision changes, memory loss(20%), anemia, neutropenia, alopecia, psychosis and restless leg(16%)', 'Anemia, nausea(60%), thrombocitopenia(40%), neutropenia, febrile meutropenia, ataxia, mood alteration, somnolence (20%)', 'PHASE I OBATOCLAX + TOPOTECAN by dose level', NULL, 'PHASE I', ''),
	(294, NULL, 'ABT-263 (Navitoclax)  ', 'Gandhi L,  J Clin Oncol. 2011', 56, NULL, NULL, 'Diarrhea, nausea, vomiting, fatigue, trombocitopenia, decreased appetite', 'Trombocitopenia, fatigue, weight decreased', 'Navitoclax is a potent and highly selective inhibitor of antiapoptotic members of the Bcl-2 family, with nanomolar affinity for Bcl-2, Bcl-xL, and Bcl-w. The potency and specificity of this agent are related to its unique mechanism of action, as a BH3 doma', NULL, 'PHASE I', ''),
	(295, NULL, 'BM-1074', 'BCL2 INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(296, NULL, 'TW-37', 'BCL2 INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(297, NULL, 'JNJ-7706621', 'CDK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(298, NULL, 'BMS-265246', 'CDK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(299, NULL, 'A-674563', 'CDK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(300, NULL, 'BAY 1000394', 'CDK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(301, NULL, 'PF-477736', 'CS1 INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(302, NULL, 'NU7441 (KU-57788)', 'DNA-PK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(303, NULL, 'PI-103', 'DNA-PK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(304, NULL, 'NU7026', 'DNA-PK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(305, NULL, 'PIK-75', 'DNA-PK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(306, NULL, 'PP121', 'DNA-PK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(307, NULL, 'KU-0060648', 'DNA-PK INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(308, NULL, 'LAPATINIB', 'Registered in FDA approved drugs', 12, NULL, NULL, '', '', '', NULL, '', ''),
	(309, NULL, 'Varlitinib', 'ERbB INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(310, NULL, 'AST-1306', 'ERbB INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(311, NULL, 'Mubritinib (TAK 165) ', 'ERbB INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(312, NULL, 'WZ4002', 'ERbB INHIBITORS  EGFR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(313, NULL, 'WZ4002 EGFR', 'Takahashi T,Invest New Drugs. 2012', 12, NULL, NULL, '', '', '', NULL, '', ''),
	(314, NULL, 'AG-490', 'ERbB INHIBITORS  EGFR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(315, NULL, 'CUDC-101  EGFR ', 'Siqing Fu, ASCO 2012', 12, NULL, NULL, '', '', '', NULL, '', ''),
	(316, NULL, 'AG-1478  EGFR', 'ERbB INHIBITORS  EGFR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(317, NULL, 'Pelitinib (EKB-569)  EGFR', '', 12, NULL, NULL, '', '', '', NULL, '', ''),
	(318, NULL, 'Canertinib (CI-1033)', 'Sklarin NT, Invest New Drugs. 1997', 12, NULL, NULL, 'Nausea, vomiting, anorexia, constipation, stomatitis, dyspepsia, erythema, fever, and fatigue.', '', 'CI-980 is a synthetic mitotic inhibitor that binds to the colchicine binding site of tubulin. It demonstrates broad activity against human and murine tumor models and shows no cross resistance with tumor models whose mechanism of resistance is mediated by ', NULL, 'PHASE I', ''),
	(319, NULL, 'CP-724714', 'Guo F, Cancer Chemother Pharmacol. 2008', 12, NULL, NULL, 'Elevated ALT and AST, hyperbilirubinemia, rash, asthenia, nausea and vomiting ', '', 'CP-724,714 is an orally available, small molecule, potent HER-2 tyrosine kinase inhibitor under development for the treatment of advanced HER2-overexpressing cancers. ', NULL, 'PHASE I ', ''),
	(320, NULL, 'AEE788 (NVP-AEE788)', 'Reardon DA, Cancer Chemother Pharmacol. 2012', 12, NULL, NULL, 'ALT, confusion, diarrhea, fatigue, headache, insomnia, nausea, rash and vomiting', '', 'AEE788, an orally active TK inhibitor (TKI), potently inhibits EGFR/ErbB-1 and HER-2/neu (ErbB-2) as well as the VEGF receptor KDR (VEGFR-2), making it a logical potential treatment for glioblastoma', NULL, 'PHASE I', ''),
	(321, NULL, 'AC480 (BMS-599626)  HER', 'Soria JC,Ann Oncol. 2012 ', 12, NULL, NULL, 'Diarrhea, anorexia, asthenia, skin rash, AST/ALT ', '', 'BMS-599626, an orally bioavailable inhibitor of the human epidermal growth factor receptor (HER) family of receptor tyrosine kinases. ', NULL, 'PHASE I ', ''),
	(322, NULL, 'CNX-2006', 'ErBb inhibitor', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(323, NULL, 'Varlitinib', 'ERbB inhibitor', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(324, NULL, 'TAK-285', 'Doi T, Br J Cancer. 2012', 12, NULL, NULL, 'AST/ALT, rash, hiperbilirrubinemia, diarrhea, constipation, GGT increased, decreased appetite, pyrexia, alk increased, nausea, dry skin, vomiting, creatinine increased, anemia and stomatitis.', '', 'TAK-285 is a novel low-molecular weight compound that was designed and synthesised by Takeda. TAK-285 inhibits HER2 and EGFR phosphorylation, with 50% inhibition concentrations of 17 and 23 nmol l–1, respectively', NULL, 'PHASE I ', ''),
	(325, NULL, 'Tyrphostin 9  EGFR', 'ERbB inhibitor', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(326, NULL, 'WZ3146  EGFR', 'ERbB INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(327, NULL, 'WZ8040 EGFR', 'ERbB', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(328, NULL, '	AG-18 EGFR', 'ERbB ', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(329, NULL, 'BGJ398 (NVP-BGJ398)', 'FGFR INH', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(331, NULL, 'RO4929097 GAMMA', 'Strosberg JR, Eur J Cancer. 2012', 10, NULL, NULL, 'Nausea 3%,Vomiting 5%, Fatigue 3%, Pruritis 5%, Rash 3 %, Skin hyperpigmentation 3%, Dizziness 3%,  Stomatitis 3%.', '', 'RO4929097 is a selective inhibitor of &#947;-secretase. We tested the activity of RO4929097 in patients with metastatic, refractory colorectal cancer.', NULL, 'PHASE II', ''),
	(332, NULL, 'MK-0752', 'Krop I, J Clin Oncol. 2012', 10, NULL, NULL, 'Nausea, vomiting, diarrhea, AST increased, fatigue, decreased appetite, headache and rash. ', '', 'MK-0752 is a potent, oral inhibitor of &#947;-secretase, an enzyme required for Notch pathway activation.\r\n\r\n', NULL, 'PHASE I', ''),
	(333, NULL, 'YO-01027', 'secretase inhibitor', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(334, NULL, 'LY900009', 'Shubham Pant, ASCO 2012', 10, NULL, NULL, 'Diarrhea (27%), vomiting (23%), nausea (18%), fatigue (23%), anorexia (23%), hypophosphatemia (14%), and rash (18%). ', '', '', NULL, 'PHASE I', ''),
	(335, NULL, 'LY411575', 'NOTCH', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(336, NULL, 'LY2811376', 'NOTCH', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(337, NULL, 'Rocilinostat (ACY-1215)', 'HDAC INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(338, NULL, 'Vorinostat (SAHA, MK0683)', 'Kelly WK, J Clinic Oncol 2005', 53, NULL, NULL, 'Anemia, thrombocitopenia,anorexia, diarrhea, creatinine increased, fatigue, hyperglicemia, hypocalcemia,nausea and vomiting', 'Fatigue, thrombocitopenia, hyperglicemia and anemia.(> 5%)', '', NULL, 'PHASE I', ''),
	(340, NULL, 'Entinostat (MS-275)', 'Gore L, Clin Cancer Res. 2008', 53, NULL, NULL, 'Neutropenia, nausea, asthenia, anorexia, rash, vomiting and hypophosphatemia', 'Neutropenia and decreased hemoglobin, asthenia', 'MS-275 is a synthetic small-molecule benzamide derivative that has been shown to inhibit HDAC activity in vitro. MS-275 can up-regulate the expression of the transforming growth factor receptor II gene, which could lead to increased activity of transformin', NULL, 'PHASE I', ''),
	(341, NULL, 'Romidepsin (FK228, Depsipeptide)', 'PHASE I in combination with gemcitabine', 53, NULL, NULL, '', '', '', NULL, '', ''),
	(342, NULL, 'Trichostatin A (TSA) 	', 'HDAC INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(343, NULL, 'Mocetinostat (MGCD0103)', 'Siu LL,, J Clin Oncol. 2008', 53, NULL, NULL, 'Fatigue, anorexia,nausea, vomiting, diarrhea, ', 'Fatigue', 'MGCD0103 is a novel isotype-selective inhibitor of human histone deaceylases (HDACs) with the potential to regulate aberrant gene expression and restore normal growth control in malignancies.', NULL, 'PHASE I', ''),
	(344, NULL, 'JNJ-26481585', 'R. D. Baird, ASCO 2011', 53, NULL, NULL, 'fatigue, anorexia, and nausea.', '', 'JNJ-26481585 is a potent, hydroxamate, pan-HDACi with broad activity in solid and hematologic tumor models. ', NULL, 'PHASE I', ''),
	(345, NULL, 'PCI-34051', 'HDAC INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(346, NULL, 'CUDC-101', 'Siqing Fu, ASCO 2012', 53, NULL, NULL, 'Fatigue,increased creatinine, nausea, vomiting, decreased appetite, anemia and asthenia,', '', 'CUDC-101 is a small molecule EGFR/HER2 receptor tyrosine kinase and HDAC inhibitor that has shown promising activity in cancer cell lines and tumor xenograft models. ', NULL, 'PHASE I', ''),
	(347, NULL, 'MC1568', 'HDAC INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(348, NULL, 'Pracinostat (SB939) 	', 'Razak AR, Br J Cancer. 2011', 53, NULL, NULL, 'Fatigue (53%), nausea (39%), vomiting (29%), anorexia (29%) and diarrhoea (18%). ', 'Fatigue, diarrhea and vomiting', 'SB939 is an orally available, competitive histone deacetylase (HDAC) inhibitor selective for class I, II and IV histone deacetylases.', NULL, 'PHASE I', ''),
	(349, NULL, 'Belinostat (PXD101) 	', 'Steele NL,Clin Cancer Res. 2008 ', 53, NULL, NULL, 'Nausea, vomiting, lethargy, fatigue, constipation and diarrhea', '', 'Belinostat (previously PXD101) is a novel hydroxamic acid HDAC inhibitor with potent antiproliferative and HDAC inhibitory activities in vitro (6). Belinostat has growth inhibitory and proapoptotic activities in a variety of human tumor cell lines at nanom', NULL, 'PHASE I', ''),
	(350, NULL, 'CUDC-907', 'HDAC INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(351, NULL, 'Droxinostat', 'HDAC INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(352, NULL, 'Tubastatin A', 'HDAC INH', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(353, NULL, 'CI994 (Tacedinaline) 	', 'HDAC INH', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(354, NULL, 'LAQ824 (Dacinostat)', 'HDAC INH', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(355, NULL, 'AR-42', 'HDAC INH', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(356, NULL, 'Scriptaid ', 'HDAC INH', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(357, NULL, 'Resminostat', 'HDAC INH', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(358, NULL, 'RGFP966', 'HDAC INH', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(359, NULL, 'Vismodegib (GDC-0449)', 'LoRusso PM, Clin Cancer Res. 2011', 6, NULL, NULL, 'Muscle spams, dysgeusia, fatigue, alopecia, nausea, decreased appetite, diarrhea, weight decreased, cough, back pain, dyspnea, constipation, vomiting, abdominal pain, anxiety, hyponatremia, insomnio, pruritus,dyspepsia, musculoeskeletal pain, pyrexia, arth', '', 'Vismodegib (GDC-0449) is a small-molecule inhibitor of smoothened, a key component of Hh signaling. ', NULL, 'PHASE I', ''),
	(360, NULL, 'LY2940680', 'HEDGEOG', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(361, NULL, '	PF-5274857', 'HEDGEOG', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(362, NULL, 'GANT61', 'HEDGEOG', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(363, NULL, 'AUY922 (NVP-AUY922)', 'HSP INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(365, NULL, 'NVP-BEP800', 'HSP INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(366, NULL, 'KW-2478', 'HSP INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(367, NULL, 'XL888', 'HSP INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(368, NULL, 'VER 155008', 'HSP INH', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(369, NULL, 'OSI-906 (Linsitinib) 	', 'Jorge A. Garcia, ASCO 2013', 5, NULL, NULL, 'AST/ALT changes 18%, fatigue (59%), nausea/vomiting (35%)', '', 'Linsitinib is a small molecule potent dual inhibitor of IGF-1R and insulin receptor TK activity. ', NULL, 'PHASE II', ''),
	(370, NULL, 'BMS-754807', 'J. Desai, ASCO 2010', 5, NULL, NULL, 'Hyperglicemia', 'Fatigue and hiperglicemia', 'BMS-754807 is a potent reversible inhibitor of IGF-1R and IR family kinases (IGF-1R, IR; Ki <2nM).', NULL, 'PHASE I', ''),
	(371, NULL, 'NVP-ADW742', 'IGFR INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(372, NULL, 'GSK1838705A', 'IGFR INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(373, NULL, 'AZD1480', 'JAK INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(374, NULL, 'AZ 960', 'IGFR INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(375, NULL, 'LY2784544', 'IGFR INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(376, NULL, 'BMS-911543', 'IGFR INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(377, NULL, 'PD0325901', 'LoRusso PM, Clin Cancer Res. 2010', 13, NULL, NULL, 'Rash, diarrhea, fatigue, nausea, edema, pruritus and vomiting', 'Rash, fatigue and vomiting', 'PD-0325901, a highly potent, selective, oral mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase 1/2 inhibitor in advanced cancer patients. ', NULL, 'PHASE I ', ''),
	(378, NULL, 'U0126', 'MEK INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(379, NULL, 'PD98059', 'MEK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(380, NULL, 'BIX 02189', 'MEK INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(381, NULL, 'AZD8330', 'Cohen RB,, Eur J Cancer. 2013 ', 13, NULL, NULL, 'Dermatitis (16%), fatigue (13%), diarrhoea ( 13%) and vomiting (11%). ', '', 'AZD8330 (ARRY-424704) is a potent, selective, uncompetitive MEK1/2 inhibitor, with a half-maximum inhibitory concentration (IC50) of 7 nM.', NULL, 'PHASE I', ''),
	(382, NULL, 'BIX 02188', 'MEK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(383, NULL, 'SL-327', 'MEK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(384, NULL, 'PD318088', 'MEK INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(385, NULL, 'Tivantinib (ARQ 197)	', 'Rosen LS, Clin Cancer Res. 2011', 7, NULL, NULL, 'Nausea and fatigue 13.9% and vomiting 10,1%', '', 'Tivantinib, an oral, non-ATP competitive, selective c-MET inhibitor, exhibited antitumor activity in preclinical models.', NULL, 'PHASE I', ''),
	(386, NULL, 'SGX-523', 'MET INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(387, NULL, 'JNJ-38877605', 'MET INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(388, NULL, 'PF-04217903', 'MET INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(389, NULL, 'SU11274', 'MET INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(390, NULL, 'MK-2461', 'MET INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(391, NULL, 'BMS-794833', 'MET INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(392, NULL, 'AMG-458', 'MET INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(393, NULL, 'NVP-BVU972', 'MET INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(394, NULL, 'SB203580', 'P38 INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(395, NULL, 'BIRB 796 (Doramapimod)', 'P38 INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(396, NULL, 'SB202190', 'P38 INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(397, NULL, 'TAK-715', 'P38 INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(398, NULL, 'VX-745', 'P38 INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(400, NULL, 'AG-14361', 'PARP INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(401, NULL, 'PJ34', 'PARP INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(402, NULL, 'A-966492 ', 'PARP INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(403, NULL, 'UPF 1069', 'PARP INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(404, NULL, 'AZD2461', 'PARP INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(405, NULL, 'IMATINIB', 'PDGFR INHIBITORS', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(409, NULL, 'PKI-402', 'PI3K/Mtor INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(410, NULL, 'IPI-145 (INK1197) ', 'PI3K INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(411, NULL, 'LY294002', 'PI3K INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(412, NULL, 'GSK2636771 ', 'PI3K INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(413, NULL, 'PI-103', 'PI3K INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(407, NULL, 'CP-673451', 'PDGFR INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(425, NULL, 'GDC-0349', 'PI3K MTOR INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(418, NULL, 'PF-04691502', 'PI3K MTOR INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(419, NULL, 'TG100-115', 'PI3K INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(420, NULL, 'GSK1059615', 'PI3K MTOR INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(421, NULL, 'EVEROLIMUS mTOR INHIBITOR', 'REGISTERED IN FDA APROVED DURGS', 2, NULL, NULL, '', '', '', NULL, '', ''),
	(422, NULL, 'AZD8055 mTOR ', 'Naing A, Br J Cancer. 2012', 2, NULL, NULL, 'Nausea, stomatitis AST/ALT increased, GGT, fatigue and hyperglicemia.', '', 'AZD8055 is a first-in-class dual mTORC1/mTORC2 inhibitor, which was shown to prevent the mTORC2-mediated AKT activation seen with rapalogues in preclinical models ', NULL, 'PHASE I', ''),
	(423, NULL, 'INK 128 (MLN0128)	 mTOR', 'PI3K MTOR INHIBITOR', 26, NULL, NULL, '', '', '', NULL, '', ''),
	(424, NULL, 'TEMSIROLIMUS  mTOR', 'REGISTERED IN FDA APRPOVED DRUGS', 2, NULL, NULL, '', '', '', NULL, '', '');
/*!40000 ALTER TABLE `farmacos_inv` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.farmacos_inv_diana
CREATE TABLE IF NOT EXISTS `farmacos_inv_diana` (
  `id_farmaco` mediumint(9) unsigned NOT NULL DEFAULT '0',
  `id_diana` smallint(4) unsigned NOT NULL DEFAULT '0',
  `valor_diana` varchar(50) COLLATE utf8_unicode_ci DEFAULT NULL,
  PRIMARY KEY (`id_farmaco`,`id_diana`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.farmacos_inv_diana: 261 rows
/*!40000 ALTER TABLE `farmacos_inv_diana` DISABLE KEYS */;
INSERT INTO `farmacos_inv_diana` (`id_farmaco`, `id_diana`, `valor_diana`) VALUES
	(1, 64, '3nM'),
	(1, 67, '33nM'),
	(1, 68, '75nM'),
	(1, 69, '3nM'),
	(2, 64, '0.014 mM'),
	(2, 67, '0.12 mM'),
	(2, 68, '0.036 mM'),
	(2, 69, '0.50 mM'),
	(3, 64, '52-99 nM'),
	(3, 67, '166nM'),
	(3, 68, '262nM'),
	(3, 69, '116nM'),
	(7, 53, '157nM'),
	(7, 64, '39nM'),
	(7, 67, '113nM'),
	(7, 68, '9nM'),
	(7, 69, '43nM'),
	(8, 65, '40nM'),
	(8, 66, '40nM'),
	(10, 53, '1,6nM'),
	(10, 64, '0,4nM'),
	(10, 68, '5,4nM'),
	(12, 64, '0,469nM'),
	(12, 67, '3,7nM'),
	(13, 69, '2,5nM'),
	(14, 80, '9nM'),
	(14, 90, '9nM'),
	(15, 53, '1nM'),
	(15, 63, '1nM'),
	(16, 54, '32nM'),
	(114, 93, '58.2 nM'),
	(114, 44, '15.9 nM'),
	(114, 42, '1.86 nM'),
	(114, 10, '350 nM'),
	(114, 9, '14 nM'),
	(18, 54, '0,18nM'),
	(18, 55, '0,3nM'),
	(18, 64, '0,019nM'),
	(18, 67, '0,13nM'),
	(18, 68, '0,024nM'),
	(18, 69, '0,06nM'),
	(19, 64, '4nM'),
	(19, 67, '75nM'),
	(19, 68, '5nM'),
	(19, 69, '7nM'),
	(20, 53, '17nM'),
	(20, 64, '5nM'),
	(20, 67, '27nM'),
	(20, 68, '14nM'),
	(21, 5, '8nM'),
	(21, 6, '12nM'),
	(21, 7, '65nM'),
	(23, 5, '5nM'),
	(23, 6, '18nM'),
	(23, 7, '8nM'),
	(24, 54, '0,18'),
	(24, 55, '0,3'),
	(24, 64, '0,019'),
	(24, 67, '0,13'),
	(24, 68, '0,024'),
	(24, 69, '0,06'),
	(25, 95, '4.7mM'),
	(33, 84, '13nM'),
	(33, 85, '2.5nM'),
	(34, 24, '9,3nM'),
	(35, 24, '14nM'),
	(35, 93, '16nM'),
	(36, 51, '0,9nM'),
	(36, 61, '0,4 Nm'),
	(37, 24, '2,5nM'),
	(37, 36, '65nM'),
	(37, 37, '39nM'),
	(37, 38, '50nM'),
	(37, 40, '22nM'),
	(37, 41, '10nM'),
	(37, 60, '24nM'),
	(37, 76, '22nM'),
	(37, 82, '7nM'),
	(38, 61, '1nM'),
	(38, 82, '2nM'),
	(38, 89, '7nM'),
	(38, 92, '3nM'),
	(38, 93, '3nM'),
	(38, 94, '4nM'),
	(39, 1, '0,6nM'),
	(39, 22, '37nM'),
	(39, 23, '79nM'),
	(39, 86, '0,8nM'),
	(40, 16, '0,5nM'),
	(41, 1, '1nM'),
	(41, 86, '1,2nM'),
	(42, 45, '26nM'),
	(42, 46, '60nM'),
	(42, 48, '9nM'),
	(42, 79, '13nM'),
	(44, 9, '0,6nM'),
	(44, 10, '18nM'),
	(44, 11, '4,6nM'),
	(45, 9, '1,2nM'),
	(46, 10, '0,37nM'),
	(47, 9, '13nM'),
	(47, 10, '79nM'),
	(47, 11, '71nM'),
	(47, 15, '25nM'),
	(47, 26, '31nM'),
	(47, 35, '47nM'),
	(48, 9, '4nM'),
	(49, 1, '4nM'),
	(49, 9, '3nM'),
	(49, 10, '3nM'),
	(49, 49, '1,1nM'),
	(49, 50, '1,2nM'),
	(50, 9, '9nM'),
	(50, 10, '31nM'),
	(50, 11, '3,4nM'),
	(51, 9, '14nM'),
	(51, 10, '350nM'),
	(51, 42, '1,86nM'),
	(51, 44, '15,9nM'),
	(51, 93, '58,2nM'),
	(52, 9, '5nM'),
	(52, 10, '4nM'),
	(52, 11, '1nM'),
	(52, 70, '53nM'),
	(53, 9, '0.064 nM'),
	(54, 12, '12,0nM'),
	(54, 13, '12,1nM'),
	(54, 14, '10,9nM'),
	(55, 8, '2,6nM'),
	(55, 62, '2,9nM'),
	(56, 21, '1,7nM'),
	(56, 76, '1,6nM'),
	(56, 92, '0,1nM'),
	(56, 93, '0,2nM'),
	(56, 94, '0,1-0,3'),
	(57, 36, '69nM'),
	(57, 37, '37nM'),
	(57, 38, '108nM'),
	(57, 72, '59nM'),
	(57, 76, '65nM'),
	(57, 92, '34nM'),
	(57, 93, '13nM'),
	(57, 94, '13nM'),
	(58, 1, '0,37nM'),
	(58, 36, '2,2nM'),
	(58, 72, '1,1nM'),
	(58, 86, '5,4nM'),
	(58, 93, '1,5nM'),
	(59, 27, '3nM'),
	(59, 40, '3nM'),
	(59, 42, '4nM'),
	(59, 51, '4nM'),
	(59, 76, '66nM'),
	(59, 88, '4nM'),
	(61, 52, '200nM'),
	(61, 72, '540nM'),
	(61, 76, '800nM'),
	(62, 21, '1,63nM'),
	(62, 71, '1,72nM'),
	(62, 92, '0,21nM'),
	(62, 93, '0,16nM'),
	(62, 94, '0,24nM'),
	(63, 22, '10nM'),
	(63, 43, '81nM'),
	(63, 73, '40nM'),
	(64, 37, '1,2uM'),
	(64, 40, '2,1uM'),
	(64, 51, '2,1uM'),
	(64, 76, '0,008uM'),
	(65, 62, '11nM'),
	(65, 64, '10 Nm'),
	(65, 67, '0,9nM'),
	(65, 68, '1,8nM'),
	(65, 72, '11nM'),
	(65, 74, '10nM'),
	(65, 75, '0,9nM'),
	(65, 77, '1,8nM'),
	(66, 21, '1nM'),
	(66, 62, '15nM'),
	(66, 72, '15nM'),
	(66, 93, '6nM'),
	(66, 94, '4nM'),
	(67, 21, '2nM'),
	(67, 36, '8nM'),
	(67, 38, '9nM'),
	(67, 42, '1nM'),
	(67, 72, '210nM'),
	(67, 76, '27nM'),
	(67, 92, '10nM'),
	(67, 93, '13nM'),
	(67, 94, '8nM'),
	(68, 30, '10nM'),
	(68, 31, '0,4nM'),
	(68, 32, '0,5nM'),
	(68, 47, '14nM'),
	(69, 29, '92nM'),
	(69, 47, '59nM'),
	(70, 29, '4nM'),
	(70, 33, '3nM'),
	(70, 34, '4nM'),
	(70, 57, '14nM'),
	(71, 14, '14nM'),
	(71, 57, '14nM'),
	(72, 57, '0,92nM'),
	(72, 58, '1,8nM'),
	(73, 57, '5nM'),
	(73, 58, '11nM'),
	(74, 57, '3,2nM'),
	(74, 58, '3,2nM'),
	(79, 96, '5nM'),
	(79, 97, '1nM'),
	(80, 96, '5.2nM'),
	(80, 97, '2.9nM'),
	(82, 98, '50nM'),
	(83, 96, '3.8nM'),
	(83, 97, '2.1nM'),
	(278, 24, '11nM'),
	(271, 42, '2.1 nM'),
	(276, 9, '0.8nM'),
	(276, 10, '5nM'),
	(276, 40, '10nM'),
	(159, 99, '2 nM'),
	(159, 100, '10 nM'),
	(160, 99, '11 nM'),
	(160, 100, '16 nM'),
	(164, 18, '210 nM'),
	(164, 19, '47 nM'),
	(164, 20, '360 nM'),
	(164, 99, '100 nM'),
	(164, 101, '13 nM'),
	(164, 100, '170 nM'),
	(321, 47, '30 nM'),
	(321, 102, '20 nM'),
	(320, 29, '2 nM'),
	(320, 33, '6 nM'),
	(315, 47, '15.7 nM'),
	(315, 29, '2.4 nM'),
	(318, 29, '1.5 nM'),
	(318, 33, '9 nM'),
	(319, 29, '10 nM'),
	(319, 33, '10 nM'),
	(308, 29, '10.8 nM'),
	(308, 33, '9.2 nM'),
	(317, 29, '38.5 nM'),
	(324, 47, '17 nM'),
	(324, 29, '23 nM'),
	(313, 30, '8 nM'),
	(313, 31, '2 nM'),
	(106, 92, '0.1 nM'),
	(106, 93, '0.2 nM'),
	(106, 94, '0.1-0.3 nM'),
	(106, 76, '1.6 nM'),
	(106, 21, '1.7 nM'),
	(97, 51, '2.1 microM'),
	(97, 35, '1.2 microM'),
	(97, 77, '0.008 microM'),
	(162, 18, '40 nM'),
	(162, 19, '40 nM'),
	(162, 99, '40 nM'),
	(162, 100, '40 nM'),
	(162, 103, '300 nM');
/*!40000 ALTER TABLE `farmacos_inv_diana` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.farmacos_inv_link
CREATE TABLE IF NOT EXISTS `farmacos_inv_link` (
  `id_link` mediumint(9) unsigned NOT NULL AUTO_INCREMENT,
  `id_farmaco` mediumint(9) unsigned NOT NULL DEFAULT '0',
  `descripcion_link` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `url_link` varchar(500) COLLATE utf8_unicode_ci NOT NULL,
  `tipo_link` tinyint(1) unsigned NOT NULL DEFAULT '0',
  PRIMARY KEY (`id_link`)
) ENGINE=MyISAM AUTO_INCREMENT=498 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci ROW_FORMAT=COMPACT;

-- Volcando datos para la tabla farmacos.farmacos_inv_link: 415 rows
/*!40000 ALTER TABLE `farmacos_inv_link` DISABLE KEYS */;
INSERT INTO `farmacos_inv_link` (`id_link`, `id_farmaco`, `descripcion_link`, `url_link`, `tipo_link`) VALUES
	(1, 1, 'Links D. D. Von Hoff ASCO 2011', 'http://meetinglibrary.asco.org/content/80533-102                                              ', 3),
	(2, 1, 'Ilic N, Proc Natl Acad Sci U S A. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21876152?dopt=Abstract   ', 4),
	(3, 2, 'Aurelius Gabriel Omlin, ASCO 2012', 'https://meetinglibrary.asco.org/content/95044-114', 3),
	(271, 11, 'Ana M. Gonzalez-Angulo, ASCO 2013', 'http://meetinglibrary.asco.org/content/114843-132', 3),
	(5, 3, 'Pei Y, Cancer Cell 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22340590?dopt=Abstract', 4),
	(275, 14, 'Rigosertib phase I + GemcitabinePubl', 'http://www.ncbi.nlm.nih.gov/pubmed/22338014', 0),
	(8, 6, 'E. G. Chiorean ASCO 2009', 'http://meetinglibrary.asco.org/content/31782-65', 3),
	(9, 7, 'I. Brana, ASCO 2010', 'https://meetinglibrary.asco.org/content/48412-74', 3),
	(10, 8, ' Shapiro ASCO 2009 ', 'https://meetinglibrary.asco.org/content/34767-65', 3),
	(11, 8, 'Martina JA, Autophagy 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22576015?dopt=Abstract', 4),
	(13, 10, ' Millham, AACR 2011', 'http://mct.aacrjournals.org/cgi/content/short/10/11_MeetingAbstracts/A167?rss=1', 3),
	(15, 12, ' Patnaik, ASCO 2011', 'https://meetinglibrary.asco.org/content/82099-102', 3),
	(17, 13, 'Schwamb J,, Blood 2012', ' http://www.ncbi.nlm.nih.gov/pubmed/22927247?dopt=Abstract          ', 4),
	(18, 14, 'Daniel W. Bowles ASCO 2012', 'https://meetinglibrary.asco.org/content/98060-114', 3),
	(19, 14, 'Joshi K,Stem Cells 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23404835?dopt=Abstract', 4),
	(20, 15, ' Markman B, Ann Oncol 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22357447', 3),
	(23, 18, ' P. N. Munste ASCO 2011', 'https://meetinglibrary.asco.org/content/82568-102', 3),
	(24, 19, 'Burris ASCO 2010', 'https://meetinglibrary.asco.org/content/53432-74', 3),
	(25, 19, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/1057', 5),
	(477, 19, 'Pei Y, Cancer Cell. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22340590?dopt=Abstract', 4),
	(225, 20, 'A. J. Wagner,, ASCO 2011', 'http://meetinglibrary.asco.org/content/82516-102', 3),
	(216, 21, 'Yap TA, J Clinical Oncol. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=mk2206', 3),
	(29, 21, 'MK-2206  Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/1053', 5),
	(30, 21, 'Shuda M, J Clin Invest 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21841310?dopt=Abstract   ', 4),
	(32, 23, ' Tabernero, ASCO 2011', 'https://meetinglibrary.asco.org/content/82750-102\r\n', 3),
	(33, 24, 'H. A. Burris, ASCO 2011', ' https://meetinglibrary.asco.org/content/80659-102', 3),
	(34, 25, 'Unger C, Eur J Cancer. 2010 ', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=Unger+perifosine+2010', 3),
	(35, 26, ' Calvo E ASCO 2012', 'https://meetinglibrary.asco.org/content/99941-114', 3),
	(36, 27, 'Udai Banerji, ASCO 2012', 'https://meetinglibrary.asco.org/content/94229-114', 3),
	(252, 28, 'Andrea Varga, ASCO 2013', 'http://meetinglibrary.asco.org/content/112074-132', 3),
	(232, 29, '3- WATKINGS ASCO 2009', 'http://meetinglibrary.asco.org/content/31620-65', 0),
	(233, 29, '2-GASTROINTESTINAL SIMPOSIUM', 'http://meetinglibrary.asco.org/content/83647-102', 0),
	(40, 31, 'Murakami H, Cancer Chemother Pharmacol. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22810805', 3),
	(41, 32, ' DC Smith ASCO 2010', 'https://meetinglibrary.asco.org/content/53431-74', 3),
	(42, 33, '  HA Tawbi ASCO 2011', 'https://meetinglibrary.asco.org/content/80034-102', 3),
	(43, 34, 'David S. Hong, 2013 Genitourinary Cancers Symposium', 'https://meetinglibrary.asco.org/content/106477-134', 3),
	(44, 35, ' Toshihiko Doi, ASCO 2012 ', 'https://meetinglibrary.asco.org/content/95142-114', 3),
	(45, 36, 'Thomas Cheung Yau ASCO 2012', 'https://meetinglibrary.asco.org/content/98320-114', 3),
	(46, 36, 'Tiedt R, Cancer Res 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21697284?dopt=Abstract      ', 4),
	(266, 57, 'Mross K, Clinical Cancer Res 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20028771', 3),
	(48, 38, 'MA Drouin, ASCO 2010', 'https://meetinglibrary.asco.org/content/50255-74', 3),
	(50, 39, 'John Sarantopoulos ASCO 2012', 'https://meetinglibrary.asco.org/content/99141-114', 0),
	(51, 39, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/51', 5),
	(52, 39, 'Zhong H, Cell Res 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21423276?dopt=Abstract   ', 4),
	(53, 40, ' John C. Byrd ASCO 2012', 'https://meetinglibrary.asco.org/content/99350-114', 3),
	(54, 40, 'Schwamb J,, Blood 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22927247?dopt=Abstract', 4),
	(282, 41, 'Phase I adults healthy', 'http://www.ncbi.nlm.nih.gov/pubmed/21691746', 0),
	(56, 41, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/1019', 5),
	(57, 41, 'Trimmer C, Cancer Res 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20709760?dopt=Abstract    ', 4),
	(58, 42, ' A. A. Adjei ASCO 2009', 'https://meetinglibrary.asco.org/content/35459-65', 3),
	(59, 44, 'VX-680 + DASATINIB PHASE I', 'https://meetinglibrary.asco.org/content/32568-65', 0),
	(60, 44, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Search', 5),
	(61, 44, 'Tanenbaum ME, Curr Biol 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21820309?dopt=Abstract    ', 4),
	(224, 19, 'Mohamad Adham Salkeni, ASCO 2013', 'http://meetinglibrary.asco.org/content/114177-132', 3),
	(63, 45, 'Sardon T, EMBO Rep. 2010', ' http://www.ncbi.nlm.nih.gov/pubmed/21072059?dopt=Abstract   ', 4),
	(65, 46, 'Tanenbaum ME, Curr Biol 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21820309?dopt=Abstract    ', 4),
	(364, 47, 'Markant SL, Cancer Res 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/24067506?dopt=Abstract', 4),
	(69, 48, 'Salmela AL, Exp Cell Res. 2012 ', 'http://www.ncbi.nlm.nih.gov/pubmed/22227008?dopt=Abstract\r\n', 4),
	(70, 49, 'R. Kristeleit ASCO 2009', 'https://meetinglibrary.asco.org/content/32863-65', 3),
	(71, 49, 'Gäbler K, J Cell Mol Med. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23301855?dopt=Abstract', 4),
	(72, 50, 'F. Robert ASCO 2009', 'https://meetinglibrary.asco.org/content/34949-65', 3),
	(374, 50, 'Ansbro MR, PLoS One. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23593196?dopt=Abstract', 4),
	(221, 48, ' *Dees EC, Cancer Chemother Pharmacol. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/20607239', 0),
	(75, 52, 'Michael Anthony Carducci ASCO 2012', 'https://meetinglibrary.asco.org/content/92852-114', 3),
	(76, 53, 'Shimomura T,Mol Cancer Ther. 2010  with Docetaxel', 'http://www.ncbi.nlm.nih.gov/pubmed/20053775', 3),
	(77, 54, 'Links Abstracts WWW.ASCO.ORG', 'ONLY INHIBITORS', 3),
	(78, 54, 'Links Abstracts SELLECKCHEM', 'http://www.ncbi.nlm.nih.gov/pubmed/22334705?dopt=Abstract', 3),
	(79, 55, 'Links Abstracts WWW.ASCO.ORG', 'ONLY INHIBITORS', 3),
	(80, 56, 'AXITINIB Phase I + chemoteraphy', 'https://meetinglibrary.asco.org/content/32749-65', 0),
	(81, 56, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/1021', 5),
	(82, 56, 'Martin MJ, Cancer Discov 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22576211?dopt=Abstract   ', 4),
	(83, 57, 'Török S', 'http://www.ncbi.nlm.nih.gov/pubmed/23008829', 0),
	(84, 57, 'Chen H, Nature 2011', ' http://www.ncbi.nlm.nih.gov/pubmed/21993628?dopt=Abstract   ', 4),
	(85, 58, ' M. Talpaz ASCO 2011', 'https://meetinglibrary.asco.org/content/81698-102', 3),
	(86, 58, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Search', 5),
	(87, 58, 'Melkus M, Exp Hematol 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23287417?dopt=Abstract', 4),
	(88, 59, 'Link BC Goh ASCO 2010', 'https://meetinglibrary.asco.org/content/40737-74', 0),
	(89, 59, 'Fingas CD, Liver Int. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22133064?dopt=Abstract', 4),
	(268, 62, 'Eskens FA. Clin Cancer Res. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21976547', 3),
	(267, 66, 'Eskens FA,J Clin Oncol. 2009', 'http://www.ncbi.nlm.nih.gov/pubmed/19636022', 3),
	(92, 62, 'Link FF Kabbinavar 2011', 'https://meetinglibrary.asco.org/content/72482-104', 0),
	(93, 63, 'Tibes R,Cancer Chemother Pharmacol. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23178951', 3),
	(94, 64, 'Phase I plus S1', 'https://meetinglibrary.asco.org/content/105654-133', 0),
	(95, 64, 'Jin ZH,, Angiogenesis 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22644563?dopt=Abstract', 4),
	(96, 65, 'Lewis NL, J Clinic Oncol 2009', 'http://www.ncbi.nlm.nih.gov/pubmed/19738123', 3),
	(214, 67, 'Angevin E Clinical Cancer Res 2013', 'http://meetinglibrary.asco.org/content/93667-114', 3),
	(99, 67, 'Wasag B, Hematologica 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21330321?dopt=Abstract   ', 4),
	(100, 68, 'Afatinib + vinorelbine phase I', 'https://meetinglibrary.asco.org/content/83807-102', 0),
	(101, 68, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/1032', 5),
	(102, 68, 'Wang W, Clin Cancer Res 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22317763?dopt=Abstract  ', 4),
	(103, 69, 'Wong KK,  Clin Cancer Res. 2009', 'http://www.ncbi.nlm.nih.gov/pubmed/19318484', 3),
	(104, 69, 'Lee HJ, Cancer Discov 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23229345?dopt=Abstract', 4),
	(105, 70, 'U. Keilholz, ASCO 2011', 'https://meetinglibrary.asco.org/content/78242-102', 3),
	(239, 71, 'Leijen S, Cancer Chemother Pharmacol. 2011 ', 'http://www.ncbi.nlm.nih.gov/pubmed/21953275', 3),
	(107, 71, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/1062', 5),
	(108, 71, 'Nazarian R, Nature 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/21107323?dopt=Abstract  ', 4),
	(109, 72, ' WA Messersmith, Gastrointestinal Cancer Symposium 2011 ', 'https://meetinglibrary.asco.org/content/71253-103', 3),
	(110, 72, 'Ohashi K, Proc Natl Acad Sci U S A. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22773810?dopt=Abstract', 4),
	(111, 73, ' J. Delord ASCO 2010', 'https://meetinglibrary.asco.org/content/43866-74', 3),
	(247, 36, 'FORETINIB PHASE II Publ.', 'http://www.ncbi.nlm.nih.gov/pubmed/23213094', 0),
	(113, 1, 'Ohashi K,Proc Natl Acad Sci U S A. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22773810?dopt=Abstract  ', 4),
	(114, 1, 'Paraiso KH,Cancer Res. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21317224?dopt=Abstract', 4),
	(115, 13, 'Luk SK, Euro J Cancer 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22079609?dopt=Abstract', 4),
	(116, 13, 'Martín-Sánchez E, Haematologica 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22801959?dopt=Abstract', 4),
	(476, 19, 'Wilson TR,Nature. 2012 ', 'http://www.ncbi.nlm.nih.gov/pubmed/22763448?dopt=Abstract', 4),
	(119, 45, 'Wang G,J Cell Sci. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23345402?dopt=Abstract    ', 4),
	(120, 45, 'Sloane DA, ACS Chem Biol. 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20426425?dopt=Abstract', 4),
	(121, 21, 'Shi H, Cancer Res 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21803746?dopt=Abstract    ', 4),
	(122, 21, 'Yang H, Cancer Res 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22180495?dopt=Abstract', 4),
	(123, 41, 'Krapf D, J Biol Chem 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20068039?dopt=Abstract  ', 4),
	(124, 41, 'Gorbunova EE, J Virol 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21177802?dopt=Abstract', 4),
	(125, 44, 'Kuratnik A, Biochem Pharmacol. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22306067?dopt=Abstract   ', 4),
	(126, 44, 'Gäbler K, J Cell Mol Med. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23301855?dopt=Abstract', 4),
	(127, 39, 'Zauli G, Clin Cancer Res 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21106726?dopt=Abstract   ', 4),
	(128, 39, 'Gorbunova EE, J Virol 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21177802?dopt=Abstract', 4),
	(129, 67, 'Gozgit JM, Mol Cancer Ther 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22238366?dopt=Abstract  ', 4),
	(130, 67, 'Lamont FR, B R J Cancer 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21119661?dopt=Abstract', 4),
	(265, 61, 'Soria JC, Eur J Cancer 2009', 'http://www.ncbi.nlm.nih.gov/pubmed/19541476', 3),
	(264, 59, 'Asahina H,Cancer Chemother Pharmacol. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22382879', 3),
	(133, 46, 'Morozova O, Clin Cancer Res 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20651058?dopt=Abstract   ', 4),
	(134, 46, 'Wu L,J Biol Chem 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20959462?dopt=Abstract', 4),
	(135, 71, 'Johannessen Nature 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/21107320?dopt=Abstract ', 4),
	(136, 71, 'Smith MP, J Natl Cancer Inst. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23250956?dopt=Abstract', 4),
	(137, 68, 'Gong HC, Int J Proteomics. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/22091388?dopt=Abstract  ', 4),
	(138, 68, 'Lee HJ, Cancer Discov 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23229345?dopt=Abstract', 4),
	(139, 56, 'Li Q, J Biomol Screen. 2011 Feb', 'http://www.ncbi.nlm.nih.gov/pubmed/21297102?dopt=Abstract', 4),
	(140, 57, 'Harr MW, Cell Death Differ. 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20300113?dopt=Abstract  ', 4),
	(141, 57, 'Xiang QF, Cell Oncol (Dordr). 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21290212?dopt=Abstract', 4),
	(142, 79, 'OLAPARIB + BEVAZUCIMAB Phase I', 'http://www.ncbi.nlm.nih.gov/pubmed/22223088', 0),
	(143, 79, 'Schlacher K, Cell 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21565612?dopt=Abstract   ', 4),
	(144, 79, 'Link drug ', 'http://www.cancerrxgene.org/translation/Drug/1017', 5),
	(156, 82, 'Bedikian AY, Cancer Invest. 2009', 'http://www.ncbi.nlm.nih.gov/pubmed/19440934\r\n', 3),
	(157, 83, 'W. R. Schelman,, ASCO 2011', 'http://meetinglibrary.asco.org/content/84336-102\r\n', 3),
	(158, 44, 'Traynor AM, Cancer Chemother Pharmacol. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/20386909', 3),
	(159, 47, ' P. J. Rosen ASCO 2010', 'http://meetinglibrary.asco.org/content/50492-74', 3),
	(160, 48, ' T. Macarulla, Mol Cancer Ther. 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20724522', 3),
	(161, 61, 'Ph Hammel ASCO 2009', 'http://meetinglibrary.asco.org/content/30794-65', 0),
	(162, 66, 'Phase I + Bevazucimab ', 'http://meetinglibrary.asco.org/content/49065-74', 0),
	(166, 8, ' Edelmann ASCO 2010', 'https://meetinglibrary.asco.org/content/53257-74', 3),
	(167, 13, 'CAL-101 (GS-1101) + ofatumumab in leukemia', 'https://meetinglibrary.asco.org/content/97100-114', 0),
	(168, 79, 'Ullal AV, ACS Nano 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21962084?dopt=Abstract   ', 4),
	(169, 79, 'Murai J, Mol Cell Bio 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21482670?dopt=Abstract', 4),
	(258, 81, 'plus chemotherapy in ttriple negativo. Publ.', 'http://www.ncbi.nlm.nih.gov/pubmed/21208101', 0),
	(257, 81, 'Phase III + Gemcitabine/carboplatin', 'http://meetinglibrary.asco.org/content/84545-102', 0),
	(173, 80, 'ABT-888 (Veliparib)', 'http://www.cancerrxgene.org/translation/Drug/1018', 5),
	(174, 80, 'Huehls AM, Cancer Res 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21613406?dopt=Abstract   ', 4),
	(175, 80, 'Fenton AL, Nucleic Acids Res. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23449221?dopt=Abstract', 4),
	(176, 81, 'Phase Ib+ carboplatin/paclitaxel', 'https://meetinglibrary.asco.org/content/82193-102', 0),
	(177, 81, 'Haile WB, Neuroscience. 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20955770?dopt=Abstract', 4),
	(231, 29, '1- ASCO 2012 ', 'http://meetinglibrary.asco.org/content/96573-114', 0),
	(182, 84, ' Robert R. McWilliams   2013 Gastrointestinal Cancers Symposium ', 'http://meetinglibrary.asco.org/content/105409-133', 0),
	(183, 84, '17-AAG (Tanespimycin)', 'http://www.cancerrxgene.org/translation/Drug/1026', 5),
	(184, 85, 'K. Wong  ASCO 2011  Phase II', 'http://meetinglibrary.asco.org/content/82185-102', 3),
	(185, 84, 'Weigert O,J Expect Med 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22271575?dopt=Abstract  ', 4),
	(186, 84, 'Katayama R, Proc Natl Acad Sci U S A. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21502504?dopt=Abstract  ', 4),
	(187, 84, 'Kim KH, J Biol Chem 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/23144451?dopt=Abstract', 4),
	(188, 86, 'Bukong TN,, Hepatology 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/22898980?dopt=Abstract  ', 4),
	(189, 86, 'Koizumi H, J Thorac Oncol. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22592212?dopt=Abstract', 4),
	(190, 86, 'Lamoth F, Eukaryot Cell. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22822234?dopt=Abstract', 4),
	(191, 86, ' Pacey S,  Clin Cancer Res. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21278242', 3),
	(192, 87, ' Daruka Mahadevan ASCO 2012', 'http://meetinglibrary.asco.org/content/98734-114', 3),
	(193, 88, 'Phase II ASCO 2009', 'http://meetinglibrary.asco.org/content/33781-65', 0),
	(194, 89, 'David C. Smith asco 2012', 'http://meetinglibrary.asco.org/content/94218-114', 3),
	(195, 89, 'Thomé CH, Mol Cell Proteomics. 2012 ', ' http://www.ncbi.nlm.nih.gov/pubmed/23001822?dopt=Abstract  ', 4),
	(296, 158, 'Seki Y, Cancer Chemother Pharmacol. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22143378', 3),
	(197, 90, 'Phase II ASCO 2009 ', 'http://meetinglibrary.asco.org/content/32810-65', 0),
	(198, 91, 'Volasertib+ cis carbopllatin Phase I   ASCO 2011', 'http://meetinglibrary.asco.org/content/77638-102', 0),
	(200, 119, 'R. C. Donehower ASCO 2011', 'http://meetinglibrary.asco.org/content/82236-102', 3),
	(201, 120, 'Ranee Mehra ASCO 2012', 'http://meetinglibrary.asco.org/content/95081-114', 3),
	(202, 119, 'INCB28060 ', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=25145656', 2),
	(203, 120, 'LDK378', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=57379345&loc=ec_rcs', 2),
	(204, 121, 'Reinhard Dummer ASCO 2013', 'http://meetinglibrary.asco.org/content/113515-132', 3),
	(205, 122, 'MEK 162', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=10288191  ', 2),
	(208, 124, 'CVX060 + AXITINIB Phase Ib', 'http://meetinglibrary.asco.org/content/108265-132\r\n', 0),
	(209, 125, 'W. A. Messersmith, ASCO 2011', 'http://meetinglibrary.asco.org/content/74872-102', 3),
	(210, 125, 'PF-03084014', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=136350017&loc=es_rss', 2),
	(211, 126, 'Matteo Simonelli ASCO 2013', 'http://meetinglibrary.asco.org/content/112398-132', 3),
	(212, 126, 'PF-03446962', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=160687712', 2),
	(215, 24, ' GSK1120212 (GSK212)  with  GSK2141795 (GSK795).   ', 'http://meetinglibrary.asco.org/content/74424-102', 0),
	(217, 49, 'Dent SF,Invest New Drugs. 2013 Advanced solid malignances', 'http://www.ncbi.nlm.nih.gov/pubmed/24072436', 0),
	(218, 46, 'Boss DS, Ann Oncol 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/20924078', 3),
	(219, 47, 'Steeghs N J Clin Oncol 2009', 'http://www.ncbi.nlm.nih.gov/pubmed/19770380', 3),
	(220, 51, 'Diamond JR, Clin Cancer Res. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21131552', 3),
	(223, 45, 'Dees EC,  Clin Cancer Res. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22767670', 3),
	(484, 417, 'Markman B,Ann Oncol. 2012 ', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=BGT226+(NVP-BGT226)', 3),
	(227, 84, '17 AAG WITH TRASTUZUMAB IN BREAST CANCER', 'http://www.ncbi.nlm.nih.gov/pubmed/21558407', 0),
	(228, 87, '*Khanh Tu Do, ASCO 2012', 'http://meetinglibrary.asco.org/content/99279-114', 3),
	(229, 85, ' D. C. Cho ASCO 2011 Phase I', 'http://meetinglibrary.asco.org/content/81941-102', 3),
	(230, 31, 'AMG IN COMBINATION AÑADIR?', 'http://www.ncbi.nlm.nih.gov/pubmed/22510349', 0),
	(234, 29, 'Atzori F, Clinical Cancer Res 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21810918', 0),
	(235, 30, 'Kurzrock R, Clinical Cancer Res 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20371689', 3),
	(236, 30, ' Phase II in combination with erlotinib ', 'http://www.ncbi.nlm.nih.gov/pubmed/22025157', 4),
	(237, 84, 'Richardson PG,  Br J Haematol. 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20618337', 3),
	(238, 71, 'Banerji U, Clinical cancer Research 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20179232', 3),
	(240, 71, 'Selumetinib + MK2206 phase I', 'http://meetinglibrary.asco.org/content/77652-102', 0),
	(241, 72, 'Phase I melanoma', 'http://www.ncbi.nlm.nih.gov/pubmed/22805292', 0),
	(242, 72, 'Phase II melanoma', 'http://www.ncbi.nlm.nih.gov/pubmed/23248257', 0),
	(243, 122, 'MEK162 phase II  Melanoma Publ.', 'http://www.ncbi.nlm.nih.gov/pubmed/23414587', 0),
	(244, 122, 'LGX818+ MEK162 phase Ib/II ASCO 2013', 'http://meetinglibrary.asco.org/content/115328-132', 0),
	(245, 122, 'Richard S, Gastrointestinal Cancer symposium 2012 ', 'http://meetinglibrary.asco.org/content/88653-115', 3),
	(246, 74, 'Alex A. Adje, ASCO 2013 ', 'http://meetinglibrary.asco.org/content/112399-132', 3),
	(248, 36, 'FORETINIB + LAPATINIB  PHASE IB ', 'http://www.asco.org/search/site/FORETINIB', 0),
	(249, 38, 'phase I solo revisar Alberto.', 'http://meetinglibrary.asco.org/content/96776-114', 0),
	(250, 38, 'MGCD265 + DOCETAXEL', 'http://meetinglibrary.asco.org/content/96214-114', 0),
	(251, 38, 'MGCD265 + ERLOTINIB', 'http://meetinglibrary.asco.org/content/96526-114', 0),
	(253, 80, 'Phase 0 sin toxicidad publ.', 'http://www.ncbi.nlm.nih.gov/pubmed/19364967', 0),
	(254, 80, 'Phase I+metronomic cyclophosphamide Publ.', 'http://www.ncbi.nlm.nih.gov/pubmed/22307137', 0),
	(255, 80, 'Phase I with Topotecan Publ.', 'www.ncbi.nlm.nih.gov/pubmed/21795476', 0),
	(256, 81, 'Phase II + Gemcitabine/Carboplatin', 'http://meetinglibrary.asco.org/content/82175-102', 0),
	(259, 79, 'Yamamoto N, Cancer Sci. 2012 ', 'http://www.ncbi.nlm.nih.gov/pubmed/22145984', 3),
	(260, 63, 'MP-470 + 5 SOC', 'http://meetinglibrary.asco.org/content/63058', 0),
	(261, 63, 'MP-470 in healthy volunteers Phase I', 'http://www.ncbi.nlm.nih.gov/pubmed/22349808', 0),
	(262, 56, 'Fujiwara Y, Invest New Drugs. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/21301929', 3),
	(269, 64, 'Ueda Y, Cancer Chemother Pharmacol. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/20676675', 3),
	(270, 3, 'Bendell JC,, J Clinic Oncol 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=BKM120', 3),
	(294, 157, 'M. M. Mita, ASCO 2011', 'http://meetinglibrary.asco.org/content/84102-102', 0),
	(274, 5, 'Hong DS, Clin Cancer Res 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=PX-866', 3),
	(276, 6, 'Mahadevan D, Euro J cancer 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22921184', 0),
	(277, 8, 'XL147 + Erlotinib phase I', 'http://meetinglibrary.asco.org/content/44415-74', 0),
	(278, 7, 'XL765 + Erlotinib', 'http://meetinglibrary.asco.org/content/50991-74', 0),
	(279, 90, 'Mross K,J Clinic Oncol 2008', 'http://www.ncbi.nlm.nih.gov/pubmed/18955456', 3),
	(280, 91, 'Schöffski P, Euro J Cancer 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=(Volasertib)', 3),
	(281, 41, 'Daud AI, Clin Cancer Res 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22179664', 3),
	(283, 39, 'Demetri GD, Clin Cancer Res 2009', 'http://www.ncbi.nlm.nih.gov/pubmed/19789325', 3),
	(284, 39, 'Takahashi S, Cancer Sci 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21781226', 3),
	(285, 39, 'Phase I Dasatinib + ixabepilone 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/22392508', 0),
	(286, 42, 'Antonarakis ES, Cancer Chemother Pharmacol. 2013 Phase II', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=KX2-391', 0),
	(287, 126, 'Simulation (PK M&S) supported dose escalation of PF-03446962,', 'http://meetinglibrary.asco.org/content/94784-114', 0),
	(288, 121, 'LGX818+ MEK 162 Phase Ib/II', 'http://meetinglibrary.asco.org/content/115328-132', 0),
	(290, 68, 'Afatinib + Docetaxel phase I', 'http://www.ncbi.nlm.nih.gov/pubmed/23414476', 0),
	(291, 68, 'Yap TA, J Clin Oncol. 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20679611', 3),
	(292, 69, 'Ito Y, Jpn J Clin Oncol. 2012 ', 'http://www.ncbi.nlm.nih.gov/pubmed/22371427', 3),
	(293, 88, 'OConnor OA, Clin Cancer Res 2009', 'http://www.ncbi.nlm.nih.gov/pubmed/19903785', 3),
	(295, 157, 'Zhang D, Cancer Chemother Pharmacol. 2012 ', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=DINACICLIB', 3),
	(297, 159, 'Geoffrey Shapiro, ASCO 2013', 'http://meetinglibrary.asco.org/content/111069-132', 3),
	(298, 160, 'Flaherty KT,Clin Cancer Res 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22090362', 3),
	(299, 160, 'Liu NA, Proc Natl Acad Sci U S A. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21536883?dopt=Abstract', 4),
	(300, 160, 'Fung C, Pigment Cell Melanoma Res. 2013 ', 'http://www.ncbi.nlm.nih.gov/pubmed/23279822?dopt=Abstract', 4),
	(301, 160, 'Basile KJ, Am J Cancer Res. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/23226618?dopt=Abstract', 4),
	(302, 161, 'Le Tourneau C,Eur J Cancer. 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20822897', 3),
	(303, 161, 'Liu NA, Proc Natl Acad Sci U S A. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21536883?dopt=Abstract', 4),
	(304, 161, 'Takitoh T, J Neurosci. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22875938?dopt=Abstract', 4),
	(305, 161, 'Coley HM, Br J Cancer. 2012 ', 'http://www.ncbi.nlm.nih.gov/pubmed/22233925?dopt=Abstract', 4),
	(306, 162, 'B. Ramaswamy, ASCO 2009', 'http://meetinglibrary.asco.org/content/31223-65', 3),
	(307, 162, 'Liu NA, Proc Natl Acad Sci U S A. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21536883?dopt=Abstract', 4),
	(308, 162, 'Natoni A, Mol Cancer Ther. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21768328?dopt=Abstract', 4),
	(309, 162, 'Phelps MA, Blood. 2009 Mar IN LEUKEMIA', 'http://www.ncbi.nlm.nih.gov/pubmed/18981292', 0),
	(310, 162, 'Phase I Flavopiridol + Gemcitabina', 'http://www.ncbi.nlm.nih.gov/pubmed/19884803', 0),
	(311, 162, 'Phase I vorinostat with flavopiridol', 'http://www.ncbi.nlm.nih.gov/pubmed/20461440', 0),
	(312, 163, 'Boss DS, Ann Oncol. 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=AZD5438', 3),
	(313, 163, 'Nagaria TS, Neoplasia 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23908594?dopt=Abstract', 4),
	(314, 164, 'Mahadevan D, Ann Oncol. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=AT7519', 3),
	(315, 164, 'Chu PC, J Biol Chem 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/23115237?dopt=Abstract', 4),
	(316, 164, 'Alessandri AL, PLoS One. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21984938?dopt=Abstract', 4),
	(317, 168, 'Tong WG, J Clinic Oncol 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20479412', 3),
	(318, 168, 'Johnson TP,Proc Natl Acad Sci U S A. 2013 ', 'http://www.ncbi.nlm.nih.gov/pubmed/23898208?dopt=Abstract', 4),
	(319, 168, 'Natoni A, Mol Cancer Ther. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21768328?dopt=Abstract', 4),
	(320, 170, 'Massard C,Cell cycle 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21368575', 3),
	(321, 170, 'Greenhalf W, Anticancer Agents Med Chem. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21521155?dopt=Abstract', 4),
	(322, 173, 'Weiss GJ, Invest New Drugs. 2012 ', 'http://www.ncbi.nlm.nih.gov/pubmed/22160853', 3),
	(325, 179, 'Camacho LH,J Clin Oncol 2009', 'http://www.ncbi.nlm.nih.gov/pubmed/19139427', 3),
	(324, 178, 'Ronald B. ASCO 2012', 'http://meetinglibrary.asco.org/content/100704-114', 3),
	(326, 180, 'Mario Campone, ASCO 2012 CEP-9722 + temozolomide', 'http://meetinglibrary.asco.org/content/97512-114', 0),
	(327, 190, 'Toshihiko Doi, Cancer Chemotherapy and Pharmacology 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23124648', 3),
	(328, 191, 'Gordon MS, Clin Cancer Res 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20068101', 3),
	(379, 293, 'PHASE I OBATOCLAX + TOPOTECAN ', 'http://www.ncbi.nlm.nih.gov/pubmed/20165849 ', 0),
	(330, 195, 'Patricia LoRusso, ASCO 2012.  GDC-0973 + GDC-0941', 'http://meetinglibrary.asco.org/content/94732-114', 3),
	(331, 201, 'Kreahling JM,PLoS One. 2013 + GEMCITABINE', 'http://www.ncbi.nlm.nih.gov/pubmed/23520471', 3),
	(491, 426, 'Gallerani E, Eur J Cancer. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=CEP-18770+(Delanzomib)', 3),
	(333, 158, 'Ansbro MR, PLoS One. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23593196?dopt=Abstract', 4),
	(334, 158, 'Ashe KM,Mol Genet Metab. 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20554235?dopt=Abstract', 4),
	(335, 205, 'Amita Patnaik, ASCO 2012', 'http://meetinglibrary.asco.org/content/100724-114', 3),
	(336, 205, 'MK-3475 ( Lambrolizumab) in melanoma pubmed', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=MK-3475', 0),
	(464, 399, 'Johann Sebastian De Bono, ASCO 2013', 'http://meetinglibrary.asco.org/content/111725-132', 3),
	(338, 207, 'Suzanne Louise Topalian, ASCO 2013', 'http://meetinglibrary.asco.org/content/113543-132', 3),
	(339, 207, 'Nivolumab plus ipilimumab  in melanoma', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=Nivolumab', 0),
	(340, 208, 'Zonder JA, Blood 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22184404', 3),
	(341, 210, 'Matthew P. Goetz ASCO 2012', 'http://meetinglibrary.asco.org/content/99456-114', 3),
	(342, 217, 'Kuenen B,Clin Cancer Res 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=Necitumumab+(IMC-11F8)', 3),
	(343, 222, 'Falchook GS, Lancel Oncol 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22805292', 3),
	(344, 224, 'Kathleen N. Moore, ASCO 2013', 'http://meetinglibrary.asco.org/content/111447-132', 3),
	(345, 235, 'Marika Ciprotti,ASCO 2013', 'http://meetinglibrary.asco.org/content/114113-132', 3),
	(346, 236, 'Pishvaian MJ, Cancer 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22570147', 3),
	(347, 237, 'J. Berlin, ASCO 2011', 'http://meetinglibrary.asco.org/content/84026-102', 3),
	(348, 239, 'Rosen LS, Clin Cancer Res. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21976535', 3),
	(349, 242, 'Gordon MS,Clin Cancer Res. 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20068101', 0),
	(350, 242, 'Schöffski P, BJU Int. 2011 PHASE II ONLY', 'http://www.ncbi.nlm.nih.gov/pubmed/21156020', 3),
	(351, 244, 'Amita Patnaik, ASCO 2013', 'http://meetinglibrary.asco.org/content/117114-132', 3),
	(353, 252, 'Drew Warren Rasco, ASCO 2013', 'http://meetinglibrary.asco.org/content/109770-132', 3),
	(354, 255, 'Ignacio Melero, ASCO 2013', 'http://meetinglibrary.asco.org/content/113124-132', 3),
	(355, 257, 'Naiyer A, ASCO 2013 + ipilimumab', 'http://meetinglibrary.asco.org/content/112624-132', 0),
	(356, 257, 'Rachel E ASCO 2013 +nivolumab (anti-PD-1)', 'http://meetinglibrary.asco.org/content/113473-132', 0),
	(357, 263, '', 'http://www.clinicaltrials.gov/ct2/show/NCT01522664?term=DEDN6526A&rank=1', 3),
	(358, 265, '', 'http://www.clinicaltrials.gov/ct2/show/NCT01363947?term=DNIB0600A&rank=1', 0),
	(359, 267, '', 'http://www.clinicaltrials.gov/ct2/results?term=MPDL3280A&rank=1', 3),
	(361, 271, 'D. Ross Camidge, ASCO 2013', 'http://meetinglibrary.asco.org/content/114967-132', 3),
	(362, 272, 'Seto T, Lancet Oncol. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=CH5424802', 3),
	(363, 272, 'Uitdehaag JC, Br J Pharmacol. 2012 ', 'http://www.ncbi.nlm.nih.gov/pubmed/22250956?dopt=Abstract', 0),
	(365, 47, 'Xie L,Biochem Pharmacol. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22100984?dopt=Abstract', 4),
	(366, 47, 'Glaser KB,J Pharmacol Exp Ther. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22935731?dopt=Abstract', 4),
	(368, 49, 'Lee DF,Cell Stem Cell. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22862944?dopt=Abstract', 4),
	(369, 49, 'Markant SL, Cancer Res. 2013 ', 'http://www.ncbi.nlm.nih.gov/pubmed/24067506?dopt=Abstract', 4),
	(370, 52, 'Uitdehaag JC,Br J Pharmacol. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22250956?dopt=Abstract', 4),
	(371, 53, 'Uitdehaag JC,Br J Pharmacol. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22250956?dopt=Abstract', 4),
	(372, 53, 'Horwacik I, Cancer Lett. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23962557?dopt=Abstract', 4),
	(373, 50, 'Markant SL,Cancer Res. 2013 ', 'http://www.ncbi.nlm.nih.gov/pubmed/24067506?dopt=Abstract', 4),
	(375, 50, 'Francescangeli F, Stem Cells. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22753241?dopt=Abstract', 4),
	(376, 276, 'Schöffski P, Eur J Cancer. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=PF-03814735', 3),
	(377, 51, 'Markant SL, Cancer Res 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/24067506?dopt=Abstract', 4),
	(378, 51, 'Shiomitsu K, Vet Comp Oncol. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23763774?dopt=Abstract', 4),
	(380, 294, 'Gandhi L,  J Clin Oncol. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21282543', 3),
	(381, 294, 'NAVITOCLAX PLUS GEMCITABINE PHASE I', 'http://meetinglibrary.asco.org/content/77333-102', 0),
	(382, 179, 'TREMELIMUMAB+SUNITINIB', 'http://meetinglibrary.asco.org/content/31517-65', 0),
	(383, 313, 'Takahashi T,Invest New Drugs. 2012 ', 'http://www.ncbi.nlm.nih.gov/pubmed/22249430', 3),
	(384, 315, 'Siqing Fu, ASCO 2012', 'http://meetinglibrary.asco.org/content/99903-114', 3),
	(385, 317, 'Erlichman C, J Clin Oncol 2006', 'http://www.ncbi.nlm.nih.gov/pubmed/16710023', 3),
	(386, 318, 'Sklarin NT, Invest New Drugs. 1997', 'http://www.ncbi.nlm.nih.gov/pubmed/9387046', 3),
	(387, 318, 'Vivanco I,Cancer Discov. 2012 ', 'http://www.ncbi.nlm.nih.gov/pubmed/22588883?dopt=Abstract', 0),
	(388, 318, 'Choi W,J Cell Sci. 2010 ', 'http://www.ncbi.nlm.nih.gov/pubmed/20736300?dopt=Abstract', 0),
	(389, 318, 'Dong Z,Carcinogenesis. 2010 ', 'http://www.ncbi.nlm.nih.gov/pubmed/20837598?dopt=Abstract', 0),
	(390, 318, 'PHASE II SOLO', 'http://www.ncbi.nlm.nih.gov/pubmed/19294387', 3),
	(391, 318, 'PHASE I IN COMBINATION WITH PDOCETAXEL ', 'http://www.ncbi.nlm.nih.gov/pubmed/16857802', 0),
	(392, 319, 'Guo F,  Cancer Chemother Pharmacol. 2008', 'www.ncbi.nlm.nih.gov/pubmed/17805538', 3),
	(393, 320, 'Reardon DA, Cancer Chemother Pharmacol. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22392572', 3),
	(394, 321, 'Soria JC,Ann Oncol. 2012 ', 'http://www.ncbi.nlm.nih.gov/pubmed/21576284', 3),
	(395, 321, 'Bicocca VT, Cancer Cell. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/23153538?dopt=Abstract', 4),
	(396, 321, 'Mazumder S,Cancer Res. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22525702?dopt=Abstract', 4),
	(397, 321, 'Yi YW, J Cell Mol Med. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23601074?dopt=Abstract', 4),
	(398, 324, 'Doi T, Br J Cancer. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=TAK-285', 3),
	(399, 331, 'Strosberg JR, Eur J Cancer. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22445247', 3),
	(400, 331, 'Norihiko Saito, STEM CELLS 2013', 'http://onlinelibrary.wiley.com/doi/10.1002/stem.1528/abstract', 4),
	(401, 331, 'Liu J, Oncotarget. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/24091605?dopt=Abstract', 4),
	(402, 331, 'Münch J, Development. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23344707?dopt=Abstract', 4),
	(403, 331, 'PHASE I + CAPECITABINE', 'http://meetinglibrary.asco.org/content/100247-114', 0),
	(404, 332, 'Krop I, J Clin Oncol. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22547604', 3),
	(405, 334, 'Shubham Pant, ASCO 2012', 'http://meetinglibrary.asco.org/content/98676-114', 3),
	(406, 338, 'Kelly WK, J Clinic Oncol 2005', 'http://www.ncbi.nlm.nih.gov/pubmed/15897550', 3),
	(407, 338, 'Mullighan CG, Nature. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21390130?dopt=Abstract', 4),
	(408, 338, 'Bantscheff M,Nat Biotechnol. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21258344?dopt=Abstract', 4),
	(409, 338, 'Kaufmann KB,J Exp Med. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22231305?dopt=Abstract', 4),
	(410, 339, 'Fukutomi A, Invest New Drugs. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/21484248', 3),
	(411, 339, 'Bantscheff M, Nat Biotechnol. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21258344?dopt=Abstract', 4),
	(412, 339, 'Milde T,Acta Neuropathol. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21863243?dopt=Abstract', 4),
	(413, 339, 'Mannava S, Blood. 2012 ', 'http://www.ncbi.nlm.nih.gov/pubmed/22144178?dopt=Abstract', 4),
	(414, 340, 'Gore L, Clin Cancer Res. 2008', 'http://www.ncbi.nlm.nih.gov/pubmed/18579665', 3),
	(415, 340, 'Bantscheff M,Nat Biotechnol. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21258344?dopt=Abstract', 4),
	(416, 340, 'Cavasin MA, Circ Res. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22282194?dopt=Abstract', 4),
	(417, 340, 'Engmann O,Brain. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21772061?dopt=Abstract', 4),
	(418, 341, 'in combination with gemcitabine', 'http://www.ncbi.nlm.nih.gov/pubmed/22536933', 0),
	(419, 341, 'Johnson AA, J Neurosci. 2013 ', 'http://www.ncbi.nlm.nih.gov/pubmed/23616558?dopt=Abstract', 4),
	(420, 341, 'Mithraprabhu S,Br J Haematol. 2013 ', 'http://www.ncbi.nlm.nih.gov/pubmed/23692150?dopt=Abstract', 4),
	(421, 342, 'Yano R,Plant J. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23464703?dopt=Abstract', 4),
	(422, 342, 'Mateen S, Epigenetics. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22965008?dopt=Abstract', 4),
	(423, 343, 'Siu LL,, J Clin Oncol. 2008', 'http://www.ncbi.nlm.nih.gov/pubmed/18421048', 3),
	(424, 343, 'Tang J, Nat Struct Mol Biol. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23377543?dopt=Abstract', 4),
	(425, 343, 'Cavasin MA, Circ Res. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22282194?dopt=Abstract', 4),
	(426, 343, 'Duque-Afonso J, Oncogene. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21577204?dopt=Abstract', 4),
	(427, 344, 'R. D. Baird,  ASCO 2011', 'http://meetinglibrary.asco.org/content/75077-102', 3),
	(428, 346, 'Siqing Fu, ASCO 2012', 'http://meetinglibrary.asco.org/content/99903-114', 3),
	(429, 346, 'Qingqing Meng, ACS Med. Chem. Lett., 2013', 'http://pubs.acs.org/doi/abs/10.1021/ml400191z', 4),
	(430, 348, 'Razak AR, Br J Cancer. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21285985', 3),
	(431, 349, 'Steele NL,Clin Cancer Res. 2008 ', 'http://www.ncbi.nlm.nih.gov/pubmed/18245542', 3),
	(432, 349, 'Bantscheff M, Nat Biotechnol. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21258344?dopt=Abstract', 4),
	(433, 349, 'Huang Y, Breast Cancer Res Treat. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/21452019?dopt=Abstract', 4),
	(434, 349, 'Xu X, PLoS One. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21359182?dopt=Abstract', 4),
	(435, 33, 'Petrova E, Nat Chem Biol. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23416332?dopt=Abstract', 4),
	(436, 359, 'LoRusso PM, Clin Cancer Res. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21300762', 3),
	(437, 359, 'Chen Y, Gastroenterology. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22885334?dopt=Abstract', 4),
	(438, 359, 'Choi SS,  Hepatology. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21793033?dopt=Abstract', 4),
	(439, 359, 'Syn WK, Gut. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22427237?dopt=Abstract', 4),
	(440, 364, 'Saif MW, Clin Cancer Res. 2014', 'http://www.ncbi.nlm.nih.gov/pubmed/24097863', 3),
	(441, 87, 'Jia J, PLoS One. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23565147?dopt=Abstract', 4),
	(442, 369, 'Jorge A. Garcia, ASCO 2013', 'http://meetinglibrary.asco.org/content/117363-132', 3),
	(443, 369, 'Scagliotti GV, Cancer Treat Rev. 2012 ', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=OSI-906+%28Linsitinib%29', 0),
	(444, 369, 'Yaktapour N,  Blood. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23863897?dopt=Abstract', 4),
	(445, 369, 'Cortot AB, Cancer Res. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23172312?dopt=Abstract', 4),
	(446, 369, 'Fox EM,  Cancer Res. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21908557?dopt=Abstract', 4),
	(447, 370, 'J. Desai, ASCO 2010', 'http://meetinglibrary.asco.org/content/44688-74', 3),
	(448, 377, 'LoRusso PM, Clin Cancer Res. 2010', 'http://www.ncbi.nlm.nih.gov/pubmed/20215549', 3),
	(449, 377, 'Huang S, Cell. 2012 Nov', 'http://www.ncbi.nlm.nih.gov/pubmed/23178117?dopt=Abstract', 4),
	(450, 377, 'Gibbs KD Jr, Cell Stem Cell. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22305570?dopt=Abstract', 4),
	(451, 377, 'Millard BL, Nat Methods. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21516115?dopt=Abstract', 4),
	(452, 222, 'Ohashi K, Proc Natl Acad Sci U S A. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22773810?dopt=Abstract', 4),
	(453, 222, 'Basile KJ, Cancer Res. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/24121492?dopt=Abstract', 4),
	(454, 222, 'Ohashi K,  Clin Cancer Res. 2013 ', 'http://www.ncbi.nlm.nih.gov/pubmed/23515407?dopt=Abstract', 4),
	(455, 381, 'Cohen RB,, Eur J Cancer. 2013 ', 'http://www.ncbi.nlm.nih.gov/pubmed/?term=AZD8330', 3),
	(456, 381, 'Sunaga N, Oncogene. 2013 ', 'http://www.ncbi.nlm.nih.gov/pubmed/22964644?dopt=Abstract', 4),
	(457, 36, 'Zhang Z, Nat Genet. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22751098?dopt=Abstract', 4),
	(458, 36, 'Wang Q, Cancer Lett. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23811285?dopt=Abstract', 4),
	(459, 385, 'Rosen LS, Clin Cancer Res. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21976535', 3),
	(460, 385, 'Yang Q, Cell Signal. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/24012497?dopt=Abstract', 4),
	(461, 210, 'Baudet A, Blood. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22555972?dopt=Abstract', 4),
	(462, 210, 'Cloninger C,Mol Cancer Ther. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21911485?dopt=Abstract', 4),
	(463, 210, 'Rubinow KB, J Biol Chem. 2013 ', 'http://www.ncbi.nlm.nih.gov/pubmed/23426369?dopt=Abstract', 4),
	(465, 58, 'Bicocca VT, Cancer Cell. 2012 ', 'http://www.ncbi.nlm.nih.gov/pubmed/23153538?dopt=Abstract', 4),
	(466, 58, 'Byron SA,Neoplasia. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23908597?dopt=Abstract', 4),
	(478, 19, 'Fallahi-Sichani M, Nat Chem Biol. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/24013279?dopt=Abstract', 4),
	(475, 65, 'Ansbro MR, PLoS One. 2013 ', 'http://www.ncbi.nlm.nih.gov/pubmed/23593196?dopt=Abstract', 4),
	(474, 65, 'Dai J, Clin Cancer Res. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/24132921?dopt=Abstract', 4),
	(470, 61, 'Avula MN, Biomaterials. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/24060424?dopt=Abstract', 4),
	(471, 61, 'Ansbro MR, PLoS One. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23593196?dopt=Abstract', 4),
	(472, 64, 'Trzcinska-Daneluti AM, Mol Cell Proteomics. 2012', 'http://www.ncbi.nlm.nih.gov/pubmed/22700489?dopt=Abstract', 4),
	(480, 3, 'Renshaw J, Clin Cancer Res. 2013 ', 'http://www.ncbi.nlm.nih.gov/pubmed/23918606?dopt=Abstract', 4),
	(481, 3, 'Baba A, BMC Cancer. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/24103747?dopt=Abstract', 4),
	(492, 427, 'Fujisaka Y,Invest New Drugs. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/22415795', 3),
	(490, 20, 'Lazo JS,  J Pharmacol Exp Ther. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/24068833?dopt=Abstract', 4),
	(486, 422, 'Naing A, Br J Cancer. 2012 ', 'http://www.ncbi.nlm.nih.gov/pubmed/22935583', 3),
	(487, 422, 'Martin KR,Autophagy. 2013 ', 'http://www.ncbi.nlm.nih.gov/pubmed/23196898?dopt=Abstract', 4),
	(488, 422, 'Wu Y, Antioxid Redox Signal. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/24063548?dopt=Abstract', 4),
	(489, 422, 'Furukawa S, Am J Transplant. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23841834?dopt=Abstract', 4),
	(493, 427, 'Higashida C,Nat Cell Biol. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/23455479?dopt=Abstract', 4),
	(494, 427, ' Liu H,Cancer Res. 2011', 'http://www.ncbi.nlm.nih.gov/pubmed/21994334?dopt=Abstract', 4),
	(495, 427, 'Liu KJ, Int J Cancer. 2013', 'http://www.ncbi.nlm.nih.gov/pubmed/22623106?dopt=Abstract', 4),
	(496, 276, 'Jitesh P. Jani, Mol Cancer Ther April 2010 ', 'http://mct.aacrjournals.org/content/9/4/883.abstract', 4),
	(497, 284, 'TAFINLAR (Dabrafenib)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806s000lbl.pdf', 0);
/*!40000 ALTER TABLE `farmacos_inv_link` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.farmacos_inv_pathways
CREATE TABLE IF NOT EXISTS `farmacos_inv_pathways` (
  `id_farmaco` smallint(9) unsigned NOT NULL,
  `id_pathway` smallint(5) unsigned NOT NULL,
  PRIMARY KEY (`id_farmaco`,`id_pathway`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.farmacos_inv_pathways: 806 rows
/*!40000 ALTER TABLE `farmacos_inv_pathways` DISABLE KEYS */;
INSERT INTO `farmacos_inv_pathways` (`id_farmaco`, `id_pathway`) VALUES
	(1, 35),
	(1, 51),
	(1, 53),
	(1, 158),
	(1, 159),
	(1, 160),
	(1, 161),
	(1, 162),
	(1, 163),
	(2, 35),
	(2, 51),
	(2, 53),
	(2, 158),
	(2, 159),
	(2, 160),
	(2, 161),
	(2, 162),
	(2, 163),
	(3, 35),
	(3, 51),
	(3, 53),
	(3, 158),
	(3, 159),
	(3, 160),
	(3, 161),
	(3, 162),
	(3, 163),
	(5, 35),
	(5, 51),
	(5, 53),
	(5, 158),
	(5, 159),
	(5, 160),
	(5, 161),
	(5, 162),
	(5, 163),
	(6, 35),
	(6, 51),
	(6, 53),
	(6, 158),
	(6, 159),
	(6, 160),
	(6, 161),
	(6, 162),
	(6, 163),
	(7, 35),
	(7, 51),
	(7, 53),
	(7, 158),
	(7, 159),
	(7, 160),
	(7, 161),
	(7, 162),
	(7, 163),
	(8, 35),
	(8, 51),
	(8, 53),
	(8, 158),
	(8, 159),
	(8, 160),
	(8, 161),
	(8, 162),
	(8, 163),
	(10, 35),
	(10, 51),
	(10, 53),
	(10, 158),
	(10, 159),
	(10, 160),
	(10, 161),
	(10, 162),
	(10, 163),
	(11, 35),
	(11, 51),
	(11, 53),
	(11, 158),
	(11, 159),
	(11, 160),
	(11, 161),
	(11, 162),
	(11, 163),
	(12, 35),
	(12, 51),
	(12, 53),
	(12, 158),
	(12, 159),
	(12, 160),
	(12, 161),
	(12, 162),
	(12, 163),
	(13, 35),
	(13, 51),
	(13, 53),
	(13, 158),
	(13, 159),
	(13, 160),
	(13, 161),
	(13, 162),
	(13, 163),
	(14, 35),
	(14, 51),
	(14, 53),
	(14, 158),
	(14, 159),
	(14, 160),
	(14, 161),
	(14, 162),
	(14, 163),
	(15, 35),
	(15, 51),
	(15, 53),
	(15, 135),
	(15, 136),
	(15, 158),
	(15, 159),
	(15, 160),
	(15, 161),
	(15, 162),
	(15, 163),
	(16, 35),
	(16, 51),
	(16, 53),
	(16, 135),
	(16, 136),
	(16, 158),
	(16, 159),
	(16, 160),
	(16, 161),
	(16, 162),
	(16, 163),
	(17, 35),
	(17, 51),
	(17, 53),
	(17, 135),
	(17, 136),
	(17, 158),
	(17, 159),
	(17, 160),
	(17, 161),
	(17, 163),
	(18, 35),
	(18, 51),
	(18, 53),
	(18, 135),
	(18, 136),
	(18, 158),
	(18, 159),
	(18, 160),
	(18, 161),
	(18, 162),
	(18, 163),
	(19, 35),
	(19, 51),
	(19, 53),
	(19, 135),
	(19, 136),
	(19, 158),
	(19, 159),
	(19, 160),
	(19, 161),
	(19, 162),
	(19, 163),
	(20, 35),
	(20, 51),
	(20, 53),
	(20, 135),
	(20, 136),
	(20, 158),
	(20, 159),
	(20, 160),
	(20, 161),
	(20, 162),
	(20, 163),
	(21, 51),
	(21, 53),
	(21, 160),
	(21, 161),
	(21, 162),
	(21, 163),
	(22, 35),
	(22, 51),
	(22, 53),
	(22, 160),
	(22, 161),
	(22, 162),
	(22, 163),
	(23, 51),
	(23, 53),
	(23, 160),
	(23, 161),
	(23, 162),
	(23, 163),
	(24, 51),
	(24, 53),
	(24, 160),
	(24, 161),
	(24, 162),
	(24, 163),
	(25, 51),
	(25, 53),
	(25, 160),
	(25, 161),
	(25, 162),
	(25, 163),
	(26, 51),
	(26, 53),
	(26, 160),
	(26, 161),
	(26, 162),
	(26, 163),
	(27, 135),
	(27, 136),
	(28, 135),
	(28, 136),
	(29, 107),
	(29, 112),
	(29, 113),
	(29, 114),
	(30, 107),
	(30, 112),
	(30, 113),
	(30, 114),
	(31, 107),
	(31, 112),
	(31, 113),
	(31, 114),
	(32, 107),
	(32, 112),
	(32, 113),
	(32, 114),
	(33, 96),
	(33, 97),
	(34, 238),
	(34, 239),
	(34, 240),
	(35, 238),
	(35, 239),
	(35, 240),
	(36, 238),
	(36, 239),
	(36, 240),
	(37, 84),
	(37, 85),
	(37, 205),
	(37, 233),
	(37, 242),
	(38, 238),
	(38, 239),
	(38, 240),
	(39, 13),
	(39, 84),
	(39, 85),
	(39, 124),
	(39, 125),
	(39, 201),
	(39, 217),
	(40, 13),
	(40, 84),
	(40, 85),
	(40, 124),
	(40, 125),
	(40, 201),
	(40, 217),
	(41, 13),
	(41, 35),
	(41, 51),
	(41, 53),
	(41, 84),
	(41, 85),
	(41, 124),
	(41, 125),
	(41, 158),
	(41, 159),
	(41, 160),
	(41, 161),
	(41, 162),
	(41, 163),
	(41, 201),
	(42, 13),
	(42, 84),
	(42, 85),
	(42, 124),
	(42, 125),
	(42, 201),
	(44, 22),
	(44, 38),
	(44, 39),
	(44, 41),
	(44, 42),
	(44, 43),
	(44, 250),
	(44, 251),
	(45, 22),
	(45, 38),
	(45, 39),
	(45, 41),
	(45, 42),
	(45, 43),
	(45, 250),
	(45, 251),
	(46, 22),
	(46, 38),
	(46, 39),
	(46, 41),
	(46, 42),
	(46, 43),
	(46, 250),
	(46, 251),
	(47, 22),
	(47, 38),
	(47, 39),
	(47, 41),
	(47, 42),
	(47, 43),
	(47, 250),
	(47, 251),
	(48, 22),
	(48, 38),
	(48, 39),
	(48, 41),
	(48, 42),
	(48, 43),
	(48, 250),
	(48, 251),
	(49, 22),
	(49, 38),
	(49, 39),
	(49, 41),
	(49, 42),
	(49, 43),
	(49, 250),
	(49, 251),
	(50, 22),
	(50, 38),
	(50, 39),
	(50, 41),
	(50, 42),
	(50, 43),
	(50, 250),
	(50, 251),
	(51, 22),
	(51, 38),
	(51, 39),
	(51, 41),
	(51, 42),
	(51, 43),
	(51, 250),
	(51, 251),
	(52, 22),
	(52, 38),
	(52, 39),
	(52, 41),
	(52, 42),
	(52, 43),
	(52, 250),
	(52, 251),
	(53, 22),
	(53, 38),
	(53, 39),
	(53, 41),
	(53, 42),
	(53, 43),
	(53, 250),
	(53, 251),
	(54, 2),
	(54, 147),
	(54, 148),
	(55, 2),
	(55, 147),
	(55, 148),
	(56, 13),
	(56, 124),
	(56, 125),
	(56, 158),
	(56, 242),
	(56, 252),
	(56, 259),
	(57, 13),
	(57, 124),
	(57, 125),
	(57, 158),
	(57, 242),
	(57, 252),
	(57, 259),
	(58, 13),
	(58, 124),
	(58, 125),
	(58, 158),
	(58, 242),
	(58, 252),
	(58, 259),
	(59, 13),
	(59, 124),
	(59, 125),
	(59, 158),
	(59, 242),
	(59, 252),
	(59, 259),
	(60, 84),
	(60, 85),
	(60, 205),
	(60, 233),
	(60, 242),
	(61, 13),
	(61, 124),
	(61, 125),
	(61, 158),
	(61, 242),
	(61, 252),
	(61, 259),
	(62, 13),
	(62, 124),
	(62, 125),
	(62, 158),
	(62, 242),
	(62, 252),
	(62, 259),
	(63, 13),
	(63, 124),
	(63, 125),
	(63, 158),
	(63, 242),
	(63, 252),
	(63, 259),
	(64, 13),
	(64, 124),
	(64, 125),
	(64, 158),
	(64, 242),
	(64, 252),
	(64, 259),
	(65, 13),
	(65, 124),
	(65, 125),
	(65, 158),
	(65, 242),
	(65, 252),
	(65, 259),
	(66, 13),
	(66, 124),
	(66, 125),
	(66, 158),
	(66, 242),
	(66, 252),
	(66, 259),
	(67, 13),
	(67, 124),
	(67, 125),
	(67, 158),
	(67, 242),
	(67, 252),
	(67, 259),
	(68, 65),
	(68, 66),
	(68, 67),
	(68, 71),
	(68, 72),
	(68, 73),
	(69, 65),
	(69, 66),
	(69, 67),
	(69, 71),
	(69, 72),
	(69, 73),
	(70, 65),
	(70, 66),
	(70, 67),
	(70, 71),
	(70, 72),
	(70, 73),
	(71, 13),
	(71, 124),
	(71, 125),
	(72, 13),
	(72, 124),
	(72, 125),
	(73, 13),
	(73, 124),
	(73, 125),
	(74, 13),
	(74, 124),
	(74, 125),
	(79, 58),
	(79, 59),
	(79, 60),
	(79, 166),
	(79, 167),
	(80, 58),
	(80, 59),
	(80, 60),
	(80, 166),
	(80, 167),
	(81, 58),
	(81, 59),
	(81, 60),
	(81, 166),
	(81, 167),
	(82, 58),
	(82, 59),
	(82, 60),
	(82, 166),
	(82, 167),
	(83, 58),
	(83, 59),
	(83, 60),
	(83, 166),
	(83, 167),
	(84, 171),
	(84, 255),
	(85, 171),
	(85, 255),
	(86, 171),
	(86, 255),
	(87, 171),
	(87, 255),
	(88, 258),
	(89, 258),
	(90, 38),
	(90, 39),
	(90, 40),
	(90, 41),
	(90, 42),
	(90, 43),
	(91, 38),
	(91, 39),
	(91, 40),
	(91, 41),
	(91, 42),
	(91, 43),
	(92, 38),
	(92, 39),
	(92, 40),
	(92, 41),
	(92, 42),
	(92, 43),
	(93, 242),
	(94, 242),
	(95, 22),
	(95, 38),
	(95, 39),
	(95, 41),
	(95, 42),
	(95, 43),
	(95, 250),
	(95, 251),
	(96, 242),
	(97, 242),
	(106, 84),
	(106, 85),
	(106, 205),
	(106, 233),
	(106, 242),
	(114, 22),
	(114, 38),
	(114, 39),
	(114, 40),
	(114, 41),
	(114, 42),
	(114, 43),
	(114, 250),
	(114, 251),
	(119, 238),
	(119, 239),
	(119, 240),
	(120, 66),
	(120, 67),
	(120, 253),
	(121, 124),
	(121, 125),
	(121, 208),
	(122, 13),
	(122, 124),
	(122, 125),
	(125, 147),
	(125, 148),
	(126, 66),
	(126, 67),
	(126, 253),
	(157, 38),
	(157, 39),
	(157, 40),
	(157, 41),
	(157, 42),
	(157, 43),
	(159, 38),
	(159, 39),
	(159, 40),
	(159, 41),
	(159, 42),
	(159, 43),
	(160, 38),
	(160, 39),
	(160, 40),
	(160, 41),
	(160, 42),
	(160, 43),
	(161, 38),
	(161, 39),
	(161, 40),
	(161, 41),
	(161, 42),
	(161, 43),
	(162, 38),
	(162, 39),
	(162, 40),
	(162, 41),
	(162, 42),
	(162, 43),
	(163, 38),
	(163, 39),
	(163, 40),
	(163, 41),
	(163, 42),
	(163, 43),
	(164, 38),
	(164, 39),
	(164, 40),
	(164, 41),
	(164, 42),
	(164, 43),
	(168, 38),
	(168, 39),
	(168, 40),
	(168, 41),
	(168, 42),
	(168, 43),
	(170, 38),
	(170, 39),
	(170, 40),
	(170, 41),
	(170, 42),
	(170, 43),
	(173, 38),
	(173, 39),
	(173, 40),
	(173, 41),
	(173, 42),
	(173, 43),
	(178, 35),
	(178, 51),
	(178, 53),
	(178, 160),
	(178, 161),
	(178, 162),
	(178, 163),
	(179, 55),
	(180, 58),
	(180, 59),
	(180, 60),
	(180, 166),
	(180, 167),
	(190, 35),
	(190, 51),
	(190, 53),
	(190, 160),
	(190, 161),
	(190, 162),
	(190, 163),
	(191, 238),
	(191, 239),
	(191, 240),
	(195, 13),
	(195, 124),
	(195, 125),
	(201, 38),
	(201, 39),
	(201, 40),
	(201, 41),
	(201, 42),
	(201, 43),
	(205, 155),
	(207, 155),
	(208, 55),
	(210, 13),
	(210, 124),
	(210, 125),
	(210, 152),
	(222, 13),
	(222, 124),
	(222, 125),
	(235, 16),
	(235, 17),
	(235, 19),
	(244, 66),
	(244, 67),
	(244, 253),
	(252, 13),
	(252, 124),
	(252, 125),
	(255, 55),
	(255, 217),
	(257, 256),
	(268, 58),
	(268, 59),
	(271, 66),
	(271, 67),
	(271, 253),
	(272, 66),
	(272, 67),
	(272, 253),
	(276, 22),
	(276, 38),
	(276, 39),
	(276, 41),
	(276, 42),
	(276, 43),
	(276, 250),
	(276, 251),
	(278, 65),
	(278, 67),
	(278, 253),
	(279, 58),
	(279, 59),
	(279, 60),
	(281, 58),
	(281, 59),
	(281, 60),
	(282, 3),
	(282, 15),
	(284, 124),
	(284, 125),
	(284, 208),
	(293, 17),
	(293, 18),
	(293, 19),
	(294, 17),
	(294, 18),
	(294, 19),
	(308, 65),
	(308, 66),
	(308, 71),
	(308, 72),
	(308, 73),
	(313, 65),
	(313, 66),
	(313, 67),
	(313, 71),
	(313, 72),
	(313, 73),
	(315, 65),
	(315, 66),
	(315, 67),
	(315, 71),
	(315, 72),
	(315, 73),
	(317, 65),
	(317, 66),
	(317, 67),
	(317, 71),
	(317, 72),
	(317, 73),
	(318, 65),
	(318, 66),
	(318, 67),
	(318, 71),
	(318, 72),
	(318, 73),
	(319, 65),
	(319, 66),
	(319, 67),
	(319, 71),
	(319, 72),
	(319, 73),
	(320, 65),
	(320, 66),
	(320, 67),
	(320, 71),
	(320, 72),
	(320, 73),
	(321, 65),
	(321, 66),
	(321, 67),
	(321, 71),
	(321, 72),
	(321, 73),
	(324, 65),
	(324, 66),
	(324, 67),
	(324, 71),
	(324, 72),
	(324, 73),
	(331, 147),
	(331, 148),
	(332, 147),
	(332, 148),
	(334, 147),
	(334, 148),
	(359, 96),
	(359, 97),
	(364, 171),
	(364, 255),
	(377, 13),
	(377, 124),
	(377, 125),
	(381, 13),
	(381, 124),
	(381, 125),
	(385, 238),
	(385, 239),
	(385, 240),
	(399, 58),
	(399, 59),
	(399, 60),
	(399, 166),
	(399, 167),
	(426, 258);
/*!40000 ALTER TABLE `farmacos_inv_pathways` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.farmacos_inv_toxicidad
CREATE TABLE IF NOT EXISTS `farmacos_inv_toxicidad` (
  `id_farmaco` mediumint(9) unsigned NOT NULL DEFAULT '0',
  `id_toxicidad` smallint(4) unsigned NOT NULL DEFAULT '0',
  `tx1` tinyint(1) NOT NULL DEFAULT '0',
  `tx2` tinyint(1) NOT NULL DEFAULT '0',
  PRIMARY KEY (`id_farmaco`,`id_toxicidad`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.farmacos_inv_toxicidad: 948 rows
/*!40000 ALTER TABLE `farmacos_inv_toxicidad` DISABLE KEYS */;
INSERT INTO `farmacos_inv_toxicidad` (`id_farmaco`, `id_toxicidad`, `tx1`, `tx2`) VALUES
	(42, 107, 0, 1),
	(1, 8, 1, 0),
	(1, 35, 1, 0),
	(1, 38, 1, 0),
	(1, 45, 1, 0),
	(158, 57, 1, 1),
	(1, 83, 1, 0),
	(1, 96, 1, 0),
	(39, 200, 1, 1),
	(1, 113, 1, 0),
	(158, 7, 1, 1),
	(2, 6, 1, 0),
	(2, 7, 1, 0),
	(2, 12, 0, 1),
	(2, 35, 1, 0),
	(2, 45, 1, 0),
	(2, 83, 1, 0),
	(2, 84, 1, 0),
	(2, 102, 1, 0),
	(158, 171, 1, 0),
	(159, 35, 1, 1),
	(3, 35, 1, 0),
	(3, 45, 1, 0),
	(3, 94, 1, 0),
	(3, 57, 1, 0),
	(3, 80, 1, 0),
	(3, 83, 1, 0),
	(3, 96, 1, 0),
	(159, 45, 1, 1),
	(159, 83, 1, 1),
	(158, 163, 1, 0),
	(39, 12, 1, 0),
	(5, 45, 1, 0),
	(5, 35, 1, 0),
	(90, 36, 1, 0),
	(5, 83, 1, 0),
	(39, 76, 1, 0),
	(5, 113, 1, 0),
	(39, 23, 1, 0),
	(6, 35, 0, 1),
	(158, 74, 1, 1),
	(158, 102, 1, 1),
	(158, 93, 1, 0),
	(7, 7, 1, 0),
	(7, 35, 1, 0),
	(7, 83, 1, 0),
	(7, 96, 0, 1),
	(7, 99, 1, 0),
	(7, 113, 1, 0),
	(8, 50, 1, 0),
	(8, 57, 1, 0),
	(35, 12, 1, 1),
	(64, 45, 1, 0),
	(8, 96, 1, 1),
	(8, 144, 0, 1),
	(8, 160, 1, 0),
	(10, 12, 0, 1),
	(10, 35, 1, 1),
	(10, 45, 1, 1),
	(10, 50, 1, 1),
	(10, 57, 1, 1),
	(10, 80, 1, 1),
	(10, 83, 1, 1),
	(10, 96, 1, 1),
	(10, 102, 1, 1),
	(11, 8, 1, 0),
	(11, 35, 1, 0),
	(11, 50, 1, 0),
	(11, 57, 1, 0),
	(11, 83, 1, 0),
	(11, 45, 1, 0),
	(11, 113, 1, 0),
	(12, 3, 1, 0),
	(12, 6, 0, 1),
	(12, 35, 1, 0),
	(12, 38, 1, 1),
	(12, 45, 1, 1),
	(12, 50, 1, 1),
	(12, 57, 1, 1),
	(12, 80, 1, 0),
	(12, 83, 1, 1),
	(12, 84, 0, 1),
	(12, 88, 0, 1),
	(12, 96, 0, 1),
	(12, 102, 1, 0),
	(12, 107, 0, 1),
	(12, 113, 1, 1),
	(12, 144, 1, 1),
	(12, 163, 0, 1),
	(158, 23, 1, 0),
	(158, 156, 1, 0),
	(158, 45, 1, 0),
	(14, 1, 1, 0),
	(14, 6, 1, 1),
	(14, 35, 0, 1),
	(14, 45, 1, 0),
	(14, 83, 1, 1),
	(14, 84, 1, 1),
	(14, 102, 0, 1),
	(14, 107, 1, 1),
	(14, 113, 0, 1),
	(14, 144, 1, 1),
	(14, 155, 1, 1),
	(14, 164, 1, 0),
	(14, 166, 1, 0),
	(14, 167, 1, 0),
	(14, 168, 1, 0),
	(64, 1, 1, 0),
	(74, 196, 0, 1),
	(15, 35, 1, 1),
	(15, 45, 1, 0),
	(15, 83, 1, 1),
	(64, 7, 1, 0),
	(79, 12, 1, 0),
	(15, 113, 1, 1),
	(74, 33, 1, 1),
	(71, 41, 1, 0),
	(71, 36, 1, 0),
	(71, 52, 1, 0),
	(71, 94, 1, 0),
	(71, 40, 1, 1),
	(31, 74, 1, 1),
	(417, 1, 1, 0),
	(417, 6, 1, 0),
	(417, 45, 1, 0),
	(417, 8, 1, 0),
	(85, 1, 1, 0),
	(417, 113, 1, 1),
	(417, 35, 1, 1),
	(86, 113, 1, 0),
	(417, 83, 1, 0),
	(18, 35, 1, 1),
	(18, 45, 1, 1),
	(18, 83, 1, 1),
	(18, 96, 1, 1),
	(18, 102, 1, 1),
	(18, 144, 1, 0),
	(19, 6, 1, 0),
	(19, 7, 1, 0),
	(19, 13, 1, 0),
	(19, 35, 1, 0),
	(19, 45, 1, 0),
	(19, 83, 1, 0),
	(19, 102, 1, 0),
	(19, 113, 1, 0),
	(24, 37, 1, 0),
	(20, 35, 1, 0),
	(20, 45, 1, 1),
	(20, 83, 1, 0),
	(20, 80, 1, 0),
	(20, 8, 1, 0),
	(20, 96, 1, 0),
	(21, 57, 1, 0),
	(21, 35, 1, 0),
	(48, 7, 1, 0),
	(21, 99, 1, 0),
	(21, 94, 1, 0),
	(21, 83, 1, 0),
	(22, 7, 1, 1),
	(22, 35, 1, 1),
	(22, 39, 1, 1),
	(22, 45, 1, 1),
	(22, 83, 1, 1),
	(22, 84, 0, 1),
	(22, 102, 1, 0),
	(22, 107, 0, 1),
	(22, 144, 1, 0),
	(23, 8, 1, 0),
	(23, 13, 1, 0),
	(24, 6, 1, 0),
	(24, 45, 1, 0),
	(23, 57, 1, 0),
	(23, 83, 1, 0),
	(24, 12, 1, 0),
	(24, 83, 1, 0),
	(24, 35, 1, 1),
	(48, 13, 1, 0),
	(24, 57, 1, 1),
	(24, 96, 1, 1),
	(24, 102, 1, 1),
	(64, 83, 1, 0),
	(25, 1, 1, 0),
	(25, 35, 1, 0),
	(25, 45, 1, 1),
	(25, 83, 1, 0),
	(25, 191, 1, 0),
	(25, 113, 1, 0),
	(47, 74, 1, 0),
	(26, 6, 0, 1),
	(26, 12, 0, 1),
	(26, 23, 1, 1),
	(26, 35, 1, 1),
	(26, 45, 1, 1),
	(26, 49, 0, 1),
	(26, 83, 1, 1),
	(26, 84, 0, 1),
	(26, 102, 1, 1),
	(26, 113, 1, 1),
	(26, 144, 1, 0),
	(27, 1, 0, 1),
	(27, 8, 1, 0),
	(27, 35, 1, 1),
	(27, 45, 1, 0),
	(27, 80, 0, 1),
	(27, 83, 1, 1),
	(27, 102, 1, 1),
	(27, 113, 0, 1),
	(27, 130, 0, 1),
	(27, 144, 1, 1),
	(28, 7, 1, 0),
	(28, 35, 1, 0),
	(28, 45, 1, 0),
	(79, 96, 1, 0),
	(28, 57, 1, 0),
	(79, 23, 1, 0),
	(28, 83, 1, 0),
	(28, 96, 1, 0),
	(28, 102, 1, 0),
	(28, 113, 1, 0),
	(79, 45, 1, 0),
	(158, 84, 1, 1),
	(158, 107, 1, 0),
	(157, 153, 0, 1),
	(157, 149, 1, 0),
	(29, 14, 1, 0),
	(29, 57, 1, 1),
	(157, 12, 1, 1),
	(157, 74, 1, 1),
	(29, 13, 1, 1),
	(29, 12, 1, 0),
	(30, 7, 1, 0),
	(84, 45, 1, 0),
	(32, 193, 1, 0),
	(85, 113, 1, 0),
	(71, 24, 1, 0),
	(30, 45, 1, 0),
	(71, 7, 1, 0),
	(84, 137, 1, 0),
	(84, 35, 1, 0),
	(84, 14, 1, 0),
	(71, 1, 1, 1),
	(31, 12, 1, 0),
	(31, 45, 1, 0),
	(31, 83, 1, 0),
	(31, 168, 0, 1),
	(31, 84, 1, 1),
	(31, 107, 1, 0),
	(31, 113, 1, 0),
	(71, 23, 1, 1),
	(32, 6, 1, 1),
	(32, 38, 1, 0),
	(32, 45, 1, 0),
	(32, 194, 0, 1),
	(32, 57, 1, 1),
	(32, 60, 1, 0),
	(32, 83, 1, 0),
	(32, 84, 1, 1),
	(32, 113, 1, 0),
	(32, 144, 1, 0),
	(33, 8, 1, 0),
	(33, 38, 1, 0),
	(33, 45, 1, 0),
	(33, 81, 1, 0),
	(33, 83, 1, 0),
	(33, 113, 1, 0),
	(33, 138, 1, 0),
	(33, 144, 1, 0),
	(34, 35, 1, 0),
	(34, 45, 1, 0),
	(34, 55, 1, 1),
	(69, 12, 1, 1),
	(34, 83, 1, 0),
	(34, 107, 0, 1),
	(35, 8, 1, 1),
	(35, 35, 1, 1),
	(122, 155, 0, 1),
	(67, 190, 0, 1),
	(35, 74, 1, 1),
	(35, 83, 1, 1),
	(35, 93, 1, 1),
	(35, 113, 1, 1),
	(35, 148, 1, 1),
	(36, 8, 1, 1),
	(36, 55, 1, 1),
	(36, 95, 1, 1),
	(57, 83, 1, 0),
	(57, 113, 1, 0),
	(57, 35, 1, 0),
	(38, 6, 1, 0),
	(38, 35, 1, 0),
	(38, 55, 1, 0),
	(38, 83, 1, 0),
	(39, 52, 1, 0),
	(39, 35, 1, 0),
	(39, 45, 1, 1),
	(39, 83, 1, 1),
	(39, 94, 1, 0),
	(39, 96, 1, 0),
	(39, 113, 1, 0),
	(39, 40, 1, 0),
	(40, 35, 1, 1),
	(40, 45, 1, 1),
	(40, 68, 0, 1),
	(40, 83, 1, 1),
	(40, 172, 0, 1),
	(39, 130, 1, 0),
	(41, 35, 1, 0),
	(41, 83, 1, 0),
	(39, 7, 1, 0),
	(41, 7, 1, 0),
	(41, 45, 1, 0),
	(41, 113, 1, 0),
	(42, 6, 1, 0),
	(42, 12, 1, 0),
	(42, 23, 1, 0),
	(42, 40, 1, 0),
	(42, 45, 1, 0),
	(42, 46, 1, 0),
	(42, 53, 1, 0),
	(42, 59, 1, 0),
	(42, 84, 1, 1),
	(42, 68, 0, 1),
	(42, 113, 1, 0),
	(42, 168, 1, 1),
	(44, 35, 1, 0),
	(44, 45, 1, 0),
	(44, 83, 1, 0),
	(44, 113, 1, 0),
	(20, 23, 1, 0),
	(45, 45, 1, 0),
	(20, 113, 1, 0),
	(45, 84, 1, 0),
	(45, 83, 1, 0),
	(20, 57, 1, 0),
	(46, 85, 1, 1),
	(51, 84, 0, 1),
	(47, 6, 1, 1),
	(47, 45, 1, 0),
	(47, 84, 1, 0),
	(47, 107, 0, 1),
	(47, 147, 0, 1),
	(49, 45, 1, 0),
	(49, 85, 1, 0),
	(50, 23, 1, 0),
	(50, 45, 1, 0),
	(50, 83, 1, 0),
	(50, 88, 1, 0),
	(50, 113, 1, 0),
	(51, 113, 1, 0),
	(51, 45, 1, 0),
	(51, 55, 1, 1),
	(51, 83, 1, 0),
	(52, 6, 1, 0),
	(52, 74, 1, 0),
	(52, 84, 1, 0),
	(52, 85, 1, 1),
	(52, 107, 1, 0),
	(294, 107, 1, 1),
	(318, 83, 1, 0),
	(294, 83, 1, 0),
	(294, 8, 1, 0),
	(56, 35, 1, 0),
	(56, 45, 1, 1),
	(56, 55, 1, 1),
	(59, 1, 0, 1),
	(59, 45, 1, 1),
	(59, 81, 1, 1),
	(59, 124, 0, 1),
	(62, 7, 1, 0),
	(62, 96, 1, 0),
	(57, 45, 1, 0),
	(64, 35, 1, 0),
	(57, 36, 1, 0),
	(61, 6, 0, 1),
	(61, 13, 0, 1),
	(61, 35, 1, 1),
	(61, 74, 0, 1),
	(61, 84, 0, 1),
	(61, 96, 0, 1),
	(61, 147, 0, 1),
	(62, 93, 0, 1),
	(62, 35, 1, 0),
	(62, 45, 1, 0),
	(62, 83, 1, 0),
	(62, 102, 1, 0),
	(62, 81, 1, 0),
	(62, 113, 1, 0),
	(62, 55, 1, 1),
	(56, 7, 1, 0),
	(65, 7, 0, 1),
	(65, 12, 1, 1),
	(56, 51, 1, 0),
	(65, 49, 0, 1),
	(65, 83, 1, 1),
	(65, 13, 1, 0),
	(65, 35, 1, 0),
	(65, 113, 1, 1),
	(62, 126, 1, 0),
	(62, 52, 1, 0),
	(66, 55, 1, 1),
	(66, 83, 1, 0),
	(67, 13, 1, 1),
	(67, 35, 1, 1),
	(34, 12, 0, 1),
	(67, 83, 1, 1),
	(24, 59, 1, 0),
	(67, 113, 1, 1),
	(24, 8, 1, 0),
	(88, 58, 1, 0),
	(88, 95, 1, 0),
	(88, 24, 1, 0),
	(88, 40, 1, 1),
	(69, 113, 1, 0),
	(69, 84, 0, 1),
	(88, 41, 1, 0),
	(70, 203, 1, 0),
	(69, 1, 1, 0),
	(69, 7, 1, 0),
	(69, 28, 1, 1),
	(69, 35, 1, 1),
	(69, 45, 1, 0),
	(122, 80, 0, 1),
	(69, 83, 1, 0),
	(69, 96, 1, 0),
	(70, 35, 0, 1),
	(70, 99, 1, 0),
	(71, 35, 1, 0),
	(71, 45, 1, 0),
	(71, 46, 1, 0),
	(71, 83, 1, 1),
	(71, 96, 1, 1),
	(71, 113, 1, 1),
	(71, 126, 1, 0),
	(71, 6, 1, 1),
	(72, 35, 1, 1),
	(72, 96, 1, 1),
	(73, 13, 1, 1),
	(73, 23, 1, 1),
	(73, 35, 1, 1),
	(73, 83, 1, 1),
	(73, 113, 1, 1),
	(79, 196, 1, 0),
	(79, 83, 1, 0),
	(79, 113, 1, 0),
	(79, 94, 1, 0),
	(79, 7, 1, 0),
	(79, 175, 1, 0),
	(79, 38, 1, 0),
	(79, 107, 1, 0),
	(79, 57, 1, 0),
	(79, 6, 1, 0),
	(79, 168, 1, 0),
	(83, 7, 1, 0),
	(83, 45, 1, 0),
	(83, 197, 1, 0),
	(79, 74, 1, 0),
	(83, 83, 1, 0),
	(158, 96, 1, 1),
	(34, 202, 0, 1),
	(158, 6, 1, 1),
	(84, 83, 1, 0),
	(84, 107, 1, 0),
	(84, 6, 1, 0),
	(84, 12, 1, 0),
	(84, 23, 1, 0),
	(84, 138, 1, 0),
	(84, 40, 1, 0),
	(85, 35, 1, 0),
	(85, 45, 1, 0),
	(85, 83, 1, 0),
	(85, 7, 1, 0),
	(85, 23, 1, 0),
	(85, 40, 1, 0),
	(86, 177, 1, 0),
	(86, 45, 1, 0),
	(86, 83, 1, 0),
	(85, 52, 1, 0),
	(85, 6, 1, 0),
	(86, 12, 0, 1),
	(86, 184, 1, 0),
	(87, 113, 1, 0),
	(87, 83, 1, 0),
	(87, 37, 1, 0),
	(87, 35, 1, 0),
	(87, 1, 1, 0),
	(87, 45, 1, 0),
	(88, 45, 1, 1),
	(88, 52, 1, 0),
	(88, 35, 1, 0),
	(88, 83, 1, 0),
	(88, 23, 1, 0),
	(89, 45, 1, 0),
	(89, 107, 1, 0),
	(89, 96, 1, 0),
	(89, 83, 1, 0),
	(90, 84, 1, 1),
	(90, 45, 1, 0),
	(90, 83, 1, 0),
	(90, 7, 1, 0),
	(90, 113, 1, 0),
	(90, 3, 1, 0),
	(90, 74, 1, 1),
	(91, 6, 1, 1),
	(91, 84, 1, 1),
	(91, 107, 1, 1),
	(39, 6, 1, 0),
	(39, 93, 1, 0),
	(91, 45, 1, 1),
	(8, 12, 1, 0),
	(122, 54, 1, 0),
	(122, 45, 1, 0),
	(122, 59, 0, 1),
	(119, 83, 1, 0),
	(119, 45, 1, 0),
	(119, 52, 1, 0),
	(119, 35, 1, 0),
	(119, 186, 1, 0),
	(119, 185, 1, 0),
	(120, 83, 1, 0),
	(120, 35, 1, 1),
	(120, 113, 1, 0),
	(120, 40, 0, 1),
	(121, 96, 1, 0),
	(121, 126, 1, 0),
	(121, 94, 1, 0),
	(121, 3, 1, 0),
	(121, 137, 1, 0),
	(121, 9, 1, 0),
	(121, 45, 1, 0),
	(121, 188, 1, 0),
	(121, 187, 1, 0),
	(122, 83, 1, 0),
	(122, 41, 1, 0),
	(122, 35, 1, 0),
	(122, 96, 1, 0),
	(122, 113, 1, 0),
	(88, 89, 1, 0),
	(157, 84, 1, 1),
	(157, 35, 1, 1),
	(157, 45, 1, 0),
	(157, 113, 1, 0),
	(157, 83, 1, 0),
	(125, 83, 1, 0),
	(125, 35, 1, 0),
	(125, 8, 1, 0),
	(125, 153, 0, 1),
	(126, 107, 0, 1),
	(126, 189, 0, 1),
	(126, 12, 0, 1),
	(126, 1, 0, 1),
	(46, 84, 1, 1),
	(48, 71, 1, 0),
	(48, 100, 1, 1),
	(24, 113, 1, 0),
	(64, 19, 1, 0),
	(64, 113, 1, 0),
	(64, 2, 1, 0),
	(64, 12, 1, 0),
	(64, 199, 1, 0),
	(159, 113, 1, 1),
	(159, 84, 1, 1),
	(160, 45, 1, 1),
	(160, 83, 1, 1),
	(160, 113, 1, 0),
	(160, 23, 1, 0),
	(160, 35, 1, 0),
	(160, 40, 1, 0),
	(160, 9, 1, 0),
	(160, 1, 0, 1),
	(160, 74, 0, 1),
	(160, 84, 0, 1),
	(162, 35, 0, 1),
	(162, 12, 0, 1),
	(162, 85, 0, 1),
	(162, 68, 0, 1),
	(162, 45, 0, 1),
	(162, 83, 0, 1),
	(163, 83, 1, 1),
	(163, 35, 1, 1),
	(163, 113, 1, 1),
	(163, 23, 1, 1),
	(163, 45, 1, 1),
	(163, 7, 1, 1),
	(163, 14, 1, 1),
	(163, 132, 1, 1),
	(163, 1, 0, 1),
	(163, 95, 0, 1),
	(163, 24, 0, 1),
	(163, 39, 0, 1),
	(164, 83, 1, 0),
	(164, 45, 1, 0),
	(164, 113, 1, 0),
	(164, 7, 1, 0),
	(164, 23, 1, 0),
	(164, 41, 1, 0),
	(164, 95, 1, 0),
	(164, 60, 1, 0),
	(168, 83, 1, 0),
	(168, 35, 1, 0),
	(168, 113, 1, 0),
	(168, 23, 1, 0),
	(168, 7, 1, 0),
	(168, 95, 1, 0),
	(168, 45, 1, 1),
	(168, 59, 1, 0),
	(168, 154, 1, 0),
	(168, 99, 1, 0),
	(168, 24, 1, 0),
	(168, 84, 0, 1),
	(168, 1, 0, 1),
	(168, 12, 0, 1),
	(168, 92, 0, 1),
	(168, 13, 0, 1),
	(170, 83, 1, 0),
	(170, 113, 1, 1),
	(170, 13, 1, 0),
	(170, 6, 1, 0),
	(170, 168, 1, 1),
	(170, 12, 0, 1),
	(61, 99, 1, 1),
	(61, 83, 1, 0),
	(61, 113, 1, 0),
	(61, 44, 1, 0),
	(161, 83, 1, 1),
	(161, 113, 1, 1),
	(161, 13, 1, 1),
	(161, 7, 1, 0),
	(161, 56, 1, 0),
	(161, 49, 1, 1),
	(161, 12, 1, 1),
	(161, 59, 1, 1),
	(161, 26, 1, 0),
	(173, 83, 1, 0),
	(173, 35, 1, 1),
	(173, 113, 1, 0),
	(173, 45, 1, 0),
	(173, 204, 1, 1),
	(173, 36, 1, 0),
	(173, 34, 1, 0),
	(178, 45, 1, 0),
	(178, 35, 1, 0),
	(178, 83, 1, 0),
	(178, 38, 1, 0),
	(178, 52, 1, 0),
	(179, 35, 1, 1),
	(179, 96, 1, 1),
	(179, 94, 1, 1),
	(179, 45, 1, 1),
	(179, 83, 1, 1),
	(190, 41, 1, 0),
	(190, 49, 1, 1),
	(190, 23, 1, 0),
	(190, 45, 1, 0),
	(190, 95, 1, 0),
	(190, 7, 1, 0),
	(190, 35, 1, 0),
	(190, 55, 1, 0),
	(190, 83, 1, 0),
	(190, 96, 1, 0),
	(190, 102, 1, 0),
	(191, 45, 1, 0),
	(276, 84, 0, 1),
	(276, 35, 1, 0),
	(276, 45, 1, 0),
	(276, 83, 1, 0),
	(276, 13, 0, 1),
	(158, 211, 1, 0),
	(158, 210, 1, 0),
	(205, 45, 1, 0),
	(205, 83, 1, 0),
	(205, 35, 1, 0),
	(205, 94, 1, 0),
	(205, 38, 1, 0),
	(205, 212, 1, 0),
	(207, 92, 1, 1),
	(208, 95, 1, 0),
	(208, 19, 1, 0),
	(208, 45, 1, 0),
	(208, 52, 1, 0),
	(208, 201, 1, 0),
	(208, 113, 1, 0),
	(208, 7, 1, 0),
	(208, 40, 1, 0),
	(210, 45, 1, 0),
	(210, 83, 1, 0),
	(210, 96, 1, 0),
	(210, 23, 1, 0),
	(210, 113, 1, 0),
	(210, 94, 1, 0),
	(217, 52, 1, 0),
	(217, 83, 1, 0),
	(217, 113, 1, 0),
	(217, 208, 1, 0),
	(217, 33, 1, 0),
	(217, 6, 1, 0),
	(217, 35, 1, 0),
	(217, 126, 1, 0),
	(217, 45, 1, 0),
	(217, 95, 1, 0),
	(217, 94, 1, 0),
	(217, 59, 1, 0),
	(222, 96, 1, 1),
	(222, 33, 1, 0),
	(222, 35, 1, 0),
	(224, 45, 1, 0),
	(224, 6, 1, 0),
	(224, 13, 1, 0),
	(237, 45, 1, 0),
	(237, 35, 1, 0),
	(237, 83, 1, 0),
	(237, 6, 0, 1),
	(237, 96, 0, 1),
	(237, 40, 0, 1),
	(237, 216, 0, 1),
	(239, 83, 1, 0),
	(239, 113, 1, 0),
	(239, 45, 1, 0),
	(242, 41, 1, 1),
	(242, 45, 1, 0),
	(242, 83, 1, 0),
	(244, 23, 1, 0),
	(244, 113, 1, 0),
	(244, 35, 1, 0),
	(244, 83, 1, 0),
	(244, 1, 1, 0),
	(252, 45, 1, 1),
	(252, 6, 0, 1),
	(252, 40, 0, 1),
	(252, 81, 1, 0),
	(252, 9, 1, 0),
	(252, 218, 1, 0),
	(271, 35, 1, 1),
	(271, 45, 1, 0),
	(272, 83, 1, 0),
	(272, 81, 1, 0),
	(271, 83, 1, 0),
	(272, 148, 1, 0),
	(272, 102, 1, 0),
	(272, 84, 1, 1),
	(272, 12, 1, 1),
	(272, 23, 1, 0),
	(272, 96, 1, 1),
	(272, 196, 1, 1),
	(272, 38, 1, 0),
	(272, 26, 1, 0),
	(272, 56, 1, 1),
	(47, 85, 1, 0),
	(47, 7, 1, 0),
	(47, 35, 1, 0),
	(47, 83, 1, 0),
	(318, 113, 1, 0),
	(294, 171, 0, 1),
	(294, 45, 1, 1),
	(318, 7, 1, 0),
	(190, 1, 1, 0),
	(294, 113, 1, 0),
	(294, 35, 1, 0),
	(190, 209, 1, 0),
	(318, 23, 1, 0),
	(318, 102, 1, 0),
	(318, 39, 1, 0),
	(318, 46, 1, 0),
	(318, 45, 1, 0),
	(318, 43, 1, 0),
	(319, 12, 1, 0),
	(319, 56, 1, 0),
	(319, 96, 1, 0),
	(319, 13, 1, 0),
	(319, 83, 1, 0),
	(319, 113, 1, 0),
	(320, 12, 1, 0),
	(320, 192, 1, 0),
	(320, 35, 1, 0),
	(320, 45, 1, 0),
	(320, 52, 1, 0),
	(320, 71, 1, 0),
	(320, 83, 1, 0),
	(320, 96, 1, 0),
	(320, 113, 1, 0),
	(321, 35, 1, 0),
	(321, 7, 1, 0),
	(321, 13, 1, 0),
	(321, 99, 1, 0),
	(321, 12, 1, 0),
	(324, 12, 1, 0),
	(324, 96, 1, 0),
	(324, 175, 1, 0),
	(324, 56, 1, 0),
	(324, 35, 1, 0),
	(324, 23, 1, 0),
	(324, 49, 1, 0),
	(324, 8, 1, 0),
	(324, 95, 1, 0),
	(324, 2, 1, 0),
	(324, 83, 1, 0),
	(324, 126, 1, 0),
	(324, 113, 1, 0),
	(324, 26, 1, 0),
	(324, 102, 1, 0),
	(332, 83, 1, 0),
	(332, 113, 1, 0),
	(332, 35, 1, 0),
	(332, 12, 1, 0),
	(332, 45, 1, 0),
	(332, 8, 1, 0),
	(332, 52, 1, 0),
	(332, 96, 1, 0),
	(334, 35, 1, 0),
	(334, 113, 1, 0),
	(334, 83, 1, 0),
	(334, 45, 1, 0),
	(334, 7, 1, 0),
	(334, 153, 1, 0),
	(334, 96, 1, 0),
	(338, 6, 1, 1),
	(338, 107, 1, 1),
	(338, 7, 1, 0),
	(338, 35, 1, 0),
	(338, 26, 1, 0),
	(338, 45, 1, 1),
	(338, 57, 1, 1),
	(338, 152, 1, 0),
	(338, 83, 1, 0),
	(338, 113, 1, 0),
	(339, 107, 1, 1),
	(339, 175, 1, 1),
	(339, 35, 1, 0),
	(339, 83, 1, 1),
	(339, 113, 1, 1),
	(339, 45, 1, 0),
	(339, 95, 1, 0),
	(339, 171, 1, 1),
	(339, 199, 1, 0),
	(339, 7, 1, 0),
	(339, 14, 1, 0),
	(339, 137, 1, 0),
	(339, 36, 1, 0),
	(339, 38, 1, 0),
	(339, 24, 1, 0),
	(339, 94, 1, 0),
	(340, 84, 1, 1),
	(340, 83, 1, 0),
	(340, 13, 1, 1),
	(340, 7, 1, 0),
	(340, 175, 0, 1),
	(340, 96, 1, 0),
	(340, 113, 1, 0),
	(340, 153, 1, 0),
	(343, 45, 1, 1),
	(343, 7, 1, 0),
	(343, 83, 1, 0),
	(343, 113, 1, 0),
	(343, 35, 1, 0),
	(344, 45, 1, 0),
	(344, 7, 1, 0),
	(344, 83, 1, 0),
	(346, 45, 1, 0),
	(346, 26, 1, 0),
	(346, 83, 1, 0),
	(346, 113, 1, 0),
	(346, 8, 1, 0),
	(346, 6, 1, 0),
	(346, 13, 1, 0),
	(348, 45, 1, 1),
	(348, 83, 1, 0),
	(348, 113, 1, 1),
	(348, 7, 1, 0),
	(348, 35, 1, 1),
	(349, 83, 1, 0),
	(349, 113, 1, 0),
	(349, 130, 1, 0),
	(349, 45, 1, 0),
	(349, 23, 1, 0),
	(349, 35, 1, 0),
	(359, 138, 1, 0),
	(359, 38, 1, 0),
	(359, 45, 1, 0),
	(359, 3, 1, 0),
	(359, 83, 1, 0),
	(359, 8, 1, 0),
	(359, 35, 1, 0),
	(359, 171, 1, 0),
	(359, 24, 1, 0),
	(359, 14, 1, 0),
	(359, 40, 1, 0),
	(359, 23, 1, 0),
	(359, 113, 1, 0),
	(359, 1, 1, 0),
	(359, 133, 1, 0),
	(359, 155, 1, 0),
	(359, 71, 1, 0),
	(359, 94, 1, 0),
	(359, 39, 1, 0),
	(359, 139, 1, 0),
	(359, 95, 1, 0),
	(359, 9, 1, 0),
	(359, 43, 1, 0),
	(359, 59, 1, 0),
	(359, 154, 1, 0),
	(359, 88, 1, 0),
	(359, 137, 1, 0),
	(359, 142, 1, 0),
	(369, 12, 1, 0),
	(369, 83, 1, 0),
	(369, 113, 1, 0),
	(369, 45, 1, 0),
	(370, 45, 0, 1),
	(370, 57, 1, 1),
	(222, 94, 1, 0),
	(222, 126, 1, 0),
	(222, 83, 1, 0),
	(222, 45, 1, 1),
	(222, 41, 1, 0),
	(377, 96, 1, 1),
	(377, 35, 1, 0),
	(377, 45, 1, 1),
	(377, 83, 1, 0),
	(377, 41, 1, 0),
	(377, 94, 1, 0),
	(377, 113, 1, 1),
	(381, 33, 1, 0),
	(381, 45, 1, 0),
	(381, 35, 1, 0),
	(381, 113, 1, 0),
	(191, 83, 1, 0),
	(191, 113, 1, 0),
	(191, 7, 1, 0),
	(191, 8, 1, 0),
	(191, 41, 1, 0),
	(191, 40, 1, 0),
	(385, 83, 1, 0),
	(385, 45, 1, 0),
	(385, 113, 1, 0),
	(399, 45, 1, 0),
	(399, 83, 1, 0),
	(399, 169, 1, 0),
	(399, 6, 1, 1),
	(399, 107, 1, 1),
	(399, 84, 1, 1),
	(276, 74, 0, 1),
	(276, 107, 0, 1),
	(422, 12, 1, 0),
	(422, 83, 1, 0),
	(276, 85, 0, 1),
	(422, 102, 1, 0),
	(422, 49, 1, 0),
	(422, 45, 1, 0),
	(422, 57, 1, 0);
/*!40000 ALTER TABLE `farmacos_inv_toxicidad` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.farmacos_links
CREATE TABLE IF NOT EXISTS `farmacos_links` (
  `id_link` mediumint(9) unsigned NOT NULL AUTO_INCREMENT,
  `id_farmaco` mediumint(9) unsigned NOT NULL DEFAULT '0',
  `descripcion_link` varchar(255) COLLATE utf8_unicode_ci NOT NULL,
  `url_link` varchar(500) COLLATE utf8_unicode_ci NOT NULL,
  `tipo_link` tinyint(1) unsigned NOT NULL DEFAULT '0',
  PRIMARY KEY (`id_link`)
) ENGINE=MyISAM AUTO_INCREMENT=117 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.farmacos_links: 108 rows
/*!40000 ALTER TABLE `farmacos_links` DISABLE KEYS */;
INSERT INTO `farmacos_links` (`id_link`, `id_farmaco`, `descripcion_link`, `url_link`, `tipo_link`) VALUES
	(1, 1, 'XELODA(Capecitabine)+ DOCETAXEL', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020896s026lbl.pdf', 1),
	(2, 1, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=60953&loc=ec_rcs', 2),
	(3, 2, 'XELODA (Capecitabine)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020896s026lbl.pdf', 1),
	(4, 3, 'GEMCITABINE (GEMZAR)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/020509s033lbl.pdf', 1),
	(5, 3, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=60749&loc=ec_rcs', 2),
	(6, 3, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/135', 5),
	(7, 4, 'TOPOTECAN', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022453s000lbl.pdf', 1),
	(8, 5, 'OXALIPLATINO (for injection)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022160s004lbl.pdf', 1),
	(9, 5, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6857599&loc=ec_rcs', 2),
	(10, 6, 'OXALIPLATINO + IRINOTECAN', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022160s004lbl.pdf', 1),
	(11, 7, 'OXALIPLATINO + 5FU/LV', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022160s004lbl.pdf', 1),
	(12, 8, 'IRINOTECAN (CAMPTOSAR)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020571s042lbl.pdf', 1),
	(13, 8, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=60838&loc=ec_rcs', 2),
	(14, 9, 'VINORELBINE TARTRATE', 'http://www.drugs.com/pro/vinorelbine.html', 1),
	(15, 9, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=60780&loc=ec_rcs', 2),
	(16, 9, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/140', 5),
	(17, 10, 'VINORELBINE  + CISPLATIN ', 'http://www.drugs.com/pro/vinorelbine.html', 1),
	(18, 11, 'CARBOPLATIN (PARAPLATIN)', 'http://www.drugs.com/pro/paraplatin.html', 1),
	(19, 11, 'CARBOPLATIN', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=56840877&loc=ec_rcs', 2),
	(20, 12, 'ETOPOSIDO', 'http://www.drugs.com/pro/etoposide.html', 1),
	(21, 12, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=36462&loc=ec_rcs', 2),
	(22, 13, 'PEMETREXED (ALIMTA)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021462s042lbl.pdf', 1),
	(23, 13, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=60843&loc=ec_rcs', 2),
	(24, 14, 'TAXOTERE (DOCETAXEL) 60 MG', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020449s065lbl.pdf', 1),
	(25, 14, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=148124&loc=ec_rcs', 2),
	(26, 14, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/1007', 5),
	(27, 15, 'TAXOTERE (DOCETAXEL) 100 MG', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020449s065lbl.pdf', 1),
	(28, 15, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=148124&loc=ec_rcs', 2),
	(29, 15, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/1007', 5),
	(30, 16, 'TAXOL (PACLITAXEL) ', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf', 1),
	(31, 16, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=36314&loc=ec_rcs', 2),
	(32, 16, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/11', 5),
	(33, 17, 'DOXORRUBICIN (ADRIAMICIN) for injection', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/062921s022lbl.pdf', 1),
	(34, 17, 'DOXORRUBICIN STRUCTURE', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=31703&loc=ec_rcs', 2),
	(35, 18, 'DOXORUBICIN (DOXIL)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050718s043lbl.pdf', 1),
	(36, 18, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/133', 5),
	(37, 19, 'CYCLOPHOSPHAMIDE', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/012141s089lbl.pdf', 1),
	(38, 19, 'CYCLOPHOSPHAMIDE STRUCTURE', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=31703&loc=ec_rcs', 2),
	(39, 20, 'CISPLATIN (PLATINOL) + CHEMOTERAPEUTICS AGENTS', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018057s081lbl.pdf', 1),
	(40, 20, 'CISPLATIN STRUCTURE', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=441203', 2),
	(41, 21, 'ERIBULIN (HALAVEN)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201532s004lbl.pdf', 1),
	(42, 21, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=17755248&loc=ec_rcs', 2),
	(104, 51, 'ELLENCE (EPIRUBICIN)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050778s019lbl.pdf', 1),
	(101, 49, 'BORTEZOMIB (VELCADE)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021602s027lbl.pdf', 1),
	(100, 48, 'VECTIBIX (panitumab)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125147s169lbl.pdf', 3),
	(48, 24, 'CABEZITAXEL (JEVTANA)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/201023s003lbl.pdf', 1),
	(49, 24, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9854073', 2),
	(50, 25, 'AVASTIN(BEVACIZUMAB) + IFL', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125085s263lbl.pdf', 1),
	(51, 25, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=24801580&loc=ec_rcs', 2),
	(52, 26, 'AVASTIN(BEVACIZUMAB) + 5-FL/UV', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125085s263lbl.pdf', 1),
	(53, 27, 'Herceptin (trastuzumab)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5256lbl.pdf', 1),
	(54, 27, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9903', 2),
	(55, 28, 'Lapatinib (Tykerb) + CAPECITABINE ', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022059s013lbl.pdf', 1),
	(56, 28, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=208908&loc=ec_rcs', 2),
	(57, 28, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/119', 5),
	(58, 29, 'Lapatinib (Tykerb) +LETROZOLE', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022059s013lbl.pdf', 1),
	(59, 29, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/119', 5),
	(60, 30, 'ERLOTINIB (TARCEVA) ', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021743s017lbl.pdf', 1),
	(61, 30, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=176870&loc=ec_rcs', 2),
	(62, 30, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/1', 5),
	(63, 31, 'ERLOTINIB (TARCEVA) 3-10%', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021743s017lbl.pdf', 1),
	(64, 32, 'ERLOTINIB (TARCEVA) + gemcitabine', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021743s017lbl.pdf', 1),
	(65, 33, 'GEFITINIB (IRESSA)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021399s008lbl.pdf', 1),
	(66, 33, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=123631&loc=ec_rcs', 2),
	(67, 33, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/1010', 5),
	(68, 34, 'SORAFENIB (NEXAVAR) HCC', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021923s011lbl.pdf', 1),
	(69, 34, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=216239&loc=ec_rcs', 2),
	(70, 34, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/30', 5),
	(71, 35, 'SORAFENIB (NEXAVAR) RCC', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021923s011lbl.pdf', 1),
	(72, 35, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/30', 5),
	(73, 36, 'EVEROLIMUS (AFINITOR)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s018lbl.pdf', 1),
	(74, 36, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6442177&loc=ec_rcs', 2),
	(75, 37, 'PAZOPANIB(VOTRIENT)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022465s-010S-012lbl.pdf', 1),
	(76, 37, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11525740', 2),
	(77, 37, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/199', 5),
	(78, 38, 'SUNITINIB MALATE( SUTENT)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021938s021s022s023lbl.pdf', 1),
	(79, 38, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=53398689&loc=ec_rcs', 2),
	(80, 38, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/5', 5),
	(81, 39, 'TEMSIROLIMUS (TORISEL)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022088s014lbl.pdf', 1),
	(82, 39, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=23724530&loc=ec_rcs', 2),
	(83, 39, 'Link to Drug Sensibility', 'http://www.cancerrxgene.org/translation/Drug/1016', 5),
	(84, 40, 'VEMURAFENIB (ZELBORAF)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf', 1),
	(85, 40, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=42611257&loc=ec_rcs', 2),
	(86, 41, 'CABOZANTINIB (COMETRIQ)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203756lbl.pdf', 1),
	(87, 41, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=25102847&loc=ec_rcs', 2),
	(88, 42, 'CRIZOTINIB (XALKORI)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202570s003lbl.pdf', 1),
	(89, 42, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11626560&loc=ec_rcs', 2),
	(90, 43, 'YONDELIS (Trabectedin)', 'http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM171149.pdf\r\n\r\n', 1),
	(91, 43, 'Data sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=108150&loc=ec_rcs\r\n', 2),
	(92, 44, 'MEKINIST(trametinib)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204114s000lbl.pdf', 1),
	(93, 44, 'MEKINIST structure', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3081361&loc=ec_rcs\r\n', 2),
	(94, 45, 'TAFINLAR(dabrafenib)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202806s000lbl.pdf\r\n', 1),
	(95, 45, 'TAFINLAR structure', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3081361&loc=ec_rcs\r\n', 2),
	(96, 46, 'STRIVARGA(Regorafenib) ', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf\r\n', 1),
	(97, 46, 'STRIVARGA structure', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=11167602&loc=ec_rcs\r\n', 2),
	(98, 47, 'CAPRELSA(Vandetanib)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022405s003lbl.pdf\r\n', 1),
	(99, 47, 'CAPRELSA Structure', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3081361&loc=ec_rcs\r\n', 2),
	(105, 51, 'Data Sheet', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=65348&loc=ec_rcs', 2),
	(106, 52, 'GILOTRIF (afatinib)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/201292s001lbl.pdf', 1),
	(107, 52, 'GILOTRIF (afatinib) structure', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=10184653', 2),
	(108, 53, 'YERVOY (ipilinumab)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125377s033lbl.pdf', 1),
	(109, 54, 'ERBITUX (cetuximab)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/125084lbl.pdf', 1),
	(110, 56, 'ERBITUX (cetuximab) + irinotecan', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/125084lbl.pdf', 1),
	(111, 57, 'SPRYCEL (dasatinib)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf', 1),
	(112, 58, 'GLEEVEC (IMATINIB)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf', 1),
	(113, 59, 'XTANDI (enzalutamide)', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf', 1),
	(114, 59, 'MDV 3100 (XTANDI )', 'http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=15951529', 2),
	(115, 60, 'PERJETA (PERTUZUMAB) + COMBINACIONES', 'http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125409s051lbl.pdf', 1);
/*!40000 ALTER TABLE `farmacos_links` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.farmacos_toxicidad
CREATE TABLE IF NOT EXISTS `farmacos_toxicidad` (
  `id_farmaco` mediumint(9) unsigned NOT NULL DEFAULT '0',
  `id_toxicidad` smallint(4) unsigned NOT NULL DEFAULT '0',
  `id_categoria` tinyint(3) unsigned NOT NULL DEFAULT '0',
  `valor_toxicidad` decimal(4,1) DEFAULT '0.0',
  PRIMARY KEY (`id_farmaco`,`id_toxicidad`,`id_categoria`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.farmacos_toxicidad: 1.835 rows
/*!40000 ALTER TABLE `farmacos_toxicidad` DISABLE KEYS */;
INSERT INTO `farmacos_toxicidad` (`id_farmaco`, `id_toxicidad`, `id_categoria`, `valor_toxicidad`) VALUES
	(1, 1, 0, 30.0),
	(1, 1, 4, 3.0),
	(1, 3, 0, 41.0),
	(1, 3, 4, 6.0),
	(1, 6, 0, 80.0),
	(1, 6, 4, 7.0),
	(1, 7, 0, 13.0),
	(1, 7, 4, 1.0),
	(1, 8, 0, 10.0),
	(1, 9, 0, 15.0),
	(1, 9, 4, 2.0),
	(1, 13, 0, 26.0),
	(1, 13, 4, 4.0),
	(1, 14, 0, 12.0),
	(1, 14, 4, 1.0),
	(1, 17, 0, 8.0),
	(1, 17, 4, 1.0),
	(1, 19, 0, 4.0),
	(1, 19, 4, 1.0),
	(1, 22, 0, 5.0),
	(1, 23, 0, 20.0),
	(1, 23, 4, 2.0),
	(1, 24, 0, 13.0),
	(1, 24, 4, 1.0),
	(1, 33, 0, 8.0),
	(1, 34, 0, 10.0),
	(1, 34, 4, 2.0),
	(1, 35, 0, 67.0),
	(1, 35, 4, 14.0),
	(1, 36, 0, 12.0),
	(1, 37, 0, 6.0),
	(1, 37, 4, 1.0),
	(1, 39, 0, 14.0),
	(1, 40, 0, 14.0),
	(1, 40, 4, 2.0),
	(1, 42, 0, 7.0),
	(1, 42, 4, 1.0),
	(1, 44, 0, 5.0),
	(1, 45, 0, 22.0),
	(1, 45, 4, 4.0),
	(1, 51, 4, 24.0),
	(1, 52, 0, 15.0),
	(1, 52, 4, 3.0),
	(1, 56, 0, 20.0),
	(1, 56, 4, 7.0),
	(1, 58, 0, 4.0),
	(1, 71, 0, 8.0),
	(1, 72, 0, 12.0),
	(1, 74, 0, 91.0),
	(1, 74, 4, 37.0),
	(1, 81, 0, 15.0),
	(1, 81, 4, 2.0),
	(1, 82, 0, 14.0),
	(1, 82, 4, 2.0),
	(1, 83, 0, 45.0),
	(1, 83, 4, 7.0),
	(1, 84, 0, 86.0),
	(1, 84, 4, 20.0),
	(1, 88, 0, 7.0),
	(1, 88, 4, 1.0),
	(1, 89, 0, 12.0),
	(1, 89, 4, 1.0),
	(1, 90, 0, 6.0),
	(1, 91, 0, 2.0),
	(1, 91, 4, 1.0),
	(1, 94, 0, 4.0),
	(1, 95, 0, 28.0),
	(1, 95, 4, 2.0),
	(1, 96, 0, 9.0),
	(1, 96, 4, 1.0),
	(1, 97, 0, 5.0),
	(1, 101, 0, 12.0),
	(1, 101, 4, 2.0),
	(1, 102, 0, 67.0),
	(1, 102, 4, 17.0),
	(1, 103, 0, 16.0),
	(1, 107, 0, 41.0),
	(1, 107, 4, 2.0),
	(1, 109, 0, 6.0),
	(1, 109, 4, 1.0),
	(1, 113, 0, 35.0),
	(1, 113, 4, 4.0),
	(1, 115, 0, 7.0),
	(1, 130, 0, 7.0),
	(1, 147, 0, 99.0),
	(1, 147, 4, 48.0),
	(2, 1, 0, 14.0),
	(2, 1, 4, 3.0),
	(2, 3, 0, 6.0),
	(2, 6, 0, 80.0),
	(2, 7, 0, 9.0),
	(2, 7, 4, 1.0),
	(2, 13, 0, 10.0),
	(2, 13, 4, 1.0),
	(2, 22, 0, 5.0),
	(2, 22, 4, 1.0),
	(2, 23, 0, 9.0),
	(2, 28, 0, 1.0),
	(2, 30, 0, 13.0),
	(2, 31, 0, 1.0),
	(2, 33, 0, 27.0),
	(2, 35, 0, 47.0),
	(2, 35, 4, 12.0),
	(2, 36, 0, 6.0),
	(2, 36, 4, 1.0),
	(2, 38, 0, 6.0),
	(2, 39, 0, 6.0),
	(2, 39, 4, 1.0),
	(2, 42, 0, 2.0),
	(2, 45, 0, 16.0),
	(2, 45, 4, 1.0),
	(2, 51, 0, 60.0),
	(2, 51, 4, 17.0),
	(2, 52, 0, 5.0),
	(2, 52, 4, 1.0),
	(2, 56, 0, 48.0),
	(2, 56, 4, 18.0),
	(2, 62, 0, 1.6),
	(2, 66, 0, 1.1),
	(2, 67, 0, 20.0),
	(2, 83, 0, 34.0),
	(2, 83, 4, 2.0),
	(2, 84, 0, 135.0),
	(2, 84, 4, 2.2),
	(2, 95, 0, 7.0),
	(2, 95, 4, 1.0),
	(2, 96, 0, 7.0),
	(2, 102, 0, 22.0),
	(2, 102, 4, 2.0),
	(2, 113, 0, 15.0),
	(2, 113, 4, 2.0),
	(2, 130, 0, 10.0),
	(2, 130, 4, 1.0),
	(3, 2, 0, 77.0),
	(3, 2, 4, 16.0),
	(3, 3, 0, 16.0),
	(44, 96, 0, 57.0),
	(44, 1, 4, 1.0),
	(3, 6, 0, 73.0),
	(3, 6, 4, 8.0),
	(3, 12, 0, 78.0),
	(3, 12, 4, 12.0),
	(3, 56, 0, 26.0),
	(3, 56, 4, 2.0),
	(3, 18, 0, 15.0),
	(3, 26, 0, 6.0),
	(3, 35, 0, 30.0),
	(3, 35, 4, 3.0),
	(3, 40, 0, 10.0),
	(3, 46, 0, 38.0),
	(3, 46, 4, 2.0),
	(3, 53, 0, 23.0),
	(3, 54, 0, 4.0),
	(3, 54, 4, 2.0),
	(3, 68, 0, 10.0),
	(3, 68, 4, 2.0),
	(3, 74, 0, 64.0),
	(3, 74, 4, 8.0),
	(3, 83, 0, 71.0),
	(3, 83, 4, 10.0),
	(3, 84, 0, 61.0),
	(3, 84, 4, 24.0),
	(3, 89, 0, 10.0),
	(3, 89, 4, 1.0),
	(3, 93, 0, 31.0),
	(3, 96, 0, 28.0),
	(3, 96, 4, 1.0),
	(3, 100, 0, 11.0),
	(3, 100, 4, 2.0),
	(3, 102, 0, 10.0),
	(3, 102, 4, 1.0),
	(3, 107, 0, 36.0),
	(3, 107, 4, 7.0),
	(3, 113, 0, 71.0),
	(3, 113, 4, 10.0),
	(4, 1, 0, 22.0),
	(4, 1, 4, 4.0),
	(4, 3, 0, 49.0),
	(4, 6, 4, 89.0),
	(4, 7, 0, 19.0),
	(4, 7, 4, 3.0),
	(4, 13, 0, 25.0),
	(4, 13, 4, 6.0),
	(4, 23, 0, 29.0),
	(4, 23, 4, 3.0),
	(4, 24, 0, 15.0),
	(4, 24, 4, 1.0),
	(4, 35, 0, 32.0),
	(4, 35, 4, 4.0),
	(4, 40, 0, 22.0),
	(4, 40, 4, 8.0),
	(4, 45, 0, 29.0),
	(4, 45, 4, 5.0),
	(4, 52, 0, 18.0),
	(4, 52, 4, 2.0),
	(4, 74, 4, 97.0),
	(4, 83, 0, 64.0),
	(4, 83, 4, 8.0),
	(4, 84, 4, 97.0),
	(4, 88, 0, 23.0),
	(4, 88, 4, 3.0),
	(4, 95, 0, 28.0),
	(4, 95, 4, 2.0),
	(4, 96, 0, 16.0),
	(4, 96, 4, 1.0),
	(4, 102, 0, 18.0),
	(4, 102, 4, 3.0),
	(4, 107, 4, 69.0),
	(4, 113, 0, 45.0),
	(4, 113, 4, 5.0),
	(5, 1, 0, 31.0),
	(5, 1, 4, 7.0),
	(5, 3, 0, 30.0),
	(5, 6, 0, 64.0),
	(5, 6, 4, 1.0),
	(5, 7, 0, 20.0),
	(5, 7, 4, 2.0),
	(5, 14, 0, 11.0),
	(5, 19, 0, 5.0),
	(5, 19, 4, 1.0),
	(5, 22, 0, 9.0),
	(5, 23, 0, 22.0),
	(5, 24, 0, 11.0),
	(5, 34, 0, 5.0),
	(5, 34, 4, 3.0),
	(5, 35, 0, 46.0),
	(5, 35, 4, 4.0),
	(5, 39, 0, 8.0),
	(5, 40, 0, 13.0),
	(5, 40, 4, 7.0),
	(5, 42, 0, 16.0),
	(5, 45, 0, 61.0),
	(5, 45, 4, 9.0),
	(5, 46, 0, 25.0),
	(5, 46, 4, 1.0),
	(5, 47, 0, 1.0),
	(5, 52, 0, 7.0),
	(5, 59, 0, 3.0),
	(5, 59, 4, 2.0),
	(5, 70, 0, 9.0),
	(5, 72, 0, 4.0),
	(5, 74, 0, 13.0),
	(5, 83, 0, 64.0),
	(5, 83, 4, 4.0),
	(5, 84, 0, 7.0),
	(5, 88, 0, 14.0),
	(5, 88, 4, 3.0),
	(5, 99, 0, 32.0),
	(5, 99, 4, 2.0),
	(5, 102, 0, 14.0),
	(5, 104, 0, 2.0),
	(5, 104, 4, 1.0),
	(5, 107, 0, 30.0),
	(5, 107, 4, 3.0),
	(5, 113, 0, 37.0),
	(5, 113, 4, 4.0),
	(6, 3, 0, 67.0),
	(6, 6, 0, 25.0),
	(6, 6, 4, 3.0),
	(6, 9, 0, 8.0),
	(6, 32, 0, 7.0),
	(6, 36, 0, 10.0),
	(6, 39, 0, 5.0),
	(6, 42, 0, 2.0),
	(6, 52, 0, 9.0),
	(6, 71, 0, 11.0),
	(6, 74, 0, 76.0),
	(6, 74, 4, 24.0),
	(6, 84, 0, 71.0),
	(6, 84, 4, 36.0),
	(6, 94, 0, 2.0),
	(6, 96, 4, 7.0),
	(6, 107, 0, 44.0),
	(6, 107, 4, 4.0),
	(6, 115, 0, 11.0),
	(6, 126, 0, 5.0),
	(6, 133, 0, 6.0),
	(6, 142, 0, 6.0),
	(7, 1, 0, 18.0),
	(7, 1, 4, 1.0),
	(7, 3, 0, 38.0),
	(7, 6, 0, 76.0),
	(7, 6, 4, 1.0),
	(7, 7, 4, 1.0),
	(7, 9, 0, 5.0),
	(7, 32, 0, 9.0),
	(7, 35, 0, 56.0),
	(7, 35, 4, 11.0),
	(7, 36, 0, 8.0),
	(7, 39, 0, 12.0),
	(7, 42, 0, 10.0),
	(7, 45, 0, 44.0),
	(7, 45, 4, 4.0),
	(7, 52, 0, 13.0),
	(7, 68, 0, 25.0),
	(7, 68, 4, 4.0),
	(7, 71, 0, 13.0),
	(7, 83, 0, 74.0),
	(7, 83, 4, 5.0),
	(7, 84, 0, 79.0),
	(7, 84, 4, 41.0),
	(7, 94, 0, 6.0),
	(7, 96, 4, 11.0),
	(7, 102, 0, 42.0),
	(7, 102, 4, 3.0),
	(7, 107, 0, 77.0),
	(7, 107, 4, 2.0),
	(7, 113, 0, 47.0),
	(7, 113, 4, 6.0),
	(7, 115, 0, 11.0),
	(7, 126, 0, 6.0),
	(7, 133, 0, 5.0),
	(7, 142, 0, 10.0),
	(8, 1, 0, 57.0),
	(8, 1, 4, 16.0),
	(8, 3, 0, 60.0),
	(8, 6, 0, 96.4),
	(8, 6, 4, 21.5),
	(8, 7, 0, 55.0),
	(8, 7, 4, 6.0),
	(8, 13, 0, 76.0),
	(8, 13, 4, 12.0),
	(8, 23, 0, 30.0),
	(8, 23, 4, 2.0),
	(8, 24, 0, 17.0),
	(8, 34, 0, 15.0),
	(8, 34, 4, 4.0),
	(8, 35, 0, 88.0),
	(8, 35, 4, 31.0),
	(8, 36, 0, 15.0),
	(8, 39, 0, 10.0),
	(8, 40, 0, 22.0),
	(8, 40, 4, 4.0),
	(8, 46, 0, 45.0),
	(8, 46, 4, 1.0),
	(8, 67, 0, 83.9),
	(8, 67, 4, 7.2),
	(8, 71, 0, 19.0),
	(8, 74, 0, 96.4),
	(8, 74, 4, 21.5),
	(8, 83, 0, 86.0),
	(8, 83, 4, 17.0),
	(8, 84, 0, 96.4),
	(8, 84, 4, 31.4),
	(8, 85, 4, 5.8),
	(8, 86, 4, 2.2),
	(8, 88, 0, 24.0),
	(8, 88, 4, 2.0),
	(8, 96, 0, 13.0),
	(8, 96, 4, 1.0),
	(8, 107, 0, 96.0),
	(8, 107, 4, 1.7),
	(8, 110, 0, 11.0),
	(8, 113, 0, 67.0),
	(8, 113, 4, 17.0),
	(8, 115, 0, 30.0),
	(8, 115, 4, 1.0),
	(8, 142, 0, 16.0),
	(9, 3, 0, 39.0),
	(9, 3, 4, 2.0),
	(9, 6, 0, 77.0),
	(9, 6, 4, 1.0),
	(9, 23, 0, 44.0),
	(9, 26, 0, 13.0),
	(9, 35, 0, 13.0),
	(9, 35, 4, 1.0),
	(9, 67, 0, 9.0),
	(9, 67, 4, 3.0),
	(9, 74, 0, 83.0),
	(9, 74, 4, 30.0),
	(9, 83, 0, 34.0),
	(9, 83, 4, 1.0),
	(9, 84, 0, 85.0),
	(9, 84, 4, 28.0),
	(9, 107, 0, 3.0),
	(9, 113, 0, 15.0),
	(9, 113, 4, 1.0),
	(10, 3, 0, 34.0),
	(10, 6, 0, 88.0),
	(10, 6, 4, 21.0),
	(10, 7, 0, 46.0),
	(10, 9, 0, 12.0),
	(10, 9, 4, 1.0),
	(10, 23, 0, 35.0),
	(10, 23, 4, 3.0),
	(10, 35, 0, 17.0),
	(10, 35, 4, 2.0),
	(10, 36, 0, 9.0),
	(10, 36, 4, 1.0),
	(10, 45, 0, 67.0),
	(10, 45, 4, 12.0),
	(10, 46, 0, 20.0),
	(10, 46, 4, 2.0),
	(10, 70, 0, 17.0),
	(10, 74, 0, 88.0),
	(10, 74, 4, 39.0),
	(10, 81, 0, 12.0),
	(10, 81, 4, 1.0),
	(10, 83, 0, 58.0),
	(10, 83, 4, 14.0),
	(10, 84, 0, 89.0),
	(10, 84, 4, 22.0),
	(10, 89, 0, 17.0),
	(10, 89, 4, 1.0),
	(10, 107, 0, 29.0),
	(10, 107, 4, 4.0),
	(10, 111, 0, 10.0),
	(10, 111, 4, 3.0),
	(10, 113, 0, 60.0),
	(10, 113, 4, 7.0),
	(10, 115, 0, 34.0),
	(10, 115, 4, 1.0),
	(10, 143, 0, 10.0),
	(10, 143, 4, 4.0),
	(11, 3, 0, 43.0),
	(11, 6, 0, 88.0),
	(11, 13, 0, 43.0),
	(11, 67, 0, 5.0),
	(11, 68, 0, 18.0),
	(11, 74, 0, 97.0),
	(11, 77, 0, 58.0),
	(11, 80, 0, 6.0),
	(11, 83, 0, 94.0),
	(11, 84, 0, 95.0),
	(11, 88, 0, 54.0),
	(11, 90, 0, 13.0),
	(11, 107, 0, 59.0),
	(11, 113, 0, 94.0),
	(11, 144, 0, 12.0),
	(12, 1, 0, 2.0),
	(12, 3, 0, 66.0),
	(12, 6, 0, 33.0),
	(12, 7, 0, 13.0),
	(12, 35, 0, 13.0),
	(12, 60, 0, 2.0),
	(12, 74, 0, 91.0),
	(12, 74, 4, 17.0),
	(12, 83, 0, 43.0),
	(12, 90, 0, 2.0),
	(12, 102, 0, 6.0),
	(12, 107, 0, 41.0),
	(12, 107, 4, 20.0),
	(12, 113, 0, 43.0),
	(12, 146, 0, 2.0),
	(13, 6, 0, 15.0),
	(13, 6, 4, 3.0),
	(13, 7, 0, 19.0),
	(13, 7, 4, 2.0),
	(13, 45, 0, 25.0),
	(13, 45, 4, 5.0),
	(13, 46, 0, 35.0),
	(13, 46, 4, 2.0),
	(49, 113, 4, 3.0),
	(49, 113, 0, 35.0),
	(13, 68, 0, 22.0),
	(13, 68, 4, 6.0),
	(13, 74, 0, 6.0),
	(13, 74, 4, 2.0),
	(13, 80, 0, 7.0),
	(13, 80, 4, 1.0),
	(13, 83, 0, 19.0),
	(13, 83, 4, 1.0),
	(13, 84, 0, 6.0),
	(13, 84, 4, 3.0),
	(13, 96, 0, 10.0),
	(13, 113, 0, 9.0),
	(14, 6, 0, 65.0),
	(14, 13, 0, 66.0),
	(14, 41, 0, 13.0),
	(14, 68, 0, 1.0),
	(14, 74, 0, 99.0),
	(14, 74, 4, 44.0),
	(14, 81, 0, 3.0),
	(14, 84, 0, 95.0),
	(14, 84, 4, 75.0),
	(14, 99, 0, 31.0),
	(14, 102, 0, 19.0),
	(14, 102, 4, 1.0),
	(14, 107, 0, 14.0),
	(14, 107, 4, 1.0),
	(14, 131, 0, 20.0),
	(14, 145, 0, 1.0),
	(15, 3, 0, 74.0),
	(15, 6, 0, 95.0),
	(15, 9, 0, 8.0),
	(15, 13, 0, 65.0),
	(15, 13, 4, 17.0),
	(15, 33, 0, 47.0),
	(15, 33, 4, 5.0),
	(15, 35, 0, 42.0),
	(15, 35, 4, 6.0),
	(15, 41, 0, 56.0),
	(15, 41, 4, 8.0),
	(15, 68, 0, 23.0),
	(15, 68, 4, 7.0),
	(15, 81, 0, 23.0),
	(15, 81, 4, 2.0),
	(15, 83, 0, 42.0),
	(15, 84, 0, 98.0),
	(15, 84, 4, 84.0),
	(15, 85, 0, 12.0),
	(15, 85, 4, 2.0),
	(15, 99, 0, 45.0),
	(15, 99, 4, 5.0),
	(15, 102, 0, 53.0),
	(15, 102, 4, 8.0),
	(15, 107, 0, 11.0),
	(15, 107, 4, 1.0),
	(15, 113, 0, 23.0),
	(15, 131, 0, 57.0),
	(15, 131, 4, 6.0),
	(15, 145, 0, 13.0),
	(15, 145, 4, 1.0),
	(16, 3, 0, 96.0),
	(16, 3, 4, 51.0),
	(16, 6, 0, 96.0),
	(16, 6, 4, 3.0),
	(16, 7, 0, 12.0),
	(16, 9, 0, 60.0),
	(16, 9, 4, 6.0),
	(16, 35, 0, 37.0),
	(16, 35, 4, 2.0),
	(16, 81, 0, 60.0),
	(16, 81, 4, 6.0),
	(16, 83, 0, 88.0),
	(16, 83, 4, 18.0),
	(16, 84, 4, 91.0),
	(16, 85, 0, 33.0),
	(16, 102, 0, 8.0),
	(16, 107, 0, 21.0),
	(16, 107, 4, 3.0),
	(16, 113, 0, 88.0),
	(16, 113, 4, 18.0),
	(17, 3, 0, 92.4),
	(17, 83, 0, 15.5),
	(17, 113, 4, 36.8),
	(17, 115, 0, 10.6),
	(18, 3, 0, 19.2),
	(18, 6, 0, 5.4),
	(18, 7, 0, 20.1),
	(18, 7, 4, 2.5),
	(18, 13, 0, 40.2),
	(18, 13, 4, 7.1),
	(18, 14, 0, 11.7),
	(18, 14, 4, 1.7),
	(18, 24, 0, 9.6),
	(18, 35, 0, 20.9),
	(18, 35, 4, 2.5),
	(18, 36, 0, 4.2),
	(18, 39, 0, 12.1),
	(18, 39, 4, 0.8),
	(18, 40, 0, 15.1),
	(18, 40, 4, 4.1),
	(18, 46, 0, 21.3),
	(18, 46, 4, 0.8),
	(18, 51, 0, 50.6),
	(18, 51, 4, 23.8),
	(18, 52, 0, 10.5),
	(18, 52, 4, 0.8),
	(18, 68, 0, 11.7),
	(18, 68, 4, 2.1),
	(18, 74, 0, 3.4),
	(18, 83, 0, 46.0),
	(18, 83, 4, 5.4),
	(18, 84, 0, 7.9),
	(18, 84, 4, 4.2),
	(18, 96, 0, 28.5),
	(18, 96, 4, 4.2),
	(18, 102, 0, 41.4),
	(18, 102, 4, 8.3),
	(18, 107, 0, 1.3),
	(18, 113, 0, 32.6),
	(18, 113, 4, 7.9),
	(18, 141, 0, 15.9),
	(20, 18, 0, 36.0),
	(20, 26, 0, 36.0),
	(20, 40, 4, 4.0),
	(20, 45, 4, 10.0),
	(20, 74, 0, 30.0),
	(20, 85, 0, 30.0),
	(20, 107, 0, 30.0),
	(20, 144, 0, 31.0),
	(20, 149, 0, 36.0),
	(20, 159, 0, 36.0),
	(21, 3, 0, 45.0),
	(21, 7, 0, 20.0),
	(21, 7, 4, 1.0),
	(21, 9, 0, 22.0),
	(21, 9, 4, 1.0),
	(21, 13, 0, 54.0),
	(21, 13, 4, 10.0),
	(21, 14, 0, 16.0),
	(21, 14, 4, 1.0),
	(21, 17, 0, 12.0),
	(21, 17, 4, 2.0),
	(21, 23, 0, 25.0),
	(21, 23, 4, 1.0),
	(21, 24, 0, 14.0),
	(21, 35, 0, 18.0),
	(21, 35, 4, 1.0),
	(21, 40, 0, 16.0),
	(21, 40, 4, 4.0),
	(21, 52, 0, 19.0),
	(21, 52, 4, 1.0),
	(21, 81, 0, 22.0),
	(21, 81, 4, 1.0),
	(21, 83, 0, 35.0),
	(21, 83, 4, 1.0),
	(21, 90, 0, 35.0),
	(21, 90, 4, 8.0),
	(21, 109, 0, 10.0),
	(21, 109, 4, 1.0),
	(21, 113, 0, 18.0),
	(21, 113, 4, 1.0),
	(21, 137, 0, 11.0),
	(21, 137, 4, 1.0),
	(49, 83, 4, 2.0),
	(49, 83, 0, 57.0),
	(49, 35, 4, 7.0),
	(49, 35, 0, 57.0),
	(49, 13, 4, 12.0),
	(49, 13, 0, 61.0),
	(48, 208, 4, 1.0),
	(48, 208, 0, 13.0),
	(48, 126, 0, 10.0),
	(48, 44, 0, 15.0),
	(48, 96, 4, 1.0),
	(48, 96, 0, 22.0),
	(48, 134, 4, 2.0),
	(48, 134, 0, 25.0),
	(48, 82, 4, 2.0),
	(48, 82, 0, 29.0),
	(48, 94, 4, 2.0),
	(48, 94, 0, 57.0),
	(48, 33, 4, 7.0),
	(48, 33, 0, 57.0),
	(48, 43, 4, 5.0),
	(48, 43, 0, 65.0),
	(48, 99, 4, 14.0),
	(48, 99, 0, 90.0),
	(48, 24, 0, 14.0),
	(48, 41, 4, 1.0),
	(48, 41, 0, 12.0),
	(48, 154, 4, 4.0),
	(48, 154, 0, 38.0),
	(48, 102, 0, 7.0),
	(48, 113, 4, 2.0),
	(48, 113, 0, 19.0),
	(48, 23, 4, 3.0),
	(48, 23, 0, 210.0),
	(48, 35, 4, 2.0),
	(48, 35, 0, 21.0),
	(48, 83, 4, 1.0),
	(48, 83, 0, 23.0),
	(48, 1, 4, 7.0),
	(48, 1, 0, 25.0),
	(48, 45, 4, 4.0),
	(48, 45, 0, 26.0),
	(24, 1, 0, 17.0),
	(24, 1, 4, 2.0),
	(24, 3, 0, 10.0),
	(24, 6, 0, 69.0),
	(24, 6, 4, 94.0),
	(24, 7, 0, 16.0),
	(24, 7, 4, 1.0),
	(24, 9, 0, 11.0),
	(24, 9, 4, 1.0),
	(24, 13, 0, 20.0),
	(24, 13, 4, 5.0),
	(24, 14, 0, 16.0),
	(24, 14, 4, 4.0),
	(24, 23, 0, 20.0),
	(24, 23, 4, 1.0),
	(24, 24, 0, 11.0),
	(24, 34, 0, 5.0),
	(24, 34, 4, 2.0),
	(24, 35, 0, 47.0),
	(24, 35, 4, 6.0),
	(24, 36, 0, 8.0),
	(24, 38, 0, 11.0),
	(24, 39, 0, 10.0),
	(24, 40, 0, 12.0),
	(24, 40, 4, 1.0),
	(24, 45, 0, 37.0),
	(24, 45, 4, 5.0),
	(24, 52, 0, 8.0),
	(24, 53, 0, 17.0),
	(24, 53, 4, 2.0),
	(24, 60, 0, 5.0),
	(24, 60, 4, 1.0),
	(24, 74, 0, 82.0),
	(24, 74, 4, 48.0),
	(24, 80, 0, 6.0),
	(24, 80, 4, 1.0),
	(24, 83, 0, 34.0),
	(24, 83, 4, 2.0),
	(24, 84, 0, 4.0),
	(24, 84, 4, 11.0),
	(24, 88, 0, 5.0),
	(24, 88, 4, 1.0),
	(24, 95, 0, 12.0),
	(24, 95, 4, 1.0),
	(24, 109, 0, 8.0),
	(24, 109, 4, 2.0),
	(24, 113, 0, 22.0),
	(24, 113, 4, 2.0),
	(24, 115, 0, 9.0),
	(24, 138, 0, 7.0),
	(25, 1, 0, 61.0),
	(25, 3, 0, 32.0),
	(25, 7, 0, 43.0),
	(25, 23, 0, 40.0),
	(25, 36, 0, 26.0),
	(25, 37, 0, 7.0),
	(25, 39, 0, 24.0),
	(25, 40, 0, 26.0),
	(25, 42, 0, 35.0),
	(25, 52, 0, 26.0),
	(25, 55, 0, 23.0),
	(25, 60, 0, 15.0),
	(25, 88, 0, 61.0),
	(25, 93, 0, 36.0),
	(25, 102, 0, 32.0),
	(25, 111, 0, 9.0),
	(25, 113, 0, 52.0),
	(25, 115, 0, 15.0),
	(25, 128, 0, 6.0),
	(25, 140, 0, 47.0),
	(26, 1, 0, 50.0),
	(26, 3, 0, 6.0),
	(26, 6, 4, 82.0),
	(26, 7, 0, 35.0),
	(26, 23, 0, 29.0),
	(26, 36, 0, 19.0),
	(26, 37, 0, 4.0),
	(26, 39, 0, 17.0),
	(26, 40, 0, 25.0),
	(26, 42, 0, 32.0),
	(26, 52, 0, 26.0),
	(26, 55, 0, 34.0),
	(26, 60, 0, 7.0),
	(26, 74, 0, 57.0),
	(26, 84, 4, 58.0),
	(26, 85, 0, 2.0),
	(26, 88, 0, 62.0),
	(26, 93, 0, 36.0),
	(26, 102, 0, 30.0),
	(26, 111, 0, 6.0),
	(26, 113, 0, 47.0),
	(26, 115, 0, 16.0),
	(26, 128, 0, 6.0),
	(26, 140, 0, 40.0),
	(27, 9, 0, 8.0),
	(27, 13, 0, 4.5),
	(27, 14, 0, 5.0),
	(27, 17, 0, 3.0),
	(27, 23, 0, 2.0),
	(27, 24, 0, 5.0),
	(27, 35, 0, 7.0),
	(27, 36, 0, 4.0),
	(27, 39, 0, 2.0),
	(27, 40, 0, 3.0),
	(27, 42, 0, 2.0),
	(27, 52, 0, 10.0),
	(27, 82, 0, 2.0),
	(27, 83, 0, 6.0),
	(27, 89, 0, 2.0),
	(27, 94, 0, 2.0),
	(27, 95, 0, 6.0),
	(27, 96, 0, 4.0),
	(27, 113, 0, 3.5),
	(27, 122, 0, 2.0),
	(27, 123, 0, 4.0),
	(44, 1, 0, 13.0),
	(44, 102, 4, 2.0),
	(28, 12, 0, 49.0),
	(28, 12, 4, 2.0),
	(28, 14, 0, 11.0),
	(28, 14, 4, 1.0),
	(28, 35, 0, 65.0),
	(28, 35, 4, 13.0),
	(28, 39, 0, 11.0),
	(28, 39, 4, 1.0),
	(28, 40, 0, 12.0),
	(28, 40, 4, 3.0),
	(28, 71, 0, 10.0),
	(28, 71, 4, 1.0),
	(28, 83, 0, 44.0),
	(28, 83, 4, 2.0),
	(28, 84, 0, 22.0),
	(28, 84, 4, 3.0),
	(28, 96, 0, 28.0),
	(28, 96, 4, 2.0),
	(28, 102, 0, 14.0),
	(28, 105, 0, 45.0),
	(28, 107, 0, 18.0),
	(28, 107, 4, 1.0),
	(28, 113, 0, 26.0),
	(28, 113, 4, 2.0),
	(28, 124, 0, 53.0),
	(28, 124, 4, 12.0),
	(28, 126, 0, 10.0),
	(28, 129, 0, 15.0),
	(28, 137, 0, 12.0),
	(28, 137, 4, 1.0),
	(29, 3, 0, 13.0),
	(29, 3, 4, 1.0),
	(44, 102, 0, 15.0),
	(44, 35, 0, 43.0),
	(29, 7, 0, 11.0),
	(29, 7, 4, 1.0),
	(29, 12, 0, 53.0),
	(29, 12, 4, 6.0),
	(29, 13, 0, 12.0),
	(29, 13, 4, 1.0),
	(29, 35, 0, 64.0),
	(29, 35, 4, 9.0),
	(29, 42, 0, 11.0),
	(29, 42, 4, 1.0),
	(29, 45, 0, 20.0),
	(29, 45, 4, 2.0),
	(29, 52, 0, 14.0),
	(29, 52, 4, 1.0),
	(29, 82, 0, 11.0),
	(29, 82, 4, 1.0),
	(29, 83, 0, 31.0),
	(29, 83, 4, 1.0),
	(29, 94, 0, 12.0),
	(29, 94, 4, 1.0),
	(29, 96, 0, 44.0),
	(29, 96, 4, 1.0),
	(29, 105, 0, 22.0),
	(29, 113, 0, 17.0),
	(29, 113, 4, 1.0),
	(29, 126, 0, 13.0),
	(29, 126, 4, 1.0),
	(30, 7, 0, 9.2),
	(30, 7, 4, 1.0),
	(30, 33, 0, 4.6),
	(30, 33, 4, 1.0),
	(30, 35, 0, 20.3),
	(30, 35, 4, 1.8),
	(30, 45, 0, 9.0),
	(30, 45, 4, 1.8),
	(30, 68, 0, 24.0),
	(30, 68, 4, 4.0),
	(30, 94, 0, 7.4),
	(30, 94, 4, 1.0),
	(30, 96, 0, 49.2),
	(30, 96, 4, 6.0),
	(30, 102, 0, 17.0),
	(30, 115, 0, 3.9),
	(30, 115, 4, 1.0),
	(30, 126, 0, 4.4),
	(30, 134, 0, 3.9),
	(30, 134, 4, 1.0),
	(30, 136, 0, 12.0),
	(31, 1, 0, 11.0),
	(31, 1, 4, 2.0),
	(31, 6, 0, 68.0),
	(31, 6, 4, 6.0),
	(31, 7, 0, 52.0),
	(31, 7, 4, 8.0),
	(31, 22, 0, 12.0),
	(31, 22, 4, 1.0),
	(31, 24, 0, 33.0),
	(31, 24, 4, 4.0),
	(31, 35, 0, 54.0),
	(31, 35, 4, 6.0),
	(31, 40, 0, 41.0),
	(31, 40, 4, 17.0),
	(31, 45, 0, 52.0),
	(31, 45, 4, 14.0),
	(31, 68, 0, 24.0),
	(31, 68, 4, 4.0),
	(31, 83, 0, 33.0),
	(31, 83, 4, 3.0),
	(31, 94, 0, 13.0),
	(31, 94, 4, 1.0),
	(31, 96, 0, 75.0),
	(31, 96, 4, 8.0),
	(31, 102, 0, 17.0),
	(31, 102, 4, 1.0),
	(31, 113, 0, 23.0),
	(31, 113, 4, 2.0),
	(31, 126, 0, 12.0),
	(33, 7, 0, 7.0),
	(33, 13, 0, 6.0),
	(33, 13, 4, 1.0),
	(33, 35, 0, 48.0),
	(33, 35, 4, 1.0),
	(33, 83, 0, 13.0),
	(33, 83, 4, 1.0),
	(33, 94, 0, 8.0),
	(33, 96, 0, 43.0),
	(33, 113, 0, 12.0),
	(33, 113, 4, 1.0),
	(33, 126, 0, 13.0),
	(34, 1, 0, 31.0),
	(34, 1, 4, 9.0),
	(34, 3, 0, 14.0),
	(34, 7, 0, 29.0),
	(34, 7, 4, 3.0),
	(34, 23, 0, 14.0),
	(34, 35, 0, 55.0),
	(34, 35, 4, 10.0),
	(34, 45, 0, 46.0),
	(34, 45, 4, 9.0),
	(34, 51, 0, 21.0),
	(34, 51, 4, 8.0),
	(34, 83, 0, 24.0),
	(34, 83, 4, 1.0),
	(34, 94, 0, 14.0),
	(34, 94, 4, 1.0),
	(34, 96, 0, 19.0),
	(34, 96, 4, 1.0),
	(34, 107, 0, 46.0),
	(34, 107, 4, 4.0),
	(34, 113, 0, 15.0),
	(34, 113, 4, 2.0),
	(34, 115, 0, 30.0),
	(34, 115, 4, 2.0),
	(34, 120, 0, 11.0),
	(34, 120, 4, 2.0),
	(34, 126, 0, 10.0),
	(34, 147, 0, 47.0),
	(34, 150, 0, 40.0),
	(34, 150, 4, 9.0),
	(34, 151, 0, 34.0),
	(34, 151, 4, 2.0),
	(34, 153, 0, 35.0),
	(34, 153, 4, 11.0),
	(34, 156, 0, 59.0),
	(34, 157, 0, 42.0),
	(34, 157, 4, 4.0),
	(35, 1, 0, 11.0),
	(35, 1, 4, 2.0),
	(35, 3, 0, 27.0),
	(35, 3, 4, 1.0),
	(35, 151, 0, 30.0),
	(35, 6, 0, 44.0),
	(35, 6, 4, 2.0),
	(35, 7, 0, 16.0),
	(35, 7, 4, 1.0),
	(35, 23, 0, 15.0),
	(35, 23, 4, 1.0),
	(35, 35, 0, 43.0),
	(35, 35, 4, 2.0),
	(35, 40, 0, 14.0),
	(35, 40, 4, 3.0),
	(35, 45, 0, 37.0),
	(35, 45, 4, 5.0),
	(35, 51, 0, 30.0),
	(35, 51, 4, 6.0),
	(35, 54, 0, 15.0),
	(35, 54, 4, 2.0),
	(35, 55, 0, 17.0),
	(35, 55, 4, 3.0),
	(35, 83, 0, 23.0),
	(35, 83, 4, 1.0),
	(35, 84, 0, 18.0),
	(35, 84, 4, 5.0),
	(35, 94, 0, 19.0),
	(35, 94, 4, 1.0),
	(35, 96, 0, 40.0),
	(35, 96, 4, 1.0),
	(35, 107, 0, 12.0),
	(35, 107, 4, 1.0),
	(35, 113, 0, 16.0),
	(35, 113, 4, 1.0),
	(35, 115, 0, 10.0),
	(35, 115, 4, 1.0),
	(35, 126, 0, 11.0),
	(35, 131, 0, 15.0),
	(35, 131, 4, 2.0),
	(35, 147, 0, 23.0),
	(35, 147, 4, 13.0),
	(35, 150, 0, 41.0),
	(35, 150, 4, 12.0),
	(35, 153, 0, 45.0),
	(35, 153, 4, 13.0),
	(36, 1, 0, 36.0),
	(36, 1, 4, 4.0),
	(36, 8, 0, 30.0),
	(36, 8, 4, 1.0),
	(36, 9, 0, 15.0),
	(36, 9, 4, 1.0),
	(36, 13, 0, 19.0),
	(36, 13, 4, 3.0),
	(36, 14, 0, 15.0),
	(36, 14, 4, 1.0),
	(36, 23, 0, 14.0),
	(36, 24, 0, 25.0),
	(36, 24, 4, 0.5),
	(36, 26, 0, 19.0),
	(36, 28, 0, 0.5),
	(36, 35, 0, 50.0),
	(36, 35, 4, 5.0),
	(36, 36, 0, 12.0),
	(36, 36, 4, 0.5),
	(36, 37, 0, 11.0),
	(36, 38, 0, 19.0),
	(36, 40, 0, 20.0),
	(36, 40, 4, 2.0),
	(36, 42, 0, 22.0),
	(36, 45, 0, 45.0),
	(36, 45, 4, 3.0),
	(36, 46, 0, 31.0),
	(36, 46, 4, 0.5),
	(36, 52, 0, 30.0),
	(36, 52, 4, 0.5),
	(36, 55, 0, 13.0),
	(36, 55, 4, 1.0),
	(36, 62, 0, 48.0),
	(36, 62, 4, 2.0),
	(36, 12, 0, 48.0),
	(36, 12, 4, 2.0),
	(36, 66, 0, 37.0),
	(36, 71, 0, 14.0),
	(36, 76, 0, 4.0),
	(36, 78, 0, 23.0),
	(36, 79, 0, 16.0),
	(36, 79, 4, 1.0),
	(36, 83, 0, 32.0),
	(36, 83, 4, 2.0),
	(36, 84, 0, 30.0),
	(36, 84, 4, 4.0),
	(36, 92, 0, 17.0),
	(36, 92, 4, 3.0),
	(36, 94, 0, 21.0),
	(36, 96, 0, 59.0),
	(36, 96, 4, 0.5),
	(36, 102, 0, 70.0),
	(36, 102, 4, 7.0),
	(36, 107, 0, 45.0),
	(36, 107, 4, 3.0),
	(36, 109, 0, 16.0),
	(36, 113, 0, 29.0),
	(36, 113, 4, 1.0),
	(36, 174, 0, 43.0),
	(36, 174, 4, 2.0),
	(36, 121, 0, 11.0),
	(36, 126, 0, 13.0),
	(36, 137, 0, 14.0),
	(36, 137, 4, 0.5),
	(36, 138, 0, 10.0),
	(36, 142, 0, 25.0),
	(36, 147, 0, 45.0),
	(36, 147, 4, 16.0),
	(37, 1, 0, 11.0),
	(37, 1, 4, 2.0),
	(37, 7, 0, 22.0),
	(37, 7, 4, 2.0),
	(37, 13, 0, 14.0),
	(37, 13, 4, 3.0),
	(37, 35, 0, 52.0),
	(37, 35, 4, 3.0),
	(37, 45, 0, 19.0),
	(37, 45, 4, 2.0),
	(37, 50, 0, 41.0),
	(37, 50, 4, 1.0),
	(37, 52, 0, 10.0),
	(37, 55, 0, 40.0),
	(37, 55, 4, 4.0),
	(37, 62, 0, 53.0),
	(37, 62, 4, 4.0),
	(37, 12, 0, 53.0),
	(37, 12, 4, 7.0),
	(37, 74, 0, 37.0),
	(37, 79, 0, 31.0),
	(37, 79, 4, 4.0),
	(37, 83, 0, 26.0),
	(37, 83, 4, 1.0),
	(37, 84, 0, 34.0),
	(37, 84, 4, 1.0),
	(37, 107, 0, 32.0),
	(37, 107, 4, 1.0),
	(37, 113, 0, 21.0),
	(37, 113, 4, 2.0),
	(37, 147, 0, 31.0),
	(37, 147, 4, 4.0),
	(37, 158, 0, 17.0),
	(38, 2, 0, 24.0),
	(38, 2, 4, 4.0),
	(38, 151, 0, 17.0),
	(38, 7, 0, 33.0),
	(38, 7, 4, 1.0),
	(38, 12, 0, 39.0),
	(38, 12, 4, 2.0),
	(38, 13, 0, 22.0),
	(38, 13, 4, 5.0),
	(38, 23, 0, 20.0),
	(38, 29, 0, 11.0),
	(38, 29, 4, 1.0),
	(38, 35, 0, 40.0),
	(38, 35, 4, 4.0),
	(38, 51, 0, 14.0),
	(38, 51, 4, 4.0),
	(38, 55, 0, 15.0),
	(38, 67, 0, 10.0),
	(38, 75, 0, 25.0),
	(38, 75, 4, 10.0),
	(38, 84, 0, 53.0),
	(38, 84, 4, 10.0),
	(38, 96, 0, 14.0),
	(38, 96, 4, 1.0),
	(38, 98, 0, 30.0),
	(38, 102, 0, 29.0),
	(38, 102, 4, 1.0),
	(38, 105, 0, 16.0),
	(38, 107, 0, 38.0),
	(38, 107, 4, 5.0),
	(38, 147, 0, 38.0),
	(39, 1, 0, 21.0),
	(39, 1, 4, 4.0),
	(39, 7, 0, 32.0),
	(39, 7, 4, 3.0),
	(39, 9, 0, 18.0),
	(39, 9, 4, 1.0),
	(39, 13, 0, 51.0),
	(39, 13, 4, 11.0),
	(39, 14, 0, 20.0),
	(39, 14, 4, 3.0),
	(39, 19, 0, 16.0),
	(39, 19, 4, 1.0),
	(39, 23, 0, 20.0),
	(39, 24, 0, 26.0),
	(39, 24, 4, 1.0),
	(39, 32, 0, 4.0),
	(39, 35, 0, 27.0),
	(39, 35, 4, 1.0),
	(39, 40, 0, 28.0),
	(39, 40, 4, 9.0),
	(39, 42, 0, 12.0),
	(39, 50, 0, 89.0),
	(39, 50, 4, 16.0),
	(39, 52, 0, 15.0),
	(39, 52, 4, 1.0),
	(39, 12, 0, 38.0),
	(39, 12, 4, 2.0),
	(39, 68, 0, 20.0),
	(39, 68, 4, 3.0),
	(39, 71, 0, 12.0),
	(39, 71, 4, 1.0),
	(39, 74, 0, 32.0),
	(39, 74, 4, 1.0),
	(39, 80, 0, 41.0),
	(39, 80, 4, 3.0),
	(39, 81, 0, 8.0),
	(39, 81, 4, 1.0),
	(39, 82, 0, 14.0),
	(39, 83, 0, 37.0),
	(39, 83, 4, 2.0),
	(39, 84, 0, 19.0),
	(39, 84, 4, 5.0),
	(39, 88, 0, 28.0),
	(39, 88, 4, 5.0),
	(39, 94, 0, 19.0),
	(39, 94, 4, 1.0),
	(39, 95, 0, 24.0),
	(39, 95, 4, 1.0),
	(39, 96, 0, 47.0),
	(39, 96, 4, 5.0),
	(39, 106, 0, 8.0),
	(39, 106, 4, 1.0),
	(39, 107, 0, 40.0),
	(39, 107, 4, 1.0),
	(39, 109, 0, 15.0),
	(39, 109, 4, 1.0),
	(39, 113, 0, 19.0),
	(39, 113, 4, 2.0),
	(39, 115, 0, 19.0),
	(39, 115, 4, 1.0),
	(39, 126, 0, 11.0),
	(39, 126, 4, 1.0),
	(39, 141, 0, 12.0),
	(39, 142, 0, 10.0),
	(40, 3, 0, 45.0),
	(40, 3, 4, 1.0),
	(40, 8, 0, 18.0),
	(40, 9, 0, 53.0),
	(40, 9, 4, 4.0),
	(40, 13, 0, 11.0),
	(40, 13, 4, 1.0),
	(40, 14, 0, 8.0),
	(40, 14, 4, 1.0),
	(40, 23, 0, 12.0),
	(40, 23, 4, 1.0),
	(40, 24, 0, 8.0),
	(40, 35, 0, 28.0),
	(40, 35, 4, 1.0),
	(40, 38, 0, 14.0),
	(40, 43, 0, 14.0),
	(40, 45, 0, 38.0),
	(40, 45, 4, 2.0),
	(40, 55, 0, 17.0),
	(40, 55, 4, 3.0),
	(40, 81, 0, 13.0),
	(40, 81, 4, 1.0),
	(40, 83, 0, 35.0),
	(40, 83, 4, 2.0),
	(40, 88, 0, 18.0),
	(40, 88, 4, 1.0),
	(40, 94, 0, 23.0),
	(40, 94, 4, 1.0),
	(40, 95, 0, 19.0),
	(40, 95, 4, 1.0),
	(40, 96, 0, 37.0),
	(40, 96, 4, 8.0),
	(40, 99, 0, 24.0),
	(40, 99, 4, 22.0),
	(40, 113, 0, 18.0),
	(40, 113, 4, 1.0),
	(40, 125, 0, 24.0),
	(40, 125, 4, 1.0),
	(40, 126, 0, 19.0),
	(41, 1, 0, 27.0),
	(41, 1, 4, 3.0),
	(41, 3, 0, 16.0),
	(41, 8, 0, 46.0),
	(41, 8, 4, 5.0),
	(41, 9, 0, 14.0),
	(41, 9, 4, 1.0),
	(41, 13, 0, 21.0),
	(41, 13, 4, 6.0),
	(41, 23, 0, 27.0),
	(41, 34, 0, 7.0),
	(41, 34, 4, 2.0),
	(41, 35, 0, 63.0),
	(41, 35, 4, 16.0),
	(41, 36, 0, 14.0),
	(41, 38, 0, 34.0),
	(41, 39, 0, 11.0),
	(41, 43, 0, 11.0),
	(41, 43, 4, 1.0),
	(41, 45, 0, 41.0),
	(41, 45, 4, 9.0),
	(41, 51, 0, 50.0),
	(41, 51, 4, 13.0),
	(41, 52, 0, 18.0),
	(41, 55, 0, 33.0),
	(41, 55, 4, 8.0),
	(41, 56, 0, 25.0),
	(41, 56, 4, 2.0),
	(41, 59, 0, 18.0),
	(41, 59, 4, 4.0),
	(41, 60, 0, 7.0),
	(41, 60, 4, 1.0),
	(42, 12, 4, 7.0),
	(42, 12, 0, 15.0),
	(41, 12, 4, 6.0),
	(41, 12, 0, 86.0),
	(41, 83, 0, 43.0),
	(41, 83, 4, 1.0),
	(41, 84, 0, 35.0),
	(41, 84, 4, 3.0),
	(41, 89, 0, 7.0),
	(41, 90, 0, 5.0),
	(41, 96, 0, 19.0),
	(41, 96, 4, 1.0),
	(41, 102, 0, 51.0),
	(41, 102, 4, 5.0),
	(41, 107, 0, 35.0),
	(41, 113, 0, 24.0),
	(41, 113, 4, 2.0),
	(41, 115, 0, 48.0),
	(41, 115, 4, 5.0),
	(41, 116, 0, 36.0),
	(41, 116, 4, 2.0),
	(41, 117, 0, 13.0),
	(41, 117, 4, 4.0),
	(41, 119, 0, 9.0),
	(41, 125, 0, 7.0),
	(41, 126, 0, 19.0),
	(41, 127, 0, 34.0),
	(41, 131, 0, 7.0),
	(41, 132, 0, 20.0),
	(41, 133, 0, 9.0),
	(41, 138, 0, 12.0),
	(41, 139, 0, 9.0),
	(41, 139, 4, 1.0),
	(41, 148, 0, 52.0),
	(41, 148, 4, 3.0),
	(41, 152, 0, 52.0),
	(41, 152, 4, 12.0),
	(41, 153, 0, 28.0),
	(41, 153, 4, 3.0),
	(41, 154, 0, 19.0),
	(41, 154, 4, 1.0),
	(41, 155, 0, 10.0),
	(41, 155, 4, 2.0),
	(42, 1, 0, 16.0),
	(42, 1, 4, 1.0),
	(42, 8, 0, 27.0),
	(42, 8, 4, 1.0),
	(42, 9, 0, 11.0),
	(42, 9, 4, 1.0),
	(42, 14, 0, 11.0),
	(42, 19, 0, 12.0),
	(42, 19, 4, 1.0),
	(42, 23, 0, 38.0),
	(42, 23, 4, 1.0),
	(42, 24, 0, 21.0),
	(42, 24, 4, 1.0),
	(42, 35, 0, 49.0),
	(42, 35, 4, 1.0),
	(42, 36, 0, 24.0),
	(42, 38, 0, 13.0),
	(42, 40, 0, 22.0),
	(42, 40, 4, 6.0),
	(42, 45, 0, 31.0),
	(42, 45, 4, 2.0),
	(42, 46, 0, 12.0),
	(42, 46, 4, 1.0),
	(42, 52, 0, 13.0),
	(42, 52, 4, 1.0),
	(49, 90, 4, 7.0),
	(49, 90, 0, 36.0),
	(46, 12, 4, 5.0),
	(46, 12, 0, 65.0),
	(42, 71, 0, 12.0),
	(42, 83, 0, 57.0),
	(42, 83, 4, 1.0),
	(42, 84, 4, 5.2),
	(42, 90, 0, 23.0),
	(42, 90, 4, 1.0),
	(42, 96, 0, 16.0),
	(42, 102, 0, 11.0),
	(42, 102, 4, 1.0),
	(42, 107, 4, 0.4),
	(42, 113, 0, 45.0),
	(42, 113, 4, 1.0),
	(42, 118, 0, 20.0),
	(42, 118, 4, 1.0),
	(42, 135, 0, 64.0),
	(42, 140, 0, 20.0),
	(42, 140, 4, 1.0),
	(43, 1, 0, 20.0),
	(43, 1, 4, 1.0),
	(43, 3, 0, 12.0),
	(43, 6, 0, 48.0),
	(43, 6, 4, 10.0),
	(43, 7, 0, 32.0),
	(43, 7, 4, 2.0),
	(43, 13, 0, 17.0),
	(43, 13, 4, 2.0),
	(43, 23, 0, 32.0),
	(43, 23, 4, 2.0),
	(43, 24, 0, 12.0),
	(43, 35, 0, 26.0),
	(43, 35, 4, 2.0),
	(43, 39, 0, 13.0),
	(43, 40, 0, 15.0),
	(43, 40, 4, 3.0),
	(43, 45, 0, 46.0),
	(43, 45, 4, 8.0),
	(43, 51, 0, 24.0),
	(43, 51, 4, 4.0),
	(43, 52, 0, 16.0),
	(43, 52, 4, 1.0),
	(43, 56, 0, 16.0),
	(43, 56, 4, 1.0),
	(43, 59, 0, 11.0),
	(43, 59, 4, 4.0),
	(43, 12, 0, 40.0),
	(43, 12, 4, 6.0),
	(43, 71, 0, 10.0),
	(43, 74, 0, 48.0),
	(43, 74, 4, 25.0),
	(43, 83, 0, 74.0),
	(43, 83, 4, 10.0),
	(43, 84, 0, 77.0),
	(43, 84, 4, 29.0),
	(43, 95, 0, 20.0),
	(43, 95, 4, 1.0),
	(43, 96, 0, 11.0),
	(43, 102, 0, 20.0),
	(43, 102, 4, 1.0),
	(43, 107, 0, 36.0),
	(43, 107, 4, 10.0),
	(43, 113, 0, 56.0),
	(43, 113, 4, 12.0),
	(43, 129, 0, 12.0),
	(43, 129, 4, 2.0),
	(43, 148, 0, 23.0),
	(43, 148, 4, 1.0),
	(44, 96, 4, 8.0),
	(44, 33, 0, 19.0),
	(44, 126, 0, 11.0),
	(44, 94, 0, 10.0),
	(44, 94, 4, 2.0),
	(44, 134, 0, 10.0),
	(44, 55, 0, 15.0),
	(44, 55, 4, 12.0),
	(44, 54, 0, 13.0),
	(45, 125, 0, 37.0),
	(45, 125, 4, 1.0),
	(45, 3, 0, 22.0),
	(45, 124, 0, 20.0),
	(45, 124, 4, 2.0),
	(45, 96, 0, 17.0),
	(45, 52, 0, 32.0),
	(45, 95, 0, 28.0),
	(45, 95, 4, 3.0),
	(45, 9, 0, 27.0),
	(45, 9, 4, 1.0),
	(45, 14, 0, 12.0),
	(45, 14, 4, 3.0),
	(45, 81, 0, 11.0),
	(45, 23, 0, 11.0),
	(45, 23, 4, 2.0),
	(45, 24, 0, 12.0),
	(46, 13, 0, 64.0),
	(46, 13, 4, 15.0),
	(46, 88, 0, 29.0),
	(46, 88, 4, 3.0),
	(46, 46, 0, 28.0),
	(46, 46, 4, 2.0),
	(46, 8, 0, 47.0),
	(46, 8, 4, 5.0),
	(46, 96, 0, 26.0),
	(46, 96, 4, 6.0),
	(46, 35, 0, 43.0),
	(46, 35, 4, 8.0),
	(46, 80, 0, 33.0),
	(46, 80, 4, 4.0),
	(46, 171, 0, 32.0),
	(46, 68, 0, 31.0),
	(46, 68, 4, 9.0),
	(46, 55, 0, 30.0),
	(46, 55, 4, 8.0),
	(46, 54, 0, 21.0),
	(46, 54, 4, 2.0),
	(46, 132, 0, 30.0),
	(46, 52, 0, 10.0),
	(46, 6, 0, 79.0),
	(46, 6, 4, 5.0),
	(46, 107, 0, 41.0),
	(46, 107, 4, 2.0),
	(46, 84, 0, 3.0),
	(46, 84, 4, 1.0),
	(46, 168, 0, 54.0),
	(46, 168, 4, 9.0),
	(46, 152, 0, 59.0),
	(46, 152, 4, 1.0),
	(46, 59, 0, 26.0),
	(46, 59, 4, 4.0),
	(46, 155, 0, 30.0),
	(46, 155, 4, 7.0),
	(46, 153, 0, 57.0),
	(46, 153, 4, 31.0),
	(46, 56, 0, 45.0),
	(46, 56, 4, 10.0),
	(49, 23, 4, 7.0),
	(49, 23, 0, 42.0),
	(10, 56, 0, 6.0),
	(10, 195, 0, 46.0),
	(46, 93, 0, 60.0),
	(47, 35, 0, 57.0),
	(47, 35, 4, 11.0),
	(47, 110, 0, 33.0),
	(47, 110, 4, 1.0),
	(47, 1, 0, 21.0),
	(47, 1, 4, 3.0),
	(47, 113, 0, 15.0),
	(47, 113, 4, 1.0),
	(47, 39, 0, 11.0),
	(47, 37, 0, 9.0),
	(47, 96, 0, 53.0),
	(47, 96, 4, 5.0),
	(47, 33, 0, 35.0),
	(47, 33, 4, 1.0),
	(47, 126, 0, 15.0),
	(47, 94, 0, 11.0),
	(47, 94, 4, 1.0),
	(47, 82, 0, 9.0),
	(47, 3, 0, 8.0),
	(47, 55, 0, 33.0),
	(47, 55, 4, 9.0),
	(47, 52, 0, 26.0),
	(47, 52, 4, 1.0),
	(47, 38, 0, 8.0),
	(47, 45, 0, 24.0),
	(47, 45, 4, 6.0),
	(47, 140, 0, 23.0),
	(47, 8, 0, 21.0),
	(47, 8, 4, 4.0),
	(47, 152, 0, 11.0),
	(47, 152, 4, 2.0),
	(47, 32, 0, 10.0),
	(47, 32, 4, 2.0),
	(47, 138, 0, 6.0),
	(47, 180, 0, 6.0),
	(47, 177, 0, 9.0),
	(47, 178, 0, 9.0),
	(47, 179, 0, 13.0),
	(47, 179, 4, 2.0),
	(44, 181, 0, 32.0),
	(44, 181, 4, 1.0),
	(46, 182, 0, 45.0),
	(46, 182, 4, 17.0),
	(45, 183, 0, 10.0),
	(13, 12, 0, 10.0),
	(49, 95, 0, 35.0),
	(49, 95, 4, 2.0),
	(49, 107, 0, 35.0),
	(49, 107, 4, 26.0),
	(49, 7, 0, 34.0),
	(49, 7, 4, 3.0),
	(49, 89, 0, 27.0),
	(49, 89, 4, 2.0),
	(49, 6, 0, 26.0),
	(49, 6, 4, 9.0),
	(49, 52, 0, 26.0),
	(49, 24, 0, 21.0),
	(49, 40, 0, 20.0),
	(49, 40, 4, 0.0),
	(49, 84, 0, 19.0),
	(49, 84, 4, 12.0),
	(49, 96, 0, 18.0),
	(49, 96, 4, 1.0),
	(49, 71, 0, 18.0),
	(49, 1, 0, 16.0),
	(49, 1, 4, 2.0),
	(49, 17, 0, 16.0),
	(49, 17, 4, 4.0),
	(49, 68, 0, 15.0),
	(49, 68, 4, 4.0),
	(49, 14, 0, 14.0),
	(49, 14, 4, 3.0),
	(49, 9, 0, 14.0),
	(49, 36, 0, 14.0),
	(49, 41, 0, 11.0),
	(49, 81, 0, 12.0),
	(49, 138, 0, 12.0),
	(49, 183, 0, 14.0),
	(51, 74, 0, 80.3),
	(51, 74, 4, 58.6),
	(51, 84, 0, 80.3),
	(51, 84, 4, 67.2),
	(51, 6, 0, 72.2),
	(51, 6, 4, 5.8),
	(51, 107, 0, 48.8),
	(51, 107, 4, 4.0),
	(51, 213, 0, 71.8),
	(51, 214, 0, 38.9),
	(51, 214, 4, 4.0),
	(51, 130, 0, 45.8),
	(51, 130, 4, 1.9),
	(51, 46, 0, 5.2),
	(51, 83, 0, 92.4),
	(51, 83, 4, 25.0),
	(51, 113, 0, 92.4),
	(51, 113, 4, 25.0),
	(51, 80, 0, 58.5),
	(51, 80, 4, 8.9),
	(51, 35, 0, 24.8),
	(51, 35, 4, 0.8),
	(51, 7, 0, 2.9),
	(51, 68, 0, 21.5),
	(51, 68, 4, 1.6),
	(51, 85, 4, 6.1),
	(51, 22, 0, 14.8),
	(51, 3, 0, 95.5),
	(51, 3, 4, 56.6),
	(51, 96, 0, 8.9),
	(51, 96, 4, 0.3),
	(51, 99, 0, 4.7),
	(52, 35, 0, 96.0),
	(52, 35, 4, 15.0),
	(52, 102, 0, 71.0),
	(52, 102, 4, 9.0),
	(52, 96, 0, 90.0),
	(52, 96, 4, 16.0),
	(52, 94, 0, 21.0),
	(52, 126, 0, 31.0),
	(52, 134, 0, 58.0),
	(52, 134, 4, 11.0),
	(52, 166, 0, 13.0),
	(52, 166, 4, 1.0),
	(52, 8, 0, 29.0),
	(52, 8, 4, 4.0),
	(52, 42, 0, 17.0),
	(52, 97, 0, 11.0),
	(52, 171, 0, 17.0),
	(52, 171, 4, 1.0),
	(52, 95, 0, 12.0),
	(52, 22, 0, 11.0),
	(52, 12, 0, 11.0),
	(52, 12, 4, 2.0),
	(52, 59, 0, 11.0),
	(52, 59, 4, 4.0),
	(53, 35, 0, 32.0),
	(53, 35, 4, 5.0),
	(53, 94, 0, 31.0),
	(53, 96, 0, 29.0),
	(53, 96, 4, 2.0),
	(53, 45, 0, 41.0),
	(53, 45, 4, 7.0),
	(53, 215, 0, 8.0),
	(53, 215, 4, 0.0),
	(54, 13, 0, 49.0),
	(54, 13, 4, 10.0),
	(54, 1, 0, 25.0),
	(54, 1, 4, 7.0),
	(54, 46, 0, 33.0),
	(54, 88, 0, 19.0),
	(54, 88, 4, 5.0),
	(54, 68, 0, 11.0),
	(54, 68, 4, 1.0),
	(54, 14, 0, 11.0),
	(54, 14, 4, 3.0),
	(54, 52, 0, 25.0),
	(54, 52, 4, 3.0),
	(54, 35, 0, 28.0),
	(54, 35, 4, 2.0),
	(54, 83, 0, 29.0),
	(54, 83, 4, 2.0),
	(54, 113, 0, 25.0),
	(54, 113, 4, 3.0),
	(54, 7, 0, 25.0),
	(54, 7, 4, 3.0),
	(54, 23, 0, 28.0),
	(54, 23, 4, 1.0),
	(54, 102, 0, 11.0),
	(54, 34, 0, 9.0),
	(54, 39, 0, 7.0),
	(54, 74, 0, 1.0),
	(54, 6, 0, 10.0),
	(54, 6, 4, 4.0),
	(54, 171, 0, 9.0),
	(54, 171, 4, 1.0),
	(54, 41, 0, 10.0),
	(54, 34, 4, 2.0),
	(54, 71, 0, 10.0),
	(54, 32, 0, 9.0),
	(54, 40, 0, 20.0),
	(54, 40, 4, 7.0),
	(54, 24, 0, 10.0),
	(54, 24, 4, 1.0),
	(54, 96, 0, 90.0),
	(54, 96, 4, 10.0),
	(54, 3, 0, 5.0),
	(54, 99, 0, 5.0),
	(54, 82, 0, 16.0),
	(54, 94, 0, 10.0),
	(54, 22, 0, 7.0),
	(56, 13, 0, 73.0),
	(56, 13, 4, 16.0),
	(56, 1, 0, 45.0),
	(56, 1, 4, 8.0),
	(56, 46, 0, 34.0),
	(56, 46, 4, 4.0),
	(56, 88, 0, 23.0),
	(56, 88, 4, 6.0),
	(56, 68, 0, 16.0),
	(56, 68, 4, 1.0),
	(56, 14, 0, 16.0),
	(56, 14, 4, 3.0),
	(56, 52, 0, 14.0),
	(56, 52, 4, 2.0),
	(56, 35, 0, 72.0),
	(56, 35, 4, 22.0),
	(56, 83, 0, 55.0),
	(56, 83, 4, 6.0),
	(56, 113, 0, 41.0),
	(56, 113, 4, 7.0),
	(56, 7, 0, 36.0),
	(56, 7, 4, 4.0),
	(56, 23, 0, 30.0),
	(56, 23, 4, 2.0),
	(56, 102, 0, 26.0),
	(56, 102, 4, 2.0),
	(56, 39, 0, 14.0),
	(56, 74, 0, 25.0),
	(56, 74, 4, 17.0),
	(56, 6, 0, 16.0),
	(56, 6, 4, 5.0),
	(56, 171, 0, 21.0),
	(56, 41, 0, 16.0),
	(56, 41, 4, 1.0),
	(56, 31, 0, 15.0),
	(56, 31, 4, 6.0),
	(56, 71, 0, 12.0),
	(56, 32, 0, 10.0),
	(56, 40, 0, 23.0),
	(56, 40, 4, 2.0),
	(56, 24, 0, 20.0),
	(56, 96, 0, 88.0),
	(56, 96, 4, 14.0),
	(56, 3, 0, 0.0),
	(56, 99, 0, 15.0),
	(56, 99, 4, 1.0),
	(56, 82, 0, 12.0),
	(56, 94, 0, 10.0),
	(56, 94, 4, 1.0),
	(56, 22, 0, 14.0),
	(56, 22, 4, 1.0),
	(57, 91, 0, 12.0),
	(57, 35, 0, 18.0),
	(57, 52, 0, 12.0),
	(57, 139, 0, 12.0),
	(57, 96, 0, 11.0),
	(57, 83, 0, 9.0),
	(57, 45, 0, 8.0),
	(57, 81, 0, 6.0),
	(57, 54, 0, 6.0),
	(57, 54, 4, 1.0),
	(57, 113, 0, 5.0),
	(58, 83, 0, 49.5),
	(58, 83, 4, 1.3),
	(58, 138, 0, 49.2),
	(58, 138, 4, 2.2),
	(58, 139, 0, 47.0),
	(58, 139, 4, 5.4),
	(58, 45, 0, 38.8),
	(58, 45, 4, 1.8),
	(58, 35, 0, 45.4),
	(58, 35, 4, 3.3),
	(58, 96, 0, 2.9),
	(58, 52, 0, 37.0),
	(58, 52, 4, 0.5),
	(58, 1, 0, 36.5),
	(58, 1, 4, 4.2),
	(58, 183, 0, 30.5),
	(58, 54, 0, 28.9),
	(58, 54, 4, 1.8),
	(58, 81, 0, 24.1),
	(58, 81, 4, 1.5),
	(58, 113, 0, 22.5),
	(58, 113, 4, 2.0),
	(58, 39, 0, 18.9),
	(58, 24, 0, 20.0),
	(58, 24, 4, 0.2),
	(58, 36, 0, 19.4),
	(58, 36, 4, 0.9),
	(58, 95, 0, 17.8),
	(58, 95, 4, 0.9),
	(58, 71, 0, 14.7),
	(58, 32, 0, 14.9),
	(58, 32, 4, 0.5),
	(58, 17, 0, 11.3),
	(58, 17, 4, 1.6),
	(58, 23, 0, 11.4),
	(58, 23, 4, 0.7),
	(58, 122, 0, 11.4),
	(58, 122, 4, 0.2),
	(59, 13, 0, 50.6),
	(59, 13, 4, 9.0),
	(59, 41, 0, 15.4),
	(59, 41, 4, 1.0),
	(59, 14, 0, 26.4),
	(59, 14, 4, 5.3),
	(59, 9, 0, 20.5),
	(59, 9, 4, 2.5),
	(59, 139, 0, 15.0),
	(59, 139, 4, 1.3),
	(59, 35, 0, 21.8),
	(59, 35, 4, 1.1),
	(59, 214, 0, 20.3),
	(59, 55, 0, 6.4),
	(59, 55, 4, 2.1),
	(59, 52, 0, 12.1),
	(59, 52, 4, 0.9),
	(59, 36, 0, 9.5),
	(59, 36, 4, 0.5),
	(59, 89, 0, 6.6),
	(59, 71, 0, 8.8),
	(59, 133, 0, 6.5),
	(59, 133, 4, 0.3),
	(59, 42, 0, 3.3),
	(59, 42, 4, 0.1),
	(59, 126, 0, 3.5),
	(59, 94, 0, 3.8),
	(59, 53, 0, 6.9),
	(59, 53, 4, 1.8),
	(59, 140, 0, 10.9),
	(59, 58, 0, 4.0),
	(59, 58, 4, 0.3),
	(59, 217, 0, 4.8),
	(60, 45, 0, 37.6),
	(60, 45, 4, 2.2),
	(60, 13, 0, 26.0),
	(60, 13, 4, 2.5),
	(60, 41, 0, 23.1),
	(60, 41, 4, 0.5),
	(60, 129, 0, 27.8),
	(60, 129, 4, 1.5),
	(60, 95, 0, 18.7),
	(60, 95, 4, 1.2),
	(60, 3, 0, 60.9),
	(60, 96, 0, 33.7),
	(60, 96, 4, 0.7),
	(60, 82, 0, 22.9),
	(60, 82, 4, 1.2),
	(60, 94, 0, 14.0),
	(60, 189, 0, 10.6),
	(60, 35, 0, 66.8),
	(60, 35, 4, 7.9),
	(60, 83, 0, 42.3),
	(60, 83, 4, 1.2),
	(60, 113, 0, 24.1),
	(60, 113, 4, 1.5),
	(60, 23, 0, 15.0),
	(60, 102, 0, 18.9),
	(60, 102, 4, 0.5),
	(60, 84, 0, 52.8),
	(60, 84, 4, 48.9),
	(60, 6, 0, 23.1),
	(60, 6, 4, 2.5),
	(60, 74, 0, 18.2),
	(60, 74, 4, 12.3),
	(60, 85, 0, 13.8),
	(60, 85, 4, 13.0),
	(60, 220, 0, 32.4),
	(60, 220, 4, 3.2),
	(60, 52, 0, 20.9),
	(60, 52, 4, 1.2),
	(60, 38, 0, 18.4),
	(60, 36, 0, 12.5),
	(60, 36, 4, 0.5),
	(60, 81, 0, 22.9),
	(60, 81, 4, 1.0),
	(60, 9, 0, 15.5),
	(60, 9, 4, 0.2),
	(60, 71, 0, 13.3),
	(60, 40, 0, 14.0),
	(60, 40, 4, 1.0),
	(60, 183, 0, 11.8),
	(60, 140, 0, 16.7),
	(60, 140, 4, 0.7),
	(60, 222, 0, 14.0),
	(60, 8, 0, 29.2),
	(60, 8, 4, 1.7),
	(45, 223, 0, 27.0);
/*!40000 ALTER TABLE `farmacos_toxicidad` ENABLE KEYS */;


CREATE TABLE `f_fda_temp` (
	`IdUsuario` SMALLINT(6) NOT NULL,
	`id_farmaco` MEDIUMINT(9) NOT NULL,
	`id_pathway` MEDIUMINT(11) NOT NULL,
	`pw_activo` TINYINT(1) UNSIGNED NOT NULL DEFAULT '1',
	PRIMARY KEY (`IdUsuario`, `id_farmaco`, `id_pathway`)
)
COLLATE='latin1_swedish_ci'
ENGINE=MyISAM;
CREATE TABLE `f_inv_temp` (
	`IdUsuario` SMALLINT(6) NOT NULL,
	`id_farmaco` MEDIUMINT(9) NOT NULL,
	`id_pathway` MEDIUMINT(11) NOT NULL,
	`pw_activo` TINYINT(1) UNSIGNED NOT NULL DEFAULT '1',
	PRIMARY KEY (`IdUsuario`, `id_farmaco`, `id_pathway`)
)
COLLATE='latin1_swedish_ci'
ENGINE=MyISAM;

-- Volcando estructura para tabla farmacos.histologia_n0
CREATE TABLE IF NOT EXISTS `histologia_n0` (
  `id_histologia_n0` smallint(5) unsigned NOT NULL AUTO_INCREMENT,
  `nombre_histologia_n0` varchar(255) DEFAULT NULL,
  PRIMARY KEY (`id_histologia_n0`)
) ENGINE=MyISAM AUTO_INCREMENT=41 DEFAULT CHARSET=utf8;

-- Volcando datos para la tabla farmacos.histologia_n0: 40 rows
/*!40000 ALTER TABLE `histologia_n0` DISABLE KEYS */;
INSERT INTO `histologia_n0` (`id_histologia_n0`, `nombre_histologia_n0`) VALUES
	(1, 'Adenoma'),
	(2, 'Adrenal cortical adenoma'),
	(3, 'Adrenal cortical carcinoma'),
	(4, 'Angiosarcoma'),
	(5, 'Atypical teratoid-rhabdoid tumour'),
	(6, 'Benign melanocytic nevus'),
	(7, 'Carcinoid-endocrine tumour'),
	(8, 'Carcinoma'),
	(9, 'Carcinoma in situ'),
	(10, 'Chondrosarcoma'),
	(11, 'Ewings sarcoma-peripheral primitive neuroectodermal tumour'),
	(12, 'Fibrosarcoma'),
	(13, 'Ganglioneuroblastoma'),
	(14, 'Ganglioneuroma'),
	(15, 'Germ cell tumour'),
	(16, 'GIST tumourlet'),
	(17, 'Glioma'),
	(18, 'Hyperplasia'),
	(19, 'In situ neoplasm'),
	(20, 'Kaposi sarcoma'),
	(21, 'Leiomyosarcoma'),
	(22, 'Lipoma'),
	(23, 'Liposarcoma'),
	(24, 'Malignant fibrous histiocytoma-pleomorphic sarcoma'),
	(25, 'Malignant melanoma'),
	(26, 'Meningioma'),
	(27, 'Mesothelioma'),
	(28, 'Neuroblastoma'),
	(29, 'NS'),
	(30, 'Osteosarcoma'),
	(31, 'Other'),
	(32, 'Pheochromocytoma'),
	(33, 'Primitive neuroectodermal tumour-medulloblastoma'),
	(34, 'Rhabdoid tumour'),
	(35, 'Rhabdomyosarcoma'),
	(36, 'Sarcoma'),
	(37, 'Sex cord-stromal tumour'),
	(38, 'Synovial sarcoma'),
	(39, 'Thymoma'),
	(40, 'Wilms tumour');
/*!40000 ALTER TABLE `histologia_n0` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.histologia_n1
CREATE TABLE IF NOT EXISTS `histologia_n1` (
  `id_histologia_n1` smallint(6) unsigned NOT NULL AUTO_INCREMENT,
  `nombre_histologia_n1` varchar(255) DEFAULT NULL,
  PRIMARY KEY (`id_histologia_n1`)
) ENGINE=MyISAM AUTO_INCREMENT=74 DEFAULT CHARSET=utf8;

-- Volcando datos para la tabla farmacos.histologia_n1: 73 rows
/*!40000 ALTER TABLE `histologia_n1` DISABLE KEYS */;
INSERT INTO `histologia_n1` (`id_histologia_n1`, `nombre_histologia_n1`) VALUES
	(1, 'Adenocarcinoma'),
	(2, 'Adenoma'),
	(3, 'Astrocytoma'),
	(4, 'Astrocytoma Grade I'),
	(5, 'Astrocytoma Grade II'),
	(6, 'Astrocytoma Grade III'),
	(7, 'Astrocytoma Grade IV'),
	(8, 'Atypical'),
	(9, 'Atypical ductal hyperplasia'),
	(10, 'Atypical lobular hyperplasia'),
	(11, 'Basal (triple-negative) carcinoma'),
	(12, 'Basal cell carcinoma'),
	(13, 'Blue'),
	(14, 'Carcinosarcoma-malignant mesodermal mixed tumour'),
	(15, 'Cervical intraepithelial neoplasia Grade I'),
	(16, 'Cervical intraepithelial neoplasia Grade III'),
	(17, 'Choriocarcinoma'),
	(18, 'Classic'),
	(19, 'Clear cell carcinoma'),
	(20, 'Clear cell renal cell carcinoma'),
	(21, 'Compound'),
	(22, 'Congenital'),
	(23, 'Diffuse adenocarcinoma'),
	(24, 'Ductal carcinoma'),
	(25, 'Ductal carcinoma in situ'),
	(26, 'Dysgerminoma'),
	(27, 'Dysplastic'),
	(28, 'Embryonal carcinoma'),
	(29, 'Endometrioid carcinoma'),
	(30, 'Ependymoma'),
	(31, 'Ependymoma Grade III-IV'),
	(32, 'ER-PR-positive carcinoma'),
	(33, 'Germinoma'),
	(34, 'Glandular intraepithelial neoplasia Grade III'),
	(35, 'Gliomatosis cerebri'),
	(36, 'Gliosarcoma'),
	(37, 'Hepatocellular carcinoma'),
	(38, 'HER-positive carcinoma'),
	(39, 'Intradermal'),
	(40, 'Junctional'),
	(41, 'Leydig cell tumour'),
	(42, 'Lobular carcinoma'),
	(43, 'Lobular carcinoma in situ'),
	(44, 'Luminal A carcinoma'),
	(45, 'Luminal B carcinoma'),
	(46, 'Medullary carcinoma'),
	(47, 'Merkel cell carcinoma'),
	(48, 'Metaplastic carcinoma'),
	(49, 'Mixed'),
	(50, 'Mucinous carcinoma'),
	(51, 'Non seminoma'),
	(52, 'Non small cell carcinoma'),
	(53, 'NS'),
	(54, 'Oligoastrocytoma'),
	(55, 'Oligoastrocytoma Grade II'),
	(56, 'Oligoastrocytoma Grade III'),
	(57, 'Oligoastrocytoma Grade IV'),
	(58, 'Oligodendroglioma'),
	(59, 'Oligodendroglioma Grade II'),
	(60, 'Oligodendroglioma Grade III'),
	(61, 'Papillary renal cell carcinoma'),
	(62, 'Peritoneal serous surface carcinoma'),
	(63, 'Seminoma'),
	(64, 'Serous carcinoma'),
	(65, 'Serous micropapillary carcinoma'),
	(66, 'Sertoli cell tumour'),
	(67, 'Small cell carcinoma'),
	(68, 'Spitz'),
	(69, 'Squamous cell carcinoma'),
	(70, 'Teratoma'),
	(71, 'Transitional cell carcinoma'),
	(72, 'Typical'),
	(73, 'Yolk sac tumour');
/*!40000 ALTER TABLE `histologia_n1` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.indicaciones
CREATE TABLE IF NOT EXISTS `indicaciones` (
  `id_indicacion` smallint(4) NOT NULL AUTO_INCREMENT,
  `descripcion_indicacion` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  PRIMARY KEY (`id_indicacion`)
) ENGINE=MyISAM AUTO_INCREMENT=32 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.indicaciones: 26 rows
/*!40000 ALTER TABLE `indicaciones` DISABLE KEYS */;
INSERT INTO `indicaciones` (`id_indicacion`, `descripcion_indicacion`) VALUES
	(1, 'COLON CANCER'),
	(2, 'BREAST CANCER'),
	(3, 'CUTANEOUS SQUAMOUS CELLS CARCINOMAS (cuSCC)'),
	(4, 'METASTATIC MELANOMA'),
	(5, 'OVARIAN CANCER'),
	(6, 'BLADDER CANCER'),
	(7, 'TESTICULAR  CANCER'),
	(8, 'CERVICAL CANCER'),
	(9, 'PANCREATIC CANCER'),
	(10, 'SMALL CELL LUNG CANCER'),
	(11, 'NON SMALL CELL LUNG CANCER (NSCLC)'),
	(31, 'NEOADJUVANT BREAST CANER'),
	(13, 'COLORRECTAL CANCER'),
	(14, 'GASTRIC  CANCER'),
	(15, 'PROSTATE/METASTASIC PROSTATE CANCER'),
	(16, 'HEAD AND NECK CANCER'),
	(17, 'MULTIPLE MYELOMA '),
	(18, 'GLIOBLASTOMA'),
	(19, 'RENAL CELL CARCINOMA'),
	(29, 'MYELOID LEUKEMIA'),
	(21, 'HEPATOCELULAR CARCINOMA'),
	(30, 'METASTATIC BREAST CANCER'),
	(23, 'GASTROINTESTINAL STROMAL '),
	(24, 'PROGRESIVE, METASTATIC MEDULLARY THYROID '),
	(25, 'NO SPECIFIC'),
	(28, 'MELANOMA');
/*!40000 ALTER TABLE `indicaciones` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.indicacion_pathways
CREATE TABLE IF NOT EXISTS `indicacion_pathways` (
  `id_indicacion` mediumint(8) unsigned NOT NULL,
  `id_pathway` mediumint(8) unsigned NOT NULL,
  PRIMARY KEY (`id_indicacion`,`id_pathway`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

-- Volcando datos para la tabla farmacos.indicacion_pathways: 566 rows
/*!40000 ALTER TABLE `indicacion_pathways` DISABLE KEYS */;
INSERT INTO `indicacion_pathways` (`id_indicacion`, `id_pathway`) VALUES
	(1, 38),
	(1, 39),
	(1, 40),
	(1, 41),
	(1, 42),
	(1, 43),
	(1, 58),
	(1, 59),
	(1, 60),
	(2, 2),
	(2, 8),
	(2, 13),
	(2, 15),
	(2, 16),
	(2, 17),
	(2, 18),
	(2, 19),
	(2, 21),
	(2, 22),
	(2, 23),
	(2, 24),
	(2, 25),
	(2, 30),
	(2, 34),
	(2, 38),
	(2, 39),
	(2, 40),
	(2, 41),
	(2, 42),
	(2, 43),
	(2, 44),
	(2, 45),
	(2, 58),
	(2, 59),
	(2, 60),
	(2, 61),
	(2, 62),
	(2, 63),
	(2, 64),
	(2, 65),
	(2, 66),
	(2, 70),
	(2, 71),
	(2, 72),
	(2, 84),
	(2, 85),
	(2, 102),
	(2, 103),
	(2, 107),
	(2, 109),
	(2, 112),
	(2, 113),
	(2, 114),
	(2, 115),
	(2, 116),
	(2, 118),
	(2, 120),
	(2, 121),
	(2, 122),
	(2, 124),
	(2, 125),
	(2, 135),
	(2, 136),
	(2, 143),
	(2, 144),
	(2, 147),
	(2, 148),
	(2, 152),
	(2, 153),
	(2, 158),
	(2, 159),
	(2, 160),
	(2, 161),
	(2, 162),
	(2, 163),
	(2, 175),
	(2, 177),
	(2, 190),
	(2, 192),
	(2, 193),
	(2, 197),
	(2, 198),
	(2, 206),
	(2, 207),
	(2, 208),
	(2, 218),
	(2, 219),
	(2, 220),
	(2, 221),
	(2, 222),
	(2, 227),
	(2, 228),
	(2, 230),
	(2, 234),
	(2, 235),
	(2, 236),
	(2, 237),
	(3, 8),
	(3, 13),
	(3, 15),
	(3, 16),
	(3, 17),
	(3, 18),
	(3, 19),
	(3, 22),
	(3, 35),
	(3, 38),
	(3, 39),
	(3, 40),
	(3, 41),
	(3, 42),
	(3, 43),
	(3, 51),
	(3, 53),
	(3, 59),
	(3, 65),
	(3, 66),
	(3, 67),
	(3, 71),
	(3, 72),
	(3, 84),
	(3, 85),
	(3, 96),
	(3, 97),
	(3, 109),
	(3, 118),
	(3, 119),
	(3, 124),
	(3, 125),
	(3, 158),
	(3, 159),
	(3, 160),
	(3, 161),
	(3, 162),
	(3, 163),
	(3, 208),
	(3, 219),
	(3, 220),
	(3, 221),
	(3, 222),
	(3, 234),
	(3, 235),
	(3, 236),
	(3, 241),
	(5, 13),
	(5, 15),
	(5, 16),
	(5, 17),
	(5, 18),
	(5, 19),
	(5, 22),
	(5, 31),
	(5, 38),
	(5, 39),
	(5, 40),
	(5, 41),
	(5, 43),
	(5, 44),
	(5, 45),
	(5, 58),
	(5, 59),
	(5, 62),
	(5, 63),
	(5, 64),
	(5, 66),
	(5, 71),
	(5, 72),
	(5, 84),
	(5, 85),
	(5, 109),
	(5, 115),
	(5, 116),
	(5, 118),
	(5, 119),
	(5, 124),
	(5, 125),
	(5, 135),
	(5, 136),
	(5, 147),
	(5, 148),
	(5, 150),
	(5, 158),
	(5, 159),
	(5, 160),
	(5, 161),
	(5, 162),
	(5, 163),
	(5, 169),
	(5, 175),
	(5, 208),
	(5, 218),
	(5, 219),
	(5, 220),
	(5, 221),
	(5, 222),
	(5, 227),
	(5, 228),
	(5, 232),
	(5, 234),
	(5, 235),
	(5, 236),
	(6, 8),
	(6, 13),
	(6, 15),
	(6, 16),
	(6, 17),
	(6, 18),
	(6, 19),
	(6, 22),
	(6, 23),
	(6, 24),
	(6, 25),
	(6, 38),
	(6, 39),
	(6, 40),
	(6, 41),
	(6, 42),
	(6, 43),
	(6, 44),
	(6, 45),
	(6, 46),
	(6, 58),
	(6, 59),
	(6, 62),
	(6, 63),
	(6, 64),
	(6, 71),
	(6, 72),
	(6, 82),
	(6, 84),
	(6, 85),
	(6, 102),
	(6, 103),
	(6, 109),
	(6, 112),
	(6, 113),
	(6, 118),
	(6, 121),
	(6, 122),
	(6, 124),
	(6, 125),
	(6, 135),
	(6, 136),
	(6, 147),
	(6, 148),
	(6, 156),
	(6, 158),
	(6, 162),
	(6, 169),
	(6, 175),
	(6, 192),
	(6, 193),
	(6, 208),
	(6, 218),
	(6, 219),
	(6, 220),
	(6, 221),
	(6, 222),
	(6, 227),
	(6, 228),
	(6, 234),
	(6, 235),
	(6, 236),
	(8, 7),
	(8, 8),
	(8, 13),
	(8, 15),
	(8, 16),
	(8, 17),
	(8, 18),
	(8, 19),
	(8, 22),
	(8, 23),
	(8, 24),
	(8, 25),
	(8, 38),
	(8, 39),
	(8, 40),
	(8, 41),
	(8, 42),
	(8, 43),
	(8, 46),
	(8, 53),
	(8, 58),
	(8, 59),
	(8, 71),
	(8, 72),
	(8, 82),
	(8, 83),
	(8, 84),
	(8, 85),
	(8, 109),
	(8, 113),
	(8, 114),
	(8, 115),
	(8, 118),
	(8, 124),
	(8, 125),
	(8, 135),
	(8, 136),
	(8, 147),
	(8, 148),
	(8, 153),
	(8, 158),
	(8, 160),
	(8, 161),
	(8, 162),
	(8, 163),
	(8, 175),
	(8, 192),
	(8, 193),
	(8, 208),
	(8, 218),
	(8, 219),
	(8, 220),
	(8, 221),
	(8, 222),
	(8, 227),
	(8, 228),
	(8, 234),
	(8, 235),
	(8, 236),
	(11, 16),
	(13, 8),
	(13, 15),
	(13, 16),
	(13, 17),
	(13, 18),
	(13, 19),
	(13, 158),
	(13, 186),
	(13, 187),
	(13, 208),
	(13, 217),
	(13, 227),
	(13, 228),
	(13, 234),
	(13, 236),
	(14, 84),
	(14, 85),
	(14, 124),
	(14, 125),
	(14, 135),
	(14, 136),
	(14, 208),
	(15, 8),
	(15, 13),
	(15, 15),
	(15, 16),
	(15, 17),
	(15, 18),
	(15, 19),
	(15, 22),
	(15, 23),
	(15, 24),
	(15, 25),
	(15, 26),
	(15, 27),
	(15, 38),
	(15, 39),
	(15, 40),
	(15, 42),
	(15, 43),
	(15, 46),
	(15, 51),
	(15, 58),
	(15, 59),
	(15, 62),
	(15, 63),
	(15, 65),
	(15, 66),
	(15, 71),
	(15, 84),
	(15, 86),
	(15, 96),
	(15, 97),
	(15, 109),
	(15, 110),
	(15, 117),
	(15, 118),
	(15, 124),
	(15, 125),
	(15, 135),
	(15, 136),
	(15, 153),
	(15, 158),
	(15, 160),
	(15, 161),
	(15, 162),
	(15, 163),
	(15, 169),
	(15, 175),
	(15, 182),
	(15, 193),
	(15, 208),
	(15, 209),
	(15, 218),
	(15, 219),
	(15, 220),
	(15, 221),
	(15, 222),
	(15, 227),
	(15, 228),
	(15, 232),
	(15, 234),
	(15, 235),
	(15, 236),
	(15, 241),
	(16, 7),
	(16, 8),
	(16, 13),
	(16, 15),
	(16, 16),
	(16, 17),
	(16, 18),
	(16, 19),
	(16, 22),
	(16, 23),
	(16, 24),
	(16, 25),
	(16, 38),
	(16, 39),
	(16, 40),
	(16, 41),
	(16, 42),
	(16, 43),
	(16, 44),
	(16, 45),
	(16, 58),
	(16, 59),
	(16, 64),
	(16, 66),
	(16, 71),
	(16, 72),
	(16, 84),
	(16, 85),
	(16, 95),
	(16, 109),
	(16, 124),
	(16, 125),
	(16, 135),
	(16, 136),
	(16, 142),
	(16, 158),
	(16, 159),
	(16, 196),
	(16, 208),
	(16, 218),
	(16, 219),
	(16, 220),
	(16, 221),
	(16, 222),
	(16, 234),
	(16, 235),
	(16, 236),
	(18, 2),
	(18, 13),
	(18, 15),
	(18, 16),
	(18, 17),
	(18, 18),
	(18, 19),
	(18, 22),
	(18, 23),
	(18, 24),
	(18, 25),
	(18, 38),
	(18, 39),
	(18, 41),
	(18, 42),
	(18, 43),
	(18, 46),
	(18, 50),
	(18, 58),
	(18, 59),
	(18, 62),
	(18, 63),
	(18, 66),
	(18, 71),
	(18, 72),
	(18, 73),
	(18, 84),
	(18, 85),
	(18, 109),
	(18, 112),
	(18, 113),
	(18, 114),
	(18, 124),
	(18, 125),
	(18, 135),
	(18, 136),
	(18, 139),
	(18, 147),
	(18, 148),
	(18, 153),
	(18, 156),
	(18, 158),
	(18, 159),
	(18, 160),
	(18, 161),
	(18, 162),
	(18, 163),
	(18, 173),
	(18, 192),
	(18, 193),
	(18, 194),
	(18, 208),
	(18, 218),
	(18, 219),
	(18, 220),
	(18, 221),
	(18, 222),
	(18, 224),
	(18, 227),
	(18, 228),
	(21, 15),
	(21, 16),
	(21, 17),
	(21, 18),
	(21, 19),
	(21, 22),
	(21, 23),
	(21, 24),
	(21, 25),
	(21, 38),
	(21, 39),
	(21, 40),
	(21, 41),
	(21, 42),
	(21, 43),
	(21, 46),
	(21, 55),
	(21, 58),
	(21, 59),
	(21, 62),
	(21, 63),
	(21, 71),
	(21, 72),
	(21, 84),
	(21, 85),
	(21, 109),
	(21, 124),
	(21, 125),
	(21, 135),
	(21, 136),
	(21, 153),
	(21, 158),
	(21, 159),
	(21, 160),
	(21, 161),
	(21, 162),
	(21, 163),
	(21, 169),
	(21, 175),
	(21, 193),
	(21, 208),
	(21, 234),
	(21, 235),
	(21, 236),
	(23, 84),
	(23, 85),
	(23, 124),
	(23, 125),
	(23, 135),
	(23, 136),
	(23, 208);
/*!40000 ALTER TABLE `indicacion_pathways` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.indicacion_tumores
CREATE TABLE IF NOT EXISTS `indicacion_tumores` (
  `id_indicacion` mediumint(8) unsigned NOT NULL,
  `id_tejido_n1` smallint(5) unsigned NOT NULL,
  `id_histologia_n0` smallint(5) unsigned NOT NULL,
  `id_histologia_n1` smallint(5) unsigned NOT NULL,
  PRIMARY KEY (`id_indicacion`,`id_tejido_n1`,`id_histologia_n0`,`id_histologia_n1`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

-- Volcando datos para la tabla farmacos.indicacion_tumores: 83 rows
/*!40000 ALTER TABLE `indicacion_tumores` DISABLE KEYS */;
INSERT INTO `indicacion_tumores` (`id_indicacion`, `id_tejido_n1`, `id_histologia_n0`, `id_histologia_n1`) VALUES
	(1, 21, 8, 1),
	(1, 21, 29, 53),
	(2, 7, 8, 11),
	(2, 7, 8, 24),
	(2, 7, 8, 32),
	(2, 7, 8, 38),
	(2, 7, 8, 42),
	(2, 7, 8, 44),
	(2, 7, 8, 45),
	(2, 7, 8, 46),
	(2, 7, 8, 48),
	(2, 7, 9, 25),
	(2, 7, 9, 43),
	(2, 7, 18, 9),
	(2, 7, 18, 10),
	(2, 7, 18, 53),
	(2, 7, 29, 53),
	(3, 35, 8, 12),
	(3, 35, 8, 47),
	(3, 35, 8, 69),
	(5, 29, 8, 1),
	(5, 29, 8, 14),
	(5, 29, 8, 19),
	(5, 29, 8, 29),
	(5, 29, 8, 50),
	(5, 29, 8, 53),
	(5, 29, 8, 64),
	(5, 29, 8, 65),
	(5, 29, 15, 26),
	(5, 29, 15, 49),
	(5, 29, 15, 53),
	(5, 29, 15, 73),
	(6, 55, 8, 53),
	(6, 55, 8, 69),
	(6, 55, 8, 71),
	(6, 55, 29, 53),
	(7, 45, 15, 28),
	(7, 45, 15, 33),
	(7, 45, 15, 49),
	(7, 45, 15, 51),
	(7, 45, 15, 53),
	(7, 45, 15, 63),
	(7, 45, 15, 73),
	(7, 45, 37, 41),
	(7, 45, 37, 66),
	(8, 12, 8, 1),
	(8, 12, 8, 69),
	(8, 12, 19, 15),
	(8, 12, 19, 16),
	(9, 30, 8, 24),
	(9, 30, 8, 53),
	(9, 31, 7, 53),
	(9, 31, 8, 24),
	(9, 31, 8, 53),
	(9, 31, 29, 53),
	(10, 25, 8, 67),
	(11, 25, 8, 52),
	(13, 21, 8, 1),
	(13, 21, 29, 53),
	(13, 23, 8, 1),
	(13, 23, 8, 53),
	(13, 23, 29, 53),
	(14, 44, 1, 53),
	(14, 44, 7, 53),
	(14, 44, 8, 1),
	(14, 44, 8, 23),
	(14, 44, 8, 53),
	(15, 34, 8, 1),
	(15, 34, 8, 53),
	(15, 34, 18, 53),
	(15, 34, 19, 34),
	(16, 48, 8, 53),
	(16, 48, 8, 69),
	(18, 8, 17, 56),
	(18, 8, 17, 57),
	(18, 8, 17, 60),
	(19, 20, 8, 20),
	(19, 20, 8, 61),
	(19, 20, 40, 53),
	(21, 24, 8, 37),
	(23, 17, 7, 53),
	(24, 47, 8, 53),
	(28, 35, 25, 53);
/*!40000 ALTER TABLE `indicacion_tumores` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.mutaciones
CREATE TABLE IF NOT EXISTS `mutaciones` (
  `id_mutacion` mediumint(8) unsigned NOT NULL AUTO_INCREMENT,
  `nombre_gen` varchar(255) DEFAULT NULL,
  `tipo_mutacion` tinyint(3) unsigned DEFAULT NULL,
  `l1` varchar(255) DEFAULT NULL,
  `GeneId` int(11) unsigned DEFAULT NULL,
  `sinonimos_gen` varchar(255) DEFAULT NULL,
  `protein_family` varchar(255) DEFAULT NULL,
  `definicion_comun` tinyint(1) unsigned NOT NULL DEFAULT '0',
  `id_diana` smallint(6) DEFAULT NULL,
  `diana` varchar(255) DEFAULT NULL,
  `enfermedad_asociada` text,
  `celular_process` varchar(255) DEFAULT NULL,
  `l2_1` varchar(255) DEFAULT NULL,
  `l2_2` varchar(255) DEFAULT NULL,
  `l2_3` varchar(255) DEFAULT NULL,
  `l2_4` varchar(255) DEFAULT NULL,
  `l2_5` varchar(255) DEFAULT NULL,
  `l3` varchar(255) DEFAULT NULL,
  PRIMARY KEY (`id_mutacion`)
) ENGINE=MyISAM AUTO_INCREMENT=345 DEFAULT CHARSET=utf8;

-- Volcando datos para la tabla farmacos.mutaciones: 344 rows
/*!40000 ALTER TABLE `mutaciones` DISABLE KEYS */;
INSERT INTO `mutaciones` (`id_mutacion`, `nombre_gen`, `tipo_mutacion`, `l1`, `GeneId`, `sinonimos_gen`, `protein_family`, `definicion_comun`, `id_diana`, `diana`, `enfermedad_asociada`, `celular_process`, `l2_1`, `l2_2`, `l2_3`, `l2_4`, `l2_5`, `l3`) VALUES
	(1, 'ABL1', 1, 'http://www.ncbi.nlm.nih.gov/gene/25', 25, 'ABL; JTK7; p150; c-ABL; v-abl; bcr/abl ', 'cytoplasmic and nuclear protein tyrosine kinase that has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response\r\nCELL SURVIVAL', 1, 15, 'bcr/abl', 'chronic myelogeneous leukemia', 'cell survival', 'Cell cycle, organism-specific biosystem', 'Axon guidance, organism-specific biosystem', 'Chronic myeloid leukemia, organism-specific biosystem', 'Apoptosis, organism-specific biosystem', NULL, 'Neurotrophin signaling pathway, organism-specific biosystem'),
	(2, 'ABL2', 0, 'http://www.ncbi.nlm.nih.gov/gene/27', 27, 'ARG; ABLL', ' Abelson family of nonreceptor tyrosine protein kinases.it plays a role in cytoskeletal rearrangements through its C-terminal F-actin- and microtubule-binding sequences', 0, 0, 'ABL2', 'leukemia', '', 'ErbB signaling pathway, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(3, 'ACSL6', 0, 'http://www.ncbi.nlm.nih.gov/gene/23305', 23305, 'ACS2; FACL6; LACS2; LACS5; LACS 6', 'The protein encoded by this gene catalyzes the formation of acyl-CoA from fatty acids, ATP, and CoA, using magnesium as a cofactor', 0, 0, 'acsl6', 'myelodysplastic syndrome with basophilia, acute myelogenous leukemia with eosinophilia, and acute eosinophilic leukemia', NULL, 'Fatty Acyl-CoA Biosynthesis, organism-specific biosystem', 'Fatty acid metabolism, organism-specific biosystem', 'Adipocytokine signaling pathway, organism-specific biosystem', NULL, NULL, NULL),
	(4, 'ACVR1B', 1, 'http://www.ncbi.nlm.nih.gov/gene/91', 91, 'ALK4; SKR2; ACTRIB; ACVRLK4', 'activin A type IB receptor.This protein is a type I receptor which is essential for signaling', 0, 0, 'ACVR1B', 'pituitary tumors', 'Cell survival', 'Signaling by Activin, organism-specific biosystem', 'TGF-beta signaling pathway, organism-specific biosystem', 'TGF-beta signaling pathway, conserved biosystem', NULL, NULL, NULL),
	(5, 'AFF3', 0, 'http://www.ncbi.nlm.nih.gov/gene/3899', 3899, 'LAF4; MLLT2-like', 'a tissue-restricted nuclear transcriptional activator that is preferentially expressed in lymphoid tissue', 0, 0, 'AFF3', '', NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(6, 'AFF4', 0, 'http://www.ncbi.nlm.nih.gov/gene/27125', 27125, 'MCEF; AF5Q31', 'AF4 family of transcription factors.It is a component of the positive transcription elongation factor b (P-TEFb) complex', 0, 0, 'AFF4', 'infant acute lymphoblastic leukemia', NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(7, 'AKAP9', 0, 'http://www.ncbi.nlm.nih.gov/gene/10142', 10142, 'LQT11; PRKA9; AKAP-9; CG-NAP; YOTIAO; AKAP350; AKAP450; PPP1R45; HYPERION; MU-RMS-40.16A', 'The A-kinase anchor proteins ', 0, 0, 'AKAP9', '', NULL, 'Cell Cycle, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(8, 'AKAP9_ENST00000356239', 0, NULL, NULL, NULL, NULL, 0, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(9, 'AKT1', 1, 'http://www.ncbi.nlm.nih.gov/gene/207', 207, 'AKT; PKB; RAC; CWS6; PRKBA; PKB-ALPHA; RAC-ALPHA', 'serine-threonine protein kinase .v-akt murine thymoma viral oncogene homolog 1\r\nCELL SURVIVAL', 1, 95, 'AKT', 'Proteus syndrome, familial cancer of breast, familial colorectal cancer,neoplasm of ovary,schizophrenia', 'Cell survival', 'Apoptosis, organism-specific biosystem', 'MAPK signaling pathway, organism-specific biosystem', 'PI3K-Akt signaling pathway, conserved biosystem', 'Focal Adhesion, organism-specific biosystem', NULL, NULL),
	(10, 'ALDH2', 0, 'http://www.ncbi.nlm.nih.gov/gene/217', 217, 'ALDM; ALDHI; ALDH-E2', 'aldehyde dehydrogenase family of proteins', 0, 0, 'ALDH2', 'acute alcohol sensitivity', NULL, 'ethanol degradation II, organism-specific biosystem', 'ethanol degradation IV, organism-specific biosystem', 'oxidative ethanol degradation III, organism-specific biosystem', 'Glycolysis / Gluconeogenesis, organism-specific biosystem', NULL, NULL),
	(11, 'ALK', 1, 'http://www.ncbi.nlm.nih.gov/gene/238', 238, 'CD246; NBLST3', 'a receptor tyrosine kinase, which belongs to the insulin receptor superfamily.anaplastic lymphoma receptor tyrosine kinase\r\nCELL SURVIVAL', 0, 0, 'ALK', 'anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer', 'Cell survival', 'PI3K Cascade, organism-specific biosystem', 'Signalling to RAS, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(12, 'APC', 1, 'http://www.ncbi.nlm.nih.gov/gene/324', 324, 'GS; DP2; DP3; BTPS2; DP2.5; PPP1R46', 'a tumor suppressor protein that acts as an antagonist of the Wnt signaling pathway\r\nCELL FATE', 0, 0, 'APC', 'Destroy user interface control Adenomatous polyposis coli,\r\nDestroy user interface control Desmoid disease, hereditary,\r\nDestroy user interface control Familial colorectal cancer,\r\nDestroy user interface control Liver cancer,\r\nDestroy user interface control N', 'Cell fate', 'APC/C-mediated degradation of cell cycle proteins', 'Apoptosis, organism-specific biosystem', 'Regulation of Actin Cytoskeleton, organism-specific biosystem', 'Wnt signaling pathway, organism-specific biosystem', NULL, NULL),
	(13, 'ARHGAP26', 0, 'http://www.ncbi.nlm.nih.gov/gene/23092', 23092, 'GRAF; GRAF1; OPHN1L; OPHN1L1', 'a GTPase activating protein that binds to focal adhesion kinase', 0, 0, 'ARHGp26', 'Destroy user interface control Juvenile myelomonocytic leukemia', NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(14, 'ARHGEF12', 0, 'http://www.ncbi.nlm.nih.gov/gene/23365', 23365, 'LARG; PRO2792', 'The encoded protein may form a complex with G proteins and stimulate Rho-dependent signals', 0, 0, 'ARHGEF12', ' Acute myeloid leukemia', NULL, 'Axon guidance, organism-specific biosystem', 'Rho GTPase cycle, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(15, 'ARID1A', 1, 'http://www.ncbi.nlm.nih.gov/gene/8289', 8289, 'ELD; B120; OSA1; P270; hELD; BM029; MRD14; hOSA1; BAF250; C1orf4; BAF250a; SMARCF1', 'protein is part of the large ATP-dependent chromatin remodeling complex SNF/SWI.AT rich interactive domain 1A (SWI-like)\r\nCELL FATE', 0, 0, 'ARID1A', ' Mental retardation, autosomal dominant 14 ', 'Cell fate', 'Prostate Cancer, organism-specific biosystem', 'chromatin modification', NULL, NULL, NULL, NULL),
	(16, 'ARID2', 1, 'http://www.ncbi.nlm.nih.gov/gene/196528', 196528, 'p200; BAF200', 'subunit of the PBAF chromatin-remodeling complex.AT rich interactive domain 2 (ARID, RFX-like)', 0, 0, 'ARID2', '', 'Cell fate', NULL, 'chromatin modification', NULL, NULL, NULL, NULL),
	(17, 'ARNT', 0, 'http://www.ncbi.nlm.nih.gov/gene/405', 405, 'HIF1B; TANGO; bHLHe2; HIF1BETA; HIF-1beta; HIF1-beta; HIF-1-beta', 'a protein that forms a complex with the ligand-bound Ah receptor, and is required for receptor function,also been identified as the beta subunit of a heterodimeric transcription factor, hypoxia-inducible factor 1', 0, 0, 'ARNT', 'acute myeloblastic leukemia', NULL, 'Regulation of Hypoxia-inducible Factor (HIF) by Oxygen, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(18, 'ASPSCR1', 0, 'http://www.ncbi.nlm.nih.gov/gene/79058', 79058, 'TUG; ASPL; ASPS; RCC17; UBXD9; UBXN9; ASPCR1', 'This protein is a tether, which sequesters the GLUT4 in intracellular vesicles in muscle and fat cells in the absence of insulin', 0, 0, 'ASPSCR1', 'Alveolar soft part sarcoma', NULL, 'Transcriptional misregulation in cancer, conserved biosystem', NULL, NULL, NULL, NULL, NULL),
	(19, 'ASXL1', 1, 'http://www.ncbi.nlm.nih.gov/gene/171023', 171023, 'MDS; BOPS', 'a chromatin-binding protein .additional sex combs like 1 (Drosophila)\r\nCELL FATE', 0, 0, 'ASXL1', 'myelodysplastic syndromes and chronic myelomonocytic leukemia', 'Cell fate', 'chromatin modification', NULL, NULL, NULL, NULL, NULL),
	(20, 'ATM', 1, 'http://www.ncbi.nlm.nih.gov/gene/472', 472, 'AT1; ATA; ATC; ATD; ATE; ATDC; TEL1; TELO1', 'an important cell cycle checkpoint kinase that phosphorylates\r\nGENOME MAINTENANCE', 0, 0, 'ATM', 'ataxia telangiectasia, an autosomal recessive disorder,Familial cancer of breast', 'Genome maintenance', 'Cell cycle, organism-specific biosystem', 'p53 signaling pathway, organism-specific biosystem', 'Apoptosis, organism-specific biosystem', 'DNA damage response (only ATM dependent)', 'DNA damage response, organism-specific biosystem', NULL),
	(21, 'ATRX', 1, 'http://www.ncbi.nlm.nih.gov/gene/546', 546, 'JMS; SHS; XH2; XNP; ATR2; SFM1; RAD54; MRXHF1; RAD54L; ZNF-HX', 'ATPase/helicase domain, and thus it belongs to the SWI/SNF family of chromatin remodeling proteins.alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, S. cerevisiae)\r\nGENOME MAINTENANCE', 0, 0, 'ATRX', 'Mental retardation-hypotonic facies syndrome X-linked, 1 ,ATR-X syndrome, Acquired hemoglobin H disease ', 'Cell fate', 'chromatin modification', NULL, NULL, NULL, NULL, NULL),
	(22, 'AXIN1', 1, 'http://www.ncbi.nlm.nih.gov/gene/8312', 8312, 'AXIN; PPP1R49', 'a cytoplasmic protein which contains a regulation of G-protein signaling (RGS) domain and a dishevelled and axin (DIX) domain\r\nCELL FATE', 0, 0, 'AXIN1', 'hepatocellular carcinoma, hepatoblastomas, ovarian endometriod adenocarcinomas, and medullablastomas', 'Cell fate', 'Wnt Signaling Pathway, organism-specific biosystem', 'APC/C-mediated degradation of cell cycle proteins', NULL, NULL, NULL, NULL),
	(23, 'BAP1', 1, 'http://www.ncbi.nlm.nih.gov/gene/8314', 8314, 'TPDS; UCHL2; hucep-6; HUCEP-13', 'The protein encoded by this gene localizes to the nucleus and it interacts with the RING finger domain of the breast cancer 1, early onset protein (BRCA1). BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase)\r\nGENOME MAINTENANCE', 0, 0, 'BAP1', 'breast cancer', 'Genome maintenance', 'DNA damage response, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(24, 'BCL2', 1, 'http://www.ncbi.nlm.nih.gov/gene/596', 596, 'Bcl-2; PPP1R50', ' integral outer mitochondrial membrane protein that blocks the apoptotic death of some cells such as lymphocytes', 0, 0, 'BCL2', 'follicular lymphoma', NULL, 'Apoptosis, organism-specific biosystem', 'Cell cycle, organism-specific biosystem', 'Focal adhesion, organism-specific biosystem', NULL, NULL, NULL),
	(25, 'BCL6', 0, 'http://www.ncbi.nlm.nih.gov/gene/604', 604, 'BCL5; LAZ3; BCL6A; ZNF51; ZBTB27', 'is a zinc finger transcription factor and contains an N-terminal POZ domain.', 0, 0, 'BCL6', 'diffuse large-cell lymphoma,pathogenesis of DLCL', NULL, 'B Cell Receptor Signaling Pathway, organism-specific biosystem', 'IL4-mediated signaling events, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(26, 'BCL7A', 0, 'http://www.ncbi.nlm.nih.gov/gene/605', 605, 'BCL7', 'is directly involved, with Myc and IgH, in a three-way gene translocation in a Burkitt lymphoma cell line', 0, 0, 'BCL7A', 'non-Hodgkin lymphoma', NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(27, 'BCL9', 0, 'http://www.ncbi.nlm.nih.gov/gene/607', 607, 'LGS', 'is associated with B-cell acute lymphoblastic leukemia,Its function is unknown', 0, 0, 'BCL9', 'acute lymphoblastic leukemia', NULL, 'Wnt Signaling Pathway NetPath, organism-specific biosystem', 'Regulation of Wnt-mediated beta catenin signaling and target gene transcription, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(28, 'BCL10', 0, 'http://www.ncbi.nlm.nih.gov/gene/8915', 8915, 'CLAP; mE10; CIPER; c-E10; CARMEN', 'The protein encoded by this gene contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB', 0, 0, 'BCL10', 'familial colorectal cancer, follicular lymphoma1, gastric lymphoma, malignant tumor of testis, mesothelioma malignant', NULL, 'B Cell Receptor Signaling Pathway, organism-specific biosystem', 'TCR Signaling Pathway, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(29, 'BCL11A', 0, 'http://www.ncbi.nlm.nih.gov/gene/53335', 53335, 'EVI9; CTIP1; ZNF856; HBFQTL5; BCL11A-L; BCL11A-S; BCL11a-M; BCL11A-XL', 'a C2H2 type zinc-finger protein ', 0, 0, 'BCL11A', 'myeloid leukemia,Genome-wide association study in German patients with attention deficit/hyperactivity disorder', NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(30, 'BCL11B', 0, 'http://www.ncbi.nlm.nih.gov/gene/64919', 64919, 'RIT1; CTIP2; CTIP-2; ZNF856B; ATL1-beta; ATL1-alpha; ATL1-delta; ATL1-gamma; hRIT1-alpha', 'a C2H2-type zinc finger protein ,carotid-femoral pulse wave velocity and excess cardiovascular disease risk', 0, 0, 'BCL11B', '', NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(31, 'BCOR', 1, 'http://www.ncbi.nlm.nih.gov/gene/54880', 54880, 'MAA2; ANOP2; MCOPS2', ' This protein selectively interacts with the POZ domain of BCL6.BCL6 co-repressor', 0, 0, 'BCOR', 'Lenz microphthalmia syndrome ,Oculofaciocardiodental syndrome ', 'Cell fate', 'Signaling events mediated by HDAC Class II, organism-specific biosystem', 'Transcriptional misregulation in cancer, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(32, 'BLM', 3, 'http://www.ncbi.nlm.nih.gov/gene/641', 641, 'BS; RECQ2; RECQL2; RECQL3', 'is related to the RecQ subset of DExH box-containing DNA helicases and has both DNA-stimulated ATPase and ATP-dependent DNA helicase activities\r\nGENOME MAINTENANCE', 0, 0, 'BLM', 'BLOOM´S SYNDROME', 'Genome maintenance', 'Bloom\'s syndrome complex, organism-specific biosystem', 'Integrated Breast Cancer Pathway, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(33, 'BRAF', 1, 'http://www.ncbi.nlm.nih.gov/gene/673', 673, 'NS7; BRAF1; RAFB1; B-RAF1', 'family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion.v-raf murine sarcoma viral oncogene homolog B1\r\nCELL SURVIVAL', 0, 0, 'BRAF', 'cardiofaciocutaneous syndrome, non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung', 'Cell survival', 'MAPK signaling pathway, organism-specific biosystem', 'mTOR signaling pathway, organism-specific biosystem', 'Focal Adhesion, organism-specific biosystem', 'Signalling to RAS, organism-specific biosystem', NULL, NULL),
	(34, 'BRCA1', 1, 'http://www.ncbi.nlm.nih.gov/gene/672', 672, 'IRIS; PSCP; BRCAI; BRCC1; PNCA4; RNF53; BROVCA1; PPP1R53', 'a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor.breast cancer 1, early onset\r\nGENOME MAINTENANCE', 0, 0, 'BRCA1', 'inherited breast cancers ,inherited breast and ovarian cancers', 'Genome maintenance', 'PI3K-Akt signaling pathway, organism-specific biosystem', 'Integrated Breast Cancer Pathway, organism-specific biosystem', 'Fanconi anemia pathway, organism-specific biosystem', 'DNA damage response, organism-specific biosystem', NULL, NULL),
	(35, 'BRCA2', 1, 'http://www.ncbi.nlm.nih.gov/gene/675', 675, 'FAD; FACD; FAD1; GLM3; BRCC2; FANCB; FANCD; PNCA2; FANCD1; BROVCA2', 'is involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair\r\nGENOMA MAINTENANCE', 0, 0, 'BRCA2', 'hereditary breast and ovarian Cancer, fanconi anemia, malignant tumor of prostate, medulloblastoma, pancreatic cancer, Wilms´tumor', 'Genome maintenance', 'Homologous recombination, organism-specific biosystem', 'Integrated Breast Cancer Pathway, organism-specific biosystem', 'Integrated Pancreatic Cancer Pathway, organism-specific biosystem', 'DNA damage response, organism-specific biosystem', NULL, NULL),
	(36, 'BRD3', 0, 'http://www.ncbi.nlm.nih.gov/gene/8019', 8019, 'ORFX; RING3L', ' RING3 protein, a serine/threonine kinase', 0, 0, 'BRD3', '', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(37, 'BRD4', 0, 'http://www.ncbi.nlm.nih.gov/gene/23476', 23476, 'CAP; MCAP; HUNK1; HUNKI', 'is homologous to the murine protein MCAP, which associates with chromosomes during mitosis, and to the human RING3 protein, a serine/threonine kinase', 0, NULL, 'BRD4', 'upper respiratory tract carcinoma in young people', NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(38, 'BRD4_ENST00000263377', 0, NULL, 0, '', '', 0, 0, '', '', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(39, 'BRIP1', 3, 'http://www.ncbi.nlm.nih.gov/gene/83990', 83990, 'OF; BACH1; FANCJ', 'is a member of the RecQ DEAH helicase family and interacts with the BRCT repeats of breast cancer, type 1 (BRCA1)', 0, 0, 'BRIP1', 'familial cancer of breast, fanconi anemia', 'Genome maintenance', 'Homologous recombination repair of replication-independent double-strand breaks, organism-specific biosystem', 'Fanconi anemia pathway, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(40, 'BTG1', 0, 'http://www.ncbi.nlm.nih.gov/gene/694', 694, '', 'anti-proliferative gene family that regulates cell growth and differentiation', 0, 0, 'BTG1', 'chronic lymphocytic leukemia', '', 'RNA degradation, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(41, 'BUB1B', 3, 'http://www.ncbi.nlm.nih.gov/gene/701', 701, 'MVA1; SSK1; BUBR1; Bub1A; MAD3L; hBUBR1; BUB1beta', ' a kinasa role in the inhibition of the anaphase-promoting complex/cyclosome (APC/C), ', 0, 0, 'BUB1B', 'familial colorectal cancer', 'Genome maintenance', 'Cell cycle, organism-specific biosystem', 'Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(42, 'C2orf44', 0, 'http://www.ncbi.nlm.nih.gov/gene/80304', 80304, 'PP384', '', 0, 0, 'C2orf44', '', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(43, 'CAMTA1', 0, 'http://www.ncbi.nlm.nih.gov/gene/23261', 23261, 'CANPMR', 'calmodulin binding transcription activator 1', 0, 0, 'CAMTA1', 'Cerebellar ataxia, nonprogressive, with mental retardation', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(44, 'CARD11', 1, 'http://www.ncbi.nlm.nih.gov/gene/84433', 84433, 'BIMP3; CARMA1', 'membrane-associated guanylate kinase (MAGUK) family, a class of proteins that functions as molecular scaffolds for the assembly of multiprotein complexes at specialized regions of the plasma membrane', 0, 0, 'CARD11', 'Cell cycle, organism-specific biosystem', 'Cell survival', 'Activation of NF-kappaB in B Cells, organism-specific biosystem', 'NF-kappa B signaling pathway, organism-specific biosystem', 'TCR Signaling Pathway, organism-specific biosystem', 'Apoptosis, organism-specific biosystem', NULL, NULL),
	(45, 'CASC5', 0, 'http://www.ncbi.nlm.nih.gov/gene/57082', 57082, 'D40; CT29; KNL1; hKNL-1; AF15Q14; PPP1R55; hSpc105', 'component of the multiprotein assembly that is required for creation of kinetochore-microtubule attachments and chromosome segregatio', 0, 0, 'CASC5', 'mixed-lineage leukemia', '', 'Cell Cycle, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(46, 'CBL', 1, 'http://www.ncbi.nlm.nih.gov/gene/867', 867, 'CBL2; NSLL; C-CBL; RNF55; FRA11B', 'a RING finger E3 ubiquitin ligase', 0, 0, 'CBL', 'many cancers including acute myeloid leukaemia', 'Cell survival', 'Insulin Pathway, organism-specific biosystem', 'Signaling by constitutively active EGFR, organism-specific biosystem', 'PI3K Cascade, organism-specific biosystem', 'positive regulation of Ras GTPase activity', 'negative regulation of Ras GTPase activity', NULL),
	(47, 'CBLB', 0, 'http://www.ncbi.nlm.nih.gov/gene/868', 868, 'Cbl-b; RNF56; Nbla00127', 'E3 ubiquitin protein ligase B', 0, NULL, 'CBLB', 'multiple sclerosis', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(48, 'CBFB', 0, 'http://www.ncbi.nlm.nih.gov/gene/865', 865, 'PEBP2B', 'beta subunit of a heterodimeric core-binding transcription factor belonging to the PEBP2/CBF transcription factor family ', 0, 0, 'CBFB', 'acute myeloid leukemia of the M4Eo subtype', '', 'ATF-2 transcription factor network, organism-specific biosystem', 'Regulation of nuclear SMAD2/3 signaling, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(49, 'CCND1', 0, 'http://www.ncbi.nlm.nih.gov/gene/595', 595, 'BCL1; PRAD1; U21B31; D11S287E', 'cyclin family,Cyclins function as regulators of CDK kinases', 0, 0, 'CCND1', 'familiar colorectal cancer, Von Hippel-Lindau syndrome', '', 'Cell Cycle, organism-specific biosystem', 'Focal Adhesion, organism-specific biosystem', 'Wnt Signaling Pathway, organism-specific biosystem', NULL, NULL, NULL),
	(50, 'CCND2', 0, 'http://www.ncbi.nlm.nih.gov/gene/894', 894, 'KIAK0002', 'cyclin family,Cyclins function as regulators of CDK kinases This protein has been shown to interact with and be involved in the phosphorylation of tumor suppressor protein Rb.', 0, NULL, 'CCND2', 'ovarian and testicular tumors', '', 'Cell cycle, organism-specific biosystem', 'Focal Adhesion, organism-specific biosystem', 'Wnt Signaling Pathway, organism-specific biosystem', NULL, NULL, NULL),
	(51, 'CCND3', 0, 'http://www.ncbi.nlm.nih.gov/gene/896', 896, '', 'cyclin family,Cyclins function as regulators of CDK kinases This protein has been shown to interact with and be involved in the phosphorylation of tumor suppressor protein Rb.', 0, NULL, NULL, '', '', 'Cell cycle, organism-specific biosystem', 'Focal Adhesion, organism-specific biosystem', 'Wnt Signaling Pathway, organism-specific biosystem', NULL, NULL, NULL),
	(52, 'CCNE1', 0, 'http://www.ncbi.nlm.nih.gov/gene/898', 898, 'CCNE', 'cyclin family,Cyclins function as regulators of CDK kinases This protein has been shown to interact with and be involved in the phosphorylation of tumor suppressor protein Rb.', 0, NULL, 'CCNE1', '', '', 'Cell cycle, organism-specific biosystem', 'Focal Adhesion, organism-specific biosystem', 'Wnt Signaling Pathway, organism-specific biosystem', NULL, NULL, NULL),
	(53, 'CCDC6', 0, 'http://www.ncbi.nlm.nih.gov/gene/8030', 8030, 'H4; PTC; TPC; TST1; D10S170', 'coiled-coil domain-containing protein. The encoded protein is ubiquitously expressed and may function as a tumor suppressor', 0, NULL, 'CCDC6', ' thyroid papillary carcinoma', '', 'Pathways in cancer, organism-specific biosystem', 'Thyroid cancer, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(54, 'CD79B', 0, 'http://www.ncbi.nlm.nih.gov/gene/974', 974, 'B29; IGB; AGM6', 'Ig-beta protein of the B-cell antigen component', 0, NULL, 'CD79B', 'agammaglobulinemia 6, autosomal recesive', '', 'B cell receptor signaling pathway, organism-specific biosystem', 'BCR signaling pathway, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(55, 'CDC73', 1, 'http://www.ncbi.nlm.nih.gov/gene/79577', 79577, 'HYX; HPTJT; HRPT2; C1orf28', 'component of the the PAF protein complex.cell division cycle 73, Paf1/RNA polymerase II complex component, homolog (S. cerevisiae)', 0, 0, 'CDC73', 'hyperparathyroidism-jaw tumor syndrome, familial isolated hyperparathyroidism, and parathyroid carcinoma', 'cell survival', 'Cell cycle, organism-specific biosystem', 'Apoptosis, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(56, 'CDH1', 4, 'http://www.ncbi.nlm.nih.gov/gene/999', 999, 'UVO; CDHE; ECAD; LCAM; Arc-1; CD324', 'classical cadherinThe encoded protein is a calcium dependent cell-cell adhesion glycoprotein comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail', 0, 0, 'CDH1', 'gastric, breast, colorectal, thyroid and ovarian cancer', 'Cell fate', 'E-cadherin signaling events, organism-specific biosystem', 'Cell-Cell communication, organism-specific biosystem', 'Adherens junctions interactions, organism-specific biosystem', 'Cell-cell junction organization, organism-specific biosystem', 'APC/C-mediated degradation of cell cycle proteins', NULL),
	(57, 'CDH11', 0, 'http://www.ncbi.nlm.nih.gov/gene/1009', 1009, 'OB; CAD11; CDHOB; OSF-4', 'type II classical cadherin from the cadherin superfamily, integral membrane proteins that mediate calcium-dependent cell-cell adhesion', 0, 0, 'CDH11', '', '', 'Cell-Cell communication, organism-specific biosystem', 'Adherens junctions interactions, organism-specific biosystem', 'Cell-cell junction organization, organism-specific biosystem', NULL, NULL, NULL),
	(58, 'CDK4', 3, 'http://www.ncbi.nlm.nih.gov/gene/1019', 1019, 'CMM3; PSK-J3', 'Ser/Thr protein kinase family', 0, 0, 'CDK4', 'variety of cancers. Familial malignant melanoma\r\n', 'Cell survival', 'Cell cycle, organism-specific biosystem', 'G1 to S cell cycle control, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(59, 'CDK12', 0, 'http://www.ncbi.nlm.nih.gov/gene/51755', 51755, 'CRK7; CRKR; CRKRS; hCDK12', 'cyclin-dependent kinase', 0, 0, '', '', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(60, 'CDKN2A', 1, 'http://www.ncbi.nlm.nih.gov/gene/1029', 1029, 'ARF; MLM; P14; P16; P19; CMM2; INK4; MTS1; TP16; CDK4I; CDKN2; INK4A; MTS-1; P14ARF; P19ARF; P16INK4; P16INK4A; P16-INK4A', 'cyclin-dependent kinase inhibitor.cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)', 0, 0, 'CDKN2A', 'melanoma astrocytoma syndrome, melanoma cutaneous malignant, melanoma pancreatic cancer syndrome', 'Cell survival', 'Cell cycle, organism-specific biosystem', 'Apoptosis Modulation and Signaling, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(61, 'CDKN2a (p14)', 0, NULL, 0, 'ss', '', 0, NULL, NULL, '', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(62, 'CDKN2C', 0, 'http://www.ncbi.nlm.nih.gov/gene/1031', 1031, 'p18; INK4C; p18-INK4C', 'INK4 family of cyclin-dependent kinase inhibitors', 0, NULL, 'CDKN2C', '', '', 'Cell cycle, conserved biosystem', NULL, NULL, NULL, NULL, NULL),
	(63, 'CEBPA', 1, 'http://www.ncbi.nlm.nih.gov/gene/1050', 1050, 'CEBP; C/EBP-alpha', 'the encoded protein can interact with CDK2 and CDK4, thereby inhibiting these kinases and causing growth arrest in cultured cells', 0, 0, 'CEBPA', 'acute myeloid leukemia', 'Cell survival', 'Acute myeloid leukemia, organism-specific biosystem', 'Transcriptional misregulation in cancer, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(64, 'CHEK2', 3, 'http://www.ncbi.nlm.nih.gov/gene/11200', 11200, 'CDS1; CHK2; LFS2; RAD53; hCds1; HuCds1; PP1425', 'a cell cycle checkpoint regulator and putative tumor suppressor', 0, 0, 'CHEK2', 'Li-Fraumeni syndrome,predisposition to sarcomas, breast cancer, and brain tumors, Malignant tumor of prostate ,Osteosarcoma', 'Cell survival', 'Cell Cycle, organism-specific biosystem', 'p53 signaling pathway, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(65, 'CHN1', 0, 'http://www.ncbi.nlm.nih.gov/gene/1123', 1123, 'NC; CHN; DURS2; ARHGAP2; RHOGAP2', 'This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases.la proteína GTPasa de la activación de Ras relacionados con p21-rac y un receptor de éster de forbol. Se expresa predominantemente en las neuronas, y juega un papel', 0, NULL, NULL, 'Duanes retraction syndrome 2', '', 'Signaling by Rho GTPases, organism-specific biosystem', 'Rho GTPase cycle, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(66, 'CIC', 1, 'http://www.ncbi.nlm.nih.gov/gene/23152', 23152, '', '', 0, 0, '', '', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(67, 'CIITA', 0, 'http://www.ncbi.nlm.nih.gov/gene/4261', 4261, 'C2TA; NLRA; MHC2TA; CIITAIV', 'an acidic transcriptional activation domain, 4 LRRs (leucine-rich repeats) and a GTP binding domain The protein also binds GTP and uses GTP binding to facilitate its own transport into the nucleus', 0, NULL, 'CIITA', ' bare lymphocyte syndrome type II ,increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardial infarction', NULL, 'Primary immunodeficiency, organism-specific biosystem', 'Antigen processing and presentation, conserved biosystem', NULL, NULL, NULL, NULL),
	(68, 'CLP1', 0, 'http://www.ncbi.nlm.nih.gov/gene/10978', 10978, 'HEAB; hClp1', 'cleavage and polyadenylation factor I subunit 1', 0, NULL, 'CLP1', '', '', 'pathways???', NULL, NULL, NULL, NULL, NULL),
	(69, 'CLTC', 0, 'http://www.ncbi.nlm.nih.gov/gene/1213', 1213, 'Hc; CHC; CHC17; CLH-17; CLTCL2', 'Clathrin is a major protein component of the cytoplasmic face of intracellular organelles, called coated vesicles and coated pits', 0, NULL, 'CLTC', NULL, NULL, 'Synaptic Vesicle Pathway, organism-specific biosystem', 'Lysosome, organism-specific biosystem', 'Gap junction trafficking and regulation, organism-specific biosystem', NULL, NULL, NULL),
	(70, 'CLTCL1', 0, 'http://www.ncbi.nlm.nih.gov/gene/8218', 8218, 'CLTD; CHC22; CLH22; CLTCL', 'a major protein of the polyhedral coat of coated pits and vesicles', 0, NULL, NULL, 'meningioma, DiGeorge syndrome, and velo-cardio-facial syndrome', '', 'Synaptic Vesicle Pathway, organism-specific biosystem', 'Lysosome, organism-specific biosystem', 'Gap junction trafficking and regulation, organism-specific biosystem', NULL, NULL, NULL),
	(71, 'CNBP', 0, 'http://www.ncbi.nlm.nih.gov/gene/7555', 7555, 'DM2; ZNF9; CNBP1; PROMM; RNF163; ZCCHC22', 'a nucleic-acid binding protein with seven zinc-finger domains. The protein has a preference for binding single stranded DNA and RNA', 0, NULL, NULL, 'Myotonic dystrophy type 2', NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(72, 'CNTRL', 0, 'http://www.ncbi.nlm.nih.gov/gene/11064', 11064, 'FAN; CEP1; CEP110; bA165P4.1', 'a centrosomal protein required for the centrosome to function as a microtubule organizing center', 0, NULL, NULL, NULL, NULL, 'Cell Cycle, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(73, 'COL1A1', 0, 'http://www.ncbi.nlm.nih.gov/gene/1277', 1277, 'OI4', 'the pro-alpha1 chains of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. Type I is a fibril-forming collagen found in most connective tissues and is abundant in bone, cornea, dermis and tendon', 0, NULL, 'COL1A1', 'osteogenesis imperfecta types I-IV, Ehlers-Danlos syndrome type VIIA, Ehlers-Danlos syndrome Classical type, Caffey Disease and idiopathic osteoporosis', '', 'Focal Adhesion, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(74, 'CREB1', 0, 'http://www.ncbi.nlm.nih.gov/gene/1385', 1385, 'CREB', 'a transcription factor that is a member of the leucine zipper family of DNA binding proteins, The protein is phosphorylated by several protein kinases, and induces transcription of genes in response to hormonal stimulation of the cAMP pathway', 0, NULL, 'CREB', 'angiomatoid fibrous histyocitoma', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(75, 'CREBBP', 1, 'http://www.ncbi.nlm.nih.gov/gene/1387', 1387, 'CBP; RSTS; KAT3A', 'The protein encoded by this gene has intrinsic histone acetyltransferase activity and also acts as a scaffold to stabilize additional protein interactions with the transcription complex', 0, 0, 'CREBBP', 'acute myeloid leukemia,Rubinstein-Taybi syndrome (RTS). ', 'Cell fate', 'Cell cycle, organism-specific biosystem', 'Jak-STAT signaling pathway, organism-specific biosystem', 'Notch Signaling Pathway, organism-specific biosystem', 'TGF-beta Receptor Signaling Pathway, organism-specific biosystem', NULL, NULL),
	(76, 'CREB3L1', 0, 'http://www.ncbi.nlm.nih.gov/gene/90993', 90993, 'OASIS', '', 0, NULL, NULL, '', '', 'PI3K-Akt signaling pathway, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(77, 'CRTC1', 0, 'http://www.ncbi.nlm.nih.gov/gene/23373', 23373, 'MECT1; TORC1; TORC-1; WAMTP1', '', 0, NULL, 'm-toc???????????\'', '', '', 'BDNF signaling pathway, organism-specific biosystem', 'HTLV-I infection, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(78, 'CSF1R', 1, 'http://www.ncbi.nlm.nih.gov/gene/1436', 1436, 'FMS; CSFR; FIM2; HDLS; C-FMS; CD115; CSF-1R; M-CSF-R', 'The encoded protein is a tyrosine kinase transmembrane receptor and member of the CSF1/PDGF receptor family of tyrosine-protein kinases', 0, 0, '', 'myeloid malignancy, gliosis familial progresive subcortical', 'Cell survival', 'Cytokine-cytokine receptor interaction, organism-specific biosystem', 'PI3K-Akt signaling pathway, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(79, 'CTNNA1', 0, 'http://www.ncbi.nlm.nih.gov/gene/1495', 1495, 'CAP102', 'catenin (cadherin-associated protein), alpha 1', 0, NULL, NULL, '', '', 'Adherens junctions interactions, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(80, 'CTNNB1', 1, 'http://www.ncbi.nlm.nih.gov/gene/1499', 1499, 'CTNNB; MRD19; armadillo', 'is part of a complex of proteins that constitute adherens junctions (AJs). this protein binds to the product of the APC gene', 0, 0, '', ' adenomatous polyposis of the colon,colorectal cancer (CRC), pilomatrixoma (PTR), medulloblastoma (MDB), and ovarian cancer, mental retardation autosomal dominant 19', 'Cell fate', 'Adherens junctions interactions, organism-specific biosystem', 'Wnt Signaling Pathway, organism-specific biosystem', 'TGF-beta receptor signaling, organism-specific biosystem', NULL, NULL, NULL),
	(81, 'CYLD', 1, 'http://www.ncbi.nlm.nih.gov/gene/1540', 1540, 'EAC; MFT; SBS; TEM; BRSS; CDMT; MFT1; CYLD1; CYLDI; USPL2', 'a cytoplasmic protein with three cytoskeletal-associated protein-glycine-conserved (CAP-GLY) domains that functions as a deubiquitinating enzyme', 0, 0, '', 'cylindromatosis, multiple familial trichoepithelioma, and Brooke-Spiegler syndrome', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(82, 'DAXX', 1, 'http://www.ncbi.nlm.nih.gov/gene/1616', 1616, 'DAP6; EAP1; BING2', 'a multifunctional protein that resides in multiple locations in the nucleus and in the cytoplasm', 0, 0, '', 'promyelocytic leukemia ', 'Cell fate', 'Apoptosis Modulation and Signaling, organism-specific biosystem', 'MAPK signaling pathway, organism-specific biosystem', 'TGF-beta Receptor Signaling Pathway, organism-specific biosystem', NULL, NULL, NULL),
	(83, 'DDX5', 0, 'http://www.ncbi.nlm.nih.gov/gene/1655', 1655, 'p68; HLR1; G17P1; HUMP68', 'DEAD box proteins', 0, NULL, NULL, '', '', 'Direct p53 effectors, organism-specific biosystem', 'Transcriptional misregulation in cancer, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(84, 'DDX10', 0, 'http://www.ncbi.nlm.nih.gov/gene/1662', 1662, 'HRH-J8', 'DEAD box proteins', 0, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(85, 'DICER1', 3, 'http://www.ncbi.nlm.nih.gov/gene/23405', 23405, 'DCR1; MNG1; Dicer; HERNA', 'a protein possessing an RNA helicase motif containing a DEXH box in its amino terminus and an RNA motif in the carboxy terminus', 0, 0, '', 'Goiter, multinodular 1, with or without sertoli-leydig cell tumors,Pleuropulmonary blastoma', 'Cell fate', 'Regulatory RNA pathways, organism-specific biosystem', 'mRNA processing, organism-specific biosystem', 'Small Interfering RNA (siRNA) Biogenesis, organism-specific biosystem', 'Gene Expression, organism-specific biosystem', NULL, NULL),
	(86, 'DNM2', 0, 'http://www.ncbi.nlm.nih.gov/gene/1785', 1785, 'DYN2; CMT2M; DYNII; CMTDI1; CMTDIB; DI-CMTB', 'subfamilies of GTP-binding proteins. These proteins share considerable sequence similarity over the N-terminal portion of the molecule, which contains the GTPase domain', 0, NULL, NULL, 'Charcot-Marie-Tooth disease,Myopathy', NULL, 'Endocytosis, organism-specific biosystem', 'Synaptic Vesicle Pathway, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(87, 'DNMT3A', 1, 'http://www.ncbi.nlm.nih.gov/gene/1788', 1788, 'DNMT3A2; M.HsaIIIA', 'DNA methyltransferase ', 0, 0, '', 'type 1 diabetes , Crohns disease', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(88, 'EBF1', 0, 'http://www.ncbi.nlm.nih.gov/gene/1879', 1879, 'EBF; COE1; OLF1; O/E-1', NULL, 0, NULL, NULL, 'pulse pressure and mean arterial pressure  and cardiovascular disease risk', NULL, 'Adipogenesis, organism-specific biosystem', 'Developmental Biology, organism-specific biosystem', 'Transcriptional Regulation of White Adipocyte Differentiation, organism-specific biosystem', NULL, NULL, NULL),
	(89, 'ECT2L', 0, 'http://www.ncbi.nlm.nih.gov/gene/345930', 345930, 'LFDH; FBXO49; C6orf91; ARHGEF32; dJ509I19.2; dJ509I19.3; dJ509I19.5', NULL, 0, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(90, 'EXT1', 3, 'http://www.ncbi.nlm.nih.gov/gene/2131', 2131, 'EXT; LGS; TTV; LGCR; TRPS2', 'endoplasmic reticulum-resident type II transmembrane glycosyltransferase involved in the chain elongation step of heparan sulfate biosynthesis', 0, 0, '', 'type I form of multiple exostoses;(Hurler syndrome, Sanfilippo syndrome,  Morquio syndrome A, organism-specific biosystem,Natowicz syndrome, organism-specific biosystem, Sly syndrome, Maroteaux-Lamy syndrome)', 'Cell fate', 'heparan sulfate biosynthesis, conserved biosystem', 'Glycosaminoglycan biosynthesis - heparan sulfate / heparin, conserved biosystem', NULL, NULL, NULL, NULL),
	(91, 'FOXP1', 0, 'http://www.ncbi.nlm.nih.gov/gene/27086', 27086, 'QRF1; 12CC4; hFKH1B; HSPC215', ' forkhead box (FOX) transcription factor family', 0, NULL, NULL, 'Mental retardation with language impairment and autistic features ,attention deficit hyperactivity disorder ', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(92, 'EGFR', 1, 'http://www.ncbi.nlm.nih.gov/gene/1956', 1956, 'ERBB; HER1; mENA; ERBB1; PIG61', 'protein kinase superfamily', 1, 29, 'ERBB1', ' lung cancer', 'Cell survival', 'EGFR downregulation, organism-specific biosystem', 'ErbB signaling pathway, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(93, 'EIF4A2', 0, 'http://www.ncbi.nlm.nih.gov/gene/1974', 1974, 'DDX2B; EIF4A; EIF4F; BM-010; eIF4A-II; eIF-4A-II', NULL, 0, NULL, NULL, NULL, NULL, 'Translation, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(94, 'ELF4', 0, 'http://www.ncbi.nlm.nih.gov/gene/2000', 2000, 'MEF; ELFR', '', 0, NULL, NULL, '', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(95, 'ELL', 0, 'http://www.ncbi.nlm.nih.gov/gene/8178', 8178, 'MEN; ELL1; PPP1R68; C19orf17', NULL, 0, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(96, 'EML4', 0, 'http://www.ncbi.nlm.nih.gov/gene/27436', 27436, 'C2orf2; ELP120; EMAP-4; EMAPL4; ROPP120', NULL, 0, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(97, 'ELN', 0, 'http://www.ncbi.nlm.nih.gov/gene/2006', 2006, 'WS; WBS; SVAS', '', 0, NULL, NULL, 'supravalvular aortic stenosis (SVAS) and autosomal dominant cutis laxa, WILLIAMS syndrome', '', 'Protein digestion and absorption, organism-specific biosystem', 'Elastic fibre formation, organism-specific biosystem', 'Extracellular matrix organization, organism-specific biosystem', NULL, NULL, NULL),
	(98, 'EP300', 1, 'http://www.ncbi.nlm.nih.gov/gene/2033', 2033, 'p300; KAT3B; RSTS2', '', 0, 0, '', ' Rubinstein-Taybi syndrome and may also play a role in epithelial cancer, familial colorectal cancer', 'Cell survival/fate', 'Notch signaling pathway, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(99, 'ERBB2', 1, 'http://www.ncbi.nlm.nih.gov/gene/2064', 2064, 'NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu', 'epidermal growth factor (EGF) receptor family of receptor tyrosine kinases', 1, 47, 'her2', 'breast and ovarian tumors,Glioma susceptibility,Hereditary diffuse gastric cancer, lung cancer, Neoplasm of stomach', 'Cell survival', 'ErbB signaling pathway, organism-specific biosystem', 'PI3K events in ERBB2 signaling, organism-specific biosystem', 'PI3K/AKT Signaling in Cancer, organism-specific biosystem', NULL, NULL, NULL),
	(100, 'ERC1', 0, 'http://www.ncbi.nlm.nih.gov/gene/23085', 23085, 'ELKS; Cast2; RAB6IP2', ' RIM-binding proteins', 0, NULL, NULL, '', '', 'NF-kappa B signaling pathway, organism-specific biosystem', 'IL1-mediated signaling events, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(101, 'ERCC2', 3, 'http://www.ncbi.nlm.nih.gov/gene/2068', 2068, 'EM9; TTD; XPD; COFS2', ' ATP-dependent DNA helicase activity and belongs to the RAD3/XPD subfamily of helicases', 0, 0, '', 'cancer-prone syndrome xeroderma pigmentosum complementation group D, trichothiodystrophy, and Cockayne syndrome', 'Genome maintenance', NULL, NULL, NULL, NULL, NULL, NULL),
	(102, 'ERCC3', 3, 'http://www.ncbi.nlm.nih.gov/gene/2071', 2071, 'XPB; BTF2; GTF2H; RAD25; TFIIH', 'ATP-dependent DNA helicase,nucleotide excision repair and complements xeroderma pigmentosum group B mutations', 0, 0, '', 'Xeroderma pigmentosum', 'Genome maintenance', 'RNA Polymerase I Transcription, organism-specific biosystem', 'RNA Polymerase II Transcription, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(103, 'ERCC4', 3, 'http://www.ncbi.nlm.nih.gov/gene/2072', 2072, 'XPF; RAD1; ERCC11', 'The protein forms a complex with ERCC1 and is involved in the 5 incision made during nucleotide excision repair', 0, 0, '', 'Nucleotide Excision Repair, organism-specific biosystem', 'Genome maintenance', 'DNA Repair, organism-specific biosystem', 'Nucleotide Excision Repair, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(104, 'ERCC5', 3, 'http://www.ncbi.nlm.nih.gov/gene/2073', 2073, 'XPG; UVDR; XPGC; COFS3; ERCM2', 'DNA endonuclease, The protein may also function in other cellular processes, including RNA polymerase II transcription, and transcription-coupled DNA repair', 0, 0, '', 'xeroderma pigmentosum complementation group G (XP-G, skin cancer development following UV exposure,Cockayne syndrome', 'Genome maintenance', 'Nucleotide Excision Repair, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(105, 'ETV6', 0, 'http://www.ncbi.nlm.nih.gov/gene/2120', 2120, 'TEL; TEL/ABL', ' ETS family transcription factor', 0, NULL, NULL, 'leukemia and congenital fibrosarcoma.', '', 'Transcriptional misregulation in cancer, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(106, 'EWSR1', 0, 'http://www.ncbi.nlm.nih.gov/gene/2130', 2130, 'EWS; bK984G1.4', 'a multifunctional protein that is involved in various cellular processes, including gene expression, cell signaling, and RNA processing and transport', 0, NULL, NULL, ' Ewing sarcoma, neuroectodermal and various other tumors', NULL, 'Transcriptional misregulation in cancer, organism-specific biosystem', 'BARD1 signaling events, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(107, 'EZH2', 1, 'http://www.ncbi.nlm.nih.gov/gene/2146', 2146, 'ENX1; EZH1; KMT6; WVS2; ENX-1; KMT6A', ' Polycomb-group (PcG) family', 0, 0, '', 'Weaver syndrome', 'Cell fate', 'Integrated Pancreatic Cancer Pathway, organism-specific biosystem', 'miRs in Muscle Cell Differentiation, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(108, 'EZH2_ENST00000350995', 0, 'NOT DATA FOUND', 0, NULL, NULL, 0, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(109, 'EZR', 0, 'http://www.ncbi.nlm.nih.gov/gene/7430', 7430, 'CVL; CVIL; VIL2', ' ERM protein family', 0, NULL, NULL, NULL, NULL, 'Regulation of Actin Cytoskeleton, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(110, 'FAM46C', 0, 'http://www.ncbi.nlm.nih.gov/gene/54855', 54855, NULL, NULL, 0, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(111, 'FAM123B', 1, 'http://www.ncbi.nlm.nih.gov/gene/139285', 139285, 'WTX; OSCS; FAM123B; RP11-403E24.2', 'The protein upregulates trancriptional activation by the Wilms tumor protein and interacts with many other proteins, including CTNNB1, APC, AXIN1, and AXIN2', 0, 0, '', 'osteopathia striata with cranial sclerosis (OSCS)', 'Cell fate', 'Signaling by Wnt, organism-specific biosystem', 'Beta-catenin phosphorylation cascade, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(112, 'FANCA', 3, 'http://www.ncbi.nlm.nih.gov/gene/2175', 2175, 'FA; FA1; FAA; FAH; FA-H; FACA; FANCH', ' protein for complementation group A', 0, 0, '', 'Fanconi anemia. ', 'Genome maintenance', 'BARD1 signaling events, organism-specific biosystem', 'DNA Repair, organism-specific biosystem', 'Fanconi Anemia pathway, organism-specific biosystem', NULL, NULL, NULL),
	(113, 'FANCD2', 3, 'http://www.ncbi.nlm.nih.gov/gene/2177', 2177, 'FA4; FAD; FACD; FAD2; FA-D2; FANCD', 'protein for complementation group D2, This protein is monoubiquinated in response to DNA damage, resulting in its localization to nuclear foci with other proteins (BRCA1 AND BRCA2) involved in homology-directed DNA repair', 0, 0, '', 'Fanconi anemia. ', 'Genome maintenance', 'BARD1 signaling events, organism-specific biosystem', 'Fanconi Anemia pathway, organism-specific biosystem', 'Regulation of the Fanconi anemia pathway, organism-specific biosystem', NULL, NULL, NULL),
	(114, 'FANCG', 3, 'http://www.ncbi.nlm.nih.gov/gene/2189', 2189, 'FAG; XRCC9', ' the protein for complementation group G', 0, 0, '', 'Fanconi anemia. ', 'Genome maintenance', 'BARD1 signaling events, organism-specific biosystem', 'DNA Repair, organism-specific biosystem', 'Fanconi Anemia pathway, organism-specific biosystem', NULL, NULL, NULL),
	(115, 'FAS', 0, 'http://www.ncbi.nlm.nih.gov/gene/355', 355, 'APT1; CD95; FAS1; APO-1; FASTM; ALPS1A; TNFRSF6', 'the TNF-receptor superfamily', 0, NULL, NULL, 'Autoimmune lymphoproliferative syndrome', '', 'Apoptosis, organism-specific biosystem', 'MAPK signaling pathway, organism-specific biosystem', NULL, NULL, NULL, 'Alzheimer\'s disease, organism-specific biosystem'),
	(116, 'FBX011', 0, 'noo en Homosapiens', 0, NULL, NULL, 0, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(117, 'FBXW7', 1, 'http://www.ncbi.nlm.nih.gov/gene/55294', 55294, 'AGO; CDC4; FBW6; FBW7; hAgo; FBX30; FBXW6; SEL10; hCdc4; FBXO30; SEL-10', ' F-box30 protein family', 0, 0, '', ' ovarian and breast cancer cell lines', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(118, 'FBXW7_NM_018315_2', 0, 'NOT DATA FOUND', 0, NULL, NULL, 0, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(119, 'FGFR1', 0, 'http://www.ncbi.nlm.nih.gov/gene/2260', 2260, 'CEK; FLG; HH2; OGD; FLT2; KAL2; BFGFR; CD331; FGFBR; FLT-2; HBGFR; N-SAM; FGFR-1; bFGF-R-1', ' fibroblast growth factor receptor (FGFR) family', 0, 0, '', ' Pfeiffer syndrome, Jackson-Weiss syndrome, Antley-Bixler syndrome, osteoglophonic dysplasia, and autosomal dominant Kallmann syndrome 2', '', 'Signaling by FGFR in disease, organism-specific biosystem', 'PI3K-Akt signaling pathway, conserved biosystem', 'MAPK signaling pathway, organism-specific biosystem', NULL, NULL, NULL),
	(120, 'FGFR2', 1, 'http://www.ncbi.nlm.nih.gov/gene/2263', 2263, 'BEK; JWS; BBDS; CEK3; CFD1; ECT1; KGFR; TK14; TK25; BFR-1; CD332; K-SAM', 'fibroblast growth factor receptor family', 1, 37, '', 'Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis', 'Cell survival', 'FGFR2 ligand binding and activation, organism-specific biosystem', 'Signaling by EGFR in Cancer, organism-specific biosystem', 'PI3K/AKT Signaling in Cancer, organism-specific biosystem', 'PI3K-Akt signaling pathway, organism-specific biosystem', NULL, NULL),
	(121, 'FGFR3', 1, 'http://www.ncbi.nlm.nih.gov/gene/2261', 2261, 'ACH; CEK2; JTK4; CD333; HSFGFR3EX', ' fibroblast growth factor receptor (FGFR) family', 1, 38, '', 'skeletal dysplasia, craniosynostosis, Achondroplasia  Camptodactyly, Carcinoma of cervix, Crouzon syndrome with acanthosis nigricans, Epidermal nevus, Familial colorectal cancer  ,Hypochondroplasia, Isolated coronal synostosis ,Levy-Hollister syndrome  , ', 'Cell survival', 'FGFR ligand binding and activation, organism-specific biosystem', 'PI3K-Akt signaling pathway, organism-specific biosystem', 'Regulation of Actin Cytoskeleton, organism-specific biosystem', NULL, NULL, NULL),
	(122, 'FGFR1OP', 0, 'http://www.ncbi.nlm.nih.gov/gene/11116', 11116, 'FOP', 'leucine-rich protein family member', 0, NULL, NULL, 'Graves disease. Crohns disease, vitiligo', '', 'Signaling by FGFR in disease, organism-specific biosystem', 'Cell Cycle, organism-specific biosystem', 'Cell Cycle, Mitotic, organism-specific biosystem', 'G2/M Transition, organism-specific biosystem', NULL, NULL),
	(123, 'FH', 3, 'http://www.ncbi.nlm.nih.gov/gene/2271', 2271, 'MCL; LRCC; HLRCC; MCUL1', 'enzymatic component of the tricarboxylic acid (TCA) cycle, or Krebs cycle, and catalyzes the formation of L-malate from fumarate', 0, 0, '', 'fumarase deficiency and lead to progressive encephalopathy, Hereditary leiomyomatosis and renal cell cancer', 'Cell survival', 'TCA Cycle, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(124, 'FLT3', 1, 'http://www.ncbi.nlm.nih.gov/gene/2322', 2322, 'FLK2; STK1; CD135; FLK-2', 'class III receptor tyrosine kinase, regulates hematopoiesis', 1, 42, '', 'myeloid leukemia and acute lymphoblastic leukemia', 'Cell survival', 'Acute myeloid leukemia, organism-specific biosystem', 'Cytokine-cytokine receptor interaction, organism-specific biosystem', 'Transcriptional misregulation in cancer, organism-specific biosystem', NULL, NULL, NULL),
	(125, 'FOXO1', 0, 'http://www.ncbi.nlm.nih.gov/gene/2308', 2308, 'FKH1; FKHR; FOXO1A', 'forkhead family of transcription factors ', 0, NULL, NULL, 'alveolar rhabdomyosarcoma', '', 'FoxO family signaling, organism-specific biosystem', 'Insulin Signaling, organism-specific biosystem', 'PI3K/AKT activation, organism-specific biosystem', NULL, NULL, NULL),
	(126, 'FOXO3', 0, 'http://www.ncbi.nlm.nih.gov/gene/2309', 2309, 'FOXO2; AF6q21; FKHRL1; FOXO3A; FKHRL1P2', ' forkhead family of transcription factors', 0, NULL, NULL, 'secondary acute leukemia', '', 'FoxO family signaling, organism-specific biosystem', 'PI3K-Akt signaling pathway, organism-specific biosystem', 'Class I PI3K signaling events mediated by Akt', NULL, NULL, NULL),
	(127, 'FOXL2', 1, 'http://www.ncbi.nlm.nih.gov/gene/668', 668, 'BPES; PFRK; POF3; BPES1; PINTO', ' forkhead transcription factor', 0, 0, '', ' blepharophimosis syndrome and premature ovarian failure 3', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(128, 'FOXP1', 0, 'http://www.ncbi.nlm.nih.gov/gene/27086', 27086, 'QRF1; 12CC4; hFKH1B; HSPC215', 'subfamily P of the forkhead box (FOX) transcription factor family', 0, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(129, 'FUBP1', 1, 'http://www.ncbi.nlm.nih.gov/gene/8880', 8880, 'FBP; FUBP', 'binding protein that activates the far upstream element (FUSE) of c-myc and stimulates expression of c-myc in undifferentiated cells. to function as an ATP-dependent DNA helicase', 0, 0, '', '', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(130, 'FUS', 0, 'http://www.ncbi.nlm.nih.gov/gene/2521', 2521, 'TLS; ALS6; ETM4; FUS1; POMP75; HNRNPP2', 'multifunctional protein component of the heterogeneous nuclear ribonucleoprotein (hnRNP) complex', 0, NULL, NULL, 'amyotrophic lateral sclerosis type 6', NULL, 'Transcriptional misregulation in cancer, organism-specific biosystem', 'mRNA Splicing, organism-specific biosystem', 'mRNA processing, organism-specific biosystem', NULL, NULL, NULL),
	(131, 'GAS7', 0, 'http://www.ncbi.nlm.nih.gov/gene/8522', 8522, 'MLL/GAS7', 'GAS7 plays a putative role in neuronal development', 0, NULL, NULL, '', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(132, 'GATA2', 1, 'http://www.ncbi.nlm.nih.gov/gene/2624', 2624, 'DCML; NFE1B; MONOMAC', 'GATA family of zinc-finger transcription factors', 0, 0, '', 'Acute myeloid leukemia ,Familial Acute Myeloid Leukemia (AML),Lymphedema, primary, with myelodysplasia  Myelodysplastic syndrome  \r\n\r\n', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(133, 'GATA3', 1, 'http://www.ncbi.nlm.nih.gov/gene/2625', 2625, 'HDR; HDRS', 'GATA family of transcription factors', 0, 0, '', 'hypoparathyroidism with sensorineural deafness and renal dysplasia', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(134, 'GNA11', 1, 'http://www.ncbi.nlm.nih.gov/gene/2767', 2767, 'GNA-11', 'G- protein', 0, 0, '', '', 'Cell survival', 'G Protein Signaling Pathways, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(135, 'GNAQ', 1, 'http://www.ncbi.nlm.nih.gov/gene/2776', 2776, 'GAQ; G-ALPHA-q', 'guanine nucleotide-binding protein', 0, 0, '', '', 'Cell survival', 'G Protein Signaling Pathways, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(136, 'GNAS', 1, 'http://www.ncbi.nlm.nih.gov/gene/2778', 2778, 'AHO; GSA; GSP; POH; GPSA; NESP; GNAS1; PHP1A; PHP1B; PHP1C; C20orf45', 'This locus has a highly complex imprinted expression pattern. It gives rise to maternally, paternally, and biallelically expressed transcripts that are derived from four alternative promoters and 5 exons', 0, 0, '', 'pseudohypoparathyroidism type 1a, pseudohypoparathyroidism type 1b, Albright hereditary osteodystrophy, pseudopseudohypoparathyroidism, McCune-Albright syndrome, progressive osseus heteroplasia, polyostotic fibrous dysplasia of bone, and some pituitary tu', 'Cell survival/fate', 'G Protein Signaling Pathways, organism-specific biosystem', 'GPCR downstream signaling, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(137, 'GNAS_NM_016592_1', 0, 'NOT DATA FOUND', 0, NULL, NULL, 0, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(138, 'GMPS', 0, 'http://www.ncbi.nlm.nih.gov/gene/8833', 8833, '', 'GMP synthetase,  which catalyzes the amination of XMP to GMP', 0, NULL, NULL, 'Acute myeloid leukemia', '', 'purine nucleotides de novo biosynthesis II, organism-specific biosystem', 'Metabolism of nucleotides, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(139, 'GOPC', 0, 'http://www.ncbi.nlm.nih.gov/gene/57120', 57120, 'CAL; FIG; PIST; GOPC1; dJ94G16.2', 'Golgi protein ', 0, NULL, NULL, 'Globozoospermia', NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(140, 'H3F3A', 1, 'http://www.ncbi.nlm.nih.gov/gene/3020', 3020, 'H3F3; H3.3A', 'The protein encoded is a replication-independent member of the histone H3 family', 0, 0, '', '', 'Cell fate', 'Transcriptional misregulation in cancer, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(141, 'HIP1', 0, 'http://www.ncbi.nlm.nih.gov/gene/3092', 3092, 'ILWEQ', 'is a membrane-associated protein that colocalizes with huntingtin', 0, NULL, NULL, 'Huntington disease. It also has been implicated in the pathogenesis of hematopoietic malignancies', NULL, 'EGFR1 Signaling Pathway, organism-specific biosystem', 'Huntington\'s disease, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(142, 'HIST1H3B', 1, 'http://www.ncbi.nlm.nih.gov/gene/8358', 8358, 'H3/l; H3FL', 'basic nuclear proteins', 0, 0, 'are responsible for the nucleosome structure of the chromosomal fiber in eukaryotes', '', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(143, 'HNF1A', 1, 'http://www.ncbi.nlm.nih.gov/gene/6927', 6927, 'HNF1; LFB1; TCF1; MODY3; TCF-1; HNF-1A; IDDM20', 'transcription factor ', 0, 0, '', ' maturity onset diabetes of the young type 3 (MODY3) and also can result in the appearance of hepatic adenomas', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(144, 'HOXA11', 0, 'http://www.ncbi.nlm.nih.gov/gene/3207', 3207, 'HOX1; HOX1I', ' transcription factors called homeobox genes', 0, NULL, NULL, ' radio-ulnar synostosis with amegakaryocytic thrombocytopenia', NULL, 'Transcriptional misregulation in cancer, conserved biosystem', NULL, NULL, NULL, NULL, NULL),
	(145, 'HRAS', 1, 'http://www.ncbi.nlm.nih.gov/gene/3265', 3265, 'CTLO; HAMSV; HRAS1; K-RAS; N-RAS; RASH1; C-H-RAS; H-RASIDX; C-BAS/HAS; C-HA-RAS1', ' Ras oncogene family. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity', 0, 0, '', 'Costello syndrome variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma', 'Cell survival', 'Signalling to RAS, organism-specific biosystem', '????????????????', NULL, NULL, NULL, NULL),
	(146, 'IDH1', 1, 'http://www.ncbi.nlm.nih.gov/gene/3417', 3417, 'IDH; IDP; IDCD; IDPC; PICD', 'Isocitrate dehydrogenases . The protein encoded by this gene is the NADP(+)-dependent isocitrate dehydrogenase found in the cytoplasm and peroxisomes', 0, 0, '', 'Glioma susceptibility', 'Cell fate', 'Citrate cycle (TCA cycle), organism-specific biosystem', 'NADPH regeneration, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(147, 'IDH2', 1, 'http://www.ncbi.nlm.nih.gov/gene/3418', 3418, 'IDH; IDP; IDHM; IDPM; ICD-M; D2HGA2; mNADP-IDH', 'Isocitrate dehydrogenases . It plays a role in intermediary metabolism and energy production', 0, 0, '', '', 'Cell fate', 'Pyruvate metabolism and Citric Acid (TCA) cycle, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(148, 'IL7R', 0, 'http://www.ncbi.nlm.nih.gov/gene/3575', 3575, 'ILRA; CD127; IL7RA; CDW127; IL-7R-alpha', 'receptor for interleukine 7 (IL7)blocking apoptosis is an essential function of this protein during differentiation and activation of T lymphocytes', 0, NULL, NULL, 'pathogenesis of the severe combined immunodeficiency (SCID)', '', 'Jak-STAT signaling pathway, organism-specific biosystem', 'IL-7 Signaling Pathway, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(149, 'IRF4', 0, 'http://www.ncbi.nlm.nih.gov/gene/3662', 3662, 'MUM1; LSIRF; NF-EM5', 'IRF (interferon regulatory factor) family of transcription factors. This family member is lymphocyte specific and negatively regulates Toll-like-receptor (TLR) signaling that is central to the activation of innate and adaptive immune systems', 0, NULL, NULL, 'multiple myeloma, chronic lymphocytic leukemia.risk of the tauopathy progressive supranuclear palsy.', NULL, 'Apoptosis, organism-specific biosystem', 'Interferon Signaling, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(150, 'ITK', 0, 'http://www.ncbi.nlm.nih.gov/gene/3702', 3702, 'EMT; LYK; LPFS1; PSCTK2', 'tyrosine kinase expressed in T-cells, play a role in T-cell proliferation and differentiation', 0, NULL, NULL, 'Lymphoproliferative syndrome, ebv-associated', '', 'TCR Signaling Pathway, organism-specific biosystem', 'T cell receptor signaling pathway, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(151, 'JAK1', 1, 'http://www.ncbi.nlm.nih.gov/gene/3716', 3716, 'JTK3; JAK1A; JAK1B', ' a new class of protein-tyrosine kinases (PTK). membrane-associated phosphoprotein.', 0, 0, 'JAK1', '', 'Cell survival', 'Jak-STAT signaling pathway, organism-specific biosystem', 'Interferon Signaling, organism-specific biosystem', 'PI3K-Akt signaling pathway, organism-specific biosystem', NULL, NULL, NULL),
	(152, 'JAK2', 1, 'http://www.ncbi.nlm.nih.gov/gene/3717', 3717, 'JTK10; THCYT3', 'is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways', 0, 0, 'JAK2', 'Acute myeloid leukemia  Budd-Chiari syndrome,Familial erythrocytosis, Myelofibrosis,Polycythemia vera,Thrombocythemia ', 'Cell survival', 'Jak-STAT signaling pathway, organism-specific biosystem', 'EPO Receptor Signaling, organism-specific biosystem', 'PI3K-Akt signaling pathway, organism-specific biosystem', NULL, NULL, NULL),
	(153, 'JAK3', 1, 'http://www.ncbi.nlm.nih.gov/gene/3718', 3718, 'JAKL; LJAK; JAK-3; L-JAK; JAK3_HUMAN', 'Janus kinase (JAK) family of tyrosine kinases ', 0, 0, 'JAK3', 'autosomal SCID (severe combined immunodeficiency disease)', 'Cell survival', NULL, 'PI3K-Akt signaling pathway, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(154, 'KDM5A', 0, 'http://www.ncbi.nlm.nih.gov/gene/5927', 5927, 'RBP2; RBBP2; RBBP-2; JARID1A', ' is a ubiquitously expressed nuclear protein', 0, 0, '', '', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(155, 'KDM5C', 1, 'http://www.ncbi.nlm.nih.gov/gene/8242', 8242, 'MRXJ; SMCX; MRXSJ; XE169; MRXSCJ; JARID1C; DXS1272E', 'SMCY homolog family. involved in the regulation of transcription and chromatin remodeling ', 0, 0, '', 'X-linked mental retardation, syndromic, Claes-Jensen type ', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(156, 'KDM6A', 1, 'http://www.ncbi.nlm.nih.gov/gene/7403', 7403, 'UTX; KABUK2; bA386N14.2', '(TPR) protein', 0, 0, '', 'Kabuki syndrome', 'Cell fate', 'Transcriptional misregulation in cancer, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(157, 'KDR', 0, 'http://www.ncbi.nlm.nih.gov/gene/3791', 3791, 'FLK1; CD309; VEGFR; VEGFR2', 'This gene encodes one of the two receptors of the VEGF, (Vascular endothelial growth factor)a type III receptor tyrosine kinase', 1, NULL, 'VEGFR2', ' infantile capillary hemangiomas', '', 'VEGF signaling pathway, organism-specific biosystem', 'PI3K-Akt signaling pathway, conserved biosystem', 'Focal adhesion, organism-specific biosystem', NULL, NULL, NULL),
	(158, 'KIT', 1, 'http://www.ncbi.nlm.nih.gov/gene/3815', 3815, 'PBT; SCFR; C-Kit; CD117', 'type 3 transmembrane receptor for MGF', 1, 52, 'KIT, C-KIT', ' gastrointestinal stromal tumors, mast cell disease, acute myelogenous lukemia, and piebaldism', 'Cell survival', 'Kit Receptor Signaling Pathway, organism-specific biosystem', 'PI3K-Akt signaling pathway, conserved biosystem', 'Signaling by EGFR, organism-specific biosystem', 'Signaling events mediated by Stem cell factor receptor (c-Kit), organism-specific biosystem', NULL, NULL),
	(159, 'KLF6', 0, 'http://www.ncbi.nlm.nih.gov/gene/1316', 1316, 'GBF; ZF9; BCD1; CBA1; CPBP; PAC1; ST12; COPEB', ' Kruppel-like family of transcription factors.  is a transcriptional activator, and functions as a tumor suppressor', 0, NULL, NULL, 'Hereditary diffuse gastric cancer ,Malignant tumor of prostate ,Neoplasm of stomach ', NULL, 'Adipogenesis, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(160, 'KRAS', 1, 'http://www.ncbi.nlm.nih.gov/gene/3845', 3845, 'NS; NS3; KRAS1; KRAS2; RASK2; KI-RAS; C-K-RAS; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B', 'oncogene homolog from the mammalian ras gene family, a protein that is a member of the small GTPase superfamily', 0, 0, '', 'lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma', 'Cell survival', 'Axon guidance, organism-specific biosystem', 'ErbB signaling pathway, organism-specific biosystem', 'MAPK signaling pathway, organism-specific biosystem', NULL, NULL, NULL),
	(161, 'KTN1', 0, 'http://www.ncbi.nlm.nih.gov/gene/3895', 3895, 'CG1; KNT; MU-RMS-40.19', 'kinectin protein family', 0, NULL, NULL, '', '', 'TNF-alpha/NF-kB Signaling Pathway, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(162, 'LCK', 0, 'http://www.ncbi.nlm.nih.gov/gene/3932', 3932, 'LSK; YT16; p56lck; pp58lck', ' Src family of protein tyrosine kinases (PTKs)', 0, NULL, NULL, NULL, NULL, 'TCR signaling in naive CD4+ T cells, organism-specific biosystem', 'TCR signaling in naive CD8+ T cells, organism-specific biosystem', 'Phosphorylation of CD3 and TCR zeta chains, organism-specific biosystem', 'CD28 dependent PI3K/Akt signaling, organism-specific biosystem', NULL, NULL),
	(163, 'LHFP', 0, 'http://www.ncbi.nlm.nih.gov/gene/10186', 10186, NULL, 'member of the lipoma HMGIC fusion partner (LHFP) gene family', 0, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(164, 'LIFR', 0, 'http://www.ncbi.nlm.nih.gov/gene/3977', 3977, 'SWS; SJS2; STWS; CD118; LIF-R', ' type I cytokine receptor family', 0, NULL, NULL, 'Schwartz-Jampel syndrome type 2', NULL, 'Cytokine-cytokine receptor interaction, organism-specific biosystem', 'Jak-STAT signaling pathway, organism-specific biosystem', 'Oncostatin M Signaling Pathway, organism-specific biosystem', NULL, NULL, NULL),
	(165, 'LRIG3', 0, 'http://www.ncbi.nlm.nih.gov/gene/121227', 121227, 'LIG3', NULL, 0, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(166, 'MAF', 0, 'http://www.ncbi.nlm.nih.gov/gene/4094', 4094, 'CCA4; c-MAF', NULL, 0, NULL, ' regulation of several cellular processes, including embryonic lens fiber cell development, increased T-cell susceptibility to apoptosis, and chondrocyte terminal differentiation.', ' juvenile-onset pulverulent cataract as well as congenital cerulean cataract 4 (CCA4)', NULL, 'Transcriptional misregulation in cancer  Calcineurin-regulated NFAT-dependent transcription in lymphocytes', NULL, NULL, NULL, NULL, NULL),
	(167, 'MAML2', 0, 'http://www.ncbi.nlm.nih.gov/gene/84441', 84441, 'MAM2; MAM3; MAM-3; MLL-MAML2', NULL, 0, NULL, NULL, NULL, NULL, 'Notch signaling pathway  Signaling by NOTCH ', NULL, NULL, NULL, NULL, NULL),
	(168, 'MAP2K4', 1, 'http://www.ncbi.nlm.nih.gov/gene/6416', 6416, 'JNKK; MEK4; MKK4; SEK1; JNKK1; SERK1; MAPKK4; PRKMK4; SAPKK1; SAPKK-1', 'Ser/Thr protein kinase family.direct activator of MAP kinases in response to various environmental stresses or mitogenic stimuli', 0, 0, '', '', 'Cell survival', 'Toll-Like Receptors Cascades  Toll-like receptor signaling pathway  MAPK signaling pathway GnRH signaling pathway,', NULL, NULL, NULL, NULL, NULL),
	(169, 'MDM4', 0, 'http://www.ncbi.nlm.nih.gov/gene/4194', 4194, 'HDMX; MDMX; MRP1', 'nuclear protein', 0, NULL, NULL, NULL, NULL, 'Signaling Pathways in Glioblastoma    p53 signaling pathway', NULL, NULL, NULL, NULL, NULL),
	(170, 'MECOM', 0, 'http://www.ncbi.nlm.nih.gov/gene/2122', 2122, 'EVI1; MDS1; PRDM3; MDS1-EVI1; AML1-EVI-1', ' transcriptional regulator and oncoprotein that may be involved in hematopoiesis, apoptosis, development, and cell differentiation and proliferation.', 0, NULL, NULL, 'leukemia', NULL, 'Chronic myeloid leukemia  MAPK signaling pathway  Pathways in cancer', NULL, NULL, NULL, NULL, NULL),
	(171, 'MED12', 1, 'http://www.ncbi.nlm.nih.gov/gene/9968', 9968, 'OKS; FGS1; HOPA; OPA1; ARC240; CAGH45; MED12S; TNRC11; TRAP230', 'is essential for activating CDK8 kinase', 0, 0, '', 'X-linked Opitz-Kaveggia syndrome, also known as FG syndrome, and Lujan-Fryns syndrome', 'Cell survival', 'PPARA Activates Gene Expression Gene Expression  Generic Transcription Pathway Metabolism', NULL, NULL, NULL, NULL, NULL),
	(172, 'MEN1', 1, 'http://www.ncbi.nlm.nih.gov/gene/4221', 4221, 'MEAI; SCG2', 'encodes menin, a putative tumor suppressor associated with a syndrome known as multiple endocrine neoplasia type 1', 0, 0, '', 'syndrome known as multiple endocrine neoplasia type 1', 'Cell fate', 'Transcriptional misregulation in cancer  Cell cycle gene expression generic transcription Pathway', NULL, NULL, NULL, NULL, NULL),
	(173, 'MET', 1, 'http://www.ncbi.nlm.nih.gov/gene/4233', 4233, 'HGFR; AUTS9; RCCP2; c-Met', 'is the hepatocyte growth factor receptor and encodes tyrosine-kinase activity.', 0, 0, 'c-MET', ' papillary renal carcinoma. ', 'Cell survival', 'Transcriptional misregulation in cancer Axon guidance  PI3K-Akt signaling pathway Renal cell carcinoma  Pathways in cancer', NULL, NULL, NULL, NULL, NULL),
	(174, 'MITF', 0, 'http://www.ncbi.nlm.nih.gov/gene/4286', 4286, 'MI; WS2; CMM8; WS2A; bHLHe32', 'It regulates the differentiation and development of melanocytes retinal pigment epithelium and is also responsible for pigment cell-specific transcription of the melanogenesis enzyme genes', 0, NULL, NULL, ' auditory-pigmentary syndromes, such as Waardenburg syndrome type 2 and Tietz syndrome', '', 'Pathways in cancer Osteoclast differentiation,Melanoma melanogenesis', NULL, NULL, NULL, NULL, NULL),
	(175, 'MKL1', 0, 'http://www.ncbi.nlm.nih.gov/gene/57591', 57591, 'MAL; BSAC; MRTF-A', 'Nuclear protein.specific translocation event that creates a fusion of this gene and the RNA-binding motif protein-15 gene', 0, NULL, NULL, 'megakaryocytic leukemia', '', 'RhoA signaling pathway', NULL, NULL, NULL, NULL, NULL),
	(176, 'MLH1', 1, 'http://www.ncbi.nlm.nih.gov/gene/4292', 4292, 'FCC2; COCA2; HNPCC; hMLH1; HNPCC2', '', 0, 0, '', ' nonpolyposis colon cancer (HNPCC)', 'Genome maintenance', NULL, NULL, NULL, NULL, NULL, NULL),
	(177, 'MLL', 0, 'http://www.ncbi.nlm.nih.gov/gene/4297', 4297, 'HRX; TRX1; ALL-1; CXXC7; HTRX1; KMT2A; MLL1A; WDSTS; MLL/GAS7; TET1-MLL', ' encodes a transcriptional coactivator that plays an essential role in regulating gene expression during early development and hematopoiesis', 0, NULL, NULL, ' lymphoid leukemias and acute myeloid leukemias', '', 'Lysine degradation  Senescence and Autophagy  Transcriptional misregulation in cancer,', NULL, NULL, NULL, NULL, NULL),
	(178, 'MLL2', 1, 'http://www.ncbi.nlm.nih.gov/gene/8085', 8085, 'ALR; KMS; MLL4; AAD10; KMT2D; KABUK1; TNRC21; CAGL114', ' histone methyltransferase that methylates the Lys-4 position of histone H3.', 0, 0, '', ' Kabuki syndrome', 'Cell fate', 'Lysine degradation', NULL, NULL, NULL, NULL, NULL),
	(179, 'MLL3', 1, 'http://www.ncbi.nlm.nih.gov/gene/58508', 58508, 'HALR; KMT2C', ' myeloid/lymphoid or mixed-lineage leukemia (MLL) family.is a member of the ASC-2/NCOA6 complex (ASCOM), which possesses histone methylation activity and is involved in transcriptional coactivation', 0, 0, '', '', 'Cell fate', 'Lysine degradation', NULL, NULL, NULL, NULL, NULL),
	(180, 'MLLT3', 0, 'http://www.ncbi.nlm.nih.gov/gene/4300', 4300, 'AF9; YEATS3', '', 0, NULL, NULL, '', '', 'Transcriptional misregulation in cancer', NULL, NULL, NULL, NULL, NULL),
	(181, 'MLLT4', 0, 'http://www.ncbi.nlm.nih.gov/gene/4301', 4301, 'AF6; RP3-431P23.3', ' a multi-domain protein involved in signaling and organization of cell junctions during embryogenesis', 0, NULL, NULL, ' acute myeloid leukemias', '', 'Adherens junction  Tight junction Leukocyte transendothelial migration ', NULL, NULL, NULL, NULL, NULL),
	(182, 'MLLT6', 0, 'http://www.ncbi.nlm.nih.gov/gene/4302', 4302, 'AF17', '', 0, NULL, NULL, 'leukemia', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(183, 'MN1', 0, 'http://www.ncbi.nlm.nih.gov/gene/4330', 4330, 'MGCR; MGCR1; MGCR1-PEN; dJ353E16.2', '', 0, NULL, NULL, 'meningioma 32 pathogenesis', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(184, 'MPL', 1, 'http://www.ncbi.nlm.nih.gov/gene/4352', 4352, 'MPLV; TPOR; C-MPL; CD110; THCYT2', '', 0, 0, '', ' murine myeloproliferative leukemia virus', 'Cell survival', 'Cytokine-cytokine receptor interaction   Jak-STAT signaling pathway Hemostasis  Platelet Aggregation (Plug Formation) platelets activation', NULL, NULL, NULL, NULL, NULL),
	(185, 'MSH2', 1, 'http://www.ncbi.nlm.nih.gov/gene/4436', 4436, 'FCC1; COCA1; HNPCC; LCFS2; HNPCC1', '', 0, 0, '', 'nonpolyposis colon cancer (HNPCC)', 'Genome maintenance', 'Colorectal cancer, Integrated Breast Cancer Pathway  Integrated Cancer pathway  Mismatch repair, Pathways in cancer prostate cancer', NULL, NULL, NULL, NULL, NULL),
	(186, 'MSH6', 1, 'http://www.ncbi.nlm.nih.gov/gene/2956', 2956, 'GTBP; HSAP; HNPCC5', ' encodes a protein similar to the MutS protein', 0, 0, '', 'nonpolyposis colon cancer (HNPCC) and endometrial cancer', 'Genome maintenance', 'Colorectal cancer Integrated Breast Cancer Pathway Mismatch repair, Integrated Cancer pathway  Pathways in cancer Prostate Cancer Signaling Pathways in Glioblastoma', NULL, NULL, NULL, NULL, NULL),
	(187, 'MSI2', 0, 'http://www.ncbi.nlm.nih.gov/gene/124540', 124540, 'MSI2H', 'This gene encodes a protein containing two conserved tandem RNA recognition motifs', 0, NULL, NULL, 'acute myeloid leukemia and  myelodysplasic syndromes', '', 'mRNA surveillance pathway', NULL, NULL, NULL, NULL, NULL),
	(188, 'MSN', 0, 'http://www.ncbi.nlm.nih.gov/gene/4478', 4478, '', 'ERM family', 0, NULL, NULL, '', '', 'Regulation of Actin Cytoskeleton Leukocyte transendothelial migration  RhoA signaling pathway  measles', NULL, NULL, NULL, NULL, NULL),
	(189, 'MUC1', 0, 'http://www.ncbi.nlm.nih.gov/gene/4582', 4582, 'EMA; PEM; PUM; KL-6; MAM6; PEMT; CD227; H23AG; MUC-1; CA 15-3; MUC-1/X; MUC1/ZD; MUC-1/SEC', 'mucin family.essential role in forming protective mucous barriers on epithelial surfaces', 0, NULL, NULL, 'carcinomas.', '', 'IL-7 Signaling Pathway  Metabolism of proteins  O-linked glycosylation of mucins   Post-translational protein modification Termination of O-glycan biosynthesis', NULL, NULL, NULL, NULL, NULL),
	(190, 'MYC', 0, 'http://www.ncbi.nlm.nih.gov/gene/4609', 4609, 'MRTL; c-Myc; bHLHe39', ' It functions as a transcription factor that regulates transcription of specific target genes', 0, NULL, NULL, 'variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma', '', 'cell cycle Wnt Signaling Pathway Signaling by NOTCH,PI3K-Akt signaling pathwayMAPK signaling pathway ErbB signaling pathway', NULL, NULL, NULL, NULL, NULL),
	(191, 'MYCN', 0, 'http://www.ncbi.nlm.nih.gov/gene/4613', 4613, 'NMYC; ODED; MODED; N-myc; bHLHe37', ' MYC family.it encodes a protein with a basic helix-loop-helix (bHLH) domain', 0, NULL, NULL, ' variety of tumors, most notably neuroblastomas.', '', 'Transcriptional misregulation in cancer', NULL, NULL, NULL, NULL, NULL),
	(192, 'MYD88', 1, 'http://www.ncbi.nlm.nih.gov/gene/4615', 4615, 'MYD88D', 'This gene encodes a cytosolic adapter protein that plays a central role in the innate and adaptive immune response', 0, 0, '', 'pyogenic bacterial infections', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(193, 'MYH9', 0, 'http://www.ncbi.nlm.nih.gov/gene/4627', 4627, 'MHA; FTNS; EPSTS; BDPLT6; DFNA17; NMMHCA; NMHC-II-A; NMMHC-IIA', 'This gene encodes a conventional non-muscle myosin', 0, NULL, NULL, 'non-syndromic sensorineural deafness autosomal dominant type 17, Epstein syndrome, Alport syndrome with macrothrombocytopenia, Sebastian syndrome, Fechtner syndrome and macrothrombocytopenia with progressive sensorineural deafness', '', 'Development biology, Regulation of actin cytoskeleton, Tight junction , Salmonella infection', NULL, NULL, NULL, NULL, NULL),
	(194, 'MYH11', 0, 'http://www.ncbi.nlm.nih.gov/gene/4629', 4629, 'AAT4; FAA4; SMHC; SMMHC', ' myosin heavy chain family.major contractile protein, converting chemical energy into mechanical energy through the hydrolysis of ATP.', 0, NULL, NULL, '', '', 'Vascular smooth muscle contraction  Tight junction  Muscle contraction  Muscle contraction', NULL, NULL, NULL, NULL, NULL),
	(195, 'MYST3     KAT6A', 0, 'http://www.ncbi.nlm.nih.gov/gene/7994', 7994, 'MOZ; MYST3; ZNF220; RUNXBP2; ZC2HC6A', '', 0, NULL, NULL, '', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(196, 'MYST4       KAT6B', 0, 'http://www.ncbi.nlm.nih.gov/gene/23522', 23522, 'qkf; MORF; MOZ2; GTPTS; MYST4; ZC2HC6B; querkopf', 'This protein is necessary for RUNX2-dependent transcriptional activation and could be involved in brain development', 0, NULL, NULL, 'genitopatellar syndrome', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(197, 'NACA', 0, 'http://www.ncbi.nlm.nih.gov/gene/4666', 4666, 'HSD48; NACA1', '', 0, NULL, NULL, '', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(198, 'NBN', 3, 'http://www.ncbi.nlm.nih.gov/gene/4683', 4683, 'ATV; NBS; P95; NBS1; AT-V1; AT-V2', ' is a member of the MRE11/RAD50 double-strand break repair complex which consists of 5 proteins.This gene product is thought to be involved in DNA double-strand break repair and DNA damage-induced checkpoint activation.', 0, 0, '', 'Nijmegen breakage syndrome, an autosomal recessive chromosomal instability syndrome ', 'Genome maintenance', 'Homologous recombination  MRN complex meiosis meiotic recombination', NULL, NULL, NULL, NULL, NULL),
	(199, 'NCOA1', 0, 'http://www.ncbi.nlm.nih.gov/gene/8648', 8648, 'SRC1; KAT13A; RIP160; F-SRC-1; bHLHe42; bHLHe74', 'p160/steroid receptor coactivator (SRC) family. The product of this gene binds nuclear receptors directly and stimulates the transcriptional activities in a hormone-dependent fashion', 0, NULL, 'SRC', '', '', 'Metabolism   Activation of Gene Expression by SREBP (SREBF)  Generic Transcription Pathway HIF-1-alpha transcription factor network,  IL-6 Signaling Pathway', NULL, NULL, NULL, NULL, NULL),
	(200, 'NCOA2', 0, 'http://www.ncbi.nlm.nih.gov/gene/10499', 10499, 'SRC2; TIF2; GRIP1; KAT13C; NCoA-2; bHLHe75', 'encodes nuclear receptor coactivator 2, which aids in the function of nuclear hormone receptors', 0, NULL, 'SRC', '', '', 'Metabolism   Activation of Gene Expression by SREBP (SREBF)  Generic Transcription Pathway HIF-1-alpha transcription factor network,  IL-6 Signaling Pathway', NULL, NULL, NULL, NULL, NULL),
	(201, 'NF1', 1, 'http://www.ncbi.nlm.nih.gov/gene/4763', 4763, 'WSS; NFNS; VRNF', 'This gene product appears to function as a negative regulator of the ras signal transduction pathway', 0, 0, '', ' neurofibromatosis type 1, juvenile myelomonocytic leukemia and Watson syndrome', 'Cell survival', 'MAPK signaling pathway,   Integrated Breast Cancer Pathway    Signaling Pathways in Glioblastoma   FOXA2 and FOXA3 transcription factor networksATF-2 transcription factor network', NULL, NULL, NULL, NULL, NULL),
	(202, 'NF2', 1, 'http://www.ncbi.nlm.nih.gov/gene/4771', 4771, 'ACN; SCH; BANF', ' ERM (ezrin, radixin, moesin) family. interact with cell-surface proteins, proteins involved in cytoskeletal dynamics and proteins involved in regulating ion transport.', 0, 0, '', 'neurofibromatosis type II', 'Cell fate', 'ErbB2/ErbB3 signaling events, Hippo signaling pathway', NULL, NULL, NULL, NULL, NULL),
	(203, 'NFE2L2', 1, 'http://www.ncbi.nlm.nih.gov/gene/4780', 4780, 'NRF2', 'small family of basic leucine zipper (bZIP) proteins. The encoded transcription factor regulates genes which contain antioxidant response elements (ARE) in their promoters; many of these genes encode proteins involved in response to injury and inflammatio', 0, 0, '', '', 'Cell survival', 'AhR pathway  Keap1-Nrf2 Pathway  Oxidative Stress, Protein processing in endoplasmic reticulum  Selenium Metabolism and Selenoproteins', NULL, NULL, NULL, NULL, NULL),
	(204, 'NFKB2', 0, 'http://www.ncbi.nlm.nih.gov/gene/4791', 4791, 'p52; p105; H2TF1; LYT10; LYT-10; NF-kB2', 'This gene encodes one of the subunits of the transcription factor complex nuclear factor-kappa-B (NFkB)  This gene encodes the p100 subunit that is processed into the active p52 subunit. This protein can function as both a transcriptional activator and re', 0, NULL, NULL, '', '', 'Toll Like Receptors cascade MAPK signaling pathway MAPK signaling pathway NF-kappa B signaling pathway Osteoclast differentiation', NULL, NULL, NULL, NULL, NULL),
	(205, 'NIN', 0, 'http://www.ncbi.nlm.nih.gov/gene/51199', 51199, 'SCKL7', 'This gene encodes one of the proteins important for centrosomal function. This protein is important for positioning and anchoring the microtubules minus-ends in epithelial cells', 0, NULL, NULL, '', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(206, 'NONO', 0, 'http://www.ncbi.nlm.nih.gov/gene/4841', 4841, 'P54; NMT55; NRB54; P54NRB', 'This gene encodes an RNA-binding protein which plays various roles in the nucleus, including transcriptional regulation and RNA splicing', 0, NULL, NULL, ' papillary renal cell carcinoma', '', 'Circadian rhythm pathway mRNA processing', NULL, NULL, NULL, NULL, NULL),
	(207, 'NOTCH1', 1, 'http://www.ncbi.nlm.nih.gov/gene/4851', 4851, 'hN1; TAN1', 'Notch family.Notch family members play a role in a variety of developmental processes by controlling cell fate decisions.', 1, 62, 'NOTCH', '', 'Cell fate', 'Activated NOTCH1 Transmits Signal to the Nucleus Constitutive Signaling by NOTCH1 HD Domain Mutants  Notch Signaling Pathway  Signaling by NOTCH and NOTCH1', NULL, NULL, NULL, NULL, NULL),
	(208, 'NOTCH2', 1, 'http://www.ncbi.nlm.nih.gov/gene/4853', 4853, 'hN2; AGS2; HJCYS', 'Notch family.', 0, 0, 'NOTCH', 'Alagille syndrome, Hajdu-Cheney syndrome  ', 'Cell fate', 'Notch Signaling Pathway', 'Signaling by NOTCH2, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(209, 'NPM1', 1, 'http://www.ncbi.nlm.nih.gov/gene/4869', 4869, 'B23; NPM', 'phosphoprotein which moves between the nucleus and the cytoplasm.involved in several processes including regulation of the ARF/p53 pathway', 0, 0, '', 'myeloid leukemia. ', 'Cell survival', 'Cell Cycle, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(210, 'NRAS', 1, 'http://www.ncbi.nlm.nih.gov/gene/4893', 4893, 'NS6; ALPS4; N-ras; NRAS1', 'N-ras oncogene encoding a membrane protein. GTPase activity', 0, 0, '', 'somatic rectal cancer, follicular thyroid cancer, autoimmune lymphoproliferative syndrome, Noonan syndrome, and juvenile myelomonocytic leukemia', 'Cell survival', 'Axon guidance, organism-specific biosystem', 'MAPK signaling pathway, organism-specific biosystem', 'Signaling by EGFR, organism-specific biosystem', 'Signalling to RAS, organism-specific biosystem', NULL, NULL),
	(211, 'NSD1', 0, 'http://www.ncbi.nlm.nih.gov/gene/64324', 64324, 'STO; KMT3B; SOTOS; ARA267; SOTOS1', '', 0, NULL, NULL, ' Sotos syndrome and Weaver syndrome.Acute myeloid leukemia  Beckwith-Wiedemann syndrome  Sotos syndrome  Weaver syndrome ', '', 'Lysine degradation, organism-specific biosystem', 'Lysine degradation, conserved biosystem', NULL, NULL, NULL, NULL),
	(212, 'NTRK1', 0, 'http://www.ncbi.nlm.nih.gov/gene/4914', 4914, 'MTC; TRK; TRK1; TRKA; Trk-A; p140-TrkA', 'neurotrophic tyrosine kinase receptor (NTKR) family', 0, NULL, NULL, ' congenital insensitivity to pain, anhidrosis, self-mutilating behavior, mental retardation and cancer.Familial medullary thyroid carcinoma  Multiple Endocrine Neoplasia Type 2Go ', '', 'MAPK signaling pathway, organism-specific biosystem', 'NGF signalling via TRKA from the plasma membrane, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(213, 'NTRK3', 0, 'http://www.ncbi.nlm.nih.gov/gene/4916', 4916, 'TRKC; gp145(trkC)', 'neurotrophic tyrosine receptor kinase (NTRK) family', 0, NULL, NULL, 'medulloblastomas, secretory breast carcinomas and other cancers', '', 'BDNF signaling pathway, organism-specific biosystem', 'Neurotrophic factor-mediated Trk receptor signaling, organism-specific biosystem', 'Neurotrophin signaling pathway, organism-specific biosystem', 'Neurotrophin signaling pathway, conserved biosystem', NULL, NULL),
	(214, 'NUMA1', 0, 'http://www.ncbi.nlm.nih.gov/gene/4926', 4926, 'NUMA', '', 0, NULL, NULL, '', '', 'Caspase cascade in apoptosis', 'Cell Cycle, organism-specific biosystem', 'Mitotic G2-G2/M phases, organism-specific biosystem', 'Recruitment of NuMA to mitotic centrosomes, organism-specific biosystem', NULL, NULL),
	(215, 'NUP98', 0, 'http://www.ncbi.nlm.nih.gov/gene/4928', 4928, 'ADIR2; NUP96; NUP196', 'important tumor-suppressor ', 0, NULL, NULL, 'Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer', '', 'Cell Cycle, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(216, 'NUP214', 0, 'http://www.ncbi.nlm.nih.gov/gene/8021', 8021, 'CAN; CAIN; N214; D9S46E', 'The protein cytoplasmic member of the FG-repeat-containing nucleoporins', 0, NULL, NULL, ' acute myeloid leukemia and myelodysplastic syndrome', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(217, 'P2RY8', 0, 'http://www.ncbi.nlm.nih.gov/gene/286530', 286530, 'P2Y8', 'family of G-protein coupled receptors', 0, NULL, NULL, NULL, NULL, 'Neuroactive ligand-receptor interaction, organism-specific biosystem', 'Neuroactive ligand-receptor interaction, conserved biosystem', NULL, NULL, NULL, NULL),
	(218, 'PALB2', 3, 'http://www.ncbi.nlm.nih.gov/gene/79728', 79728, 'FANCN; PNCA3', 'a protein that may function in tumor suppression.This protein binds to and colocalizes with the breast cancer 2 early onset protein (BRCA2)', 0, 0, '', 'Familial cancer of breast Fanconi anemia, Pancreatic cancer 3 \r\nCancer predisposition  \r\n\r\n\r\n\r\n\r\n\r\n\r\nFamilial cancer of breast  \r\n\r\n\r\n\r\nMIM: 114480 \r\n\r\nGenetic Testing Registry \r\n\r\n\r\nSummary from GeneReviews: BRCA1 and BRCA2 Hereditary Breast/Ovarian CancerGo to GeneRevie', 'Genome maintenance', 'DNA Repair, organism-specific biosystem', 'Fanconi Anemia pathway, organism-specific biosystem', 'Fanconi anemia pathway, conserved biosystem', NULL, NULL, NULL),
	(219, 'PAX7', 0, 'http://www.ncbi.nlm.nih.gov/gene/5081', 5081, 'HUP1; RMS2; PAX7B', 'paired box (PAX) family of transcription factors.', 0, NULL, NULL, 'alveolar rhabdomyosarcoma', '', 'Neural Crest Differentiation, organism-specific biosystem', 'Transcriptional misregulation in cancer, organism-specific biosystem', 'miRs in Muscle Cell Differentiation, organism-specific biosystem', NULL, NULL, NULL),
	(220, 'PAX8', 0, 'http://www.ncbi.nlm.nih.gov/gene/7849', 7849, '', ' paired box (PAX) family of transcription factors', 0, NULL, NULL, 'thyroid dysgenesis, thyroid follicular carcinomas and atypical follicular thyroid adenomas', '', 'Thyroid cancer, organism-specific biosystem', 'TSH signaling pathway, organism-specific biosystem', 'Transcriptional misregulation in cancer, organism-specific biosystem', 'Id Signaling Pathway, organism-specific biosystem', NULL, NULL),
	(221, 'PBRM1', 1, 'http://www.ncbi.nlm.nih.gov/gene/55193', 55193, 'PB1; BAF180', 'subunit of ATP-dependent chromatin-remodeling complexes.', 0, 0, '', ' primary clear cell renal cell carcinoma', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(222, 'PCM1', 0, 'http://www.ncbi.nlm.nih.gov/gene/5108', 5108, 'PTC4', ' is a component of centriolar satellites', 0, NULL, NULL, ' papillary thyroid carcinomas and a variety of hematological malignancies, including atypical chronic myeloid leukemia and T-cell lymphoma', '', 'Cell Cycle, organism-specific biosystem', 'Centrosome maturation, organism-specific biosystem', 'Loss of proteins required for interphase microtubule organizationÂ from the centrosome', NULL, NULL, NULL),
	(223, 'PDCD1LG2', 0, 'http://www.ncbi.nlm.nih.gov/gene/80380', 80380, 'B7DC; Btdc; PDL2; CD273; PD-L2; PDCD1L2; bA574F11.2', '', 0, NULL, NULL, '', '', 'Adaptive Immune System, organism-specific biosystem', 'Cell adhesion molecules (CAMs), organism-specific biosystem', 'Costimulation by the CD28 family, organism-specific biosystem', 'PD-1 signaling, organism-specific biosystem', NULL, NULL),
	(224, 'PDE4DIP', 0, 'http://www.ncbi.nlm.nih.gov/gene/9659', 9659, 'MMGL; CMYA2', '', 0, NULL, NULL, 'myeloproliferative disorder (MBD) associated with eosinophilia.', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(225, 'PDGFRA', 1, 'http://www.ncbi.nlm.nih.gov/gene/5156', 5156, 'CD140A; PDGFR2; PDGFR-2; RHEPDGFRA', 'tyrosine kinase receptor for members of the platelet-derived growth factor family', 0, 0, 'PDGFR', 'idiopathic hypereosinophilic syndrome, somatic and familial gastrointestinal stromal tumors, and a variety of other cancers', 'Cell survival', 'PI3K-Akt signaling pathway, conserved biosystem', 'Signaling by EGFR, organism-specific biosystem', 'MAPK signaling pathway, organism-specific biosystem', 'Focal Adhesion, organism-specific biosystem', NULL, NULL),
	(226, 'PDGFRB', 0, 'http://www.ncbi.nlm.nih.gov/gene/5159', 5159, 'IBGC4; JTK12; PDGFR; CD140B; PDGFR1; PDGFR-1', 'cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family', 1, 0, 'PDGFR', 'leukemia gene, results in chronic myeloproliferative disorder with eosinophilia', '', 'MAPK signaling pathway, organism-specific biosystem', 'PI3K/AKT Signaling in Cancer, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(227, 'PER1', 0, 'http://www.ncbi.nlm.nih.gov/gene/5187', 5187, 'PER; hPER; RIGUI', 'components of the circadian rhythms of locomotor activity, metabolism, and behavior', 0, NULL, NULL, NULL, NULL, 'Circadian rhythm pathway, organism-specific biosystem', 'Circadian entrainment, conserved biosystem', 'Circadian Clock, organism-specific biosystem', NULL, NULL, NULL),
	(228, 'PHF6', 1, 'http://www.ncbi.nlm.nih.gov/gene/84295', 84295, 'BFLS; BORJ; CENP-31', ' plant homeodomain (PHD)-like finger (PHF) family', 0, 0, '', ' Borjeson-Forssman-Lehmann syndrome (BFLS),', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(229, 'PHOX2B', 0, 'http://www.ncbi.nlm.nih.gov/gene/8929', 8929, 'PMX2B; NBLST2; NBPhox', ' paired family of homeobox proteins localized to the nucleus', 0, 0, '', 'Congenital central hypoventilation ,Neuroblastoma 2 ', '', 'SIDS Susceptibility Pathways, organism-specific biosystem', 'Neural Crest Differentiation, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(230, 'PIK3CA', 1, 'http://www.ncbi.nlm.nih.gov/gene/5290', 5290, 'MCM; CWS5; MCAP; PI3K; CLOVE; MCMTC; p110-alpha', 'The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2', 1, 78, 'PIK3', 'cervical cancers, Cowden disease, Epidermal nevus  Familial cancer of breast  Neoplasm of stomach \r\nFamilial colorectal cancer Hereditary diffuse gastric cancer Keratosis, seborrheic Liver cancer  Lung cancer Megalencephaly cutis marmorata telangiectatica ', 'Cell survival', 'AMPK signaling, organism-specific biosystem', 'Apoptosis, organism-specific biosystem', 'Focal Adhesion, organism-specific biosystem', 'IL2 signaling events mediated by PI3K, organism-specific biosystem', NULL, NULL),
	(231, 'PIK3R1', 1, 'http://www.ncbi.nlm.nih.gov/gene/5295', 5295, 'p85; GRB1; p85-ALPHA', 'encodes the regulatory subunit', 0, 0, '', ' insulin resistance', 'Cell survival', 'Insulin Pathway, organism-specific biosystem', 'Insulin signaling pathway, organism-specific biosystem', 'PI3K Cascade, organism-specific biosystem', 'Phosphatidylinositol signaling system, organism-specific biosystem', NULL, NULL),
	(232, 'PIM1', 0, 'http://www.ncbi.nlm.nih.gov/gene/5292', 5292, 'PIM', 'Ser/Thr protein kinase family, and PIM subfamily', 0, NULL, NULL, NULL, NULL, 'Jak-STAT signaling pathway, organism-specific biosystem', 'C-MYB transcription factor network, organism-specific biosystem', 'Validated targets of C-MYC transcriptional activation, organism-specific biosystem', NULL, NULL, NULL),
	(233, 'PLAG1', 0, 'http://www.ncbi.nlm.nih.gov/gene/5324', 5324, 'PSA; SGPA; ZNF912', ' a zinc finger protein with 2 putative nuclear localization signals', 0, NULL, NULL, 'Pleomorphic adenoma of salivary gland ', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(234, 'PMS1', 3, 'http://www.ncbi.nlm.nih.gov/gene/5378', 5378, 'PMSL1; hPMS1; HNPCC3', 'DNA mismatch repair mutL/hexB family,  involved in the repair of DNA mismatches, and it can form heterodimers with MLH1, a known DNA mismatch repair protein', 0, 0, '', ' nonpolyposis colorectal cancer type 3 (HNPCC3) either alone or in combination with mutations in other genes involved in the HNPCC phenotype, which is also known as Lynch syndrome.', 'Genome', NULL, NULL, NULL, NULL, NULL, NULL),
	(235, 'PMS2', 3, 'http://www.ncbi.nlm.nih.gov/gene/5395', 5395, 'PMSL2; HNPCC4; PMS2CL', 'PMS2 gene family', 0, 0, '', 'nonpolyposis colorectal cancer, Turcot syndrome, and are a cause of supratentorial primitive neuroectodermal tumors', 'Genome maintenance', 'BRCA1-associated genome surveillance complex (BASC), organism-specific biosystem', 'Direct p53 effectors, organism-specific biosystem', 'Mismatch repair, organism-specific biosystem', NULL, NULL, NULL),
	(236, 'PPARG', 0, 'http://www.ncbi.nlm.nih.gov/gene/5468', 5468, 'GLM1; CIMT1; NR1C3; PPARG1; PPARG2; PPARgamma', 'peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors', 0, NULL, NULL, 'obesity, diabetes, atherosclerosis and cancer', '', 'PPAR signaling pathway, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(237, 'PPP2R1A', 1, 'http://www.ncbi.nlm.nih.gov/gene/5518', 5518, 'PR65A; PP2AAALPHA; PP2A-Aalpha', 'constant regulatory subunit of protein phosphatase 2.  it is implicated in the negative control of cell growth and division', 0, 0, '', '', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(238, 'PRDM1', 1, 'http://www.ncbi.nlm.nih.gov/gene/639', 639, 'BLIMP1; PRDI-BF1', 'a protein that acts as a repressor of beta-interferon gene expression. binds specifically to the PRDI (positive regulatory domain I element) of the beta-IFN gene promoter', 0, 0, '', '', 'Cell fate', 'Direct p53 effectors, organism-specific biosystem', 'NOD pathway, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(239, 'PRDM16', 0, 'http://www.ncbi.nlm.nih.gov/gene/63976', 63976, 'MEL1; PFM13', NULL, 0, NULL, NULL, 'myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)', NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(240, 'PRDF1', 0, 'http://www.ncbi.nlm.nih.gov/gene/7500509', 7500509, NULL, NULL, 0, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(241, 'PRKAR1A', 3, 'http://www.ncbi.nlm.nih.gov/gene/5573', 5573, 'CAR; CNC; CNC1; PKR1; TSE1; ADOHR; PPNAD1; PRKAR1; ACRDYS1', 'protein kinase, cAMP-dependent. ', 0, 0, '', 'Carney complex (CNC).', 'Cell survival/fate', 'PKA activation, organism-specific biosystem', 'Phospholipase C-mediated cascade, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(242, 'PTCH1', 1, 'http://www.ncbi.nlm.nih.gov/gene/5727', 5727, 'PTC; BCNS; HPE7; PTC1; PTCH; NBCCS; PTCH11', 'patched gene family', 0, 0, '', 'basal cell nevus syndrome, esophageal squamous cell carcinoma, trichoepitheliomas, transitional cell carcinomas of the bladder, as well as holoprosencephaly', 'Cell fate', 'Hedgehog Signaling Pathway, organism-specific biosystem', 'Pathways in cancer, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(243, 'PTEN', 1, 'http://www.ncbi.nlm.nih.gov/gene/5728', 5728, 'BZS; DEC; CWS1; GLM2; MHAM; TEP1; MMAC1; PTEN1; 10q23del', 'a tumor suppressor by negatively regulating AKT/PKB signaling pathway', 0, 0, '', 'Bannayan-Riley-Ruvalcaba syndrome, Cowden syndrome  Cutaneous malignant melanoma 1  Endometrial carcinomaMacrocephaly/autism syndrome Malignant tumor of prostate Meningioma, familial  \r\nPTEN hamartoma tumor syndrome  Squamous cell carcinoma of the head and', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(244, 'PTPN11', 1, 'http://www.ncbi.nlm.nih.gov/gene/5781', 5781, 'CFC; NS1; SHP2; BPTP3; PTP2C; PTP-1D; SH-PTP2; SH-PTP3', 'protein tyrosine phosphatase (PTP) family', 0, 0, '', ' Noonan syndrome as well as acute myeloid leukemia', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(245, 'RABEP1', 0, 'http://www.ncbi.nlm.nih.gov/gene/9135', 9135, 'RAB5EP; RABPT5', NULL, 0, NULL, NULL, NULL, NULL, 'Endocytosis, organism-specific biosystem', 'Endocytosis, conserved biosystem', NULL, NULL, NULL, NULL),
	(246, 'RAD51B', 0, 'http://www.ncbi.nlm.nih.gov/gene/5890', 5890, 'REC2; R51H2; RAD51L1', 'RAD51 protein family', 0, NULL, NULL, 'breast cancer ,primary biliary cirrhosis', '', 'Hemostasis, organism-specific biosystem', 'Homologous recombination, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(247, 'RAF1', 0, 'http://www.ncbi.nlm.nih.gov/gene/5894', 5894, 'NS5; CRAF; Raf-1; c-Raf', 'MAP kinase kinase kinase (MAP3K),', 0, NULL, NULL, 'Noonan syndrome 5 and LEOPARD syndrome 2', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(248, 'RB1', 1, 'http://www.ncbi.nlm.nih.gov/gene/5925', 5925, 'RB; pRb; OSRC; pp110; p105-Rb', 'negative regulator of the cell cycle', 0, 0, '', 'childhood cancer retinoblastoma (RB), bladder cancer, and osteogenic sarcoma,Small cell cancer of the lung', 'Cell survival', 'Cell Cycle, organism-specific biosystem', 'Regulation of retinoblastoma protein, organism-specific biosystem', 'E2F mediated regulation of DNA replication, organism-specific biosystem', 'E2F transcription factor network, organism-specific biosystem', NULL, NULL),
	(249, 'REL', 0, 'http://www.ncbi.nlm.nih.gov/gene/5966', 5966, 'C-Rel', ' Rel/NFKB family,transcription factor', 0, NULL, NULL, 'psoriasis ,Hodgkins lymphoma, Ashkenazi Jewish Crohns disease ,ulcerative colitis ,rheumatoid arthritis', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(250, 'RET', 1, 'http://www.ncbi.nlm.nih.gov/gene/5979', 5979, 'PTC; MTC1; HSCR1; MEN2A; MEN2B; RET51; CDHF12; CDHR16; RET-ELE1', 'cadherin superfamily', 0, 0, 'RET', 'disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma', 'Cell survival', 'Signaling events regulated by Ret tyrosine kinase, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(251, 'RNF213', 1, 'http://www.ncbi.nlm.nih.gov/gene/57674', 57674, 'ALO17; MYMY2; MYSTR; NET57; C17orf27; KIAA1618', ' a protein containing a C3HC4-type RING finger domain, ATPase activity', 0, 0, '', ' anaplastic large cell lymphoma and inflammatory myofibroblastic tumor cases', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(252, 'ROS1', 0, 'http://www.ncbi.nlm.nih.gov/gene/6098', 6098, 'ROS; MCF3; c-ros-1', 'the sevenless subfamily of tyrosine kinase insulin receptor genes, is a type I integral membrane protein with tyrosine kinase activity.', 0, NULL, NULL, '', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(253, 'RPN1', 0, 'http://www.ncbi.nlm.nih.gov/gene/6184', 6184, 'OST1; RBPH1', ' a type I integral membrane protein ,is part of an N-oligosaccharyl transferase complex', 0, NULL, NULL, '', '', 'Protein processing in endoplasmic reticulum, organism-specific biosystem', 'Oligosaccharyltransferase, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(254, 'RUNX1', 1, 'http://www.ncbi.nlm.nih.gov/gene/861', 861, 'AML1; CBFA2; EVI-1; AMLCR1; PEBP2aB; AML1-EVI-1', ' heterodimeric transcription factor ,alpha subunit of CBF ', 0, 0, '', ' several types of leukemia', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(255, 'RUNX1T1', 0, 'http://www.ncbi.nlm.nih.gov/gene/862', 862, 'CDR; ETO; MTG8; AML1T1; ZMYND2; CBFA2T1', ' myeloid translocation gene family', 0, NULL, NULL, 'myeloid leukemia', '', 'Transcriptional misregulation in cancer, conserved biosystem', 'Pathways in cancer, organism-specific biosystem', 'Acute myeloid leukemia, organism-specific biosystem', NULL, NULL, NULL),
	(256, 'SDC4', 0, 'http://www.ncbi.nlm.nih.gov/gene/6385', 6385, 'SYND4', 'transmembrane (type I) heparan sulfate proteoglycan,receptor in intracellular signaling', 0, NULL, NULL, NULL, NULL, 'Mucopolysaccharidoses, organism-specific biosystem', 'ECM-receptor interaction, organism-specific biosystem', 'Cell adhesion molecules (CAMs), organism-specific biosystem', NULL, NULL, NULL),
	(257, 'SEPT.9', 0, 'http://www.ncbi.nlm.nih.gov/gene/10801', 10801, 'MSF; MSF1; NAPB; SINT1; PNUTL4; SeptD1; AF17q25', 'septin family,involved in cytokinesis and cell cycle control', 0, NULL, NULL, 'myelomonocytic leukemia,hereditary neuralgic amyotrophy,neuritis with brachial predilection', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(258, 'SETD2', 0, 'http://www.ncbi.nlm.nih.gov/gene/29072', 29072, 'HYPB; SET2; HIF-1; HIP-1; KMT3A; HBP231; HSPC069; p231HBP', 'histone methyltransferase', 0, NULL, NULL, 'Huntingtons disease (HD)', '', 'Lysine degradation, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(259, 'SETD2_ENST00000409792', 0, 'NOT DATA FOUND', 0, NULL, NULL, 0, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(260, 'SF3B1', 1, 'http://www.ncbi.nlm.nih.gov/gene/23451', 23451, 'MDS; PRP10; Hsh155; PRPF10; SAP155; SF3b155', 'subunit 1 of the splicing factor 3b protein complex.', 0, 0, '', 'Myelodysplastic syndrome', 'Cell fate', 'mRNA Splicing - Major Pathway, organism-specific biosystem', 'mRNA Splicing - Minor Pathway, organism-specific biosystem', 'Spliceosome, organism-specific biosystem', NULL, NULL, NULL),
	(261, 'SH3GL1', 0, 'http://www.ncbi.nlm.nih.gov/gene/6455', 6455, 'EEN; CNSA1; SH3P8; SH3D2B', ' endophilin family of Src', 0, NULL, NULL, 'acute myeloid leukemia ', '', 'Signaling events mediated by focal adhesion kinase, organism-specific biosystem (from', 'Endocytosis, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(262, 'SLC34A2', 0, 'http://www.ncbi.nlm.nih.gov/gene/10568', 10568, 'NPTIIb; NAPI-3B; NAPI-IIb', ' is a pH-sensitive sodium-dependent phosphate transporter.', 0, NULL, NULL, ' pulmonary alveolar microlithiasis', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(263, 'SLC45A3', 0, 'http://www.ncbi.nlm.nih.gov/gene/85414', 85414, 'PRST; IPCA6; IPCA-2; IPCA-6; IPCA-8; PCANAP2; PCANAP6; PCANAP8', '', 0, NULL, NULL, 'genetic risk factors for Parkinsons disease', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(264, 'SMAD4', 1, 'http://www.ncbi.nlm.nih.gov/gene/4089', 4089, 'JIP; DPC4; MADH4; MYHRS', 'Smad family of signal transduction proteins', 0, 0, '', 'pancreatic cancer, juvenile polyposis syndrome, and hereditary hemorrhagic telangiectasia syndrome', 'Cell survival', 'TGF-beta receptor signaling activates SMADs, organism-specific biosystem', 'TGF Beta Signaling Pathway, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(265, 'SMARCA4', 1, 'http://www.ncbi.nlm.nih.gov/gene/6597', 6597, 'BRG1; SNF2; SWI2; MRD16; RTPS2; BAF190; SNF2L4; SNF2LB; hSNF2b; BAF190A', 'member of the SWI/SNF family, helicase and ATPase activities ,can bind BRCA1, as well as regulate the expression of the tumorigenic protein CD44. ', 0, 0, '', 'rhabdoid tumor predisposition syndrome type 2, Mental retardation,coronary artery disease', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(266, 'SMARCB1', 1, 'http://www.ncbi.nlm.nih.gov/gene/6598', 6598, 'RDT; INI1; SNF5; Snr1; BAF47; MRD15; RTPS1; Sfh1p; hSNFS; SNF5L1', 'tumor suppressor.The protein  is part of a complex that relieves repressive chromatin structures', 0, 0, '', 'Mental retardation,Rhabdoid tumor predisposition syndrome', 'Cell fate', 'TNF-alpha/NF-kB Signaling Pathway, organism-specific biosystem', 'Regulation of retinoblastoma protein, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(267, 'SMO', 1, 'http://www.ncbi.nlm.nih.gov/gene/6608', 6608, 'Gx; SMOH; FZD11', ' G protein-coupled receptor. The encoded protein tranduces signals to other proteins after activation by a hedgehog protein/patched protein complex', 0, 0, 'smo', '', 'Cell fate', 'Hedgehog Signaling Pathway, organism-specific biosystem', 'Hedgehog signaling pathway, conserved biosystem', NULL, NULL, NULL, NULL),
	(268, 'SOCS1', 1, 'http://www.ncbi.nlm.nih.gov/gene/8651', 8651, 'JAB; CIS1; SSI1; TIP3; CISH1; SSI-1; SOCS-1', 'STAT-induced STAT inhibitor (SSI),The protein encoded by this gene functions downstream of cytokine receptors, and takes part in a negative feedback loop to attenuate cytokine signaling', 0, 0, '', '', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(269, 'SPECC1', 0, 'http://www.ncbi.nlm.nih.gov/gene/92521', 92521, 'NSP; CYTSB; HCMOGT1; HCMOGT-1', 'cytospin-A family.', 0, NULL, NULL, 'juvenile myelomonocytic leukemia', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(270, 'SRGAP3', 0, 'http://www.ncbi.nlm.nih.gov/gene/9901', 9901, 'WRP; MEGAP; SRGAP2; ARHGAP14', '', 0, NULL, NULL, '', '', 'Axon guidance, organism-specific biosystem', 'Signaling by Robo receptor, organism-specific biosystem', 'Signaling by Rho GTPases, organism-specific biosystem', NULL, NULL, NULL),
	(271, 'SRSF2', 1, 'http://www.ncbi.nlm.nih.gov/gene/6427', 6427, 'SC35; PR264; SC-35; SFRS2; SFRS2A; SRp30b', 'serine/arginine (SR)-rich family of pre-mRNA splicing factors', 0, 0, '', '', 'Cell fate', 'mRNA processing, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(272, 'SRSF3', 0, 'http://www.ncbi.nlm.nih.gov/gene/6428', 6428, 'SFRS3; SRp20', '', 0, NULL, NULL, '', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(273, 'STAT3', 0, 'http://www.ncbi.nlm.nih.gov/gene/6774', 6774, 'APRF; HIES', 'STAT protein family', 0, NULL, NULL, 'Hyperimmunoglobulin E syndrome,multiple sclerosis,Crohns disease', '', 'EGF receptor (ErbB1) signaling pathway, organism-specific biosystem', 'Jak-STAT signaling pathway, organism-specific biosystem', 'Signalling to STAT3, organism-specific biosystem', NULL, NULL, NULL),
	(274, 'STIL', 0, 'http://www.ncbi.nlm.nih.gov/gene/6491', 6491, 'SIL; MCPH7', 'cytoplasmic protein.It is proposed to regulate Cdc2 kinase activity during spindle checkpoint arrest', 0, NULL, NULL, 'T cell leukemias', NULL, 'Signaling events mediated by the Hedgehog family, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(275, 'STK11', 1, 'http://www.ncbi.nlm.nih.gov/gene/6794', 6794, 'PJS; LKB1; hLKB1', 'serine/threonine kinase family', 0, 0, '', ' Peutz-Jeghers syndrom,Genome-wide association study of Alzheimers disease with psychotic symptoms', 'Cell survival', 'AMPK signaling, organism-specific biosystem', 'PI3K-Akt signaling pathway, organism-specific biosystem', 'mTOR signaling pathway, organism-specific biosystem', NULL, NULL, NULL),
	(276, 'SUFU', 3, 'http://www.ncbi.nlm.nih.gov/gene/51684', 51684, 'SUFUH; SUFUXL; PRO1280', 'negative regulator of the hedgehog signaling pathway', 0, 0, '', 'medulloblastoma,Meningioma, familial', 'Cell fate', 'Hedgehog signaling pathway, organism-specific biosystem', 'Hedgehog signaling events mediated by Gli proteins, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(277, 'SUZ12', 0, 'http://www.ncbi.nlm.nih.gov/gene/23512', 23512, 'CHET9; JJAZ1', ' zinc finger domain in the C terminus of the coding region', 0, NULL, NULL, 'endometrial stromal sarcoma', NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(278, 'SYK', 0, 'http://www.ncbi.nlm.nih.gov/gene/6850', 6850, 'p72-Syk', 'non-receptor type Tyr protein kinases,modulator of epithelial cell growth and a potential tumour suppressor in human breast carcinomas', 0, NULL, NULL, 'prostate cancer,multiple sclerosis', '', 'PI3K-Akt signaling pathway, conserved biosystem', 'Signaling by Interleukins, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(279, 'TCF3', 0, 'http://www.ncbi.nlm.nih.gov/gene/6929', 6929, 'E2A; E47; ITF1; VDIR; TCF-3; bHLHb21', 'E protein (class I) family of helix-loop-helix transcription factors', 0, NULL, NULL, 'lymphoid malignancies', '', 'Transcriptional misregulation in cancer, organism-specific biosystem', 'p38 signaling mediated by MAPKAP kinases, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(280, 'TCF12', 0, 'http://www.ncbi.nlm.nih.gov/gene/6938', 6938, 'HEB; HTF4; bHLHb20; HsT17266', 'member of the basic helix-loop-helix (bHLH) E-protein family that recognizes the consensus binding site (E-box) CANNTG', 0, NULL, NULL, NULL, NULL, 'CDO in myogenesis, organism-specific biosystem', 'Developmental Biology, organism-specific biosystem', 'Id Signaling Pathway, organism-specific biosystem', 'Myogenesis, organism-specific biosystem', NULL, NULL),
	(281, 'TCF7L2', 0, 'http://www.ncbi.nlm.nih.gov/gene/6934', 6934, 'TCF4; TCF-4', 'high mobility group (HMG) box-containing transcription factor that plays a key role in the Wnt signaling pathway. ', 0, NULL, NULL, 'type 2 diabetes.', '', 'Wnt signaling pathway, organism-specific biosystem', 'Regulation of Wnt-mediated beta catenin signaling and target gene transcription, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(282, 'TET1', 0, 'http://www.ncbi.nlm.nih.gov/gene/80312', 80312, 'LCX; CXXC6; bA119F7.1', '', 0, NULL, NULL, '', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(283, 'TET2', 1, 'http://www.ncbi.nlm.nih.gov/gene/54790', 54790, 'MDS; KIAA1546', 'methylcytosine dioxygenase is involved in myelopoiesis', 0, 0, '', 'several myeloproliferative disorders, Myelodysplastic syndrome', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(284, 'TFG', 0, 'http://www.ncbi.nlm.nih.gov/gene/10342', 10342, 'TF6; HMSNP; SPG57; TRKT3', 'fusion oncoproteins ', 0, NULL, NULL, 'lymphoma and mixoid chondrosarcoma', '', 'Pathways in cancer, organism-specific biosystem', 'Thyroid cancer, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(285, 'THRAP3', 0, 'http://www.ncbi.nlm.nih.gov/gene/9967', 9967, 'TRAP150', NULL, 0, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(286, 'TNFAIP3', 0, 'http://www.ncbi.nlm.nih.gov/gene/7128', 7128, 'A20; OTUD7C; TNFA1P2', 'protein and ubiqitin-editing enzyme, and has been shown to inhibit NF-kappa B activation as well as TNF-mediated apoptosis.tumor necrosis factor (TNF)', 0, NULL, NULL, 'psoriasis,rheumatoid arthritis systemic lupus erythematosus', '', 'TNF-alpha/NF-kB Signaling Pathway, organism-specific biosystem', 'TNF receptor signaling pathway, organism-specific biosystem', 'NOD-like receptor signaling pathway, organism-specific biosystem', NULL, NULL, NULL),
	(287, 'TOP1', 0, 'http://www.ncbi.nlm.nih.gov/gene/7150', 7150, 'TOPI', 'DNA topoisomerase,an enzyme that controls and alters the topologic states of DNA during transcription.', 0, NULL, NULL, '', '', 'Caspase cascade in apoptosis, organism-specific biosystem', 'Integrated Pancreatic Cancer Pathway, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(288, 'TP53', 1, 'http://www.ncbi.nlm.nih.gov/gene/7157', 7157, 'P53; BCC7; LFS1; TRP53', ' a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains', 0, 0, '', 'variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome.', 'Cell survival', 'AMPK signaling, organism-specific biosystem', 'Apoptosis, organism-specific biosystem', 'Aurora A signaling, organism-specific biosystem', 'Cell Cycle Checkpoints, organism-specific biosystem', NULL, 'MAPK signaling pathway, organism-specific biosystem'),
	(289, 'TPR', 0, 'http://www.ncbi.nlm.nih.gov/gene/7175', 7175, '', 'large coiled-coil protein ', 0, NULL, NULL, 'neoplasias', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(290, 'TRIM24', 0, 'http://www.ncbi.nlm.nih.gov/gene/8805', 8805, 'PTC6; TF1A; TIF1; RNF82; TIF1A; hTIF1; TIF1ALPHA', 'member of the tripartite motif (TRIM) family', 0, NULL, NULL, 'Papillary thyroid carcinoma', '', 'Signaling by FGFR in disease, organism-specific biosystem', 'Signaling by FGFR mutants, organism-specific biosystem', 'Signaling by FGFR1 fusion mutants, organism-specific biosystem', NULL, NULL, NULL),
	(291, 'TRIM33', 0, 'http://www.ncbi.nlm.nih.gov/gene/51592', 51592, 'ECTO; PTC7; RFG7; TF1G; TIF1G; TIFGAMMA; TIF1GAMMA', 'a transcriptional corepressor,is a member of the tripartite motif family', 0, NULL, NULL, 'Papillary thyroid carcinoma', '', 'Downregulation of SMAD2/3:SMAD4 transcriptional activity, organism-specific biosystem', 'Generic Transcription Pathway, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(292, 'TRIP11', 0, 'http://www.ncbi.nlm.nih.gov/gene/9321', 9321, 'ACG1A; CEV14; TRIP-11; TRIP230; GMAP-210', NULL, 0, NULL, NULL, 'achondrogenesis type IA', NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(293, 'TSC1', 1, 'http://www.ncbi.nlm.nih.gov/gene/7248', 7248, 'LAM; TSC', 'growth inhibitory protein ', 0, 0, '', 'tuberous sclerosis,Focal cortical dysplasia of Taylor,Lymphangiomyomatosis  ,Tuberous sclerosis', 'Cell survival', 'IGF1R signaling cascade, organism-specific biosystem', 'Insulin Signaling, organism-specific biosystem', 'PI3K-Akt signaling pathway, organism-specific biosystem', 'mTOR signaling pathway, organism-specific biosystem', NULL, 'Signaling by Insulin receptor'),
	(294, 'TSC2', 3, 'http://www.ncbi.nlm.nih.gov/gene/7249', 7249, 'LAM; TSC4', ' tumor suppressor and is able to stimulate specific GTPases', 0, 0, '', 'tuberous sclerosis,Lymphangiomyomatosis', 'Cell survival', 'Insulin signaling pathway, organism-specific biosystem', 'PI3K-Akt signaling pathway, conserved biosystem', 'Constitutive PI3K/AKT Signaling in Cancer, organism-specific biosystem', 'p53 signaling pathway, organism-specific biosystem', NULL, 'mTOR signaling pathway, organism-specific biosystem'),
	(295, 'TSHR', 1, 'http://www.ncbi.nlm.nih.gov/gene/7253', 7253, 'LGR3; CHNG1; hTSHR-I', ' is a receptor for thyrothropin and thyrostimulin, and its activity is mediated by adenylate cyclase', 0, 0, '', 'Hyperthyroidism, familial gestational  ,Graves disease', 'Cell survival', 'GPCR ligand binding, organism-specific biosystem', 'Signaling by GPCR, organism-specific biosystem', 'Neuroactive ligand-receptor interaction, organism-specific biosystem', 'Signaling by GPCR', NULL, NULL),
	(296, 'TTL6_ENST00000393382', 0, 'NOT DATA FOUND', 0, NULL, NULL, 0, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL, NULL),
	(297, 'U2AF1', 1, 'http://www.ncbi.nlm.nih.gov/gene/7307', 7307, 'RN; FP793; U2AF35; U2AFBP; RNU2AF1', 'SR family of genes,is a non-snRNP protein required for the binding of U2 snRNP to the pre-mRNA branch site.', 0, 0, '', '', 'Cell fate', 'RNA Polymerase II Transcription, organism-specific biosystem', 'RNA Polymerase II Transcription Termination, organism-specific biosystem', 'Spliceosome, organism-specific biosystem', 'mRNA processing, organism-specific biosystem', NULL, NULL),
	(298, 'USP6', 0, 'http://www.ncbi.nlm.nih.gov/gene/9098', 9098, 'HRP1; TRE2; TRE17; Tre-2; USP6-short', 'ubiquitin specific peptidase 6', 0, NULL, NULL, '', '', 'Arf6 signaling events, organism-specific biosystem', NULL, NULL, NULL, NULL, NULL),
	(299, 'VHL', 1, 'http://www.ncbi.nlm.nih.gov/gene/7428', 7428, 'RCA1; VHL1; pVHL; HRCA1', 'von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase', 0, 0, '', 'Von Hippel-Lindau syndrome (VHL),Pheochromocytoma,Renal cell carcinoma, nonpapillary ', 'Cell survival', 'HIF-1 signaling pathway, organism-specific biosystem', 'Hypoxic and oxygen homeostasis regulation of HIF-1-alpha, organism-specific biosystem', 'Regulation of Hypoxia-inducible Factor (HIF) by Oxygen, organism-specific biosystem', 'Signaling events mediated by VEGFR1 and VEGFR2, organism-specific biosystem', NULL, NULL),
	(300, 'WAS', 3, 'DATA NOT FOUND', 7454, 'THC; IMD2; SCNX; THC1; WASP', 'cytoplasmic protein', 0, 0, '', 'Wiskott-Aldrich syndrome', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(301, 'WHSC1', 0, 'http://www.ncbi.nlm.nih.gov/gene/7468', 7468, 'WHS; NSD2; TRX5; MMSET; REIIBP', 'protein that contains four domains present in other developmental proteins: a PWWP domain, an HMG box, a SET domain, and a PHD-type zinc finger', 0, NULL, NULL, 'Wolf-Hirschhorn syndrome (WHS)  and multiple myelomas', '', 'Transcriptional misregulation in cancer, organism-specific biosystem', 'Lysine degradation, conserved biosystem', NULL, NULL, NULL, NULL),
	(302, 'WHSC1L1', 0, 'http://www.ncbi.nlm.nih.gov/gene/54904', 54904, 'NSD3; pp14328', 'a protein with PWWP (proline-tryptophan-tryptophan-proline) domains', 0, NULL, NULL, ' Wolf-Hirschhorn syndrome,Acute myeloid leukemia,risk of schizophrenia', '', 'Lysine degradation, conserved biosystem', NULL, NULL, NULL, NULL, NULL),
	(303, 'WRN', 3, 'http://www.ncbi.nlm.nih.gov/gene/7486', 7486, 'RECQ3; RECQL2; RECQL3', 'subfamily of DNA and RNA helicases', 0, 0, '', 'Werner syndrome', 'Genome maintenance', 'Regulation of Telomerase, organism-specific biosystem', 'Integrated Pancreatic Cancer Pathway, organism-specific biosystem', NULL, NULL, NULL, NULL),
	(304, 'WT1', 1, 'http://www.ncbi.nlm.nih.gov/gene/7490', 7490, 'GUD; AWT1; WAGR; WT33; NPHS4; WIT-2; EWS-WT1', ' transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus', 0, 0, '', ' Wilms tumors,Mesothelioma, malignant,Meacham syndrome,Frasier syndrome,Drash syndrome,Diffuse mesangial sclerosis,Congenital aniridia,11p partial monosomy syndrome', 'Cell fate', 'Transcriptional misregulation in cancer, conserved biosystem', 'Regulation of Telomerase, organism-specific biosystem', 'Integrated Pancreatic Cancer Pathway, organism-specific biosystem', NULL, NULL, NULL),
	(305, 'WWTR1', 0, 'http://www.ncbi.nlm.nih.gov/gene/25937', 25937, 'TAZ', 'is a widely used alternative name for the transcriptional coactivator with PDZ-binding motif (WWTR1) conflicting with the official symbol for tafazzin (TAZ). ', 0, NULL, NULL, '', '', 'YAP1- and WWTR1 (TAZ)-stimulated gene expression, organism-specific biosystem', 'Signaling by TGF-beta Receptor Complex, organism-specific biosystem', 'Signal Transduction, organism-specific biosystem (from REACTOME)', 'Signaling by Hippo, organism-specific biosystem', NULL, NULL),
	(306, 'XPO1', 0, 'http://www.ncbi.nlm.nih.gov/gene/7514', 7514, 'emb; CRM1; exp1', 'inhibits the nuclear export of Rev and U snRNAs. It is involved in the control of several cellular processes by controlling the localization of cyclin B, MPAK, and MAPKAP kinase 2. This protein also regulates NFAT and AP-1', 0, NULL, NULL, '', '', 'Cell Cycle, organism-specific biosystem', 'Hedgehog signaling events mediated by Gli proteins, organism-specific biosystem', 'TGF-beta receptor signaling activates SMADs, organism-specific biosystem', 'Rev-mediated nuclear export of HIV-1 RNA, organism-specific biosystem', NULL, NULL),
	(307, 'YWHAE', 0, 'http://www.ncbi.nlm.nih.gov/gene/7531', 7531, 'MDS; MDCR; KCIP-1; 14-3-3E', '14-3-3 family of proteins', 0, NULL, NULL, ' pathogenesis of small cell lung cancer', '', 'Cell cycle, organism-specific biosystem', 'Apoptosis, organism-specific biosystem', 'Hippo signaling pathway, organism-specific biosystem', 'PI3K-Akt signaling pathway, organism-specific biosystem', NULL, 'p38 signaling mediated by MAPKAP kinases, organism-specific biosystem'),
	(308, 'ZNF521', 0, 'http://www.ncbi.nlm.nih.gov/gene/25925', 25925, 'EHZF; Evi3', 'zinc finger protein 521provided ', 0, NULL, NULL, '', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(309, 'ZRSR2', 0, 'http://www.ncbi.nlm.nih.gov/gene/8233', 8233, 'URP; U2AF1L2; U2AF1RS2; U2AF1-RS2', 'essential splicing factor', 0, NULL, NULL, '', '', NULL, NULL, NULL, NULL, NULL, NULL),
	(310, 'AR', 1, NULL, 367, 'KD; AIS; TFM; DHTR; SBMA; HYSP1; NR3C4; SMAX1; HUMARA', 'androgen receptor\r\nCELL FATE', 0, 0, '', 'Androgen resistance syndrome,Malignant tumor of prostate,Reifenstein syndrome,\r\nX-linked hypospadias 1  \r\n\r\n\r\n  \r\n\r\n\r\n\r\n\r\n\r\n\r\n', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(311, 'ARID1B', 1, NULL, 57492, 'OSA2; 6A3-5; DAN15; MRD12; P250R; BRIGHT; BAF250B; ELD/OSA1', 'AT-rich DNA interacting domain-containing protein\r\nCELL FATE', 0, 0, '', 'Mental retardation, autosomal dominant 12\r\n', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(312, 'B2M', 1, NULL, 567, 'beta-2-microglobulin', 'serum protein found in association with the major histocompatibility complex\r\nCELL SURVIVAL', 0, 0, '', 'hypercatabolic hypoproteinemia\r\n', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(313, 'BCL2', 1, NULL, 596, 'Bcl-2; PPP1R50\r\n', ' integral outer mitochondrial membrane protein that blocks the apoptotic death of some cells such as lymphocytes\r\n', 0, 0, '', 'follicular lymphoma\r\n', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(314, 'BMPR1A', 3, NULL, 657, 'ALK3; SKR5; CD292; ACVRLK3; 10q23del\r\n', 'bone morphogenetic protein receptor, type IA.family of transmembrane serine/threonine kinases\r\nCELL SURVIVAL', 0, 0, '', 'Juvenile polyposis\r\n', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(315, 'CASP8', 1, NULL, 841, 'CAP4; MACH; MCH5; FLICE; ALPS2B; Casp-8\r\n', 'cysteine-aspartic acid protease (caspase) family\r\n', 0, 0, '', 'Familial cancer of breast,Liver cancer,Lung cancer\r\n', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(316, 'CRLF2', 1, NULL, 64109, 'CRL2; TSLPR; CRLF2Y', 'cytokine receptor-like factor 2.a receptor for thymic stromal lymphopoietin (TSLP). ', 0, 0, '', '', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(317, 'DNMT1', 1, NULL, 1786, 'AIM; DNMT; MCMT; CXXC9; HSN1E', 'DNA (cytosine-5-)-methyltransferase 1', 0, 0, '', 'NEUROPATHY, HEREDITARY SENSORY, TYPE IE ', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(318, 'EXT2', 3, NULL, 2132, 'SOTV\r\n', 'glycosyltransferases\r\n', 0, 0, '', 'Multiple Exostoses Type 2\r\n', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(319, 'FANCC', 3, NULL, 2176, 'FA3; FAC; FACC', 'The Fanconi anemia complementation group (FANC)', 0, 0, '', 'Fanconi anaemia C', 'Genome maintenance', NULL, NULL, NULL, NULL, NULL, NULL),
	(320, 'FANCE', 3, NULL, 2178, 'FAE; FACE', 'protein for complementation group E.', 0, 0, '', 'Fanconi anaemia E', 'Genome maintenance', NULL, NULL, NULL, NULL, NULL, NULL),
	(321, 'FANCF', 3, NULL, 2188, 'FAF', 'the protein for complementation group F.', 0, 0, '', 'Fanconi anaemia F', 'Genome maintenance', NULL, NULL, NULL, NULL, NULL, NULL),
	(322, 'FLCN', 3, NULL, 201163, 'BHD; FLCL', 'folliculin', 0, 0, '', 'Birt-Hogg-Dube syndrome', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(323, 'GATA1', 1, NULL, 2623, 'GF1; GF-1; NFE1; XLTT; ERYF1; XLANP; XLTDA; GATA-1', '', 0, 0, '', 'thrombocytopenia with dyserythropoiesis', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(324, 'GPC3', 3, NULL, 2719, 'SGB; DGSX; MXR7; SDYS; SGBS; OCI-5; SGBS1; GTR2-2', 'membrane proteoglycan family (GRIPS) ', 0, 0, '', 'Simpson-Golabi-Behmel syndrome', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(325, 'KLF4', 1, NULL, 9314, 'EZF; GKLF', '', 0, 0, '', '', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(326, 'MAP3K1', 1, NULL, 4214, 'MEKK; MEKK1; SRXY6; MEKK 1; MAPKKK1', 'protein kinase', 0, 0, '', '', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(327, 'MUTYH', 3, NULL, 4595, 'MYH; CYP2C', 'DNA glycosylase', 0, 0, '', 'Adenomatous polyposis coli', 'Genome maintenance', NULL, NULL, NULL, NULL, NULL, NULL),
	(328, 'NCOR1', 1, NULL, 9611, 'N-CoR; TRAC1; N-CoR1; hN-CoR', 'nuclear receptor corepressor 1', 0, 0, '', '', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(329, 'PAX5', 1, NULL, 5079, 'BSAP', 'the paired box (PAX) family of transcription factors', 0, 0, '', '', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(330, 'RECQL4', 3, NULL, 9401, 'RECQ4', 'DNA helicase', 0, NULL, NULL, 'Rothmund-Thompson Syndrome', 'Genome maintenance', NULL, NULL, NULL, NULL, NULL, NULL),
	(331, 'RNF43', 1, NULL, 54894, 'URCC; RNF124', 'ring finger protein 43', 0, NULL, NULL, '', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(332, 'SBDS', 3, NULL, 51119, 'DS; SWDS; CGI-97', 'protein may function in RNA metabolism', 0, NULL, NULL, 'Schwachman-Diamond syndrome', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(333, 'SDH5', 3, NULL, 54949, 'PGL2; SDH5; C11orf79,SDHF2', '', 0, NULL, NULL, 'Familial paraganglioma', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(334, 'SDHB', 3, NULL, 6390, 'IP; SDH; CWS2; PGL4; SDH1; SDH2; SDHIP', 'succinate dehydrogenase complex', 0, NULL, NULL, 'Familial paraganglioma', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(335, 'SDHC', 3, NULL, 6391, 'CYBL; PGL3; QPS1; SDH3; CYB560', 'succinate dehydrogenase', 0, NULL, NULL, 'Familial paraganglioma', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(336, 'SDHD', 3, NULL, 6392, 'PGL; CBT1; CWS3; PGL1; QPs3; SDH4; cybS; CII-4', 'succinate dehydrogenase', 0, NULL, NULL, 'Familial paraganglioma', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(337, 'SETBP1', 1, NULL, 26040, 'SEB', 'SET binding protein 1', 0, NULL, NULL, '', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(338, 'SMAD2', 1, NULL, 4087, 'JV18; MADH2; MADR2; JV18-1; hMAD-2; hSMAD2', 'SMAD family member 2', 0, NULL, NULL, '', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(339, 'SOX9', 1, NULL, 6662, 'CMD1; SRA1; CMPD1', 'HMG-box class DNA-binding proteins', 0, NULL, NULL, '', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(340, 'SPOP', 1, NULL, 8405, 'TEF2; BTBD32', 'protein that may modulate the transcriptional repression activities of death-associated protein 6 (DAXX)', 0, NULL, NULL, '', 'Cell fate', NULL, NULL, NULL, NULL, NULL, NULL),
	(341, 'STAG2', 1, NULL, 10735, 'SA2; SA-2; SCC3B; bA517O1.1', 'stromal antigen 2', 0, NULL, NULL, '', 'Genome maintenance', NULL, NULL, NULL, NULL, NULL, NULL),
	(342, 'TRAF7', 1, NULL, 84231, 'RFWD1; RNF119', 'TRAF family.TNF receptor-associated factor 7', 0, NULL, NULL, '', 'Cell survival', NULL, NULL, NULL, NULL, NULL, NULL),
	(343, 'XPA', 3, NULL, 7507, 'XP1; XPAC', 'is part of the NER (nucleotide excision repair)', 0, NULL, NULL, 'Xeroderma pigmentosum (A) ', 'Genome maintenance', NULL, NULL, NULL, NULL, NULL, NULL),
	(344, 'XPC', 3, NULL, 7508, 'XP3; RAD4; XPCC', 'xeroderma pigmentosum, complementation group C', 0, NULL, NULL, '', 'Genome maintenance', NULL, NULL, NULL, NULL, NULL, NULL);
/*!40000 ALTER TABLE `mutaciones` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.mutaciones_diana
CREATE TABLE IF NOT EXISTS `mutaciones_diana` (
  `id_mutacion` mediumint(9) unsigned NOT NULL DEFAULT '0',
  `id_diana` smallint(4) unsigned NOT NULL DEFAULT '0',
  PRIMARY KEY (`id_mutacion`,`id_diana`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.mutaciones_diana: 23 rows
/*!40000 ALTER TABLE `mutaciones_diana` DISABLE KEYS */;
INSERT INTO `mutaciones_diana` (`id_mutacion`, `id_diana`) VALUES
	(1, 1),
	(1, 15),
	(1, 17),
	(1, 90),
	(9, 95),
	(92, 29),
	(99, 47),
	(105, 1),
	(119, 36),
	(120, 37),
	(121, 38),
	(124, 42),
	(157, 39),
	(157, 91),
	(157, 93),
	(158, 52),
	(207, 62),
	(226, 71),
	(230, 63),
	(230, 64),
	(236, 98),
	(247, 25),
	(250, 81);
/*!40000 ALTER TABLE `mutaciones_diana` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.mutaciones_pathways
CREATE TABLE IF NOT EXISTS `mutaciones_pathways` (
  `id_mutacion` smallint(5) unsigned NOT NULL,
  `id_pathway` smallint(5) unsigned NOT NULL,
  PRIMARY KEY (`id_mutacion`,`id_pathway`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.mutaciones_pathways: 761 rows
/*!40000 ALTER TABLE `mutaciones_pathways` DISABLE KEYS */;
INSERT INTO `mutaciones_pathways` (`id_mutacion`, `id_pathway`) VALUES
	(1, 25),
	(1, 42),
	(1, 47),
	(1, 144),
	(2, 72),
	(3, 9),
	(3, 80),
	(3, 81),
	(4, 190),
	(4, 221),
	(4, 222),
	(7, 41),
	(9, 19),
	(9, 85),
	(9, 124),
	(9, 162),
	(10, 74),
	(10, 75),
	(10, 92),
	(10, 151),
	(11, 162),
	(11, 208),
	(12, 15),
	(12, 18),
	(12, 175),
	(12, 235),
	(14, 23),
	(14, 183),
	(15, 46),
	(15, 169),
	(16, 46),
	(17, 176),
	(18, 228),
	(19, 46),
	(20, 19),
	(20, 42),
	(20, 59),
	(20, 153),
	(21, 46),
	(22, 15),
	(22, 236),
	(23, 58),
	(24, 19),
	(24, 84),
	(25, 26),
	(25, 110),
	(25, 227),
	(27, 180),
	(27, 234),
	(28, 26),
	(28, 217),
	(31, 202),
	(31, 227),
	(32, 32),
	(32, 59),
	(32, 115),
	(33, 85),
	(33, 125),
	(33, 135),
	(33, 208),
	(34, 59),
	(34, 79),
	(34, 115),
	(34, 163),
	(35, 59),
	(35, 103),
	(35, 115),
	(35, 116),
	(39, 59),
	(39, 79),
	(39, 102),
	(40, 185),
	(41, 3),
	(41, 42),
	(41, 59),
	(44, 4),
	(44, 17),
	(44, 41),
	(44, 145),
	(44, 217),
	(45, 41),
	(46, 112),
	(46, 140),
	(46, 158),
	(46, 165),
	(46, 191),
	(47, 21),
	(47, 177),
	(48, 21),
	(48, 177),
	(49, 41),
	(49, 85),
	(49, 236),
	(50, 42),
	(50, 84),
	(50, 236),
	(51, 41),
	(51, 84),
	(51, 236),
	(52, 41),
	(52, 84),
	(52, 236),
	(53, 154),
	(53, 223),
	(54, 27),
	(54, 29),
	(55, 17),
	(55, 41),
	(56, 8),
	(56, 15),
	(56, 44),
	(56, 45),
	(56, 64),
	(57, 8),
	(57, 44),
	(57, 45),
	(58, 17),
	(58, 42),
	(58, 88),
	(60, 16),
	(60, 42),
	(62, 39),
	(63, 5),
	(63, 124),
	(63, 158),
	(63, 208),
	(63, 227),
	(64, 41),
	(64, 153),
	(65, 183),
	(65, 199),
	(66, 165),
	(66, 208),
	(67, 14),
	(67, 168),
	(68, 131),
	(68, 133),
	(68, 134),
	(68, 187),
	(69, 90),
	(69, 123),
	(69, 212),
	(70, 90),
	(70, 123),
	(70, 212),
	(72, 41),
	(73, 85),
	(74, 147),
	(74, 158),
	(74, 163),
	(74, 193),
	(74, 194),
	(74, 245),
	(74, 246),
	(75, 38),
	(75, 39),
	(75, 40),
	(75, 41),
	(75, 42),
	(75, 43),
	(75, 46),
	(75, 118),
	(75, 147),
	(75, 148),
	(75, 218),
	(75, 219),
	(75, 220),
	(75, 221),
	(75, 222),
	(75, 227),
	(76, 163),
	(77, 30),
	(77, 104),
	(78, 55),
	(78, 118),
	(78, 163),
	(78, 208),
	(78, 241),
	(79, 8),
	(80, 8),
	(80, 15),
	(80, 220),
	(80, 236),
	(81, 16),
	(81, 17),
	(81, 18),
	(81, 19),
	(81, 38),
	(81, 39),
	(81, 40),
	(81, 41),
	(81, 42),
	(81, 43),
	(82, 16),
	(82, 42),
	(82, 46),
	(82, 125),
	(82, 219),
	(83, 57),
	(83, 227),
	(85, 91),
	(85, 131),
	(85, 181),
	(85, 210),
	(85, 227),
	(86, 69),
	(86, 212),
	(87, 46),
	(88, 10),
	(88, 56),
	(88, 229),
	(90, 96),
	(90, 97),
	(92, 65),
	(92, 66),
	(92, 67),
	(92, 71),
	(92, 72),
	(92, 158),
	(92, 159),
	(92, 208),
	(93, 230),
	(97, 68),
	(97, 76),
	(97, 170),
	(98, 15),
	(98, 46),
	(98, 148),
	(98, 219),
	(99, 71),
	(99, 159),
	(99, 208),
	(100, 108),
	(100, 145),
	(101, 59),
	(101, 186),
	(101, 187),
	(102, 59),
	(102, 186),
	(102, 187),
	(103, 59),
	(103, 60),
	(103, 149),
	(104, 59),
	(104, 149),
	(105, 227),
	(106, 28),
	(106, 227),
	(107, 46),
	(107, 128),
	(109, 175),
	(111, 15),
	(111, 31),
	(111, 200),
	(112, 28),
	(112, 59),
	(112, 60),
	(112, 78),
	(113, 28),
	(113, 59),
	(113, 60),
	(113, 78),
	(113, 179),
	(114, 28),
	(114, 59),
	(114, 60),
	(114, 78),
	(115, 12),
	(115, 17),
	(115, 125),
	(117, 2),
	(117, 147),
	(117, 148),
	(119, 124),
	(119, 162),
	(119, 194),
	(120, 83),
	(120, 118),
	(120, 161),
	(120, 163),
	(120, 192),
	(120, 241),
	(121, 82),
	(121, 118),
	(121, 163),
	(121, 175),
	(121, 208),
	(121, 241),
	(122, 40),
	(122, 41),
	(122, 89),
	(122, 194),
	(123, 158),
	(123, 208),
	(123, 214),
	(124, 5),
	(124, 55),
	(124, 158),
	(124, 208),
	(124, 241),
	(125, 86),
	(125, 114),
	(125, 160),
	(126, 86),
	(126, 163),
	(127, 219),
	(129, 17),
	(129, 18),
	(129, 19),
	(129, 38),
	(129, 39),
	(129, 40),
	(129, 41),
	(129, 42),
	(129, 43),
	(130, 131),
	(130, 133),
	(130, 227),
	(132, 147),
	(132, 148),
	(132, 218),
	(132, 219),
	(132, 220),
	(132, 221),
	(132, 222),
	(133, 227),
	(133, 228),
	(134, 13),
	(134, 87),
	(134, 124),
	(134, 125),
	(134, 158),
	(134, 161),
	(134, 162),
	(134, 163),
	(134, 208),
	(135, 87),
	(135, 124),
	(135, 158),
	(135, 208),
	(136, 15),
	(136, 87),
	(136, 94),
	(136, 158),
	(136, 208),
	(136, 219),
	(138, 126),
	(138, 172),
	(140, 46),
	(140, 227),
	(141, 67),
	(141, 105),
	(142, 46),
	(143, 15),
	(144, 228),
	(145, 208),
	(146, 46),
	(146, 50),
	(146, 139),
	(147, 173),
	(148, 111),
	(148, 118),
	(149, 17),
	(149, 117),
	(150, 213),
	(150, 217),
	(151, 117),
	(151, 118),
	(152, 70),
	(152, 118),
	(153, 163),
	(155, 46),
	(156, 46),
	(156, 227),
	(157, 84),
	(157, 162),
	(157, 233),
	(158, 119),
	(158, 162),
	(158, 203),
	(158, 208),
	(159, 10),
	(160, 71),
	(160, 125),
	(160, 208),
	(161, 224),
	(162, 35),
	(162, 157),
	(162, 215),
	(162, 216),
	(164, 55),
	(164, 118),
	(164, 150),
	(166, 227),
	(167, 148),
	(168, 124),
	(168, 125),
	(168, 208),
	(168, 226),
	(169, 207),
	(171, 17),
	(171, 18),
	(171, 19),
	(171, 41),
	(171, 167),
	(171, 222),
	(172, 41),
	(172, 46),
	(172, 228),
	(173, 158),
	(173, 208),
	(173, 227),
	(174, 154),
	(174, 180),
	(175, 184),
	(176, 59),
	(177, 227),
	(178, 46),
	(178, 121),
	(179, 46),
	(179, 121),
	(180, 227),
	(181, 7),
	(181, 8),
	(184, 118),
	(184, 241),
	(185, 59),
	(185, 129),
	(186, 59),
	(186, 129),
	(187, 134),
	(188, 175),
	(188, 184),
	(189, 111),
	(189, 247),
	(190, 41),
	(190, 71),
	(190, 125),
	(190, 147),
	(190, 163),
	(190, 236),
	(191, 227),
	(192, 17),
	(192, 41),
	(193, 175),
	(193, 248),
	(194, 248),
	(198, 103),
	(199, 91),
	(199, 100),
	(200, 91),
	(200, 100),
	(201, 125),
	(201, 207),
	(201, 208),
	(202, 15),
	(202, 73),
	(203, 11),
	(203, 41),
	(204, 125),
	(204, 145),
	(206, 49),
	(206, 131),
	(207, 2),
	(207, 147),
	(207, 148),
	(208, 147),
	(209, 18),
	(209, 41),
	(210, 23),
	(210, 125),
	(210, 193),
	(210, 208),
	(211, 121),
	(212, 125),
	(212, 208),
	(212, 227),
	(213, 30),
	(213, 143),
	(213, 144),
	(214, 34),
	(214, 41),
	(214, 130),
	(214, 174),
	(215, 41),
	(215, 249),
	(216, 41),
	(216, 91),
	(216, 249),
	(217, 142),
	(218, 59),
	(218, 60),
	(218, 77),
	(219, 128),
	(219, 141),
	(219, 227),
	(220, 106),
	(220, 223),
	(220, 227),
	(221, 46),
	(222, 41),
	(222, 89),
	(222, 120),
	(223, 6),
	(223, 54),
	(223, 155),
	(225, 85),
	(225, 124),
	(225, 162),
	(225, 193),
	(225, 208),
	(226, 125),
	(226, 163),
	(227, 48),
	(227, 49),
	(228, 227),
	(229, 141),
	(229, 188),
	(229, 227),
	(230, 13),
	(230, 17),
	(230, 85),
	(230, 109),
	(230, 158),
	(230, 159),
	(231, 112),
	(231, 114),
	(231, 156),
	(231, 158),
	(232, 118),
	(232, 231),
	(234, 59),
	(235, 33),
	(235, 57),
	(235, 129),
	(236, 166),
	(236, 227),
	(237, 17),
	(237, 41),
	(238, 46),
	(238, 57),
	(238, 146),
	(241, 15),
	(241, 158),
	(241, 164),
	(242, 96),
	(242, 97),
	(243, 67),
	(243, 153),
	(243, 158),
	(243, 159),
	(243, 161),
	(243, 162),
	(243, 217),
	(243, 238),
	(243, 242),
	(244, 208),
	(245, 69),
	(246, 98),
	(247, 51),
	(247, 71),
	(247, 85),
	(247, 113),
	(247, 125),
	(247, 163),
	(247, 192),
	(247, 194),
	(248, 17),
	(248, 41),
	(248, 62),
	(248, 63),
	(249, 224),
	(249, 227),
	(250, 158),
	(250, 206),
	(250, 208),
	(253, 91),
	(253, 171),
	(253, 200),
	(254, 228),
	(255, 5),
	(255, 228),
	(256, 37),
	(256, 137),
	(258, 46),
	(258, 121),
	(260, 132),
	(260, 133),
	(260, 211),
	(260, 227),
	(261, 201),
	(264, 218),
	(264, 222),
	(265, 46),
	(265, 224),
	(265, 244),
	(266, 46),
	(266, 224),
	(266, 244),
	(267, 96),
	(267, 97),
	(268, 118),
	(268, 241),
	(270, 24),
	(270, 199),
	(271, 131),
	(271, 227),
	(271, 228),
	(272, 91),
	(272, 131),
	(272, 133),
	(272, 187),
	(273, 65),
	(273, 118),
	(273, 209),
	(273, 241),
	(274, 204),
	(275, 13),
	(275, 136),
	(275, 163),
	(276, 96),
	(276, 97),
	(278, 162),
	(279, 152),
	(279, 227),
	(280, 36),
	(280, 106),
	(280, 138),
	(281, 180),
	(281, 235),
	(283, 46),
	(284, 154),
	(286, 17),
	(286, 41),
	(286, 124),
	(286, 125),
	(286, 146),
	(286, 224),
	(287, 34),
	(288, 13),
	(288, 17),
	(288, 22),
	(288, 38),
	(288, 59),
	(288, 125),
	(289, 249),
	(290, 194),
	(290, 195),
	(291, 61),
	(291, 91),
	(291, 218),
	(293, 107),
	(293, 114),
	(293, 136),
	(293, 158),
	(293, 163),
	(293, 198),
	(294, 53),
	(294, 113),
	(294, 135),
	(294, 153),
	(294, 162),
	(295, 95),
	(295, 124),
	(295, 125),
	(295, 142),
	(295, 196),
	(297, 131),
	(297, 187),
	(297, 211),
	(297, 227),
	(298, 20),
	(299, 100),
	(299, 118),
	(299, 158),
	(299, 176),
	(299, 205),
	(299, 208),
	(299, 241),
	(300, 124),
	(300, 158),
	(301, 227),
	(302, 122),
	(303, 59),
	(303, 178),
	(304, 46),
	(304, 116),
	(304, 228),
	(305, 189),
	(305, 197),
	(305, 237),
	(306, 41),
	(306, 97),
	(306, 182),
	(306, 218),
	(307, 17),
	(307, 42),
	(307, 101),
	(307, 152),
	(307, 163),
	(310, 227),
	(311, 46),
	(312, 124),
	(312, 158),
	(312, 208),
	(314, 222),
	(315, 17),
	(315, 41),
	(316, 118),
	(316, 241),
	(317, 46),
	(318, 96),
	(318, 97),
	(319, 59),
	(319, 60),
	(320, 59),
	(320, 60),
	(321, 59),
	(321, 60),
	(322, 158),
	(323, 147),
	(323, 148),
	(323, 218),
	(323, 219),
	(323, 220),
	(323, 221),
	(323, 222),
	(324, 158),
	(325, 227),
	(325, 228),
	(325, 234),
	(325, 235),
	(325, 236),
	(326, 124),
	(326, 125),
	(326, 208),
	(327, 59),
	(328, 46),
	(329, 227),
	(331, 15),
	(332, 227),
	(333, 158),
	(333, 208),
	(334, 158),
	(334, 208),
	(335, 158),
	(335, 208),
	(336, 158),
	(336, 208),
	(337, 46),
	(337, 243),
	(338, 220),
	(338, 222),
	(339, 15),
	(340, 46),
	(340, 96),
	(340, 97),
	(341, 59),
	(342, 17),
	(343, 59),
	(343, 60);
/*!40000 ALTER TABLE `mutaciones_pathways` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.mutaciones_tumores
CREATE TABLE IF NOT EXISTS `mutaciones_tumores` (
  `id_mutacion` mediumint(8) unsigned NOT NULL,
  `id_tejido_n1` smallint(5) unsigned NOT NULL,
  `id_histologia_n0` smallint(5) unsigned NOT NULL,
  `id_histologia_n1` smallint(5) unsigned NOT NULL,
  `numero_mutaciones` smallint(5) unsigned NOT NULL,
  PRIMARY KEY (`id_mutacion`,`id_tejido_n1`,`id_histologia_n0`,`id_histologia_n1`)
) ENGINE=MyISAM DEFAULT CHARSET=utf8;

-- Volcando datos para la tabla farmacos.mutaciones_tumores: 1.354 rows
/*!40000 ALTER TABLE `mutaciones_tumores` DISABLE KEYS */;
INSERT INTO `mutaciones_tumores` (`id_mutacion`, `id_tejido_n1`, `id_histologia_n0`, `id_histologia_n1`, `numero_mutaciones`) VALUES
	(2, 7, 8, 42, 20),
	(4, 7, 8, 32, 3),
	(5, 8, 5, 53, 5),
	(5, 12, 8, 69, 25),
	(6, 8, 17, 60, 13),
	(7, 3, 28, 53, 3),
	(7, 7, 8, 38, 5),
	(7, 7, 8, 24, 6),
	(7, 23, 8, 1, 4),
	(7, 25, 8, 1, 9),
	(7, 25, 8, 69, 8),
	(9, 7, 8, 32, 7),
	(9, 7, 8, 24, 4),
	(9, 7, 8, 42, 5),
	(9, 7, 9, 25, 7),
	(9, 8, 17, 6, 4),
	(9, 31, 8, 53, 1),
	(9, 53, 8, 53, 5),
	(9, 53, 8, 71, 3),
	(11, 3, 13, 53, 18),
	(11, 3, 28, 53, 6),
	(11, 7, 8, 32, 3),
	(11, 7, 8, 38, 2),
	(11, 7, 8, 42, 20),
	(11, 21, 29, 53, 14),
	(11, 21, 8, 1, 3),
	(11, 29, 8, 50, 33),
	(12, 1, 2, 53, 67),
	(12, 1, 3, 53, 3),
	(12, 4, 8, 1, 3),
	(12, 7, 8, 38, 4),
	(12, 7, 8, 24, 7),
	(12, 7, 8, 48, 7),
	(12, 8, 33, 18, 6),
	(12, 12, 8, 69, 13),
	(12, 22, 29, 53, 100),
	(12, 22, 8, 1, 35),
	(12, 21, 29, 53, 29),
	(12, 21, 8, 1, 31),
	(12, 23, 29, 53, 75),
	(12, 23, 8, 1, 48),
	(12, 24, 8, 37, 4),
	(12, 28, 8, 1, 2),
	(12, 29, 8, 1, 14),
	(12, 29, 8, 29, 4),
	(12, 29, 8, 64, 1),
	(12, 31, 8, 24, 3),
	(12, 30, 8, 24, 42),
	(12, 34, 8, 53, 4),
	(12, 42, 21, 53, 6),
	(12, 44, 1, 53, 33),
	(12, 44, 7, 53, 50),
	(12, 44, 8, 1, 6),
	(12, 44, 8, 23, 3),
	(12, 47, 8, 53, 17),
	(12, 53, 8, 53, 11),
	(12, 53, 8, 71, 3),
	(2, 29, 8, 50, 100),
	(2, 52, 8, 69, 50),
	(4, 31, 8, 53, 2),
	(4, 31, 8, 24, 3),
	(14, 13, 8, 29, 23),
	(14, 31, 8, 53, 1),
	(15, 8, 33, 53, 1),
	(15, 21, 8, 1, 6),
	(15, 24, 8, 37, 29),
	(15, 25, 8, 53, 8),
	(15, 25, 8, 1, 5),
	(15, 29, 8, 19, 50),
	(15, 29, 8, 29, 30),
	(15, 31, 29, 53, 3),
	(15, 31, 8, 53, 2),
	(15, 31, 8, 24, 7),
	(15, 34, 8, 1, 3),
	(15, 44, 8, 1, 10),
	(15, 49, 8, 69, 12),
	(15, 53, 8, 53, 34),
	(16, 24, 8, 37, 8),
	(16, 31, 8, 24, 2),
	(19, 21, 8, 1, 4),
	(19, 25, 8, 69, 8),
	(20, 7, 8, 42, 17),
	(20, 8, 17, 4, 100),
	(20, 8, 17, 59, 29),
	(20, 9, 17, 3, 5),
	(20, 20, 8, 20, 3),
	(20, 20, 8, 61, 33),
	(20, 22, 8, 1, 7),
	(20, 21, 8, 1, 4),
	(20, 24, 8, 37, 6),
	(20, 25, 8, 1, 8),
	(20, 25, 8, 52, 17),
	(20, 31, 7, 53, 5),
	(20, 31, 8, 24, 4),
	(20, 34, 8, 53, 3),
	(20, 34, 8, 1, 6),
	(21, 6, 30, 53, 33),
	(21, 8, 17, 6, 13),
	(21, 8, 17, 7, 10),
	(21, 8, 17, 58, 8),
	(21, 9, 17, 7, 14),
	(21, 20, 8, 20, 3),
	(21, 31, 7, 53, 19),
	(21, 25, 8, 67, 8),
	(21, 52, 8, 69, 50),
	(22, 4, 8, 1, 29),
	(22, 22, 8, 1, 10),
	(22, 24, 8, 37, 14),
	(22, 29, 8, 29, 2),
	(22, 44, 8, 23, 7),
	(22, 35, 8, 47, 25),
	(23, 15, 25, 53, 36),
	(23, 20, 8, 20, 13),
	(1, 44, 8, 53, 14),
	(1, 48, 8, 53, 17),
	(25, 34, 8, 1, 5),
	(27, 21, 29, 53, 14),
	(29, 8, 17, 7, 1),
	(29, 29, 8, 19, 13),
	(30, 8, 5, 53, 5),
	(30, 8, 17, 7, 1),
	(31, 8, 33, 53, 1),
	(31, 13, 8, 29, 11),
	(33, 1, 3, 53, 4),
	(33, 4, 8, 1, 6),
	(33, 5, 8, 1, 7),
	(33, 5, 31, 2, 4),
	(33, 6, 11, 53, 1),
	(33, 7, 8, 11, 2),
	(33, 8, 17, 3, 7),
	(33, 8, 17, 4, 7),
	(33, 8, 17, 5, 2),
	(33, 8, 17, 7, 2),
	(33, 8, 17, 36, 2),
	(33, 8, 17, 59, 5),
	(33, 8, 17, 60, 2),
	(33, 9, 17, 4, 7),
	(33, 9, 17, 5, 100),
	(33, 12, 8, 1, 3),
	(33, 15, 25, 53, 3),
	(33, 17, 7, 53, 50),
	(33, 18, 15, 17, 25),
	(33, 18, 15, 49, 100),
	(33, 18, 15, 73, 4),
	(33, 20, 8, 61, 1),
	(33, 22, 8, 1, 10),
	(33, 21, 8, 1, 14),
	(33, 23, 8, 1, 3),
	(33, 23, 8, 37, 5),
	(33, 25, 8, 53, 2),
	(33, 25, 8, 52, 1),
	(33, 28, 8, 1, 1),
	(33, 29, 8, 53, 3),
	(33, 29, 8, 19, 2),
	(33, 29, 8, 29, 5),
	(33, 29, 8, 50, 7),
	(33, 29, 8, 64, 1),
	(33, 29, 8, 65, 39),
	(33, 29, 15, 70, 3),
	(33, 31, 7, 53, 1),
	(33, 31, 8, 24, 2),
	(33, 34, 8, 1, 2),
	(33, 35, 6, 53, 63),
	(33, 35, 6, 68, 7),
	(33, 35, 6, 13, 4),
	(33, 35, 6, 21, 52),
	(33, 35, 6, 22, 24),
	(33, 35, 6, 27, 44),
	(33, 35, 6, 39, 66),
	(33, 35, 6, 40, 31),
	(33, 35, 25, 53, 52),
	(33, 36, 8, 1, 21),
	(33, 39, 23, 53, 113),
	(33, 40, 38, 53, 1),
	(33, 43, 35, 53, 4),
	(33, 44, 8, 1, 1),
	(33, 44, 8, 23, 1),
	(33, 45, 15, 28, 20),
	(33, 45, 15, 33, 1),
	(33, 45, 15, 49, 21),
	(33, 45, 15, 73, 5),
	(33, 47, 8, 53, 28),
	(33, 48, 8, 69, 4),
	(33, 55, 8, 71, 1),
	(34, 7, 8, 32, 2),
	(34, 7, 8, 38, 2),
	(34, 7, 8, 11, 3),
	(34, 7, 8, 24, 14),
	(34, 7, 8, 42, 25),
	(34, 29, 8, 53, 2),
	(34, 29, 8, 29, 2),
	(34, 29, 8, 64, 3),
	(35, 7, 8, 11, 2),
	(35, 7, 8, 24, 3),
	(35, 8, 33, 53, 1),
	(35, 13, 8, 29, 7),
	(35, 25, 8, 53, 4),
	(35, 25, 8, 69, 8),
	(35, 28, 8, 69, 5),
	(35, 29, 8, 53, 1),
	(35, 29, 8, 19, 15),
	(35, 29, 8, 64, 2),
	(35, 31, 29, 53, 3),
	(35, 31, 8, 24, 2),
	(33, 24, 8, 37, 5),
	(36, 44, 8, 1, 4),
	(38, 12, 8, 69, 17),
	(38, 25, 8, 67, 10),
	(39, 55, 8, 53, 12),
	(41, 44, 8, 53, 14),
	(44, 21, 29, 53, 25),
	(44, 25, 8, 1, 8),
	(46, 21, 29, 53, 25),
	(46, 25, 8, 52, 5),
	(48, 7, 8, 32, 2),
	(55, 31, 29, 53, 1),
	(56, 4, 8, 1, 10),
	(56, 7, 8, 32, 7),
	(56, 7, 8, 38, 2),
	(56, 7, 8, 11, 2),
	(56, 7, 8, 24, 5),
	(56, 7, 8, 42, 31),
	(56, 7, 9, 25, 38),
	(56, 7, 9, 43, 58),
	(56, 7, 18, 10, 7),
	(56, 28, 8, 1, 4),
	(56, 44, 8, 1, 8),
	(56, 44, 8, 23, 20),
	(56, 48, 8, 53, 17),
	(56, 55, 8, 69, 50),
	(56, 55, 8, 71, 3),
	(57, 21, 8, 1, 4),
	(57, 29, 8, 19, 13),
	(59, 7, 8, 38, 3),
	(59, 29, 8, 64, 1),
	(60, 2, 32, 53, 2),
	(60, 1, 32, 53, 16),
	(60, 3, 28, 53, 2),
	(60, 4, 8, 53, 21),
	(60, 4, 8, 1, 18),
	(60, 5, 8, 1, 30),
	(60, 6, 11, 53, 7),
	(60, 6, 10, 53, 25),
	(60, 6, 30, 53, 9),
	(60, 7, 8, 11, 7),
	(60, 7, 8, 24, 2),
	(60, 8, 17, 3, 18),
	(60, 8, 17, 5, 1),
	(60, 8, 17, 6, 15),
	(60, 8, 17, 7, 26),
	(60, 8, 17, 56, 6),
	(60, 8, 17, 59, 2),
	(60, 8, 17, 60, 11),
	(60, 8, 33, 53, 1),
	(60, 9, 17, 5, 100),
	(60, 12, 8, 69, 12),
	(60, 12, 19, 16, 50),
	(60, 13, 8, 1, 3),
	(60, 18, 15, 33, 90),
	(60, 18, 15, 17, 50),
	(60, 18, 15, 70, 43),
	(60, 18, 15, 73, 100),
	(60, 20, 40, 53, 100),
	(60, 24, 8, 37, 11),
	(60, 20, 8, 20, 3),
	(60, 25, 7, 53, 50),
	(60, 25, 8, 53, 10),
	(60, 25, 8, 69, 15),
	(60, 25, 8, 1, 9),
	(60, 28, 8, 53, 25),
	(60, 29, 8, 1, 25),
	(60, 28, 8, 1, 10),
	(60, 28, 8, 69, 18),
	(60, 29, 8, 53, 4),
	(60, 29, 8, 19, 10),
	(60, 29, 8, 29, 12),
	(60, 29, 8, 50, 16),
	(60, 29, 8, 64, 2),
	(60, 29, 15, 26, 50),
	(60, 29, 15, 49, 67),
	(60, 35, 8, 47, 4),
	(60, 35, 8, 12, 2),
	(60, 29, 15, 73, 100),
	(60, 31, 29, 53, 7),
	(60, 31, 8, 53, 1),
	(60, 31, 8, 24, 23),
	(60, 30, 8, 24, 26),
	(60, 34, 8, 1, 2),
	(60, 35, 8, 69, 11),
	(60, 35, 25, 53, 30),
	(60, 38, 36, 53, 9),
	(60, 37, 4, 53, 6),
	(60, 39, 23, 53, 3),
	(60, 40, 12, 53, 25),
	(60, 40, 38, 53, 8),
	(60, 42, 21, 53, 4),
	(60, 44, 7, 53, 100),
	(60, 44, 8, 1, 4),
	(60, 44, 8, 23, 8),
	(60, 47, 8, 53, 100),
	(60, 48, 8, 53, 83),
	(60, 48, 8, 69, 21),
	(60, 49, 8, 53, 12),
	(60, 49, 8, 69, 15),
	(60, 50, 8, 69, 18),
	(60, 51, 8, 69, 7),
	(60, 53, 8, 53, 19),
	(60, 55, 8, 53, 8),
	(60, 55, 8, 69, 57),
	(60, 55, 8, 71, 18),
	(64, 8, 17, 7, 2),
	(64, 44, 8, 53, 7),
	(66, 7, 8, 24, 4),
	(66, 8, 17, 58, 50),
	(66, 8, 17, 60, 69),
	(75, 12, 8, 69, 25),
	(75, 13, 8, 29, 6),
	(75, 21, 8, 1, 5),
	(75, 25, 8, 67, 13),
	(75, 25, 8, 69, 9),
	(75, 29, 8, 53, 3),
	(75, 29, 8, 19, 11),
	(75, 29, 8, 29, 100),
	(75, 29, 8, 64, 2),
	(75, 31, 29, 53, 1),
	(75, 31, 8, 53, 1),
	(75, 43, 34, 53, 5),
	(75, 49, 8, 69, 18),
	(75, 55, 8, 53, 36),
	(78, 24, 8, 37, 4),
	(78, 31, 8, 53, 1),
	(80, 1, 2, 53, 32),
	(80, 1, 3, 53, 20),
	(80, 4, 8, 1, 2),
	(80, 5, 8, 1, 11),
	(80, 5, 31, 2, 60),
	(80, 7, 8, 48, 13),
	(80, 8, 33, 53, 8),
	(80, 8, 33, 18, 32),
	(80, 12, 8, 1, 8),
	(80, 12, 8, 69, 5),
	(80, 12, 19, 15, 7),
	(80, 12, 19, 16, 10),
	(80, 13, 8, 1, 11),
	(80, 13, 8, 29, 26),
	(80, 20, 40, 53, 15),
	(80, 22, 8, 1, 5),
	(80, 21, 8, 1, 5),
	(80, 23, 29, 53, 25),
	(80, 24, 8, 37, 19),
	(80, 28, 8, 1, 1),
	(80, 28, 8, 69, 2),
	(80, 29, 8, 1, 15),
	(80, 29, 8, 14, 13),
	(80, 29, 8, 19, 3),
	(80, 29, 8, 29, 26),
	(80, 29, 8, 50, 2),
	(80, 31, 8, 53, 1),
	(80, 30, 8, 24, 9),
	(80, 34, 8, 53, 2),
	(80, 34, 8, 1, 7),
	(80, 35, 8, 12, 13),
	(80, 35, 25, 53, 3),
	(80, 36, 8, 1, 6),
	(80, 40, 38, 53, 4),
	(80, 44, 1, 53, 28),
	(80, 44, 7, 53, 40),
	(80, 44, 8, 1, 4),
	(80, 44, 8, 23, 4),
	(80, 55, 8, 71, 2),
	(82, 31, 29, 53, 1),
	(82, 31, 7, 53, 24),
	(82, 51, 8, 69, 8),
	(85, 23, 29, 53, 25),
	(92, 1, 3, 53, 4),
	(92, 4, 8, 1, 4),
	(92, 5, 8, 1, 1),
	(92, 7, 8, 11, 1),
	(92, 7, 8, 24, 1),
	(92, 8, 17, 3, 4),
	(92, 8, 17, 7, 6),
	(92, 8, 17, 54, 17),
	(92, 8, 17, 56, 6),
	(92, 8, 17, 59, 12),
	(92, 15, 25, 53, 2),
	(92, 20, 8, 61, 20),
	(92, 21, 8, 1, 4),
	(92, 25, 8, 53, 29),
	(92, 25, 8, 1, 35),
	(92, 25, 8, 52, 22),
	(92, 25, 8, 67, 5),
	(92, 25, 8, 69, 6),
	(92, 28, 8, 1, 1),
	(92, 28, 8, 69, 4),
	(92, 29, 8, 1, 55),
	(92, 33, 27, 53, 13),
	(92, 34, 8, 1, 7),
	(92, 35, 8, 69, 1),
	(92, 44, 8, 1, 4),
	(92, 46, 39, 53, 1),
	(92, 48, 8, 53, 12),
	(92, 48, 8, 69, 2),
	(92, 49, 8, 69, 6),
	(92, 50, 8, 69, 2),
	(92, 51, 8, 69, 3),
	(92, 52, 8, 69, 11),
	(98, 22, 8, 1, 10),
	(98, 25, 8, 53, 20),
	(98, 25, 8, 67, 18),
	(98, 29, 8, 53, 1),
	(98, 31, 29, 53, 3),
	(98, 48, 8, 69, 50),
	(98, 52, 8, 69, 50),
	(98, 55, 8, 53, 31),
	(99, 7, 8, 38, 5),
	(99, 7, 8, 11, 2),
	(99, 7, 8, 24, 1),
	(99, 7, 8, 42, 20),
	(99, 7, 8, 25, 3),
	(99, 8, 17, 7, 1),
	(99, 23, 29, 53, 25),
	(99, 23, 8, 1, 3),
	(99, 24, 8, 37, 1),
	(99, 25, 8, 53, 3),
	(99, 25, 8, 52, 1),
	(99, 29, 8, 53, 1),
	(99, 29, 8, 50, 18),
	(99, 44, 8, 53, 7),
	(99, 1, 8, 1, 2),
	(99, 44, 8, 1, 2),
	(99, 44, 8, 23, 1),
	(99, 48, 8, 53, 11),
	(99, 49, 8, 69, 4),
	(99, 51, 8, 69, 5),
	(101, 31, 29, 53, 1),
	(102, 21, 29, 53, 25),
	(111, 21, 29, 53, 25),
	(111, 23, 8, 1, 4),
	(111, 29, 8, 1, 14),
	(113, 21, 29, 53, 25),
	(117, 4, 8, 53, 100),
	(117, 4, 8, 1, 21),
	(117, 6, 30, 53, 1),
	(117, 8, 33, 53, 1),
	(117, 13, 8, 1, 29),
	(117, 13, 8, 29, 11),
	(117, 20, 40, 53, 1),
	(117, 22, 8, 1, 6),
	(117, 21, 29, 53, 14),
	(117, 21, 8, 1, 10),
	(117, 23, 29, 53, 25),
	(117, 23, 8, 1, 8),
	(117, 25, 8, 69, 7),
	(117, 29, 8, 53, 4),
	(117, 29, 8, 1, 14),
	(117, 29, 8, 29, 3),
	(117, 31, 29, 53, 1),
	(117, 31, 8, 24, 2),
	(117, 44, 8, 1, 6),
	(117, 48, 8, 69, 1),
	(117, 50, 8, 69, 4),
	(117, 51, 8, 69, 12),
	(120, 12, 8, 69, 14),
	(120, 13, 8, 29, 12),
	(120, 29, 8, 29, 2),
	(120, 35, 25, 53, 10),
	(121, 12, 8, 69, 2),
	(121, 34, 8, 53, 2),
	(121, 45, 15, 63, 7),
	(121, 50, 8, 69, 22),
	(121, 53, 8, 71, 10),
	(121, 55, 8, 53, 46),
	(121, 55, 8, 71, 46),
	(124, 44, 8, 53, 7),
	(127, 29, 15, 53, 100),
	(129, 8, 17, 58, 14),
	(129, 8, 17, 60, 10),
	(132, 8, 5, 53, 5),
	(133, 7, 8, 24, 9),
	(134, 15, 25, 53, 36),
	(134, 35, 6, 13, 6),
	(134, 35, 25, 53, 3),
	(135, 15, 25, 53, 37),
	(135, 35, 6, 13, 28),
	(136, 1, 2, 53, 6),
	(136, 1, 32, 53, 8),
	(136, 4, 8, 1, 31),
	(136, 31, 8, 53, 2),
	(136, 45, 37, 41, 67),
	(136, 51, 8, 69, 8),
	(140, 8, 17, 6, 11),
	(140, 8, 17, 7, 17),
	(140, 9, 17, 5, 100),
	(140, 9, 17, 6, 44),
	(140, 9, 17, 7, 84),
	(143, 8, 17, 60, 6),
	(143, 22, 8, 1, 17),
	(143, 24, 8, 37, 4),
	(145, 1, 32, 53, 3),
	(145, 4, 8, 53, 22),
	(145, 12, 8, 1, 22),
	(145, 12, 8, 69, 7),
	(145, 13, 8, 1, 3),
	(145, 25, 8, 53, 6),
	(145, 28, 8, 69, 1),
	(145, 32, 8, 53, 7),
	(145, 34, 8, 1, 5),
	(145, 35, 6, 68, 19),
	(145, 35, 8, 12, 7),
	(145, 35, 8, 69, 5),
	(145, 35, 25, 53, 1),
	(145, 39, 23, 53, 4),
	(145, 40, 38, 53, 5),
	(145, 42, 21, 53, 3),
	(145, 43, 35, 53, 7),
	(145, 44, 8, 1, 2),
	(145, 44, 8, 23, 2),
	(145, 45, 15, 63, 8),
	(145, 46, 39, 53, 3),
	(145, 47, 8, 53, 2),
	(145, 48, 8, 69, 3),
	(145, 49, 8, 69, 2),
	(145, 49, 8, 53, 10),
	(145, 50, 8, 69, 11),
	(145, 51, 8, 69, 5),
	(145, 52, 8, 69, 15),
	(145, 53, 8, 53, 31),
	(145, 53, 8, 71, 4),
	(145, 55, 8, 53, 13),
	(145, 55, 8, 69, 50),
	(145, 55, 8, 71, 7),
	(146, 4, 8, 1, 7),
	(146, 6, 10, 53, 1),
	(146, 8, 17, 3, 18),
	(146, 8, 17, 4, 1),
	(146, 8, 17, 5, 62),
	(146, 8, 17, 6, 50),
	(146, 8, 17, 7, 9),
	(146, 8, 17, 35, 42),
	(146, 8, 17, 54, 46),
	(146, 8, 17, 55, 66),
	(146, 8, 17, 56, 60),
	(146, 8, 17, 58, 63),
	(146, 8, 17, 59, 70),
	(146, 8, 17, 60, 64),
	(146, 8, 33, 53, 1),
	(146, 40, 12, 53, 50),
	(147, 4, 8, 1, 3),
	(147, 6, 10, 53, 6),
	(147, 8, 17, 5, 2),
	(147, 8, 17, 6, 1),
	(147, 8, 17, 55, 1),
	(147, 8, 17, 56, 6),
	(147, 8, 17, 58, 6),
	(147, 8, 17, 59, 6),
	(147, 8, 17, 60, 6),
	(151, 34, 8, 53, 2),
	(152, 7, 8, 11, 2),
	(152, 7, 8, 45, 2),
	(152, 43, 34, 53, 4),
	(153, 44, 8, 23, 6),
	(153, 50, 8, 69, 5),
	(155, 3, 28, 53, 1),
	(155, 20, 8, 19, 5),
	(155, 28, 8, 69, 17),
	(156, 8, 17, 3, 13),
	(156, 8, 33, 53, 7),
	(156, 13, 8, 1, 29),
	(156, 28, 8, 53, 3),
	(156, 28, 8, 69, 33),
	(156, 34, 8, 53, 2),
	(156, 43, 34, 53, 7),
	(156, 55, 8, 53, 38),
	(156, 55, 8, 71, 25),
	(158, 6, 11, 53, 1),
	(158, 15, 25, 53, 3),
	(158, 18, 15, 33, 33),
	(158, 20, 8, 61, 68),
	(158, 29, 8, 53, 1),
	(158, 29, 8, 64, 1),
	(158, 29, 15, 53, 26),
	(158, 29, 15, 49, 100),
	(158, 29, 15, 70, 6),
	(158, 31, 7, 53, 8),
	(158, 35, 8, 47, 1),
	(158, 35, 25, 53, 1),
	(158, 40, 16, 53, 46),
	(158, 42, 21, 53, 2),
	(158, 45, 15, 33, 16),
	(158, 45, 15, 51, 2),
	(158, 45, 15, 63, 25),
	(160, 1, 3, 53, 1),
	(160, 3, 28, 53, 1),
	(160, 4, 8, 1, 35),
	(160, 5, 8, 1, 21),
	(160, 5, 31, 2, 30),
	(160, 7, 8, 32, 1),
	(160, 7, 8, 24, 1),
	(160, 8, 17, 4, 13),
	(160, 9, 17, 5, 50),
	(160, 12, 8, 1, 14),
	(160, 12, 8, 69, 2),
	(160, 13, 8, 1, 15),
	(160, 13, 8, 29, 17),
	(160, 18, 15, 33, 8),
	(160, 22, 29, 53, 100),
	(160, 22, 8, 1, 37),
	(160, 21, 29, 53, 29),
	(160, 21, 8, 1, 34),
	(160, 23, 29, 53, 50),
	(160, 23, 8, 1, 35),
	(160, 24, 8, 37, 3),
	(160, 25, 7, 53, 6),
	(160, 25, 7, 8, 8),
	(160, 25, 8, 53, 14),
	(160, 25, 8, 1, 20),
	(160, 25, 8, 52, 16),
	(160, 28, 8, 53, 5),
	(160, 28, 8, 1, 5),
	(160, 28, 8, 69, 1),
	(160, 29, 8, 53, 5),
	(160, 29, 8, 1, 6),
	(160, 29, 8, 14, 2),
	(160, 29, 8, 19, 8),
	(160, 29, 8, 29, 11),
	(160, 29, 8, 50, 44),
	(160, 29, 8, 64, 6),
	(160, 29, 8, 65, 33),
	(160, 29, 15, 53, 14),
	(160, 29, 15, 70, 8),
	(160, 31, 7, 53, 3),
	(160, 31, 8, 53, 45),
	(160, 31, 8, 24, 73),
	(160, 30, 8, 53, 26),
	(160, 30, 8, 24, 28),
	(160, 32, 8, 53, 4),
	(160, 33, 8, 50, 67),
	(160, 33, 8, 62, 2),
	(160, 34, 8, 1, 7),
	(160, 34, 18, 53, 5),
	(160, 35, 8, 12, 1),
	(160, 35, 25, 53, 1),
	(160, 36, 7, 53, 1),
	(160, 36, 8, 1, 83),
	(160, 37, 4, 53, 49),
	(160, 39, 23, 53, 4),
	(160, 42, 21, 53, 7),
	(160, 43, 35, 53, 3),
	(160, 44, 1, 53, 6),
	(160, 44, 8, 53, 18),
	(160, 44, 8, 1, 5),
	(160, 44, 8, 23, 5),
	(160, 45, 15, 33, 6),
	(160, 45, 15, 49, 5),
	(160, 45, 15, 63, 6),
	(160, 46, 39, 53, 1),
	(160, 47, 8, 53, 3),
	(160, 48, 8, 53, 5),
	(160, 48, 8, 69, 1),
	(160, 49, 8, 53, 4),
	(160, 49, 8, 69, 2),
	(160, 50, 8, 69, 2),
	(160, 51, 8, 69, 2),
	(160, 52, 8, 69, 2),
	(160, 53, 8, 53, 5),
	(160, 55, 8, 53, 8),
	(160, 55, 8, 71, 4),
	(168, 4, 8, 1, 7),
	(168, 7, 8, 32, 2),
	(168, 13, 8, 1, 14),
	(168, 21, 29, 53, 25),
	(168, 29, 8, 29, 3),
	(168, 31, 8, 53, 2),
	(168, 31, 8, 24, 4),
	(168, 44, 8, 53, 3),
	(168, 45, 15, 53, 33),
	(168, 55, 8, 71, 13),
	(171, 13, 8, 29, 10),
	(171, 34, 8, 53, 3),
	(171, 34, 8, 1, 4),
	(171, 42, 21, 53, 8),
	(172, 1, 2, 53, 6),
	(172, 1, 3, 53, 3),
	(172, 17, 7, 53, 9),
	(172, 25, 7, 53, 17),
	(172, 25, 7, 8, 22),
	(172, 25, 7, 72, 11),
	(172, 31, 7, 53, 41),
	(172, 39, 22, 53, 25),
	(172, 44, 7, 53, 17),
	(173, 8, 17, 58, 100),
	(173, 20, 8, 61, 4),
	(173, 25, 8, 52, 3),
	(173, 29, 8, 53, 2),
	(173, 44, 8, 53, 2),
	(173, 45, 15, 53, 100),
	(173, 48, 8, 53, 4),
	(173, 48, 8, 69, 10),
	(173, 51, 8, 69, 18),
	(173, 24, 8, 37, 3),
	(176, 7, 8, 38, 3),
	(176, 22, 8, 1, 9),
	(176, 28, 8, 69, 8),
	(176, 29, 8, 1, 10),
	(176, 29, 8, 14, 100),
	(176, 30, 8, 24, 33),
	(178, 8, 33, 53, 6),
	(178, 12, 8, 69, 25),
	(178, 13, 8, 29, 9),
	(178, 20, 8, 20, 4),
	(178, 25, 8, 1, 8),
	(178, 25, 8, 67, 11),
	(178, 25, 8, 69, 21),
	(178, 34, 8, 53, 4),
	(178, 34, 8, 1, 4),
	(178, 35, 25, 53, 8),
	(178, 50, 8, 69, 8),
	(178, 51, 8, 69, 8),
	(178, 55, 8, 53, 13),
	(179, 8, 33, 53, 4),
	(179, 12, 8, 69, 25),
	(179, 13, 8, 29, 13),
	(179, 20, 8, 20, 6),
	(179, 31, 29, 53, 13),
	(179, 29, 8, 64, 1),
	(179, 25, 8, 69, 21),
	(179, 34, 8, 53, 4),
	(179, 34, 8, 1, 7),
	(179, 35, 25, 53, 8),
	(179, 50, 8, 69, 6),
	(179, 51, 8, 69, 13),
	(179, 55, 8, 53, 30),
	(179, 4, 8, 1, 50),
	(179, 22, 8, 1, 13),
	(179, 21, 29, 53, 25),
	(179, 21, 8, 1, 3),
	(179, 31, 8, 53, 4),
	(179, 31, 8, 24, 5),
	(179, 43, 34, 53, 5),
	(185, 7, 8, 42, 25),
	(185, 13, 8, 1, 3),
	(185, 22, 8, 1, 8),
	(185, 29, 8, 50, 50),
	(186, 7, 8, 11, 2),
	(186, 8, 17, 7, 2),
	(186, 8, 17, 60, 6),
	(186, 13, 8, 1, 8),
	(186, 22, 8, 1, 22),
	(186, 35, 25, 53, 4),
	(186, 44, 8, 53, 7),
	(186, 44, 8, 1, 12),
	(186, 44, 8, 23, 2),
	(186, 53, 8, 71, 2),
	(186, 55, 8, 71, 20),
	(192, 21, 29, 53, 25),
	(198, 51, 8, 69, 13),
	(201, 3, 14, 53, 50),
	(201, 3, 28, 53, 4),
	(201, 7, 8, 24, 4),
	(201, 7, 8, 42, 33),
	(201, 8, 17, 3, 9),
	(201, 8, 17, 6, 4),
	(201, 8, 17, 7, 8),
	(201, 8, 17, 60, 6),
	(201, 12, 8, 69, 20),
	(201, 22, 8, 1, 14),
	(201, 25, 8, 1, 10),
	(201, 25, 8, 69, 10),
	(201, 29, 8, 64, 2),
	(201, 35, 25, 53, 7),
	(201, 43, 35, 53, 17),
	(201, 48, 8, 53, 17),
	(201, 55, 8, 53, 17),
	(202, 8, 5, 53, 3),
	(202, 26, 26, 53, 30),
	(202, 35, 25, 53, 4),
	(203, 12, 8, 69, 31),
	(203, 24, 8, 37, 6),
	(203, 25, 8, 69, 13),
	(203, 28, 8, 69, 18),
	(203, 48, 8, 53, 25),
	(203, 49, 8, 69, 8),
	(203, 50, 8, 69, 6),
	(207, 7, 8, 32, 2),
	(207, 7, 8, 38, 6),
	(207, 7, 8, 11, 2),
	(207, 7, 8, 24, 3),
	(207, 8, 17, 30, 8),
	(207, 8, 17, 59, 9),
	(207, 8, 17, 60, 22),
	(207, 25, 8, 69, 10),
	(207, 28, 8, 69, 13),
	(207, 49, 8, 69, 12),
	(207, 50, 8, 69, 20),
	(207, 51, 8, 69, 21),
	(208, 8, 5, 53, 5),
	(208, 8, 17, 60, 7),
	(208, 25, 8, 52, 29),
	(210, 1, 3, 53, 7),
	(210, 3, 28, 53, 2),
	(210, 4, 8, 1, 2),
	(210, 5, 8, 1, 4),
	(210, 7, 8, 11, 2),
	(210, 8, 5, 53, 3),
	(210, 8, 17, 36, 7),
	(210, 8, 17, 60, 4),
	(210, 8, 33, 53, 1),
	(210, 8, 33, 18, 3),
	(210, 12, 8, 69, 3),
	(210, 15, 25, 53, 1),
	(210, 22, 8, 1, 4),
	(210, 23, 8, 1, 4),
	(210, 24, 8, 37, 2),
	(210, 25, 8, 53, 4),
	(210, 25, 8, 52, 1),
	(210, 29, 8, 53, 1),
	(210, 29, 15, 70, 25),
	(210, 31, 7, 53, 23),
	(210, 34, 8, 1, 1),
	(210, 35, 6, 53, 6),
	(210, 35, 6, 68, 1),
	(210, 35, 6, 22, 65),
	(210, 35, 6, 39, 50),
	(210, 35, 25, 53, 18),
	(210, 40, 12, 53, 25),
	(210, 43, 35, 53, 4),
	(210, 44, 8, 23, 6),
	(210, 45, 15, 33, 2),
	(210, 45, 15, 63, 7),
	(210, 47, 8, 53, 3),
	(210, 48, 8, 53, 17),
	(210, 48, 8, 69, 1),
	(210, 49, 8, 53, 40),
	(210, 49, 8, 69, 1),
	(210, 52, 8, 69, 21),
	(210, 55, 8, 71, 1),
	(218, 7, 8, 42, 50),
	(218, 31, 29, 53, 1),
	(221, 20, 8, 20, 33),
	(225, 8, 17, 7, 1),
	(225, 8, 17, 36, 23),
	(225, 8, 33, 53, 1),
	(225, 15, 25, 53, 1),
	(225, 25, 8, 1, 7),
	(225, 34, 8, 53, 2),
	(225, 40, 16, 53, 9),
	(225, 40, 38, 53, 7),
	(229, 3, 28, 53, 1),
	(230, 4, 8, 1, 9),
	(230, 5, 8, 1, 8),
	(230, 6, 11, 53, 1),
	(230, 7, 8, 32, 24),
	(230, 7, 8, 38, 23),
	(230, 7, 8, 11, 11),
	(230, 7, 8, 24, 22),
	(230, 7, 8, 42, 41),
	(230, 7, 8, 48, 50),
	(230, 7, 9, 25, 31),
	(230, 7, 18, 9, 67),
	(230, 8, 17, 6, 5),
	(230, 8, 17, 7, 6),
	(230, 8, 17, 59, 2),
	(230, 8, 17, 60, 10),
	(230, 8, 33, 53, 2),
	(230, 12, 8, 1, 11),
	(230, 12, 8, 69, 16),
	(230, 13, 8, 1, 43),
	(230, 13, 8, 29, 28),
	(230, 20, 8, 20, 2),
	(230, 22, 8, 1, 12),
	(230, 21, 8, 1, 10),
	(230, 23, 8, 1, 9),
	(230, 24, 8, 37, 6),
	(230, 25, 7, 8, 39),
	(230, 25, 7, 72, 13),
	(230, 25, 8, 53, 2),
	(230, 25, 8, 52, 2),
	(230, 25, 8, 67, 14),
	(230, 25, 8, 69, 7),
	(230, 26, 26, 53, 1),
	(230, 28, 8, 1, 2),
	(230, 28, 8, 69, 8),
	(230, 29, 8, 53, 8),
	(230, 29, 8, 1, 22),
	(230, 29, 8, 14, 5),
	(230, 29, 8, 19, 33),
	(230, 29, 8, 29, 15),
	(230, 29, 8, 50, 6),
	(230, 29, 8, 64, 1),
	(230, 31, 7, 53, 2),
	(230, 31, 8, 24, 3),
	(230, 32, 8, 53, 29),
	(230, 34, 8, 53, 3),
	(230, 35, 8, 47, 9),
	(230, 35, 25, 53, 2),
	(230, 36, 7, 53, 20),
	(230, 37, 4, 53, 17),
	(230, 39, 23, 53, 43),
	(230, 40, 38, 53, 3),
	(230, 42, 21, 53, 2),
	(230, 43, 35, 53, 6),
	(230, 44, 8, 1, 9),
	(230, 44, 8, 23, 13),
	(230, 47, 8, 53, 7),
	(230, 48, 8, 53, 17),
	(230, 48, 8, 69, 6),
	(230, 49, 8, 69, 3),
	(230, 50, 8, 69, 7),
	(230, 51, 8, 69, 9),
	(230, 53, 8, 53, 4),
	(230, 53, 8, 71, 15),
	(230, 55, 8, 53, 12),
	(230, 55, 8, 71, 20),
	(231, 7, 8, 11, 3),
	(231, 8, 17, 7, 4),
	(231, 8, 17, 36, 100),
	(231, 8, 17, 59, 14),
	(231, 8, 17, 60, 13),
	(231, 13, 8, 1, 14),
	(231, 13, 8, 29, 16),
	(231, 29, 8, 53, 4),
	(231, 52, 8, 69, 25),
	(231, 55, 8, 71, 1),
	(235, 23, 29, 53, 25),
	(237, 13, 8, 29, 6),
	(237, 25, 8, 53, 4),
	(237, 29, 8, 19, 10),
	(237, 29, 8, 29, 11),
	(237, 29, 8, 50, 33),
	(241, 1, 2, 53, 8),
	(241, 45, 37, 66, 33),
	(242, 8, 33, 53, 5),
	(242, 8, 33, 18, 4),
	(242, 28, 8, 69, 6),
	(242, 35, 8, 12, 21),
	(242, 50, 8, 69, 6),
	(243, 4, 8, 1, 6),
	(243, 5, 8, 1, 14),
	(243, 6, 11, 53, 10),
	(243, 7, 8, 32, 3),
	(243, 7, 8, 11, 5),
	(243, 7, 8, 24, 5),
	(243, 7, 8, 42, 1),
	(243, 7, 18, 9, 12),
	(243, 8, 17, 3, 21),
	(243, 8, 17, 4, 4),
	(243, 8, 17, 5, 1),
	(243, 8, 17, 6, 11),
	(243, 8, 17, 7, 22),
	(243, 8, 17, 31, 8),
	(243, 8, 17, 35, 13),
	(243, 8, 17, 36, 46),
	(243, 8, 17, 57, 33),
	(243, 8, 17, 58, 2),
	(243, 8, 17, 59, 3),
	(243, 8, 17, 60, 4),
	(243, 8, 33, 53, 1),
	(243, 12, 8, 1, 4),
	(243, 12, 8, 69, 3),
	(243, 13, 8, 1, 30),
	(243, 13, 8, 29, 50),
	(243, 15, 25, 53, 6),
	(243, 20, 8, 20, 2),
	(243, 20, 8, 61, 3),
	(243, 22, 8, 1, 5),
	(243, 21, 8, 1, 4),
	(243, 23, 8, 1, 4),
	(243, 24, 8, 37, 4),
	(243, 25, 8, 52, 1),
	(243, 25, 8, 67, 13),
	(243, 28, 8, 1, 2),
	(243, 28, 8, 69, 1),
	(243, 29, 8, 53, 5),
	(243, 29, 8, 1, 20),
	(243, 29, 8, 19, 3),
	(243, 29, 8, 29, 17),
	(243, 29, 8, 50, 11),
	(243, 29, 8, 64, 1),
	(243, 31, 7, 53, 5),
	(243, 34, 8, 53, 5),
	(243, 34, 8, 1, 13),
	(243, 35, 8, 47, 2),
	(243, 35, 8, 69, 4),
	(243, 35, 25, 53, 16),
	(243, 39, 23, 53, 100),
	(243, 42, 21, 53, 7),
	(243, 44, 8, 1, 4),
	(243, 44, 8, 23, 7),
	(243, 45, 15, 49, 100),
	(243, 47, 8, 53, 3),
	(243, 48, 8, 69, 1),
	(243, 49, 8, 69, 16),
	(243, 50, 8, 69, 1),
	(243, 51, 8, 69, 8),
	(243, 55, 8, 71, 3),
	(244, 25, 8, 53, 3),
	(248, 1, 3, 53, 50),
	(248, 6, 11, 53, 5),
	(248, 6, 30, 53, 22),
	(248, 7, 8, 11, 8),
	(248, 7, 8, 24, 6),
	(248, 8, 17, 3, 15),
	(248, 8, 17, 6, 8),
	(248, 8, 17, 7, 6),
	(248, 8, 17, 36, 100),
	(248, 8, 17, 59, 3),
	(248, 13, 8, 1, 29),
	(248, 23, 29, 53, 25),
	(248, 24, 8, 37, 3),
	(248, 25, 7, 53, 50),
	(248, 25, 7, 8, 100),
	(248, 25, 8, 53, 29),
	(248, 25, 8, 52, 2),
	(248, 25, 8, 67, 55),
	(248, 28, 8, 53, 10),
	(248, 29, 8, 53, 23),
	(248, 29, 8, 29, 100),
	(248, 29, 8, 64, 1),
	(248, 34, 8, 53, 2),
	(248, 34, 8, 1, 4),
	(248, 35, 25, 53, 3),
	(248, 42, 21, 53, 100),
	(248, 55, 8, 53, 30),
	(248, 55, 8, 71, 26),
	(250, 1, 32, 53, 8),
	(250, 7, 8, 32, 3),
	(250, 29, 8, 50, 33),
	(254, 28, 8, 1, 19),
	(258, 20, 8, 20, 9),
	(258, 43, 34, 53, 7),
	(260, 31, 29, 53, 3),
	(260, 31, 8, 24, 3),
	(260, 45, 15, 28, 33),
	(264, 4, 8, 53, 18),
	(264, 4, 8, 1, 42),
	(264, 5, 8, 1, 25),
	(264, 22, 8, 1, 11),
	(264, 21, 8, 1, 6),
	(264, 23, 8, 1, 6),
	(264, 25, 7, 53, 50),
	(264, 28, 8, 53, 10),
	(264, 28, 8, 1, 5),
	(264, 28, 8, 69, 2),
	(264, 29, 8, 53, 17),
	(264, 29, 8, 19, 4),
	(264, 31, 29, 53, 23),
	(264, 31, 8, 53, 9),
	(264, 31, 8, 24, 22),
	(264, 30, 8, 24, 5),
	(264, 36, 8, 1, 17),
	(264, 44, 8, 1, 3),
	(264, 45, 15, 33, 10),
	(264, 48, 8, 53, 9),
	(264, 48, 8, 69, 4),
	(264, 50, 8, 69, 5),
	(264, 51, 8, 69, 11),
	(265, 1, 3, 53, 50),
	(265, 3, 28, 53, 1),
	(265, 8, 33, 53, 4),
	(265, 25, 8, 53, 4),
	(265, 25, 8, 1, 12),
	(265, 25, 8, 52, 9),
	(265, 29, 8, 19, 11),
	(265, 29, 8, 64, 1),
	(265, 31, 29, 53, 6),
	(265, 31, 8, 24, 2),
	(266, 8, 5, 53, 78),
	(266, 8, 33, 53, 2),
	(266, 26, 26, 53, 2),
	(266, 43, 34, 53, 65),
	(266, 43, 35, 53, 6),
	(267, 4, 8, 53, 20),
	(267, 8, 33, 53, 1),
	(267, 31, 8, 53, 1),
	(267, 35, 8, 12, 9),
	(267, 44, 8, 23, 5),
	(275, 12, 8, 1, 23),
	(275, 12, 8, 69, 10),
	(275, 25, 7, 53, 13),
	(275, 25, 8, 53, 15),
	(275, 25, 8, 1, 10),
	(275, 25, 8, 52, 7),
	(275, 29, 8, 1, 2),
	(275, 29, 8, 19, 7),
	(275, 31, 8, 24, 2),
	(275, 35, 25, 53, 8),
	(275, 36, 8, 1, 17),
	(275, 44, 8, 53, 7),
	(275, 44, 8, 1, 1),
	(275, 45, 15, 49, 50),
	(275, 52, 8, 69, 13),
	(275, 55, 8, 71, 1),
	(288, 1, 2, 53, 100),
	(288, 1, 3, 53, 25),
	(288, 1, 32, 53, 100),
	(288, 3, 28, 53, 5),
	(288, 4, 8, 53, 100),
	(288, 4, 8, 1, 45),
	(288, 6, 11, 53, 20),
	(288, 6, 10, 53, 4),
	(288, 6, 24, 53, 11),
	(288, 6, 30, 53, 27),
	(288, 7, 29, 53, 50),
	(288, 7, 8, 32, 13),
	(288, 7, 8, 38, 30),
	(288, 7, 8, 11, 51),
	(288, 7, 8, 24, 32),
	(288, 7, 8, 42, 50),
	(288, 7, 8, 46, 76),
	(288, 7, 9, 25, 17),
	(288, 7, 18, 53, 55),
	(288, 8, 5, 53, 3),
	(288, 8, 17, 3, 26),
	(288, 8, 17, 4, 9),
	(288, 8, 17, 5, 27),
	(288, 8, 17, 6, 28),
	(288, 8, 17, 7, 23),
	(288, 8, 17, 30, 3),
	(288, 8, 17, 31, 9),
	(288, 8, 17, 35, 50),
	(288, 8, 17, 36, 100),
	(288, 8, 17, 54, 55),
	(288, 8, 17, 55, 37),
	(288, 8, 17, 56, 41),
	(288, 8, 17, 58, 19),
	(288, 8, 17, 59, 12),
	(288, 8, 17, 60, 17),
	(288, 8, 33, 53, 4),
	(288, 8, 33, 18, 35),
	(288, 9, 17, 3, 100),
	(288, 9, 17, 6, 50),
	(288, 12, 8, 1, 7),
	(288, 12, 8, 69, 7),
	(288, 12, 19, 16, 5),
	(288, 13, 8, 1, 23),
	(288, 13, 8, 29, 21),
	(288, 16, 8, 14, 50),
	(288, 18, 15, 63, 21),
	(288, 18, 15, 73, 100),
	(288, 20, 40, 53, 10),
	(288, 20, 8, 20, 5),
	(288, 20, 8, 61, 8),
	(288, 22, 8, 1, 40),
	(288, 21, 29, 53, 29),
	(288, 21, 8, 1, 46),
	(288, 23, 8, 53, 70),
	(288, 23, 8, 1, 57),
	(288, 24, 8, 37, 31),
	(288, 25, 7, 53, 10),
	(288, 25, 8, 8, 20),
	(288, 25, 8, 53, 28),
	(288, 25, 8, 1, 39),
	(288, 25, 8, 52, 26),
	(288, 25, 8, 67, 76),
	(288, 25, 8, 69, 56),
	(288, 26, 26, 53, 3),
	(288, 28, 8, 53, 38),
	(288, 28, 8, 1, 47),
	(288, 28, 8, 69, 47),
	(288, 29, 8, 53, 35),
	(288, 29, 8, 1, 71),
	(288, 29, 8, 14, 53),
	(288, 29, 8, 19, 12),
	(288, 29, 8, 29, 68),
	(288, 29, 8, 50, 56),
	(288, 29, 8, 64, 62),
	(288, 29, 8, 65, 100),
	(288, 29, 15, 70, 10),
	(288, 31, 29, 53, 19),
	(288, 31, 7, 53, 3),
	(288, 31, 8, 53, 24),
	(288, 31, 8, 24, 53),
	(288, 32, 8, 53, 29),
	(288, 32, 8, 69, 100),
	(288, 33, 8, 62, 51),
	(288, 34, 8, 53, 17),
	(288, 34, 8, 1, 19),
	(288, 34, 18, 53, 70),
	(288, 34, 19, 34, 100),
	(288, 35, 6, 53, 100),
	(288, 35, 6, 27, 15),
	(288, 35, 8, 47, 2),
	(288, 35, 8, 12, 30),
	(288, 35, 8, 69, 26),
	(288, 35, 25, 53, 14),
	(288, 36, 7, 53, 7),
	(288, 36, 8, 1, 11),
	(288, 38, 36, 53, 14),
	(288, 37, 20, 53, 15),
	(288, 37, 4, 53, 27),
	(288, 39, 23, 53, 14),
	(288, 40, 12, 53, 33),
	(288, 40, 38, 53, 18),
	(288, 42, 21, 53, 30),
	(288, 43, 35, 53, 8),
	(288, 44, 1, 53, 9),
	(288, 44, 7, 53, 53),
	(288, 44, 8, 53, 32),
	(288, 44, 8, 1, 24),
	(288, 44, 8, 23, 35),
	(288, 45, 15, 49, 100),
	(288, 45, 15, 63, 8),
	(288, 46, 39, 53, 100),
	(288, 47, 8, 53, 7),
	(288, 48, 8, 53, 44),
	(288, 48, 8, 69, 38),
	(288, 49, 8, 53, 36),
	(288, 49, 8, 69, 52),
	(288, 50, 8, 69, 46),
	(288, 51, 8, 69, 58),
	(288, 52, 8, 69, 28),
	(288, 53, 8, 71, 51),
	(288, 55, 29, 53, 100),
	(288, 55, 8, 53, 22),
	(288, 55, 8, 69, 49),
	(288, 55, 8, 71, 44),
	(288, 54, 8, 53, 22),
	(293, 7, 8, 32, 3),
	(293, 49, 8, 69, 12),
	(294, 3, 28, 53, 1),
	(294, 12, 8, 69, 13),
	(294, 43, 34, 53, 7),
	(295, 48, 8, 1, 17),
	(299, 1, 32, 53, 16),
	(299, 20, 8, 20, 42),
	(299, 20, 8, 61, 2),
	(299, 22, 8, 1, 6),
	(303, 49, 8, 69, 12),
	(304, 20, 40, 53, 9),
	(304, 22, 29, 53, 100),
	(47, 7, 8, 32, 2),
	(62, 8, 17, 3, 8),
	(62, 8, 17, 6, 25),
	(62, 8, 17, 60, 6),
	(73, 7, 8, 42, 67),
	(73, 24, 8, 37, 4),
	(73, 34, 8, 1, 4),
	(73, 49, 8, 69, 12),
	(74, 7, 8, 32, 2),
	(79, 21, 29, 53, 14),
	(79, 28, 8, 1, 10),
	(79, 29, 8, 53, 100),
	(94, 23, 8, 1, 3),
	(97, 31, 29, 53, 3),
	(105, 21, 29, 53, 25),
	(105, 29, 8, 19, 13),
	(115, 48, 8, 69, 25),
	(119, 8, 17, 7, 1),
	(119, 44, 8, 53, 14),
	(126, 34, 8, 1, 4),
	(91, 51, 8, 69, 8),
	(131, 31, 29, 53, 1),
	(150, 29, 8, 64, 1),
	(150, 35, 25, 53, 8),
	(157, 25, 8, 69, 8),
	(157, 37, 4, 53, 10),
	(157, 44, 8, 53, 14),
	(161, 23, 29, 53, 25),
	(177, 7, 8, 38, 4),
	(177, 23, 8, 1, 3),
	(177, 25, 8, 67, 8),
	(177, 34, 8, 53, 3),
	(177, 55, 8, 53, 35),
	(180, 13, 8, 29, 6),
	(180, 25, 8, 1, 18),
	(181, 31, 8, 53, 1),
	(182, 7, 8, 32, 22),
	(182, 7, 8, 38, 3),
	(187, 31, 8, 53, 1),
	(189, 7, 8, 32, 2),
	(193, 48, 8, 69, 25),
	(194, 7, 8, 11, 2),
	(194, 21, 8, 1, 4),
	(194, 23, 8, 1, 3),
	(194, 25, 8, 1, 9),
	(194, 29, 8, 64, 1),
	(194, 34, 8, 53, 2),
	(195, 25, 8, 67, 9),
	(195, 31, 29, 53, 1),
	(196, 8, 5, 53, 5),
	(196, 23, 8, 1, 4),
	(196, 29, 8, 64, 1),
	(196, 34, 8, 53, 3),
	(197, 48, 8, 69, 25),
	(200, 21, 29, 53, 25),
	(200, 25, 8, 53, 100),
	(200, 31, 29, 53, 1),
	(200, 31, 8, 53, 1),
	(205, 51, 8, 69, 8),
	(211, 7, 8, 42, 33),
	(211, 20, 8, 19, 3),
	(211, 49, 8, 69, 29),
	(212, 25, 8, 67, 6),
	(213, 7, 8, 42, 20),
	(213, 25, 8, 52, 5),
	(213, 44, 8, 53, 9),
	(213, 44, 8, 23, 1),
	(214, 25, 8, 67, 9),
	(214, 50, 8, 69, 5),
	(215, 7, 8, 24, 4),
	(215, 29, 8, 19, 13),
	(216, 7, 8, 38, 3),
	(216, 13, 8, 29, 6),
	(222, 7, 8, 38, 5),
	(224, 13, 8, 29, 7),
	(224, 25, 8, 1, 9),
	(224, 25, 8, 67, 8),
	(224, 25, 8, 69, 13),
	(224, 34, 8, 1, 6),
	(226, 44, 8, 53, 7),
	(226, 44, 8, 1, 4),
	(233, 7, 8, 11, 2),
	(246, 7, 8, 38, 2),
	(247, 44, 8, 53, 7),
	(252, 20, 8, 20, 3),
	(252, 25, 8, 67, 11),
	(252, 25, 8, 69, 13),
	(252, 44, 8, 1, 4),
	(255, 25, 8, 1, 8),
	(255, 25, 8, 67, 12),
	(257, 7, 8, 32, 3),
	(257, 31, 8, 53, 1),
	(261, 20, 8, 20, 3),
	(262, 25, 8, 67, 9),
	(263, 34, 8, 53, 3),
	(269, 7, 8, 42, 33),
	(270, 20, 8, 20, 4),
	(273, 34, 8, 1, 4),
	(278, 44, 8, 53, 7),
	(279, 7, 8, 38, 4),
	(281, 22, 29, 53, 100),
	(281, 21, 29, 53, 25),
	(281, 23, 8, 1, 4),
	(282, 49, 8, 69, 12),
	(287, 7, 8, 32, 2),
	(287, 21, 29, 53, 25),
	(289, 8, 33, 53, 1),
	(289, 25, 8, 52, 29),
	(289, 25, 8, 69, 12),
	(289, 34, 8, 53, 2),
	(289, 55, 8, 53, 18),
	(290, 44, 8, 53, 7),
	(291, 7, 8, 42, 20),
	(298, 8, 17, 60, 6),
	(298, 23, 29, 53, 25),
	(298, 25, 8, 53, 100),
	(302, 7, 8, 32, 2),
	(305, 7, 8, 11, 6),
	(306, 34, 8, 53, 2),
	(308, 21, 29, 53, 14),
	(308, 25, 8, 1, 12),
	(308, 25, 8, 67, 16),
	(308, 50, 8, 69, 5),
	(309, 7, 8, 11, 5);
/*!40000 ALTER TABLE `mutaciones_tumores` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.pathways
CREATE TABLE IF NOT EXISTS `pathways` (
  `id_pathway` smallint(11) unsigned NOT NULL AUTO_INCREMENT,
  `id_external` mediumint(8) unsigned DEFAULT NULL,
  `nombre_pathway` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  `link_pathway` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  PRIMARY KEY (`id_pathway`)
) ENGINE=MyISAM AUTO_INCREMENT=260 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.pathways: 259 rows
/*!40000 ALTER TABLE `pathways` DISABLE KEYS */;
INSERT INTO `pathways` (`id_pathway`, `id_external`, `nombre_pathway`, `link_pathway`) VALUES
	(1, NULL, NULL, NULL),
	(2, 576270, 'Activated NOTCH1 Transmits Signal to the Nucleus Constitutive Signaling by NOTCH1 HD Domain Mutants  Notch Signaling Pathway  Signaling by NOTCH and NOTCH1', NULL),
	(3, 105829, 'Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins, organism-specific biosystem', NULL),
	(4, 576251, 'Activation of NF-kappaB in B Cells, organism-specific biosystem', NULL),
	(5, 83117, 'Acute myeloid leukemia, organism-specific biosystem', NULL),
	(6, 366160, 'Adaptive Immune System, organism-specific biosystem', NULL),
	(7, 83070, 'Adherens junction  ', NULL),
	(255, 167190, 'Protein processing in endoplasmic reticulum', NULL),
	(8, 119533, 'Adherens junctions interactions, organism-specific biosystem', NULL),
	(9, 83093, 'Adipocytokine signaling pathway, organism-specific biosystem', NULL),
	(10, 198832, 'Adipogenesis, organism-specific biosystem', NULL),
	(11, 755436, 'AhR pathway  Keap1-Nrf2 Pathway  Oxidative Stress, Protein processing in endoplasmic reticulum  Selenium Metabolism and Selenoproteins', NULL),
	(12, 83097, 'Alzheimer\'s disease, organism-specific biosystem', NULL),
	(13, 198868, 'AMPK signaling, organism-specific biosystem', NULL),
	(14, 485, 'Antigen processing and presentation, conserved biosystem', NULL),
	(15, 105825, 'APC/C-mediated degradation of cell cycle proteins', NULL),
	(16, 198822, 'Apoptosis Modulation and Signaling, organism-specific biosystem', NULL),
	(17, 198797, 'Apoptosis, organism-specific biosystem', NULL),
	(18, 105648, 'Apoptosis, organism-specific biosystem', NULL),
	(19, 83060, 'Apoptosis, organism-specific biosystem', NULL),
	(20, 138034, 'Arf6 signaling events, organism-specific biosystem', NULL),
	(21, 138006, 'ATF-2 transcription factor network, organism-specific biosystem', NULL),
	(22, 137925, 'Aurora A signaling, organism-specific biosystem', NULL),
	(23, 83065, 'Axon guidance, organism-specific biosystem', NULL),
	(24, 775967, 'Axon guidance, organism-specific biosystem', NULL),
	(25, 105688, 'Axon guidance, organism-specific biosystem', NULL),
	(26, 198909, 'B Cell Receptor Signaling Pathway, organism-specific biosystem', NULL),
	(27, 83081, 'B cell receptor signaling pathway, organism-specific biosystem', NULL),
	(28, 137959, 'BARD1 signaling events, organism-specific biosystem', NULL),
	(29, 138058, 'BCR signaling pathway, organism-specific biosystem', NULL),
	(30, 712093, 'BDNF signaling pathway, organism-specific biosystem', NULL),
	(31, 106512, 'Beta-catenin phosphorylation cascade, organism-specific biosystem', NULL),
	(32, 413477, 'Bloom\'s syndrome complex, organism-specific biosystem', NULL),
	(33, 413428, 'BRCA1-associated genome surveillance complex (BASC), organism-specific biosystem', NULL),
	(34, 137974, 'Caspase cascade in apoptosis', NULL),
	(35, 119554, 'CD28 dependent PI3K/Akt signaling, organism-specific biosystem', NULL),
	(36, 160998, 'CDO in myogenesis, organism-specific biosystem', NULL),
	(37, 83069, 'Cell adhesion molecules (CAMs), organism-specific biosystem', NULL),
	(38, 105739, 'Cell Cycle Checkpoints, organism-specific biosystem', NULL),
	(39, 463, 'Cell cycle, conserved biosystem', NULL),
	(40, 105765, 'Cell Cycle, Mitotic, organism-specific biosystem', NULL),
	(41, 530733, 'Cell Cycle, organism-specific biosystem', NULL),
	(42, 198811, 'Cell cycle, organism-specific biosystem', NULL),
	(43, 83054, 'Cell cycle, organism-specific biosystem', NULL),
	(44, 477132, 'Cell-Cell communication, organism-specific biosystem', NULL),
	(45, 119532, 'Cell-cell junction organization, organism-specific biosystem', NULL),
	(46, 496516, 'chromatin modification', NULL),
	(47, 83116, 'Chronic myeloid leukemia, organism-specific biosystem', NULL),
	(48, 187173, 'Circadian Clock, organism-specific biosystem', NULL),
	(49, 137978, 'Circadian rhythm pathway ', NULL),
	(50, 82927, 'Citrate cycle (TCA cycle), organism-specific biosystem', NULL),
	(51, 138020, 'Class I PI3K signaling events mediated by Akt', NULL),
	(52, 83106, 'Colorectal cancer Integrated Breast Cancer Pathway Mismatch repair, Integrated Cancer pathway  Pathways in cancer Prostate Cancer Signaling Pathways in Glioblastoma', NULL),
	(53, 685535, 'Constitutive PI3K/AKT Signaling in Cancer, organism-specific biosystem', NULL),
	(54, 119552, 'Costimulation by the CD28 family, organism-specific biosystem', NULL),
	(55, 83051, 'Cytokine-cytokine receptor interaction   ', NULL),
	(252, 106384, 'Signaling by PDGF', NULL),
	(253, 83119, 'Non-small cell lung cancer', NULL),
	(56, 477129, 'Developmental Biology, organism-specific biosystem', NULL),
	(57, 137939, 'Direct p53 effectors, organism-specific biosystem', NULL),
	(58, 198827, 'DNA damage response (only ATM dependent)', NULL),
	(59, 198788, 'DNA damage response, organism-specific biosystem', NULL),
	(60, 105837, 'DNA Repair, organism-specific biosystem', NULL),
	(61, 645266, 'Downregulation of SMAD2/3:SMAD4 transcriptional activity, organism-specific biosystem', NULL),
	(62, 105778, 'E2F mediated regulation of DNA replication, organism-specific biosystem', NULL),
	(63, 137934, 'E2F transcription factor network, organism-specific biosystem', NULL),
	(64, 137966, 'E-cadherin signaling events, organism-specific biosystem', NULL),
	(65, 137970, 'EGF receptor (ErbB1) signaling pathway, organism-specific biosystem', NULL),
	(66, 106342, 'EGFR downregulation, organism-specific biosystem', NULL),
	(67, 198782, 'EGFR1 Signaling Pathway, organism-specific biosystem', NULL),
	(68, 730310, 'Elastic fibre formation, organism-specific biosystem', NULL),
	(69, 102279, 'Endocytosis, organism-specific biosystem', NULL),
	(70, 198882, 'EPO Receptor Signaling, organism-specific biosystem', NULL),
	(71, 198844, 'ErbB signaling pathway, organism-specific biosystem', NULL),
	(72, 83049, 'ErbB signaling pathway, organism-specific biosystem', NULL),
	(73, 137955, 'ErbB2/ErbB3 signaling events, Hippo signaling pathway', NULL),
	(74, 142309, 'ethanol degradation II, organism-specific biosystem', NULL),
	(75, 142308, 'ethanol degradation IV, organism-specific biosystem', NULL),
	(76, 576262, 'Extracellular matrix organization, organism-specific biosystem', NULL),
	(77, 377128, 'Fanconi anemia pathway, conserved biosystem', NULL),
	(78, 105895, 'Fanconi Anemia pathway, organism-specific biosystem', NULL),
	(79, 377262, 'Fanconi anemia pathway, organism-specific biosystem', NULL),
	(80, 82935, 'Fatty acid metabolism, organism-specific biosystem', NULL),
	(81, 106115, 'Fatty Acyl-CoA Biosynthesis, organism-specific biosystem', NULL),
	(82, 106344, 'FGFR ligand binding and activation, organism-specific biosystem', NULL),
	(83, 106349, 'FGFR2 ligand binding and activation, organism-specific biosystem', NULL),
	(84, 83067, 'Focal adhesion, organism-specific biosystem', NULL),
	(85, 198795, 'Focal Adhesion, organism-specific biosystem', NULL),
	(86, 138036, 'FoxO family signaling, organism-specific biosystem', NULL),
	(87, 198849, 'G Protein Signaling Pathways, organism-specific biosystem', NULL),
	(88, 198805, 'G1 to S cell cycle control, organism-specific biosystem', NULL),
	(89, 105801, 'G2/M Transition, organism-specific biosystem', NULL),
	(90, 105926, 'Gap junction trafficking and regulation, organism-specific biosystem', NULL),
	(91, 105937, 'Gene Expression, organism-specific biosystem', NULL),
	(92, 82926, 'Glycolysis / Gluconeogenesis, organism-specific biosystem', NULL),
	(93, 358, 'Glycosaminoglycan biosynthesis - heparan sulfate / heparin, conserved biosystem', NULL),
	(94, 119548, 'GPCR downstream signaling, organism-specific biosystem', NULL),
	(95, 161020, 'GPCR ligand binding, organism-specific biosystem', NULL),
	(96, 83063, 'Hedgehog signaling pathway, organism-specific biosystem', NULL),
	(97, 198835, 'Hedgehog Signaling Pathway, organism-specific biosystem', NULL),
	(98, 106028, 'Hemostasis, organism-specific biosystem', NULL),
	(99, 545407, 'heparan sulfate biosynthesis, conserved biosystem', NULL),
	(100, 695200, 'HIF-1 signaling pathway, organism-specific biosystem', NULL),
	(101, 749777, 'Hippo signaling pathway, organism-specific biosystem', NULL),
	(102, 105863, 'Homologous recombination repair of replication-independent double-strand breaks, organism-specific biosystem', NULL),
	(103, 198890, 'Homologous recombination  MRN complex meiosis meiotic recombination', NULL),
	(104, 373901, 'HTLV-I infection, organism-specific biosystem', NULL),
	(105, 83100, 'Huntington\'s disease, organism-specific biosystem', NULL),
	(106, 198871, 'Id Signaling Pathway, organism-specific biosystem', NULL),
	(107, 730346, 'IGF1R signaling cascade, organism-specific biosystem', NULL),
	(108, 137944, 'IL1-mediated signaling events, organism-specific biosystem', NULL),
	(109, 137938, 'IL2 signaling events mediated by PI3K, organism-specific biosystem', NULL),
	(110, 137933, 'IL4-mediated signaling events, organism-specific biosystem', NULL),
	(111, 198857, 'IL-7 Signaling Pathway  ', NULL),
	(247, 161012, 'Post-translational protein modification', NULL),
	(248, 83071, 'Tight junction', NULL),
	(112, 138026, 'Insulin Pathway, organism-specific biosystem', NULL),
	(113, 83090, 'Insulin signaling pathway, organism-specific biosystem', NULL),
	(114, 198845, 'Insulin Signaling, organism-specific biosystem', NULL),
	(115, 219801, 'Integrated Breast Cancer Pathway, organism-specific biosystem', NULL),
	(116, 711360, 'Integrated Pancreatic Cancer Pathway, organism-specific biosystem', NULL),
	(117, 187103, 'Interferon Signaling, organism-specific biosystem', NULL),
	(118, 83077, 'Jak-STAT signaling pathway, organism-specific biosystem', NULL),
	(119, 198826, 'Kit Receptor Signaling Pathway, organism-specific biosystem', NULL),
	(120, 105810, 'Loss of proteins required for interphase microtubule organizationÂ from the centrosome', NULL),
	(121, 82956, 'Lysine degradation', NULL),
	(122, 320, 'Lysine degradation, conserved biosystem', NULL),
	(123, 99052, 'Lysosome, organism-specific biosystem', NULL),
	(124, 83048, 'MAPK signaling pathway, organism-specific biosystem', NULL),
	(125, 198779, 'MAPK signaling pathway, organism-specific biosystem', NULL),
	(126, 106263, 'Metabolism of nucleotides, organism-specific biosystem', NULL),
	(127, 477135, 'Metabolism   Activation of Gene Expression by SREBP (SREBF)  Generic Transcription Pathway HIF-1-alpha transcription factor network,  IL-6 Signaling Pathway', NULL),
	(128, 672449, 'miRs in Muscle Cell Differentiation, organism-specific biosystem', NULL),
	(129, 83045, 'Mismatch repair, organism-specific biosystem', NULL),
	(130, 160942, 'Mitotic G2-G2/M phases, organism-specific biosystem', NULL),
	(131, 198843, 'mRNA processing, organism-specific biosystem', NULL),
	(132, 105952, 'mRNA Splicing - Major Pathway, organism-specific biosystem', NULL),
	(133, 105951, 'mRNA Splicing, organism-specific biosystem', NULL),
	(134, 193328, 'mRNA surveillance pathway', NULL),
	(135, 138001, 'mTOR signaling pathway, organism-specific biosystem', NULL),
	(136, 83059, 'mTOR signaling pathway, organism-specific biosystem', NULL),
	(137, 685536, 'Mucopolysaccharidoses, organism-specific biosystem', NULL),
	(138, 160997, 'Myogenesis, organism-specific biosystem', NULL),
	(139, 160980, 'NADPH regeneration, organism-specific biosystem', NULL),
	(140, 503465, 'negative regulation of Ras GTPase activity', NULL),
	(141, 672460, 'Neural Crest Differentiation, organism-specific biosystem', NULL),
	(142, 83053, 'Neuroactive ligand-receptor interaction, organism-specific biosystem', NULL),
	(143, 100064, 'Neurotrophin signaling pathway, conserved biosystem', NULL),
	(144, 101143, 'Neurotrophin signaling pathway, organism-specific biosystem', NULL),
	(145, 634527, 'NF-kappa B signaling pathway, organism-specific biosystem', NULL),
	(146, 122191, 'NOD-like receptor signaling pathway, organism-specific biosystem', NULL),
	(147, 198891, 'Notch Signaling Pathway', NULL),
	(148, 83062, 'Notch signaling pathway  Signaling by NOTCH ', NULL),
	(149, 105883, 'Nucleotide Excision Repair, organism-specific biosystem', NULL),
	(150, 711361, 'Oncostatin M Signaling Pathway, organism-specific biosystem', NULL),
	(151, 142307, 'oxidative ethanol degradation III, organism-specific biosystem', NULL),
	(152, 138078, 'p38 signaling mediated by MAPKAP kinases, organism-specific biosystem', NULL),
	(153, 83055, 'p53 signaling pathway, organism-specific biosystem', NULL),
	(154, 83105, 'Pathways in cancer ', NULL),
	(250, 138080, 'Aurora B signaling', NULL),
	(155, 119557, 'PD-1 signaling, organism-specific biosystem', NULL),
	(156, 83052, 'Phosphatidylinositol signaling system, organism-specific biosystem', NULL),
	(157, 106415, 'Phosphorylation of CD3 and TCR zeta chains, organism-specific biosystem', NULL),
	(158, 106427, 'PI3K Cascade, organism-specific biosystem', NULL),
	(159, 530737, 'PI3K events in ERBB2 signaling, organism-specific biosystem', NULL),
	(160, 106474, 'PI3K/AKT activation, organism-specific biosystem', NULL),
	(161, 685534, 'PI3K/AKT Signaling in Cancer, organism-specific biosystem', NULL),
	(162, 692979, 'PI3K-Akt signaling pathway, conserved biosystem', NULL),
	(163, 692234, 'PI3K-Akt signaling pathway, organism-specific biosystem', NULL),
	(164, 106471, 'PKA activation, organism-specific biosystem', NULL),
	(165, 501555, 'positive regulation of Ras GTPase activity', NULL),
	(166, 83042, 'PPAR signaling pathway, organism-specific biosystem', NULL),
	(167, 530749, 'PPARA Activates Gene Expression Gene Expression  Generic Transcription Pathway Metabolism', NULL),
	(168, 83125, 'Primary immunodeficiency, organism-specific biosystem', NULL),
	(169, 755440, 'Prostate Cancer, organism-specific biosystem', NULL),
	(170, 172847, 'Protein digestion and absorption, organism-specific biosystem', NULL),
	(171, 167325, 'Protein processing in endoplasmic reticulum, organism-specific biosystem', NULL),
	(172, 142277, 'purine nucleotides de novo biosynthesis II, organism-specific biosystem', NULL),
	(173, 106327, 'Pyruvate metabolism and Citric Acid (TCA) cycle, organism-specific biosystem', NULL),
	(174, 105809, 'Recruitment of NuMA to mitotic centrosomes, organism-specific biosystem', NULL),
	(175, 198874, 'Regulation of Actin Cytoskeleton ', NULL),
	(254, 0, 'Mitochondrial biogenesis', NULL),
	(176, 645260, 'Regulation of Hypoxia-inducible Factor (HIF) by Oxygen, organism-specific biosystem', NULL),
	(177, 137963, 'Regulation of nuclear SMAD2/3 signaling, organism-specific biosystem', NULL),
	(178, 137987, 'Regulation of Telomerase, organism-specific biosystem', NULL),
	(179, 105896, 'Regulation of the Fanconi anemia pathway, organism-specific biosystem', NULL),
	(180, 169352, 'Regulation of Wnt-mediated beta catenin signaling and target gene transcription, organism-specific biosystem', NULL),
	(181, 106334, 'Regulatory RNA pathways, organism-specific biosystem', NULL),
	(182, 106007, 'Rev-mediated nuclear export of HIV-1 RNA, organism-specific biosystem', NULL),
	(183, 106503, 'Rho GTPase cycle, organism-specific biosystem', NULL),
	(184, 169356, 'RhoA signaling pathway', NULL),
	(185, 117291, 'RNA degradation, organism-specific biosystem', NULL),
	(186, 106550, 'RNA Polymerase I Transcription, organism-specific biosystem', NULL),
	(187, 106557, 'RNA Polymerase II Transcription, organism-specific biosystem', NULL),
	(188, 198901, 'SIDS Susceptibility Pathways, organism-specific biosystem', NULL),
	(189, 477114, 'Signal Transduction, organism-specific biosystem (from REACTOME)', NULL),
	(190, 730349, 'Signaling by Activin, organism-specific biosystem', NULL),
	(191, 530769, 'Signaling by constitutively active EGFR, organism-specific biosystem', NULL),
	(192, 530768, 'Signaling by EGFR in Cancer, organism-specific biosystem', NULL),
	(193, 106337, 'Signaling by EGFR, organism-specific biosystem', NULL),
	(194, 645274, 'Signaling by FGFR in disease, organism-specific biosystem', NULL),
	(195, 645278, 'Signaling by FGFR1 fusion mutants, organism-specific biosystem', NULL),
	(196, 106356, 'Signaling by GPCR', NULL),
	(197, 576275, 'Signaling by Hippo, organism-specific biosystem', NULL),
	(198, 106419, 'Signaling by Insulin receptor', NULL),
	(199, 106502, 'Signaling by Rho GTPases, organism-specific biosystem', NULL),
	(200, 106510, 'Signaling by Wnt, organism-specific biosystem', NULL),
	(201, 169348, 'Signaling events mediated by focal adhesion kinase, organism-specific biosystem (from', NULL),
	(202, 138062, 'Signaling events mediated by HDAC Class II, organism-specific biosystem', NULL),
	(203, 138068, 'Signaling events mediated by Stem cell factor receptor (c-Kit), organism-specific biosystem', NULL),
	(204, 137950, 'Signaling events mediated by the Hedgehog family, organism-specific biosystem', NULL),
	(205, 137940, 'Signaling events mediated by VEGFR1 and VEGFR2, organism-specific biosystem', NULL),
	(206, 137915, 'Signaling events regulated by Ret tyrosine kinase, organism-specific biosystem', NULL),
	(207, 672458, 'Signaling Pathways in Glioblastoma    p53 signaling pathway', NULL),
	(208, 106461, 'Signalling to RAS, organism-specific biosystem', NULL),
	(209, 106478, 'Signalling to STAT3, organism-specific biosystem', NULL),
	(210, 576277, 'Small Interfering RNA (siRNA) Biogenesis, organism-specific biosystem', NULL),
	(211, 125136, 'Spliceosome, organism-specific biosystem', NULL),
	(212, 672457, 'Synaptic Vesicle Pathway, organism-specific biosystem', NULL),
	(213, 83080, 'T cell receptor signaling pathway, organism-specific biosystem', NULL),
	(214, 198787, 'TCA Cycle, organism-specific biosystem', NULL),
	(215, 137998, 'TCR signaling in naive CD4+ T cells, organism-specific biosystem', NULL),
	(216, 138055, 'TCR signaling in naive CD8+ T cells, organism-specific biosystem', NULL),
	(217, 198862, 'TCR Signaling Pathway, organism-specific biosystem', NULL),
	(218, 645292, 'TGF-beta receptor signaling activates SMADs, organism-specific biosystem', NULL),
	(219, 198774, 'TGF-beta Receptor Signaling Pathway, organism-specific biosystem', NULL),
	(220, 138024, 'TGF-beta receptor signaling, organism-specific biosystem', NULL),
	(221, 475, 'TGF-beta signaling pathway, conserved biosystem', NULL),
	(222, 83064, 'TGF-beta signaling pathway, organism-specific biosystem', NULL),
	(223, 83112, 'Thyroid cancer, organism-specific biosystem', NULL),
	(224, 198884, 'TNF-alpha/NF-kB Signaling Pathway, organism-specific biosystem', NULL),
	(225, 106389, 'Toll Like Receptors ', NULL),
	(249, 177876, 'RNA transport', NULL),
	(251, 138003, 'Aurora C signaling', NULL),
	(226, 106388, 'Toll-Like Receptors Cascades  Toll-like receptor signaling pathway  MAPK signaling pathway GnRH signaling pathway,', NULL),
	(227, 523016, 'Transcriptional misregulation in cancer', NULL),
	(228, 522987, 'Transcriptional misregulation in cancer  ', NULL),
	(242, 138071, 'PDGFR-beta signaling pathway', NULL),
	(229, 205243, 'Transcriptional Regulation of White Adipocyte Differentiation, organism-specific biosystem', NULL),
	(230, 105965, 'Translation, organism-specific biosystem', NULL),
	(231, 169351, 'Validated targets of C-MYC transcriptional activation, organism-specific biosystem', NULL),
	(232, 96530, 'Vascular smooth muscle contraction  Tight junction  Muscle contraction  Muscle contraction', NULL),
	(233, 83066, 'VEGF signaling pathway, organism-specific biosystem', NULL),
	(234, 198799, 'Wnt Signaling Pathway NetPath, organism-specific biosystem', NULL),
	(235, 83061, 'Wnt signaling pathway, organism-specific biosystem', NULL),
	(236, 198789, 'Wnt Signaling Pathway, organism-specific biosystem', NULL),
	(237, 576276, 'YAP1- and WWTR1 (TAZ)-stimulated gene expression, organism-specific biosystem', NULL),
	(238, 137930, 'Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)', NULL),
	(239, 510180, 'hepatocyte growth factor receptor signaling pathway\r\n\r\n', NULL),
	(240, 490294, 'hepatocyte growth factor-activated receptor activity\r\n\r\n', NULL),
	(241, 488, 'Jak-STAT signaling pathway, conserved biosystem ', NULL),
	(243, 198771, 'DNA Replication', NULL),
	(244, 137916, 'Regulation of retinoblastoma protein', NULL),
	(245, 198863, 'Estrogen signaling pathway, organism-specific biosystem', NULL),
	(246, 530734, 'Signaling by ERBB2', NULL),
	(256, 83079, 'Natural killer cell mediated cytotoxicity', NULL),
	(257, 119557, 'PD-1 signaling', NULL),
	(258, 83040, 'Proteasome', NULL),
	(259, 138049, 'PDGFR-alpha signaling pathway', NULL);
/*!40000 ALTER TABLE `pathways` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.tejidos_n0
CREATE TABLE IF NOT EXISTS `tejidos_n0` (
  `id_tejido_n0` smallint(5) unsigned NOT NULL AUTO_INCREMENT,
  `nombre_tejido_n0` varchar(255) DEFAULT NULL,
  PRIMARY KEY (`id_tejido_n0`)
) ENGINE=MyISAM AUTO_INCREMENT=48 DEFAULT CHARSET=utf8;

-- Volcando datos para la tabla farmacos.tejidos_n0: 47 rows
/*!40000 ALTER TABLE `tejidos_n0` DISABLE KEYS */;
INSERT INTO `tejidos_n0` (`id_tejido_n0`, `nombre_tejido_n0`) VALUES
	(1, 'adrenal_gland'),
	(2, 'autonomic_ganglia'),
	(3, 'biliary_tract'),
	(4, 'bone'),
	(5, 'breast'),
	(6, 'central_nervous_system'),
	(7, 'cervix'),
	(8, 'endometrium'),
	(9, 'eye'),
	(10, 'fallopian_tube'),
	(11, 'female_genital_tract_(site_indeterminate)'),
	(12, 'gastrointestinal_tract_(site_indeterminate)'),
	(13, 'genital_tract'),
	(14, 'haematopoietic_and_lymphoid_tissue'),
	(15, 'kidney'),
	(16, 'large_intestine'),
	(17, 'liver'),
	(18, 'lung'),
	(19, 'mediastinum'),
	(20, 'meninges'),
	(21, 'midline_organs'),
	(22, 'NS'),
	(23, 'oesophagus'),
	(24, 'ovary'),
	(25, 'pancreas'),
	(26, 'paratesticular_tissues'),
	(27, 'parathyroid'),
	(28, 'penis'),
	(29, 'pericardium'),
	(30, 'peritoneum'),
	(31, 'pituitary'),
	(32, 'placenta'),
	(33, 'pleura'),
	(34, 'prostate'),
	(35, 'retroperitoneum'),
	(36, 'salivary_gland'),
	(37, 'skin'),
	(38, 'small_intestine'),
	(39, 'soft_tissue'),
	(40, 'stomach'),
	(41, 'testis'),
	(42, 'thymus'),
	(43, 'thyroid'),
	(44, 'upper_aerodigestive_tract'),
	(45, 'urinary_tract'),
	(46, 'vagina'),
	(47, 'vulva');
/*!40000 ALTER TABLE `tejidos_n0` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.tejidos_n1
CREATE TABLE IF NOT EXISTS `tejidos_n1` (
  `id_tejido_n1` smallint(5) unsigned NOT NULL AUTO_INCREMENT,
  `id_tejido_n0` smallint(5) unsigned NOT NULL,
  `nombre_tejido_n0` varchar(255) DEFAULT NULL,
  `nombre_tejido_n1` varchar(255) DEFAULT NULL,
  PRIMARY KEY (`id_tejido_n1`)
) ENGINE=MyISAM AUTO_INCREMENT=56 DEFAULT CHARSET=utf8;

-- Volcando datos para la tabla farmacos.tejidos_n1: 55 rows
/*!40000 ALTER TABLE `tejidos_n1` DISABLE KEYS */;
INSERT INTO `tejidos_n1` (`id_tejido_n1`, `id_tejido_n0`, `nombre_tejido_n0`, `nombre_tejido_n1`) VALUES
	(1, 1, 'adrenal_gland', 'adrenal_gland'),
	(2, 1, 'adrenal_gland', 'NS'),
	(3, 2, 'autonomic_ganglia', 'NS'),
	(4, 3, 'biliary_tract', 'bile_duct'),
	(5, 3, 'biliary_tract', 'gallbladder'),
	(6, 4, 'bone', 'NS'),
	(7, 5, 'breast', 'NS'),
	(8, 6, 'central_nervous_system', 'brain'),
	(9, 6, 'central_nervous_system', 'brainstem'),
	(10, 6, 'central_nervous_system', 'NS'),
	(11, 6, 'central_nervous_system', 'trigone'),
	(12, 7, 'cervix', 'NS'),
	(13, 8, 'endometrium', 'NS'),
	(14, 9, 'eye', 'NS'),
	(15, 9, 'eye', 'uveal_tract'),
	(16, 10, 'fallopian_tube', 'NS'),
	(17, 12, 'gastrointestinal_tract_(site_indeterminate)', 'NS'),
	(18, 13, 'genital_tract', 'extragonadal'),
	(19, 13, 'genital_tract', 'NS'),
	(20, 15, 'kidney', 'NS'),
	(21, 16, 'large_intestine', 'colon'),
	(22, 16, 'large_intestine', 'NS'),
	(23, 16, 'large_intestine', 'rectum'),
	(24, 17, 'liver', 'NS'),
	(25, 18, 'lung', 'NS'),
	(26, 20, 'meninges', 'NS'),
	(27, 22, 'NS', 'NS'),
	(28, 23, 'oesophagus', 'NS'),
	(29, 24, 'ovary', 'NS'),
	(30, 25, 'pancreas', 'ampulla_of_Vater'),
	(31, 25, 'pancreas', 'NS'),
	(32, 28, 'penis', 'NS'),
	(33, 30, 'peritoneum', 'NS'),
	(34, 34, 'prostate', 'NS'),
	(35, 37, 'skin', 'NS'),
	(36, 38, 'small_intestine', 'NS'),
	(37, 39, 'soft_tissue', 'blood_vessel'),
	(38, 39, 'soft_tissue', 'NS'),
	(39, 39, 'soft_tissue', 'Fat'),
	(40, 39, 'soft_tissue', 'fibrous tissue and uncertain origin'),
	(41, 39, 'soft_tissue', 'tunica_vaginalis'),
	(42, 39, 'soft_tissue', 'smooth muscle'),
	(43, 39, 'soft_tissue', 'striated muscle'),
	(44, 40, 'stomach', 'NS'),
	(45, 41, 'testis', 'NS'),
	(46, 42, 'thymus', 'NS'),
	(47, 43, 'thyroid', 'NS'),
	(48, 44, 'upper_aerodigestive_tract', 'head_neck'),
	(49, 44, 'upper_aerodigestive_tract', 'larynx'),
	(50, 44, 'upper_aerodigestive_tract', 'mouth'),
	(51, 44, 'upper_aerodigestive_tract', 'pharynx'),
	(52, 44, 'upper_aerodigestive_tract', 'sinonasal_and_nasal_cavity'),
	(53, 45, 'urinary_tract', 'NS'),
	(54, 46, 'vagina', 'NS'),
	(55, 45, 'bladder', 'bladder');
/*!40000 ALTER TABLE `tejidos_n1` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.toxicidad
CREATE TABLE IF NOT EXISTS `toxicidad` (
  `id_toxicidad` smallint(4) unsigned NOT NULL AUTO_INCREMENT,
  `nombre_toxicidad` varchar(100) COLLATE utf8_unicode_ci DEFAULT NULL,
  `observaciones_toxicidad` text COLLATE utf8_unicode_ci,
  `id_toxicidad_n0` smallint(4) DEFAULT NULL,
  PRIMARY KEY (`id_toxicidad`),
  KEY `id_toxicidad` (`id_toxicidad`)
) ENGINE=MyISAM AUTO_INCREMENT=224 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.toxicidad: 203 rows
/*!40000 ALTER TABLE `toxicidad` DISABLE KEYS */;
INSERT INTO `toxicidad` (`id_toxicidad`, `nombre_toxicidad`, `observaciones_toxicidad`, `id_toxicidad_n0`) VALUES
	(1, 'Abdominal pain', NULL, 5),
	(2, 'Akaline phosphatase', NULL, 19),
	(3, 'Alopecia', NULL, 16),
	(179, 'Photosensitivity reaction ', NULL, 16),
	(177, 'Blurred vision', NULL, 4),
	(6, 'Anemia', NULL, 2),
	(7, 'Anorexia', NULL, 10),
	(8, 'Appetite decreased', NULL, 10),
	(9, 'Arthralgia', NULL, 11),
	(12, 'AST/ALT', NULL, 19),
	(13, 'Asthenia', NULL, 6),
	(14, 'Back pain', NULL, 11),
	(16, 'Blood urea elevation', NULL, 10),
	(17, 'Bone pain', NULL, 11),
	(18, 'BUN', NULL, 2),
	(19, 'Chest pain', NULL, 3),
	(22, 'Conjuntivis', NULL, 4),
	(23, 'Constipation', NULL, 5),
	(24, 'Cough', NULL, 15),
	(178, 'Corneal abnormalities', NULL, 4),
	(26, 'Creatinine elevations', NULL, 19),
	(28, 'Decreased hemoglobin', NULL, 19),
	(29, 'Decreased LVEF  (left ventricular ejection fraction)', NULL, 19),
	(30, 'Decreased lymphocites', NULL, 19),
	(31, 'Decreased platelets', NULL, 19),
	(32, 'Deppression', NULL, 13),
	(33, 'Dermatitis', NULL, 16),
	(34, 'Deshidratation', NULL, 10),
	(35, 'Diarrhea', NULL, 5),
	(36, 'Dizziness', NULL, 12),
	(37, 'Dry mouth', NULL, 5),
	(38, 'Dysgeusia', NULL, 12),
	(39, 'Dyspepsia', NULL, 5),
	(40, 'Dyspnea', NULL, 15),
	(41, 'Edema', NULL, 6),
	(42, 'Epistaxis', NULL, 15),
	(43, 'Erythema', NULL, 16),
	(44, 'Eye irritation', NULL, 4),
	(45, 'Fatigue', NULL, 6),
	(46, 'Fever', NULL, 6),
	(47, 'Gastroesophageal refluz', NULL, 5),
	(49, 'GGT increased', NULL, 19),
	(50, 'Glucose increased', NULL, 10),
	(51, 'Hand & foot syndrome', NULL, 16),
	(52, 'Headache', NULL, 12),
	(53, '', NULL, 14),
	(54, 'Hemorrhage', NULL, 2),
	(55, 'Hypertension', NULL, 17),
	(56, 'Hyperbilirrubinemia', NULL, 19),
	(57, 'Hyperglicemia any grade', NULL, 10),
	(58, 'Hypoaestesia', NULL, 12),
	(59, 'Hypokalemia', NULL, 10),
	(60, 'Hypotension', NULL, 17),
	(62, 'Increased ALAT ', NULL, 19),
	(186, 'Indigestion', NULL, 5),
	(185, 'Agitation', NULL, 6),
	(66, 'Increased calcium', NULL, 10),
	(67, 'Indirect bilirrubin', NULL, 2),
	(68, 'Infection', NULL, 8),
	(70, 'Injection site reaction', NULL, 16),
	(71, 'Insomnio', NULL, 13),
	(72, 'Lacrimation increased', NULL, 4),
	(74, 'Leucopenia', NULL, 2),
	(75, 'Lipase', NULL, 19),
	(76, 'Loss calcium', NULL, 10),
	(77, 'Loss magnesium', NULL, 10),
	(78, 'Loss potassium', NULL, 10),
	(79, 'Loss sodium', NULL, 10),
	(80, 'Mucositis', NULL, 5),
	(81, 'Myalgia', NULL, 11),
	(82, 'Nail disorder', NULL, 16),
	(83, 'Nausea', NULL, 5),
	(84, 'Neutropenia', NULL, 2),
	(85, 'Neutropenic fever', NULL, 2),
	(86, 'Neutropenic infection', NULL, 2),
	(88, 'Pain', NULL, 6),
	(89, 'Paresthesia', NULL, 12),
	(90, 'Periperhal neuropathy', NULL, 12),
	(91, 'Pleural effusion', NULL, 15),
	(92, 'Pneumonia', NULL, 15),
	(93, 'Proteinuria', NULL, 14),
	(94, 'Pruritus', NULL, 16),
	(95, 'Pyrexia', NULL, 6),
	(96, 'Rash', NULL, 16),
	(97, 'Rhinorrhea', NULL, 15),
	(98, 'Skin discoloration', NULL, 16),
	(99, 'Skin disorder', NULL, 16),
	(100, 'Somnolence', NULL, 12),
	(101, 'Sore throat', NULL, 15),
	(102, 'Stomatitis', NULL, 5),
	(103, 'Taste disturbance', NULL, 12),
	(104, 'Thromboembolism', NULL, 3),
	(105, 'Total bilirrubin', NULL, 19),
	(106, 'Total bilirrubin increased', NULL, 19),
	(107, 'Thrombocitopenia', NULL, 2),
	(109, 'Urinary tract infection', NULL, 8),
	(110, 'Vasodilatacion', NULL, 3),
	(111, 'Venous thrombosis', NULL, 17),
	(113, 'Vomiting', NULL, 5),
	(115, 'Weight decreased', NULL, 10),
	(116, 'Oral pain', NULL, 5),
	(117, 'Dysphagia', NULL, 5),
	(118, 'Esophageal disorder', NULL, 5),
	(119, 'Hemorrhoids', NULL, 5),
	(120, 'Liver dysfunction', NULL, 7),
	(121, 'Oropharingeal', NULL, 15),
	(122, 'Sinusitis', NULL, 15),
	(123, 'Influenza', NULL, 15),
	(124, 'PLANTAR-PALMAR ERYTHRODISTESIA', NULL, 16),
	(125, 'Hyperkeratosis', NULL, 16),
	(126, 'Dry skin', NULL, 16),
	(127, 'Hair color change/ depigmentation, graying', NULL, 16),
	(128, 'Skin ulcer', NULL, 16),
	(129, 'Mucosal inflammation', NULL, 6),
	(130, 'Lethargy', NULL, 12),
	(131, 'Neuropathy-sensory', NULL, 12),
	(132, 'Dysphonia', NULL, 12),
	(133, 'Anxiety', NULL, 13),
	(134, 'Paronychia', NULL, 13),
	(135, 'Vision disorder', NULL, 4),
	(136, 'Keraconjunctivitis', NULL, 4),
	(137, 'Pain in extremity', NULL, 11),
	(138, 'Muscle spams', NULL, 11),
	(139, 'Musculoskeletal pain', NULL, 11),
	(140, 'Upper respiratory infection', NULL, 8),
	(141, 'Pharyngitis', NULL, 8),
	(142, 'Rhinitis', NULL, 8),
	(143, 'Respiratory infection', NULL, 8),
	(144, 'Others', NULL, 18),
	(145, 'Acute Hypersensitivity', NULL, 9),
	(146, 'Allergyc', NULL, 9),
	(147, 'Lymphocytopenia', NULL, 19),
	(148, 'Increased ALP', NULL, 19),
	(149, 'Hyperuricemia', NULL, 10),
	(150, 'Elevated lipase', NULL, 19),
	(151, 'Amylase elevated', NULL, 19),
	(152, 'Hypocalcemia', NULL, 10),
	(153, 'Hypophosphatemia', NULL, 10),
	(154, 'Hypomagnesemia', NULL, 10),
	(155, 'Hyponatremia', NULL, 10),
	(156, 'Hypoalbuminemia', NULL, 10),
	(157, 'INR elevatinons', NULL, 19),
	(158, 'Glucosa decreased', NULL, 10),
	(159, 'Renal insufficiency', NULL, 14),
	(160, 'Arterial thrombosis', NULL, 17),
	(161, 'Elevated LFT', NULL, 2),
	(162, 'Increased amylase', NULL, 19),
	(163, 'Pneumonitis', NULL, 15),
	(164, 'Dysuria', NULL, 14),
	(165, 'Hematuria', NULL, 14),
	(166, 'Cystitis', NULL, 14),
	(167, 'Urinary frecuency', NULL, 14),
	(168, 'Lymphopenia', NULL, 2),
	(169, 'Flatulence', NULL, 5),
	(170, 'Increased GGT', NULL, 19),
	(171, 'Weight loss', NULL, 19),
	(172, 'Citopenia', NULL, 2),
	(173, 'Angioedema', NULL, 9),
	(174, 'Decreased white blood cell ', NULL, 19),
	(175, 'Hemoglobin decreased', NULL, 2),
	(176, 'Thrombosis', NULL, 17),
	(180, 'Hypothyroidism', NULL, 20),
	(181, 'Lymphedema', NULL, 2),
	(182, 'HFSR/PPE', NULL, 16),
	(183, 'Nasopharyngitis ', NULL, 8),
	(184, 'Dry eye', NULL, 4),
	(187, 'Keratosis pilaris', NULL, 16),
	(188, 'HFSR', NULL, 16),
	(189, 'Lipase increased', NULL, 1),
	(190, 'Hypertensive crisis', NULL, 17),
	(191, 'Sweating increased', NULL, 19),
	(192, 'Confusion', NULL, 13),
	(193, 'Bradycardia', NULL, 3),
	(194, 'AV block ', NULL, 3),
	(195, 'Elevated creatinine', NULL, 14),
	(196, ' Creatine phosphokinase increase', NULL, 19),
	(197, 'Myelosuppression', NULL, 2),
	(198, 'Hypertensive crisis', NULL, 3),
	(199, 'Albumin decreased', NULL, 19),
	(200, 'Magnesium increased', NULL, 10),
	(201, 'Tachicardia', NULL, 3),
	(202, 'Myocardial infarction', NULL, 3),
	(203, 'GI Disorders', NULL, 5),
	(204, 'Ataxia', NULL, 12),
	(205, 'Albumin decreased', NULL, 10),
	(206, 'Pelvic pain', NULL, 11),
	(207, 'Calcium decreased', NULL, 19),
	(208, 'Acne', NULL, 16),
	(209, 'Ascites', NULL, 6),
	(210, 'Hypertriglyceridemia', NULL, 3),
	(211, 'Hypercholesterolemia', NULL, 3),
	(212, 'Breast pain', NULL, 3),
	(213, 'Amenorrhea', NULL, 20),
	(214, 'Hot flashes', NULL, 20),
	(215, 'Colitis', NULL, 5),
	(216, 'Hypoglucemia', NULL, 10),
	(217, 'Pollakiuria', NULL, 14),
	(218, 'Maculopapular rash', NULL, 16),
	(219, 'Mucosal inflammation', NULL, 6),
	(220, 'Neuropathy peripheral', NULL, 12),
	(221, '', NULL, 10),
	(222, 'Lacrimation increased', NULL, 4),
	(223, 'Papilloma', NULL, 21);
/*!40000 ALTER TABLE `toxicidad` ENABLE KEYS */;


-- Volcando estructura para tabla farmacos.toxicidad_n0
CREATE TABLE IF NOT EXISTS `toxicidad_n0` (
  `id_toxicidad_n0` int(11) NOT NULL AUTO_INCREMENT,
  `descripcion_toxicidad_n0` varchar(255) COLLATE utf8_unicode_ci DEFAULT NULL,
  PRIMARY KEY (`id_toxicidad_n0`)
) ENGINE=MyISAM AUTO_INCREMENT=22 DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci;

-- Volcando datos para la tabla farmacos.toxicidad_n0: 21 rows
/*!40000 ALTER TABLE `toxicidad_n0` DISABLE KEYS */;
INSERT INTO `toxicidad_n0` (`id_toxicidad_n0`, `descripcion_toxicidad_n0`) VALUES
	(1, 'BLEEDING'),
	(2, 'BLOOD & LYMPATIC SYSTEM DISORDERS'),
	(3, 'CARDIOVASCULAR'),
	(4, 'EYE DISORDER'),
	(5, 'GASTROINTESTINAL'),
	(6, 'GENERAL DISORDERS'),
	(7, 'HEPATOBILIARY'),
	(8, 'INFECTION & INFECTATIONS'),
	(9, 'INMUNE SYSTEM'),
	(10, 'METABOLISM & NUTRITION'),
	(11, 'MUSCULOSKELETAL & CONECTIVE TISSUE'),
	(12, 'NERVOUS SYSTEM'),
	(13, 'PSYCHIATRIC'),
	(14, 'RENAL & URINARY '),
	(15, 'RESPIRATORY, THORACIC & MEDIASTINAL'),
	(16, 'SKIN & SUBCUTANEOUS'),
	(17, 'VASCULAR'),
	(18, 'OTHER'),
	(19, 'INVESTIGATIONS'),
	(20, 'ENDOCRINE DISORDERS'),
	(21, 'Neaplasms benign, malignant and unspecified(including cysts and polyps)');
/*!40000 ALTER TABLE `toxicidad_n0` ENABLE KEYS */;
/*!40101 SET SQL_MODE=IFNULL(@OLD_SQL_MODE, '') */;
/*!40014 SET FOREIGN_KEY_CHECKS=IF(@OLD_FOREIGN_KEY_CHECKS IS NULL, 1, @OLD_FOREIGN_KEY_CHECKS) */;
/*!40101 SET CHARACTER_SET_CLIENT=@OLD_CHARACTER_SET_CLIENT */;

CREATE TABLE IF NOT EXISTS `user_farmacos_back` (
  `IdUsuario` tinyint(3) unsigned NOT NULL AUTO_INCREMENT,
  `Login_Usuario` varchar(50) DEFAULT '0',
  `Password_Usuario` varchar(41) DEFAULT '0',
  `Nivel` tinyint(1) unsigned DEFAULT '1',
  `Mail_usuario` varchar(25) DEFAULT NULL,
  PRIMARY KEY (`IdUsuario`)
) ENGINE=MyISAM  DEFAULT CHARSET=utf8 COLLATE=utf8_unicode_ci AUTO_INCREMENT=6 ;

--
-- Volcado de datos para la tabla `user_farmacos_back`
--

INSERT INTO `user_farmacos_back` (`IdUsuario`, `Login_Usuario`, `Password_Usuario`, `Nivel`, `Mail_usuario`) VALUES
(1, 'celso', '*F56592F5D85BEE5FA191E9C99E026B02732EE26B', 9, 'collazo@usal.es'),
(2, 'atanasio', '*58AF1987F6970BB4A1C5F2DC2D8E145617F400FD', 9, 'atanasio@usal.es'),
(3, 'fandresp', '*A054476FEA6AEA3033ECF131A55CF519C8ABCEBE', 10, 'algo@alo'),
(5, 'bea', '*3F50515DDEE62F18A2B1CE3BE819CFB2F3C869F1', 1, NULL);